FIELD OF THE INVENTION [0002] This invention generally relates to anti-inflammatory pharmaceutical agents and specifically relates to pyrazol urea compounds as . ~nkibitors of IKK-2, an IKB-kinase. The-invpntion ic further related tc compositions comprising such compounds, and methods for treating cancer, inflammation, and inflammation-associated disorders such as arthritis.

BACKGROUND OF THE INVENTION [0003] Rheumatoid arthritis is a common inflammatory disease affecting approximately 1% of the population. The disease is characterized by multiple painful swollen joints that severely limit the patient's daily function, and can progress to the destruction of the affected joints. A common treatment for rheumatoid arthritis is anti-inflammatory steroids. Steroids are clinically very effective, but are limited in their use because of multiple severe side-effects.

Thus, a need exists for an anti-rheumatoid arthritis treatment that offers the potency of steroids without the associated toxicity. One of the mechanisms by which steroids exert their broad spectrum anti-inflammatory action is by inhibiting the activation of the transcription factor NF-KB. NF-KB plays a prominent role in immune and inflammatory responses by regulating the transcription of many early, inducible genes in a variety of cells including inflammatory enzymes such as COX-2 and iNOS. NF-KB is sequestered in an inactive form in the cytoplasm by a member of the IKB family of inhibitory

proteins, and this prevents gene transcription of these responsive genes in the nucleus. Stimulation of cells leads to the phosphorylation, ubiquination and degradation of IKB thereby releasing NF-KB to the nucleus for activation of gene transcription. Chronic activation of NF-KB has been demonstrated in vascular endothelium and synovial lining cells from patients with RA. Recently the IKB kinases (IKK-1 and IKK-2), which phosphorylate IKB and thereby initiate its degradation, have been cloned and initially characterized; these kinases appear to represent the critical, common denominator in the activation of NF-KB since antisense or dominant-negative IKK constructs block NF-KB nuclear translocation and inhibit NF-KB linked reported genes. Therefore, IKK-1 and/or IKK-^ represent. nove and-powerful, targets for drug'development.- [0004] It has been reported that selective IKK-2 inhibitors could be useful for the treatment of inflammatory diseases. See, e. g. , Karin et al., Nat.

Revs. 3,17-26, 2004.

[0005] U. S. Patent No. 5,134, 142 describes 1, 5-diary pyrazoles, and specifically, 1- (4-fluorophenyl)-5- [4- (methylsulfonyl) phenyl]-3-trifluoromethyl pyrazol, as having anti-inflammatory activity.

[0006] PCT Patent Application No. WO 95/15316 discloses substituted pyrazolyl benzenesulfonamide derivatives having anti-inflammatory properties.

[0007] PCT Patent Application No. WO 01/58890 discloses pyrazole carboxamide derivatives, and other heteroaromatic carboxamide derivatives, and their use as IKK-2 inhibitors.

SUMMARY OF THE INVENTION [0008] This invention provides for, in part, IKK-2-inhibiting compounds of Formula l : [0010] wherein X'is selected from the group consisting of O, S, and NR6a ; [0011] wherein X2 is selected from the group consisting of O, S, and N R6b; [0012] wherein A is selected from the group consisting of cycloalkyl, cycloalkenyl ; heterocycloalkyl, heterocycioaikenyl, aryi, and hetei-oaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R10,-OR1', - C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, - (CH2) O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b ; [0013] wherein R is selected from the group consisting of hydrido and -L 2R5 ; [0014] wherein L'and L2 are independently selected from the group consisting of a bond,-O-,-S (=O),-,-O (CH2) d,-C (=O)-,-OC (=O)-,-C (=O) O-, - OC (=O) R'-,-C (=O) R'-,-R'C (=O)-,-OR'C (=O)-, alkylene, alkenylene, and alkynylene, wherein said R', alkylen, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R'5 ; [0015] wherein R'is selected from the group consisting of hydrido, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, -OR8a, -(CH2)eC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b,

-(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11, or R'together with R4a and the atoms to which they are attached form a heterocyclic ring moiety having the structure:

[0017] wherein R2, R2a, and R3 are independently selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl ; [0018] wherein 4a °s selected from the group consisting of hydrido.- hydroxyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, or R4a together with R'and the atoms to which they are attached form a heterocyclic ring having the structure: [0020] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, and wherein R4, when R'together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X; [0021] wherein-A-A-represents any two adjacent atoms of the pyrazol ring in Formula I ; [0022] wherein X is selected from the group consisting of a bond, - (CHR9a)x(CHR9b)y(CHR9c)z-, -NR9a-, -CR9a=CR9b-(CHR9c)g-, -(CH2)hO-, -(CH2)hS-, -NR9a-NR9b-,-N=N-,-O-NR9a-,-S-NR9a-,-CH=CH-CH2-,-CH=CH-NR9a- ,

-CH2-O-CH2-,-CH2-S-CH2-,-CH2-N=N-,-NR9a-o-CH2-,-CH2-NR9a-S-, and -NR9a-S-CH2-; [0023] wherein R5 is selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and aryl, wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R'°,-OR",-C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, <BR> <BR> <BR> -NR12aC(=O)R13a, -NR12aC(=O)OR13a, NR13aSO2R14a, -NR13aSO2NR14aR14b,<BR> -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [0024] wherein R, R6b R, R R R9a, R9b, R9c, and R are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N- dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [0025] wherein R10 is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, heterocycloalkenyl, heteroaryl, and alkenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R13a ;

[0026] wherein R", R12a, and R12b are independently selected from the group consisting of hydrido, aryl, heteroaryl, heteroaralkyl, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, N, N-dialkylaminoalkyl, alkoxy, alkoxyalkyl, heterocycloalkyl, heterocycloalkenyl, cycloalkyl, cycloalkylalkyl, aralkyl, and aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of alkyl, aminoalkyl, alkoxy and halo, wherein R12a and R12bmay be taken together to form a 3-to 7-membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [0027] wherein R13a and R'lb are independently selected fron the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl. cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [0028] wherein R'4a and R'4b are independently selected from the group consisting of hydrido, alkyl, heteroaryl, heterocycloalkenyl, haloalkyl, aralkylamino, heteroaralkyl, aryl, and aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, benzyloxy, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and

heteroaryl, wherein R"a and R14b may be taken together to form a 3-to 7- membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [0029] wherein a, d, and e are independently selected from the group consisting of 0, 1,2, 3,4, 5,6, 7, or 8 ; [0030] wherein b, c, f, and h are independently selected from the group consising of 0,1, or 2; [0031] wherein g is 0 or 1; [0032] wherein x, y, and z are independently 0,1, 2, or 3, and wherein x + y + z < 4; [0033] _ or apharmace ; tically-acçeptable salt thereof.- [0034] The instant invention is also directed to pharmaceutical compositions comprising a compound of Formula I or a pharmaceutically- acceptable salt thereof, as defined above, and a pharmaceutical acceptable carrier, diluent, or adjuvant.

[0035] The instant invention is also directed to a method of treating or preventing inflammation or an inflammation-associated disorder, the method comprising administering a compound of Formula I or a pharmaceutically acceptable salt thereof to a subject in need of such treatment or susceptible to such inflammation or inflammation-associated disorder.

[0036] Other objects of the invention will be in part apparent and in part pointed out hereinafter.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS [0037] In accordance with the present invention, Applicants have discovered a class of IKK-2-inhibiting compounds of Formula I :

[0039] wherein X'is selected from the group consisting of 0, S, and N R5a ; [0040] wherein X2 is selected from the group consisting of 0, S, and NR6b ; [0041] wherein A is selected from the group consisting of cycloalkyl, cycloalkenyl; heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R10, -OR11, - C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [0042] wherein R is selected from the group consisting of hydrido and L2R5 ; [0043] wherein L'and L2 are independently selected from the group consisting of a bond,-O-,-S (=O) c-,-O (CH2) d-,-C (=O)-,-OC (=O)-,-C (=O) O-, - OC (=O) R'-,-C (=O) R'-,-R'C (=O)-,-OR'C (=O)-, alkylene, alkenylene, and alkynylene, wherein said R7, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R'5 ; [0044] wherein R'is selected from the group consisting of hydrido, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, -OR8a, -(CH2)eC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2) eOR8a,-(CH2) eNR8aR8b, and-(CH2) eS (=O), R", or R'together with R4a and the atoms to which they are attached form a heterocyclic ring moiety having the structure:

[0046] wherein R2, R2a, and R3 are independently selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl ; [0047] wherein R4a is selected from the group consisting of hydrido, hydroxyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, or R4a together with R'and the atoms to which they are attached form a heterocyclic ring having the structure: [0049] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, and wherein R4, when R'together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X; [0050] wherein-A-A-represents any two adjacent atoms of the pyrazol ring in Formula l ; [0051] wherein X is selected from the group consisting of a bond, -(CHR9a)x(CHR9b)y(CHR9c)z-, -NR9a-, -CR9a=CR9b-(CHR9c)g-, -(CH2)hO-, -(CH2)hS-, -NR9a-NR9b-,-N=N-,-O-NR9a-,-S-NR9a-,-CH=CH-CH2-,-CH=CH-NR9a- ,

-CH2-O-CH2-,-CH2-S-CH2-,-CH2-N=N-,-NR93-O-CH2-,-CH2-NR9a-S-, and -NR9a-S-CH2-; [0052] wherein R5 is selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and aryl, wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, aCylaminoç R,-OR,-C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [0053] wherein R, Rub, R', R R R9a, Rib R"', and R'S are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N- dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [0054] wherein R10 is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, heterocycloalkenyl, heteroaryl, and alkenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R'3a ;

[0055] wherein R", R12a, and R12b are independently selected from the group consisting of hydrido, aryl, heteroaryl, heteroaralkyl, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, N, N-dialkylaminoalkyl, alkoxy, alkoxyalkyl, heterocycloalkyl, heterocycloalkenyl, cycloalkyl, cycloalkylalkyl, aralkyl, and aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of alkyl, aminoalkyl, alkoxy and halo, wherein R12a and R12bmay be taken together to form a 3-to 7-membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [0056] wherein R'la and Rl"are independently selected from the group consisting. of bydrido, alkyl, aryl, heteroaryi, aralkyl, heterfBcycloalkeny !,-. cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [0057] wherein R14a and R14b are independently selected from the group consisting of hydrido, alkyl, heteroaryl, heterocycloalkenyl, haloalkyl, aralkylamino, heteroaralkyl, aryl, and aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, benzyloxy, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and

heteroaryl, wherein R'la and R"'may be taken together to form a 3-to 7- membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a ; [0058] wherein a, d, and e are independently selected from the group consisting of 0,1, 2,3, 4,5, 6,7, or 8; [0059] wherein b, c, f, and h are independently selected from the group consising of 0,1, or 2; [0060] wherein g is 0 or 1; [0061] wherein x, y, and z are independently 0,1, 2, or 3, and wherein x + y + z < 4 ; .- [0062]-.. or a pharmaceutically-acceptable sat thereof..

[0063] Compounds of Formula I may be useful for treating, among other things, inflammation in a subject, such as, as an analgesic in the treatment of pain and headaches, or as an antipyretic for the treatment of fever. For example, compounds of the present invention may be useful to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, and pyogenic arthritis.

[0064] Compounds of the invention may be further useful in the treatment of frailty, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, menstrual cramps (e. g. , dysmenorrhea), premature labor, tendinitis, bursitis, dermatological conditions such as psoriasis, eczema, burns, sunburn, dermatitis, pancreatitis, hepatitis, and from post-operative inflammation including from ophthalmic surgery such as cataract surgery and refractive surgery.

Compounds of the invention also would be useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis. Compounds of the invention would be useful for the prevention or treatment of cancer, such as colorectal

cancer, and cancer of the breast, lung, prostate, bladder, cervix and skin, as well as treatment of cancer stem cells. Compounds of the invention would be useful in treating inflammation and tissue damage in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, plastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after injury, myocardial ischemia, and the like.

[0065] The compounds would also be useful in the treatment of pulmonary inflammation, such as that-associated with viral infections and-cystic :- fibrosis. The compounds would also be useful for the treatment of certain central nervous system disorders, such as cortical dementias including Alzheimer's disease, and central nervous system damage resulting from stroke, ischemia- and trauma. The compounds of the invention are useful as anti-inflammatory- agents, such as for the treatment of arthritis, with the additional benefit of having significantly less harmful side effects. These compounds would also be useful in the treatment of allergic rhinitis, respiratory distress syndrome, and atherosclerosis. The compounds would also be useful in the treatment of pain, but not limited to postoperative pain, dental pain, muscular pain, and pain resulting from cancer. The compounds would be useful for the prevention of dementias, such as Alzheimer's disease.

[0066] Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

[0067] The present compounds may also be used in co-therapies, partially or completely, in place of other conventional antiinflammatory therapies,

such as together with steroids, NSAIDs, COX-2 selective inhibitors, 5- lipoxygenase inhibitors, LTB4 antagonists and LTA4 hydrolase inhibitors.

[0068] Other conditions in which the compounds of the present invention may provide an advantage include cardiovascular ischemia, diabetes (type I or type 11), congestive heart failure, myocarditis, atherosclerosis, migraine, glaucoma, aortic aneurysm, reflux esophagitis, diarrhea, irritable bowel syndrome, cystic fibrosis, emphysema, asthma, bronchiectasis, hyperalgesia (allodynia), and cerebral ischemia (both focal ischemia, thrombotic stroke and global ischemia (for example, secondary to cardiac arrest).

[0069] The compounds of the present invention may also be useful in the treatment of pain including somatogenic (either nociceptive or neuropathic), both acute and chronic. A compound of the present invention could be used in any situation including neuropathic pain that a common NSAID or opioid analgesic would traditionally be administered.

[0070] Conjunctive treatment of a compound of the present invention with an antineoplastic agent may produce a beneficial effect or alternatively reduce the toxic side effects associated with chemotherapy by reducing the therapeutic dose of the side effect-causing agent needed for therapeutic efficacy or by directly reducing symptoms of toxic side effects caused by the side effect- causing agent. A compound of the present invention may further be useful as an adjunct to radiation therapy to reduce side effects or enhance efficacy. In the present invention, another agent which can be combined therapeutical with a compound of the present invention includes any therapeutic agent which is capable of inhibiting the enzyme cyclooxygenase-2 ("COX-2"). Preferably such COX-2 inhibiting agents inhibit COX-2 selectively relative to the enzyme cyclooxygenase-1 ("COX-1"). Such a COX-2 inhibitor is known as a"COX-2 selective inhibitor". More preferably, a compound of the present invention can be therapeutical combined with a COX-2 selective inhibitor wherein the COX-2 selective inhibitor selectively inhibits COX-2 at a ratio of at least 10: 1 relative to

inhibition of COX-1, more preferably at least 30: 1, and still more preferably at least 50: 1 in an in vitro test. COX-2 selective inhibitors useful in therapeutic combination with the compounds of the present invention include celecoxib, valdecoxib, deracoxib, etoricoxib, rofecoxib, ABT-963 (2- (3, 4-difluorophenyl)-4- (3-hydroxy-3-methyl-1-butoxy)-5- [4- (methylsulfonyl) phenyl-3 (2H)-pyridazinone ; described in PCT Publication No. WO 00/24719), or meloxicam. A compound of the present invention can also be advantageously used in therapeutic combination with a prodrug of a COX-2 selective inhibitor, for example parecoxib.

[0071] Another chemotherapeutic agent which may be useful in combination with a cpmpou. nd Qfthe. pjesentJrtentioncan be selected, for example, from the following non-comprehensive and non-limiting list : Alpha- difluoromethylornithine (DFMO), 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrill Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Welcome EHNA, Merck & Co. EX-015, fazarabine, floxuridine, fludarabine phosphate, 5-fluorouracil, N- (2'-furanidyl)-5- fluorouracil, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, methotrexate, Wellcome MZPES,-norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC-39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL- AC, Takeda TAC-788, thioguanine, tiazofurin, Erbamont TIF, trimetrexate, tyrosine kinase inhibitors, tyrosine protein kinase inhibitors, Taiho UFT, uricytin, Shionogi 254-S, aldo-phosphamide analogues, altretamine, anaxirone, Boehringer Mannheim BBR-2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine, Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto DACHP (Myr) 2, diphenylspiromustine, diplatinum

cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine phosphate sodium, fotemustine, Unimed G- 6-M, Chinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine, mafosfamide, mitolactol, Nippon Kayaku NK-121, NCI NSC-264395, NCI NSC- 342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine, SmithKline SK&F-101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin, trimelamol, Taiho 4181-A, aclarubicin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201-11, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL- 6859, Bristol-Myers BtAY >5P67, Bristol-Myers Bl\ ! Y-25551, Bristoe vers BMY- 26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycin sulfate, bryostatin-1, Taiho C-1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC- 88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-A1, esperamicin-Alb, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR-900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM- 5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT-6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitoxantrone, SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT-01, SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, porothramycin, pyrindamycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM-5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin-A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-868A, terpentecin, thrazine, tricrozarin A, Upjohn U-

73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405, Yoshitomi Y-25024 zorubicin, alpha-carotene, alpha-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti-neoplaston A10, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen- Beaufour BIM-23015, bisantrene, Bristo-Myers BMY-40481, Vestar boron-10, bromofosfamide, Welcome BW-502, Welcome BW-773, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemex CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert Cl- <BR> <BR> <BR> <BR> <BR> 937, Warner-Lambert CI-941, Warner-Lamb-ert. CI-958. clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha CPT-11, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleat, dacarbazine, datelliptinium, didemnin-B, dihaematoporphyrin ether, dihydrolenperone, dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, elliprabin, elliptinium acetate, Tsumura EPMTC, ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N, hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka Jl- 36, Ramot K-477, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp Kl- 8110, American Cyanamid L-623, leukoregulin, lonidamine, Lundbeck LU-23- 112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanine derivatives, methylanilinoacridine, Molecular Genetics MGI-136, minactivin, mitonafide, mitoquidone, mopidamol, motretinide, Zenyaku Kogyo MST-16, N- (retinoyl) amino acids, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, octreotide, Ono ONO-112, oquizanocine, Akzo

Org-10172, pancratistatin, pazelliptine, Warner-Lambert PD-111707, Warner- Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, probimane, procarbazine, proglumide, Invitron protease nexin 1, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP-49532, Rhone-Poulenc RP-56976, SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-10094, spatol, spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, superoxide dismutase, Toyama T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide.. thaliblastine, Eastman KodatTJB-29> tocotrien Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB6, vinblastine sulfate, vincristine, vindesine, vinestramide, vinorelbine, vintriptol, vinzolidine, withanolides, Yamanouchi YM-534, uroguanylin, combretastatin, dolastatin, idarubicin, epirubicin,-estramustine, cyclophosphamide, 9-amino-2- (S)-camptothecin, topotecan, irinotecan (Camptosar), exemestane, decapeptyl (tryptorelin), or an omega-3 fatty acid.

[0072] Examples of radioprotective agents which may be used in a combination therapy with the compounds of this invention include AD-5, adchnon, amifostine analogues, detox, dimesna, I-102, MM-159, N-acylated- dehydroalanines, TGF-Genentech, tiprotimod, amifostine, WR-151327, FUT- 187, ketoprofen transdermal, nabumetone, superoxide dismutase (Chiron) and superoxide dismutase Enzon.

[0073] The compounds of the present invention may also be useful in treatment or prevention of angiogenesis-related disorders or conditions, for example, tumor growth, metastasis, macular degeneration, and atherosclerosis.

[0074] In a further embodiment, the present invention also provides therapeutic combinations for the treatment or prevention of ophthalmic disorders or conditions such as glaucoma. For example the present inventive compounds

advantageously may be used in therapeutic combination with a drug which reduces the intraocular pressure of patients afflicted with glaucoma. Such intraocular pressure-reducing drugs include without limitation latanoprost, travoprost, bimatoprost, or unoprostol. The therapeutic combination of a compound of the present invention plus an intraocular pressure-reducing drug may be useful because each is believed to achieve its effects by affecting a different mechanism.

[0075] In another combination of the present invention, the present inventive compounds can be used in therapeutic combination with an antihyperlipidemic or cholesterol-lowering drug such as a benzothiepine or a benzothiazepine antihyperlipidemic drug. Examples of benzothiepine antihyperlipidemic drugs useful in the present inventive therapeutic combination can be found in U. S. Patent No. 5,994, 391, herein incorporated by reference.

Some benzothiazepine antihyperlipidemic drugs are described in PCT Publication No. WO 93/16055. Alternatively, the antihyperlipidemic or cholesterol-lowering drug useful in combination with a compound of the present invention can be an HMG Co-A reductase inhibitor. Examples of HMG Co-A reductase inhibitors useful in the present therapeutic combination include, individually, benfluorex, fluvastatin, lovastatin, pravastatin, simvastatin, atorvastatin, cerivastatin, bervastatin, ZD-9720' (described in PCT Publication No. WO 97/06802), ZD-4522 (CAS No. 147098-20-2 for the calcium salt ; CAS No. 147098-18-8 for the sodium salt ; described in European Patent No. EP 521471), BMS 180431 (CAS No. 129829-03-4), or NK-104 (CAS No. 141750- 63-2). The therapeutic combination of a compound of the present invention plus an antihyperlipidemic or cholesterol-lowering drug may be useful, for example, in reducing the risk of formation of atherosclerotic lesions in blood vessels. For example, atherosclerotic lesions often initiate at inflamed sites in blood vessels.

It is established that antihyperlipidemic or cholesterol-lowering drug reduce risk of formation of atherosclerotic lesions by lowering lipid levels in blood. Without

limiting the invention to a single mechanism of action, it is believed that one way the compounds of the present combination may work in concert to provide improved control of atherosclerotic lesions by, for example, reducing inflammation of the blood vessels in concert with lowering blood lipid levels.

[0076] In another embodiment of the invention, the present compounds can be used in combination with other compounds or therapies for the treatment of central nervous conditions or disorders such as migraine. For example, the present compounds can be used in therapeutic combination with caffeine, a 5-HT-1B/1D agonist (for example, a triptan such as sumatriptan, naratriptan, zolmitriptan, rizatriptan, almotriptan, or frovatriptan), a dopamine D4 antagonist (e. g., sqnepiprazole-), aspiLin acetaminophen 9 ibuprofen. indomethacin, naproxen sodium, isometheptene, dichloralphenazone, butalbital, an ergot alkaloid (e. g. , ergotamine, dihydroergotamine, bromocriptine, ergonovine, or methyl ergonovine), a tricyclic antidepressant (e. g., amitriptyline or nortriptyline), a serotonergic antagonist (e. g. , methysergide or cyproheptadine), a beta-andrenergic antagonist (e. g., propranolol, timolol, atenolol, nadolol, or metprolol), or a monoamine oxidase inhibitor (e. g., phenylzine or isocarboxazid).

[0077] The present invention includes compounds that selectively inhibit IKK-2 over other kinases. Such other kinases include, but are not limited to, Abt (h), Abl (T3151), Abl (T3151), AMPK, Aurora-A, BTK, caMKII, caMKIV, CDK1/cyclinB, CDK2, CDK2/cyclin A, CDK2/cyclinE, CHK1, CHK2, CK1, CK1 (y), CK1#, CK2, c-RAF (h), CSK, cSRC (h), DYRK1a, ERK2, Fyn, GSK3#, IGF-1R, IKK1, IKKi, IKK2 (h), JNK/SAPK1c, JNK1, JNK1a1 (h), JNK2, JNK2a2 (h), JNK3, Lck, MAPK1 (h), MAPK2 (h), MAPK2/ERK2, MAPKAP-K1a, MAPKAP-K2, MEK1, MK-2, MK-3, MKK1, MKK4, MKK6, MKK7, MKK7 ( (h), MNK, MRSK2/APKAPk1b, MSK, MSK1, NEK2a, NEK6, p38 alpha, p38 beta, p38 delta, p38 gamma, p70 S6K, PAK2, PDGFR#, PDK1, PHK, PKA, PKBAph, PKC PKCa, PKCY, PKC6, PKCE, PRAK, ROCK-II, Rsk1, Rsk2, RSKB,

SAPK2a/p38, SAPK2b, SAPK2b/p38R2, SAPK3, SAPK3/p38g, SAPK4, SAPK4/p38d, SGK, TBK-1, and ZAP-70. The compounds may have an IKK-2 IC50 of less than about 10 uM, preferably less than about 1 uM, and have a selectivity ratio of IKK-2 inhibition over IKK-1 inhibition of at least 50, or at least 100. The compounds may have an IKK-1 IC50 of greater than 10 pM, or greater than 100 uM.

[0078] In one preferred embodiment, the compound of Formula I is a compound wherein A is selected from the group consisting of C3-12 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, C5-12 aryl, and 5-to 12-membered heteroaryl, wherein A may be. optionally.. substituted by one or more substituents selected from the group consisting of halo, C1 6 alkylsulfinyl, C, 6 alkylsulfonyl, cyano, C2-7 alkoxycarbonyl, <BR> <BR> <BR> <BR> C4_, 8 alleylaryl, (C, _6 alkyl) (3- to 12-membered heterocycloalkyl), (C, .6 alkyl) (3- to 12-membered heterocycloalkenyl), (C1-6 alkyl)(5- to 12-membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, $C1-6 hydroxyalkyl, C1-6 haloalkoxy, nitro, C2-10 acylamino, R10, -OR11, -C (=N) NR'2aR'2b,-NR'2a N (=CR R), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and-C (=O) NR12aR12b; [0079] wherein L'and L2 are independently selected from the group consisting of a bond,-O-,-S (=O),-,-O (CH2) d,-C (=O)-,-OC (=O)-,-C (=O) O-, -OC(=O)R7-, -C(=O)R7-, -R7C(=O)-, -OR7C(=O)-, C1-6 alkylene, C2-6 alkenylene, and C26 alkynylene, wherein said R7, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R'5 ; [0080] wherein R'is selected from the group consisting of hydrido, alkenyl, halo, C, hydroxyalkyl, cyano (C1-6 alkyl), C5-12 aryl, 5-to 12-membered heteroaryl,-ORBa,- (CH2) eC (=O) Rea, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and- (CH,) eS (=O) fR", or R'together with R4a and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring moiety having the structure:

[0082] wherein R2, R2a, and R3 are independently selected from the group consisting of hydrido, hydroxyl, amino, C, 6 hydroxyalkyl, C2-12 alkoxyalkyl, C1-6 aminoalkyl, C3-13 alkoxycarbonylalkyl, C3-13 alkylcarbonylalkyl, C2-7 aminocarbonylalkyl, 3-to 12-membered heterocycloalkyl, C, 6 alkoxy, C, 6 alkyl, C16 haloalkyl, C512 aryl, and 5-to 12-membered heteroaryl ; [0083] wherein R4a is selected from the group consisting of hydride, hydroxyl, C, -6 alkoxy, C1-6 alkyl, C1-6 haloalkyl, C5-12 aryl, and 5-to 12-membered heteroaryl, or R4a together with R'and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring having the structure: [0085] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, C1-6 hydroxyalkyl, C2-12 alkoxyalkyl, C1-6 aminoalkyl, C3-13 alkoxycarbonylalkyl, C3-13 alkylcarbonylalkyl, C2-7 aminocarbonylalkyl, 3-to 12- membered heterocycloalkyl, C1-6 alkoxy, C1-6 alkyl, C1-6 haloalkyl, C5-12 aryl, and 5- to 12-membered heteroaryl, and wherein R4, when R'together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X ; [0086] wherein R5 is selected from the group consisting of C, 6 alkyl, C3-, 2 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, 5-to 12-membered heteroaryl, and C5, 2 aryl, wherein R5 may be optionally substituted by one or more substituents selected

from the group consisting of halo, C, 6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, C27 alkoxycarbonyl, C4 8 alkylaryl, (C1-6 alkyl)(3- to 12-membered heterocycloalkyl), (C,-6 alkyl) (3-to 12-membered heterocycloalkenyl), (C1-6 alkyl)(5- to 12- membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 haloalkoxy, nitro, C2, 0 acylamino, R'°,-OR",-C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, - (CH2) aCO2R11, -SO2NR12aR12B, -NR13AR13B, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b ; [0087] wherein R, R, R', R8a, R8b, R9a, R9b, R9C, and R15 are independently selected from the group consisting of hydrido, C1-6 alkyl, C6-12 aryl, 5-to 12-membered heteroaryl, C4-18 aralkyl, 3- to 12-membered heterocycloalkenyl, C312 cycloalkyl, 3-to 12-membered heterocycloalkyl, C1-6 haloalkyl, C418 aralkylamino, amino, C1-6 aminoalkyl, C2-10 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C1-6 alkylsulfonamido, sulfamyl, C, g alkyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, N-(C1-6 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C1-6 alkoxy, halo, C2-10 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C,-6 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C, 6 alkyl) amino (C2-10 acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, C, 6 alkyidioxy, C, 6 hydroxyalkyl, N-(C, 6 alkyl) amino, C27 alkoxycarbonyl, C2 12 alkoxyalkyl, C2-6 alkenylamino, C2-6 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N, N- di (C1-6 alkyl) amino (C1 6 alkoxy), 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [0088] wherein R10 is selected from the group consisting of C3, 2 cycloalkyl, C3-12 cycloalkenyl, C5-12 aryl, 3-to 12-membered heterocycloalkenyl, 5-

to 12-membered heteroaryl, and C26 alkenyl, wherein R'° is optionally substituted with one or more substituents selected from the group consisting of R'3a ; [0089] wherein R", R'2a, and R12b are independently selected from the group consisting of hydrido, C5-12 aryl, 5-to 12-membered heteroaryl, 4-to 18- membered heteroaralkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 hydroxyalkyl, C, 6 aminoalkyl, C2, 2 alkylaminoalkyl, N-N-di (C16 alkyl) amino (Cl-6 alkyl), C1-6 alkoxy, C2-12 alkoxyalkyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, C3-12 cycloalkyl, C4-18 cycloalkylalkyl, C4-18 aralkyl, and C4, 8 aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of C, 6 alkyl, C, 6 aminoalkyl, C, 6 alkoxy and halo, wherein R12a and R12b may be taken together to form a 3- to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [0090] wherein R'3a and R'3b are independently selected from the group consisting of hydrido, C1-6 alkyl, C5-12 aryl, 5-to 12-membered heteroaryl, C4, 8 aralkyl, 3-to 12-membered heterocycloalkenyl, C3-12 cycloalkyl, 3-to 12- membered heterocycloalkyl, C1-6 haloalkyl, C4-18 aralkylamino, amino, C, 6 aminoalkyl, C2, o aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C16 alkylsulfonamido, sulfamyl, C, 6 alkyl, C, 6 alkylthio, C, 6 alkylsulfinyl, C1-6 alkylfulfonyl, N-(C1-6 alkyl)amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C, 6 alkoxy, halo, C2, 0 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C,-6 haloalkoxy, C210 acyl, carboxyl, hydroxy, C1-6 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C, 6alkyl) amino (C2-10 acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, C1-6 alkyldioxy, C1-6 hydroxyalkyl, N- (C,-6 alkyl) amino, C27 alkoxycarbonyl, C2-12 alkoxyalkyl, C2-6 alkenylamino, C2-6 alkynylamino, C26 alkenyl, C26 alkynyl, N, N-di (C, 6 alkyl) amino (C1-6 alkoxy), 3-to

12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [0091] wherein R'4a and R'4b are independently selected from the group consisting of hydrido, C1 6 alkyl, 5-to 12-membered heteroaryl, 3-to 12- membered heterocycloalkenyl, C1 6 haloalkyl, G4 18 aralkylamino, 4-to 18- membered heteroaralkyl, C5, 2 aryl, and C4, 8 aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C, 8 alkyl, C16 alkoxy, halo, C, -6 haloalkyl, cyano, C1-=6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C, 6 hydroxyalkoxy, phenoxy, benzyloxy, N, N-di (C, 6 alkyl) amino (C, 6 alkoxy), 3-to 12- membered heterocycloalkyl, 3 to 12-membered heterocycloalkenyl, and 5 to 12-membered heteroaryl, wherein R'4a and R 14b may be taken together to form a 3-to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [0092] or a pharmaceutically-acceptable salt thereof.

[0093] In one particularly preferred embodiment, the compound of Formula I is a compound wherein A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methylphenyl, ethylphenyl, propylphenyl,

butylphenyl, pentylphenyl, hexylphenyl, methylnaphthyl, ethylnaphthyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylnaphthyl, butylnaphthyl, pentylnaphthyl, hexylnaphthyl, methylpiperidinyl, methylpyrrolidinyl, methylpyrazolidinyl, methylimidazolidinylmethyl, <BR> <BR> <BR> <BR> methylisoxazolidinyl, methyloxazolidinyl, ethylpiperidinyl, ethylpyrrolidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethylpyrazolidinyl, ethylimidazolidinyl, ethylisoxazolidinyl, ethyloxazolidinyl, propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl, propylisoxazolidinyl, propyloxazolidinyl, methylisoindolyl, methyldihydroindolyl, methylisoindoline, methyidihydrothiophenyl, methyidihydropyrrolyl, methyldihydrofuryl, methyldihydropyrazolyl, methyldihydroimidazolyl, <BR> <BR> <BR> <BR> methyldihydroisoxazolyl, methyldihydrooxazolyl, ethylisoindolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> ethyldiydro dolyi, ethylisoindoline, ethvldihydrothio, p<BR> <BR> <BR> <BR> <BR> <BR> ethyldihydrofuryl, ethyldihydropyrazolyl, ethyldihydroimidazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethyldihydroisoxazolyl, ethyldihydrooxazolyl, propylisoindolyl, propyidihydroindolyl, propylisoindoline, propyldihydrothiophenyl, propyidihydropyrrolyl, propyldihydrofuryl, propyldihydropyrazolyl, propyldihydroimidazolyl, propyidihydroisoxazolyl, propyldihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl, <BR> <BR> <BR> <BR> imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethylpyridinyl, ethylbenzothiophenyl, ethylindolyl, ethylisoquinolinyl,-- ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl, ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl, propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl, propylpyrazolyl, <BR> <BR> <BR> <BR> propylimidazolyl, propylisoxazolyl, propyloxazolyl, propylisoindoledionyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy,

dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R10,-OR'1, - C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, - C (=O) R3a, and-C (=O) NR'2aR'2b ; [0094] wherein L'and L2 are independently selected from the group consisting of a bond,-O-,-S (=O),-,-O (CH2) d-,-C (=O)-,-OC (=O)-,-C (=O) O-, -OC(=O)R7-, -C(=O)R7-, -R7C(=O)-, -OR7C(=O)-, methylene, ethylene, propylene, butylen, pentylene, hexylene, ethenylene, propenylene, butenylene, pentenylene, and ethynylene, propynylene, butynylene, pentynylene, wherein said R, methylene, ethylene, propylene, butylene, pentylene, hexylene, ethenylene, propenylene, butenylene, pentenylene, and ethynylene, propynylene, butynylene, pentynylene moieties may be substituted by one or more substituents independently selected from R15 ; [0095] wherein R'is selected from the group consisting of hydrido, cyano, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, chloro, fluoro, bromo, iodo, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl,-OR3a,-(CH2) eC (=O) R8a,-(CH2) eC (=O) OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11, or R'together with R4a and the atoms to which they are attached form a 5-to 8- membered heterocyclic ring moiety having the structure:

[0097] wherein R2, R2a, and R3 are independently selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, <BR> <BR> <BR> <BR> propoxycarbonyi. m-ethyl. butoxycarbon-ylme h.<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethoxycarbonylethyl, propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl, methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl, butoxycarbonylbutyl, methylcarbonylmethyl, <BR> <BR> <BR> <BR> ethylcarbonylmethyl, propylcarbonylmethyl, butylcarbonylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> pentylcarbonylmethyl, hexylcarbonylmethyl, methylcarbonylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethylcarbonylethyl, propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> hexylcarbonylethyl, methylcarbonylpropyl, ethylcarbonylpropyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylcarbonylpropyl, butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butylcarbonylbutyl, pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl, aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, and pyridinyl, benzothiophenyl, indolyl,

isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [0098] wherein R4a is selected from the group consisting of hydrido, hydroxyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, or R4a together with R'and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring having the structure: [00100] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, <BR> <BR> propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl,<BR> <BR> ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl,<BR> <BR> methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl, butoxycarbonylbutyl, methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, butylcarbonylmethyl, pentylcarbonylmethyl, <BR> <BR> hexylcarbonylmethyl, methylcarbonylethyl, ethylcarbonylethyl,<BR> <BR> propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl, hexylcarbonylethyl, methylcarbonylpropyl, ethylcarbonylpropyl, propylcarbonylpropyl,

butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butylcarbonylbutyl, pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl, aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindo ! edjpny), and wherein R\ when R1 together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X; [00101] wherein R5 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, and phenyl, biphenyl, naphthyl, indenyl, wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, methyinaphthyl, <BR> <BR> <BR> ethylnaphthyl, propylnaphthyl, butylnaphthyl, pentylnaphthyl, hexylnaphthyl,<BR> <BR> <BR> <BR> <BR> <BR> methylpiperidinyl, methylpyrrolidinyl, methylpyrazolidinyl,

methylimidazolidinylmethyl, methylisoxazolidinyl, methyloxazolidinyl, ethylpiperidinyl, ethylpyrrolidinyl, ethylpyrazolidinyl, ethylimidazolidinyl, ethylisoxazolidinyl, ethyloxazolidinyl, propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl, propylisoxazolidinyl, propyloxazolidinyl, methylisoindolyl, methyldihydroindolyl, methylisoindoline, methyidihydrothiophenyl, methyldihydropyrrolyl, methyldihydrofuryl, <BR> <BR> <BR> <BR> methyldihydropyrazolyl, methyldihydroimidazolyl, methyldihydroisoxazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyldihydrooxazolyl, ethylisoindolyl, ethyldihydroindolyl, ethylisoindoline,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethyldihydrothiophenyl, ethyidihydropyrrolyl, ethyldihydrofuryl, ethyldihydropyrazolyl, ethyldihydroimidazolyl, ethyldihydroisoxazolyl, <BR> <BR> <BR> <BR> ethyldihydrooxazolyl, propylisoindolyl, propyidilyd ! droindolyl, propylisoira. oline, propyidihydrothiophenyl, propyldihydropyrrolyl, propyldihydrofuryl, <BR> <BR> <BR> <BR> propyldihydropyrazolyl, propyidihydroimidazolyl, propyldihydroisoxazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propyidihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl, imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl, ethylpyridinyl, ethylbenzothipohenyl, ethylindolyl, ethylisoquinolinyl, ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl, <BR> <BR> <BR> <BR> ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl,-<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylpyrazolyl, propylimidazolyl, propylisoxazolyl, propyloxazolyl, propylisoindoledionyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino,

pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R'°,-OR",-C (=N) NR'2aR'b,-NR'2a-N (=CR'3aR'36), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [00102] wherein R6a R6b R7 R8a R8b, R9a, R9b, R9C, and R15 are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indofyl, isoquinolinyl, quinolinyl, thienyf, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyi, ~ dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl,

aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, and benzyl, phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N-

dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy, aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy, aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyidioxy, ethyldioxy, propyldioxy, butyldioxy, pentyidioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl ; [00103] wherein R10 is selected from the group consisting of cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, phenyl, biphenyl, naphthyl, indenyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl,

dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, ethenyl, propenyl, butenyl, and pentenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R'3a ; [00104] wherein R", R"", and R... are independently selected from the group consisting of hydrido, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, <BR> <BR> <BR> <BR> quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, isoindoledionylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, N, N- dimethylaminomethyl, N, N-dimethylaminoethyl, N-methyl-N-ethylaminomethyl, N-methyl-N-ethylaminoethyl, N-methyl-N-propylaminomethyl, N-methyl-N- propylaminoethyl, N, N-diethylaminomethyl, N, N-diethylaminoethyl, N-ethyl-N- propylaminomethyl, N-ethyl-N-propylaminoethyl, N, N-dipropylaminomethyl, N, N-

dipropylaminoethyl, methoxy, ethoxy, propoxy, butoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, benzylamino, and phenylethylamino, wherein said phenyl, bipheny !, nap_thyS,. indenvl is optionally substituted with one or more radicals selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxy, ethoxy, propoxy, butoxy and chloro, fluoro, bromo, iodo, wherein R12a and R12bmay be taken together to form a 3-to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [00105] wherein R and R13b are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl,

aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, <BR> <BR> <BR> <BR> furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl,.. oxazolyl, isoindoledionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, and benzyl, phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy,

trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbony !, o ethyL-N-propylaminophenylcarbonyl, N, N- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, <BR> <BR> <BR> <BR> thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyidioxy, propyldioxy, butyldioxy, pentyidioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy,

N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00106] wherein R'4a and Rl"are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazol imidazolyl, isoxazolyl_,. : oxazolyl, isoindoledionyl, indoly,, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl,. dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, <BR> <BR> <BR> <BR> trifluoromethyl, benzylamino, phenylethylamino, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, <BR> <BR> <BR> <BR> pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, isoindoledionylethyl, phenyl, biphenyl, naphthyl, indenyl, benzyl, and phenylethyl, wherein said phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, benzyl, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo,

chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, benzyloxy, N, N- dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethy. l,-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl,-pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, wherein R"a and R"'may be taken together to form a 3-to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [00107] or a pharmaceutical-acceptable salt thereof.

[00108] In a preferred embodiment, the compound of Formula I is a compound of Formula li :

[00110] whereinx', X2, L', L2, A, R, R', R2, R2a, R3, R4, and R"are as defined above for Formula I.

[00111] In a preferred embodiment, the compound of Formula ! is a compound of Formula III :

[00113] wherein A is selected from the group consisting of cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R10,-OR11, - C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, - (CH2)aS(=O)bR11, -(CH2)aCO2R11, -CO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b,

[00114] wherein R is selected from the group consisting of hydrido and L2R5 ; [00115] wherein L'is selected from the group consisting of a bond,-0-, -S(=O)c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a-, -C(=O)R7a-, - R7aC (=O)-,-OR'aC (=O)-, and alkynylene, wherein said R7a, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R"' ; [00116] wherein L2 is selected from the group consisting of a bond,-0-, - (=O) c~s-O , -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7b-, -C(=O)R7b-, - R7bC (=O)-,-OR'bC (=o)-, alkylene, alkenylene, and alkynylene, wherein said R7b, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R'5 ; [00117] wherein R'is selected from the group consisting of hydrido, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, -OR8a, -(CH2)eC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11; [00118] wherein R2 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl ; [00119] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl ; [00120] wherein Rus ils selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and aryl, wherein Rs may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl,

alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R'°,-OR",-C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, - NR'3aC (=O) NR'4aR'4b,-C (=O) R'3a, and-C (=O) NR12aR12b ; [00121] wherein Ruz is selected from the group consisting of hydrido, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyG,-a. lky_ ! _,. alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N- dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [00122] wherein R, R, R, R9a, R9b, R9C, and R'5 are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl,

alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [00123] wherein R10 is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, heterocycloalkenyl, heteroaryl, and alkenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R13a ; [00124] wherein R", R'2a and R12b are independently selected from the group consisting of hydrido, aryl, heteroaryl, heteroaralkyl, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, N, N-dialkylaminoalkyl, alkoxy, alkoxyalkyl, heterocycloalkyl, heterocycloalkenyl, cycloalkyl, cycloalkylalkyl, aralkyl, and aralkylamino, wherein said aryl s optionally substituted with one or more radicals selected from the group consisting of alkyl, aminoalkyl, alkoxy and halo, wherein R and R'2b may be taken together to form a 3-to 7-membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a ; [00125] wherein R13a and R'3b are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ;

[00126] wherein R'4a and R'4b are independently selected from the group consisting of hydrido, alkyl, heteroaryl, heterocycloalkenyl, haloalkyl, aralkylamino, heteroaralkyl, aryl, and aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, benzyloxy, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl, wherein R'4a and R'4b may be taken together to form a 3-to 7- membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; IPD127],, wherein a, d, and e are independentiy seiected from the group consisting of 0,1, 2,3, 4,5, 6,7, or 8 ; [00128] wherein b, c, and f are independently selected from the group consising of 0, 1, or 2; [00129] or a pharmaceutically-acceptable salt thereof.

[00130] In one preferred embodiment, the compound of Formula II is a compound wherein A is selected from the group consisting of C3, 2 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, C5_, aryl, and 5-to 12-membered heteroaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, C27 alkoxycarbonyl, C418 alkylaryl, (C16 alkyl) (3-to 12-membered heterocycloalkyl), (C16 alkyl) (3-to 12-membered heterocycloalkenyl), (C16 alkyl) (5- to 12-membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C1-6 haloalkoxy, nitro, C2-10 acylamino, R10, -OR¹¹, -C(=N)NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, - NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b;

[00131] wherein L'is selected from the group consisting of a bond, -O-, - (=O) C-0-O , -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a-, -C(=O)R7a-, -R7aC(=O)-, -OR7aC(=O)-, and C26 alkynylene, wherein said R7 and alkynylene moieties may be substituted by one or more substituents independently selected from R" ; [00132] wherein L2 is selected from the group consisting of a bond, -O-, - S (=O) -,-O (CH) d,-C (=O)-,-OC (=O)-,-C (=O) O-,-OC (=O) R'-,-C (=O) R'-, -R7C(=O)-, -OR7C(=O)-, C1-6 alkylene, C2-6 alkenylene, and C26 alkynylene, wherein said R', alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R15 ; [00133] wherein R1 is selected from the group consisting of hydride, cyano, C, 6 alkyl, C26 alkenyl, halo, C16 haloalkyl, C, 6 hydroxyalkyl, cyano (Cl-, alkyl), C5-12 aryl, 5-to 12-membered heteroaryl, -OR8a, -(CH2)eC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11; [00134] wherein R2 is selected from the group consisting of hydrido, hydroxyl, amino, C1-6 hydroxyalkyl, C2-12 alkoxyalkyl, C1-6 aminoalkyl, C3-13 alkoxycarbonylalkyl, C3-13 alkylcarbonylalkyl, C2-7 aminocarbonylalkyl, 3-to 12- membered heterocycloalkyl, C16 alkoxy, C, 6 alkyl, C, 6 haloalkyl, Cs 12 aryl, and 5- to 12-membered heteroaryl ; [00135] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, C16 hydroxyalkyl, C212 alkoxyalkyl, C16 aminoalkyl, C313 alkoxycarbonylalkyl, C3-13 alkylcarbonylalkyl, C2-7 aminocarbonylalkyl, 3-to 12- membered heterocycloalkyl, C1-6 alkoxy, C1-6 alkyl, C1-6 haloalkyl, C5-12 aryl, and 5- to 12-membered heteroaryl ; [00136] wherein Rs is selected from the group consisting of C1-6 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, 5-to 12-membered heteroaryl, and C5-12 aryl, wherein Rus mamy be optionally substituted by one or more substituents selected

from the group consisting of halo, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, cyano, C, _, alkoxycarbonyl, C418 alkylaryl, (C16 alkyl) (3-to 12-membered heterocycloalkyl), (C, _6 alkyl) (3- to 12-membered heterocycloalkenyl), (C1-6 alkyl)(5- to 12- membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C16 haloalkoxy, nitro, C2-10 acylamino, R10, -OR11, -C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, - (CHJ, aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [00137] wherein R7a is selected from the group consisting of hydrido, C,-12 aryl, 57 Lo 12-membered heteroaryl, C4-18 aralkyl, 3- to 12-membered heterocycloalkenyl, C312 cycloalkyl, 3-to 12-membered heterocycloalkyl, C16 haloalkyl, C418 aralkylamino, amino, C16 aminoalkyl, C210 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C16 alkylsulfonamido, sulfamyl, C1-6 alkyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, N-(C1-6 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C1-6 alkoxy, halo, C2-10 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C16 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C16 alkyl) amino (C210 acyl), Cl. thioalkyl, C210 aminoacyloxy, thiocyanato, isothiocyanato, C16 alkyldioxy, C1-6 hydroxyalkyl, N-(C1-6 alkyl) amino, C27 alkoxycarbonyl, C2, 2 alkoxyalkyl, C26 alkenylamino, C26 alkynylamino, C26 alkenyl, C26 alkynyl, N, N- di (C, 6 alkyl) amino (C, 6 alkoxy), 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [0001] wherein R7b, R8a, R8b, R9a, R9b, R9c, and R15 are independently selected from the group consisting of hydrido, C1-6 alkyl, C5-12 aryl, 5-to 12- membered heteroaryl, C4-8 aralkyl, 3-to 12-membered heterocycloalkenyl, C312 cycloalkyl, 3-to 12-membered heterocycloalkyl, C1-6 haloalkyl, C4-8 aralkylamino,

amino, C1-6 aminoalkyl, C2-10 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C16 alkylsulfonamido, sulfamyl, C16 alkyl, C, 6 alkylthio, C 6alkylsulfinyl, C1-6 alkylsulfonyl, N-(C1-6 alkyl)amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C16 alkoxy, halo, C210 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C16 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C16 alkyl) amino (C210 acyl), C16 thioalkyl, C2, 0 aminoacyloxy, thiocyanato, isothiocyanato, C1-6 alkyldioxy, C1-6 hydroxyalkyl, N- (C1-6 alkyl) amino, C27 alkoxycarbonyl, C212 alkoxyalkyl, C26 alkenylamino, C26 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N,N-di(C1-6 alkyl)amino(C1-6 alkoxy), 3- to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [00138] wherein R10 is selected from the group consisting of C312 cycloalkyl, C3-12 cycloalkenyl, C5-12 aryl, 3-to 12-membered heterocycloalkenyl, 5- to 12-membered heteroaryl, and C26 alkenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R13a ; [00139] wherein R", R 12a, and R12b are independently selected from the group consisting of hydrido, C5-12 aryl, 5-to 12-membered heteroaryl, 4-to 18- membered heteroaralkyl, C16 alkyl, C16 haloalkyl, C26 alkenyl, C26 alkynyl, C16 hydroxyalkyl, C, 6 aminoalkyl, C212 alkylaminoalkyl, N-N-di (C, 6 alkyl) amino (Cl-6 alkyl), C16 alkoxy, C2, 2 alkoxyalkyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, C3-12 cycloalkyl, C4-8 cycloalkylalkyl, C4-8 aralkyl, and C4, 8 aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of C1-6 alkyl, C1-6 aminoalkyl, C1-6 alkoxy and halo, wherein R and R12b may be taken together to form a 3-to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ;

[00140] wherein R13a and R13b are independently selected from the group consisting of hydrido, C1-6 alkyl, C5-12 aryl, 5-to 12-membered heteroaryl, C4, 8 aralkyl, 3-to 12-membered heterocycloalkenyl, C3-12 cycloalkyl, 3-to 12- membered heterocycloalkyl, C1-6 haloalkyl, C4-18 aralkylamino, amino, C16 aminoalkyl, C2-10 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C1-6 alkylsulfonamido, sulfamyl, C1-6 alkyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C16 alkylsulfonyl, N-(C16 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C16 alkoxy, halo, C210 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, G, -6hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C, _6 alkyl) amino (C2-10 acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, C1-6 alkyldioxy, C1-6 hydroxyalkyl, N- (C,-6 alkyl) amino, C27 alkoxycarbonyl, C212 alkoxyalkyl, C26 alkenylamino, C26 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N, N-di (C1-6 alkyl)amino(C1-6 alkoxy), 3-to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [00141] wherein R14a and Rllb are independently selected from the group consisting of hydrido, C, _6 alkyl, 5-to 12-membered heteroaryl, 3-to 12- membered heterocycloalkenyl, C1-6 haloalkyl, C4-18 aralkylamino, 4-to 18- membered heteroaralkyl, Cs 12 aryl, and C418 aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, C, 6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C16 hydroxyalkoxy, phenoxy, benzyloxy, N, N-di (C16 alkyl) amino (Cl-to 12- membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl, wherein R14a and R14b may be taken together to form a 3-to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO,, 0, N, and NR ;

[00142] or a pharmaceutically-acceptable salt thereof.

[00143] In one particularly preferred embodiment, the compound of Formula III is a compound wherein A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, <BR> <BR> <BR> <BR> cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, nrhereinA, may be optionally substituted ; pne or more substituents selected- from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, methylnaphthyl, ethylnaphthyl, propylnaphthyl, butyinaphthyl, pentylnaphthyl, hexylnaphthyl, methylpiperidinyl, methylpyrrolidinyl, methylpyrazolidinyl, methylimidazolidinylmethyl, methylisoxazolidinyl, methyloxazolidinyl, ethylpiperidinyl, ethylpyrrolidinyl, ethylpyrazolidinyl, ethylimidazolidinyl, ethylisoxazolidinyl, ethyloxazolidinyl, propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl, propylisoxazolidinyl, propyloxazolidinyl, methylisoindolyl, methyldihydroindolyl, <BR> <BR> <BR> <BR> methylisoindoline, methyldihydrothiophenyl, methyldihydropyrrolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyldihydrofuryl, methyldihydropyrazolyl, methyldihydroimidazolyl, methyidihydroisoxazolyl, methyldihydrooxazolyl, ethylisoindolyl, ethyldihydroindolyl, ethylisoindoline, ethyldihydrothiophenyl, ethyldihydropyrrolyl, <BR> <BR> <BR> <BR> ethyldihydrofuryl, ethyldihydropyrazolyl, ethyldihydroimidazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> ethyldihydroisoxazolyl, ethyldihydrooxazolyl, propylisoindolyl, propyldihydroindolyl, propylisoindoline, propyidihydrothiophenyl,

propyldihydropyrrolyl, propyldihydrofuryl, propyldihydropyrazolyl, propyidihydroimidazolyl, propyldihydroisoxazolyl, propyidihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, <BR> <BR> <BR> <BR> methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl, ethylpyridinyl, ethylbenzothiophenyl, ethylindolyl, ethylisoquinolinyl, ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl, ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl, propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl, propylpyrazolyl, propylimidazolyl,. propylisoxazolyl, propyloxazolyl, propylisoindoledionyl methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R'°,-OR'1, - C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [00144] wherein L'is selected from the group consisting of a bond, -O-, - S(=O)c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a-, -C(=O)R7a-, -R7aC(=O)-, -OR7aC(=O)-, ethynylene, propynylene, butynylene, and pentynylene, wherein said R7, ethynylene, propynylene, butynylene, and pentynylene moieties may be substituted by one or more substituents independently selected from R15 ;

[00145] wherein L2 is selected from the group consisting of a bond,-0-, <BR> <BR> <BR> <BR> - S (=O) -,-O (CH2) d,-C (=O)-,-OC (=O)-,-C (=O) O-,-OC (=O) R'-,-C (=0) R'-,<BR> <BR> <BR> <BR> <BR> <BR> -R'C (=O)-,-OR'C (=O)-, methylene, ethylene, propylene, butylene, pentylene, hexylen, ethenylene, propenylene, butenylene, pentenylene, ethynylene, propynylene, butynylene, and pentynylene, wherein said R', methylene, ethylene, propylene, butylen, pentylen, hexylene, ethenylene, propenylene, butenylene, pentenylene, ethynylene, propynylene, butynylene, and pentynylene moieties may be substituted by one or more substituents independently selected frorn R15 ; [00146] wherein R'is selected from the group consisting of hydrido, cyasnoz methyl, ethyl, propy',-butyl, pentyl,. hexyieethenyl, propenyl, buteny', pentenyl, chloro, fluoro, bromo, iodo, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl ;- phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl,-OR8a,-(CH2) eC (=O) R8a,-(CH2) eC (=O) OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11 ; [00147] wherein R2 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl, <BR> <BR> <BR> <BR> arninoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl,<BR> <BR> <BR> <BR> <BR> <BR> methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl,

methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl, butoxycarbonylbutyl, methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, butylcarbonylmethyl, pentylcarbonylmethyl, <BR> <BR> <BR> <BR> hexylcarbonylmethyl, methylcarbonylethyl, ethylcarbonylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl, hexylcarbonylethyl, methylcarbonylpropyl, ethylcarbonylpropyl, propylcarbonylpropyl, butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butyfcarbonylbutyl, pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl, aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl,-and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl,- quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00148] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl, methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl, butoxycarbonylbutyl, methylcarbonylmethyl, ethylcarbonylmethyl,

propylcarbonylmethyl, butylcarbonylmethyl, pentylcarbonylmethyl, hexylcarbonylmethyl, methylcarbonylethyl, ethylcarbonylethyl, propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl, hexylcarbonylethyl, methylcarbonylpropyl, ethylcarbonylpropyl, propylcarbonylpropyl, butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butylcarbonylbutyl, <BR> <BR> <BR> <BR> pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00149] wherein R'is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, and phenyl, biphenyl, naphthyl, indenyl, wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, methylnaphthyl,

ethylnaphthyl, propylnaphthyl, butylnaphthyl, pentylnaphthyl, hexylnaphthyl, methylpiperidinyl, methylpyrrolidinyl, methylpyrazolidinyl, methylimidazolidinylmethyl, methylisoxazolidinyl, methyloxazolidinyl, ethylpiperidinyl, ethylpyrrolidinyl, ethylpyrazolidinyl, ethylimidazolidinyl, ethylisoxazolidinyl, ethyloxazolidinyl, propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl, propylisoxazolidinyl, propyloxazolidinyl, methylisoindolyl, methyldihydroindolyl, methylisoindoline, methyldihydrothiophenyl, methyldihydropyrrolyl, methyldihydrofuryl, methyldihydropyrazolyl, methyldihydroimidazolyl, methyidihydroisoxazolyl, methyldihydrooxazolyl, ethylisoindolyl, ethyldihydroindolyl, ethylisoindoline, ethyldihydrothiophenyl, ethyldihydropyrrolyl, ethyldihydrofuryl, ethyidihydropyrazolyl, ethyldihydroimidazolyl, ethyldihydroisoxazolyl, ethyidihydrooxazolyl, propylisoindolyl, propyldihydroindolyl, propylisoindoline, <BR> <BR> <BR> <BR> propyldihydrothiophenyl, propyldihydropyrrolyl, propyldihydrofuryl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propyldihydropyrazolyl, propyldihydroimidazolyl, propyidihydroisoxazolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propyldihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl, imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl, ethylpyridinyl, ethylbenzothiophenyl, ethylindolyl, ethylisoquinolinyl, ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl, ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl, propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl, propylpyrazolyl, propylimidazolyl, propylisoxazolyl, propyloxazolyl, propylisoindoledionyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy, dichloromethoxy, trichloromethoxy,

fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R'°,-OR",-C (=N) NR'2aR'2b,-NR'a-N (=CR'3aR'3b), - (CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, - NR'3aC (=O) NR'4aR14b,-C (=O R'3a and-C (=O) NR'aR'2b ; [00150] wherein R"is selected from the group consisting of hydrido, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, <BR> <BR> <BR> <BR> dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, <BR> <BR> <BR> <BR> aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl,

aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, benzyl, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, <BR> <BR> <BR> <BR> ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylarninopropyltmethylaminobuvt. yl, ethy. Larninobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylarninohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- <BR> <BR> <BR> <BR> ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- <BR> <BR> <BR> <BR> diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N-

dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy, <BR> <BR> <BR> <BR> aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyldioxy, propyldioxy, butyldioxy, pentyldioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl ; [00151] wherein R'b, Rea, RBb, R9a, R9b, R9, and R are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl,

oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, <BR> <BR> <BR> <BR> pyredinDylethyl, benzothiophenylmethyl, benzethiQphenylethyl, indolylmethyl,. indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl,. imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, benzyl, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, <BR> <BR> <BR> <BR> aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl,

propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy,, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- <BR> <BR> <BR> <BR> ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- <BR> <BR> <BR> <BR> diethylam inophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, <BR> <BR> <BR> <BR> thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyldioxy, propyldioxy, butyldioxy, pentyldioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl,

ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl,-oxazolyl, and isoindoledionyl ; [00152] wherein R10 is selected from the group consisting of cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, phenyl, biphenyl, naphthyl, indenyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, ethenyl, propenyl, butenyl, and pentenyl, wherein R'° is optionally substituted with one or more substituents selected from the group consisting of R'3a ; [00153] wherein R", R 12,,, and R'2b are independently selected from the group consisting of hydrido, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, pyridinylmethyl,

pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, <BR> <BR> <BR> <BR> quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolyiethyl, isoindoledionylmethyl, isoindoledionylethyl, methyl, ethyl, propyl, butyl, pentyl, <BR> <BR> <BR> <BR> hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, <BR> <BR> <BR> <BR> propylarninomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, N, N- dimethylaminomethyl, N, N-dimethylaminoethyl, N-methyl-N-ethylaminomethyl, N-methyl-N-ethylaminoethyl, N-methyl-N-propylaminomethyl, N-methyl-N- propylaminoethyl, N, N-diethylaminomethyl, N, N-diethylaminoethyl, N-ethyl-N- propylaminomethyl, N-ethyl-N-propylaminoethyl, N, N-dipropylaminomethyl, N, N- dipropylarninoethyl, methoxy, ethoxy, propoxy, butoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, <BR> <BR> <BR> <BR> propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> butoxypropyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, benzylamino, and phenylethylamino,

wherein said phenyl, biphenyl, naphthyl, indenyl is optionally substituted with one or more radicals selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxy, ethoxy, propoxy, butoxy and chloro, fluoro, bromo, iodo, wherein R'2a and R'2b may be taken together to form a 3-to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a ; [00154] wherein R13a and R13b are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, <BR> <BR> <BR> <BR> aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl,

pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, and benzyl, phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylarninomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, <BR> <BR> <BR> <BR> trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl,- pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylarninomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- <BR> <BR> <BR> diethylarninophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N-

propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy, <BR> <BR> <BR> <BR> aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyidioxy, ethyidioxy, propyldioxy, butyidioxy, pentyidioxy, hexyidioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, metb. oxmymethyl, methoxyethyl ; methoxypropyll.-ethoxymathyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino,-ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylarninomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00155] wherein R'la and R"'are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl,

pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, isoindoledionylethyl, phenyl, biphenyl, naphthyl, indenyl. benzyl, and phenylethyl, wherein said phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl,-isoxazolyl, oxazolyl, isoindoledionyl, isoindolyl, dihydroindolyl, isoindaline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, benzyl, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, chlorornethyl, dichloromethyl, trichloromethyl, fluoromethyl, diflu6romethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, ffuoromethoxy, diffuoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, benzyloxy, N, N- dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy,

N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, wherein R'4a and R"'may be taken together to form a 3-to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a ; [00156] or a pharmaceutically-acceptable salt thereof.

[00157] In a preferred embodiment, the compound of Formula I is a compound of Formula IV : [00159] wherein L', L2, A, R, R', R2, and R4 are as defined above for Formula Ill.

[00160] In a preferred embodiment, the compound of Formula I is a compound of Formula V:

[00162] wherein L', A, R, R', R2, and R4 are as defined above for Formula III.

[00163] In a preferred embodiment, the compound of Formula I is a compound of Formula VI :

[00165] wherein L1, A, R, R1, R2, and R4 are as defined above for Formula 111.

[00166] In a preferred embodiment, the compound of Formula I is a compound of Formula VII : [00168] wherein L', A, R, R', R2, and R4 are as defined above for Formula III.

[00169] In a preferred embodiment, the compound of Formula I is a compound of Formula V) ! ! :

[00171] wherein. A ! s selected from the group consisting of cycioalleyl,- cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, and heteroaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R'°,-OR", -c (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b,-NR12aC(=O)R13a, - NR12aC (=O) OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b;.

[00172] wherein R is selected from the group consisting of hydrido and -L2R5; [00173] wherein L1 is selected from the group consisting of a bond, -O-, - (=O) c-,-O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a-, -C(=O)R7a-, -R7aC(=O)-, -OR7aC(=O)-, and alkynylene, wherein said R7a, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R15 ; [00174] wherein L2 is selected from the group consisting of a bond, -O-, - (=O) c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7b-, -C(=O)R7b-,

- R"C (=O)-,-OR'bC (=O)-, alkylene, alkenylene, and alkynylene, wherein said R", alkylen, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R15 ; [00175] wherein R'is selected from the group consisting of hydrido, cyano, alkyl, alkenyl, halo, haloalkyl, hydroxyalkyl, cyanoalkyl, aryl, heteroaryl, -OR8a, -(CH2)eC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2) eOR8a,-(CH2) eNR8aR8b, and-(CH2) eS (=O) fR11, or R'together with R4a and the atoms to which they are attached form a heterocyclic ring moiety having the structure: [00177] wherein R'is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl ; [00178] wherein R4a is selected from the group consisting of hydrido, hydroxyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, or R4a together with R'and the atoms to which they are attached form a heterocyclic ring having the structure: [00180] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkoxycarbonylalkyl, alkylcarbonylalkyl, aminocarbonylalkyl, heterocycloalkyl, alkoxy, alkyl, haloalkyl, aryl, and heteroaryl, and wherein R4, when R'together with R4a and the atoms to

which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X; [00181] wherein X is selected from the group consisting of a bond, - (CHR9a)x(CHR9b)y(CHR9c)z-, -NR9a-, -CR9a=CR9b-(CHR9c)g-,-(CH2)hO-, -(CH2)hS-, -NR93-NR9b-,-N=N-,-O-NR9a-,-S-NR9a-,-CH=CH-CH2-,-CH=CH-NR9a- , -CH2-O-CH2-,-CH2-S-CH2-,-CH2-N=N-,-NR9a-o-CH2-,-CH2-NR9a-S-, and - NR9a-S-CH2 ; [00182] wherein R 5 is selected from the group consisting of alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, and aryl, wherein R6 may be optionally substituted by one or more substituents . selected from the. group consisting of halo, alkylsulfinyl, alkylsulfonyl, cyano, alkoxycarbonyl, alkylaryl, alkylheterocycloalkyl, alkylheterocycloalkenyl, alkylheteroaryl, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, haloalkoxy, nitro, acylamino, R'°,-OR",-C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12; [00183] wherein Ruz is selected from the group consisting of hydrido, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aratkytamino, amino, aminoafkyf, aminoacyt, nitro, azido, and heteroaralkyl, wherein said aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N- dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ;

[00184] wherein R", R", R", R", R", R", and R'5 are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl, aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alky ! amino, aCkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [00185] wherein Rlo is selected from the group consisting of cycloalkyl, cycloalkenyl, aryl, heterocycloalkenyl, heteroaryl, and alkenyl, wherein R10 is optionally substituted with one or more substituents selected from the group consisting of R13a ; [00186] wherein R", R"', and Rllb are independently selected from the group consisting of hydrido, aryl, heteroaryl, heteroaralkyl, alkyl, haloalkyl, alkenyl, alkynyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, N, N-dialkylaminoalkyl, alkoxy, alkoxyalkyl, heterocycloalkyl, heterocycloalkenyl, cycloalkyl, cycloalkylalkyl, aralkyl, and aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of alkyl, aminoalkyl, alkoxy and halo, wherein R12a and R12bmay be taken together to form a 3-to 7-membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO,, 0, N, and NR13a ; [00187] wherein R"a and R13b are independently selected from the group consisting of hydrido, alkyl, aryl, heteroaryl, aralkyl, heterocycloalkenyl, cycloalkyl, heterocycloalkyl, haloalkyl, aralkylamino, amino, aminoalkyl,

aminoacyl, nitro, azido, and heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkylsulfonamido, sulfamyl, alkyl, alkylthio, alkylsulfinyl, alkylsulfonyl, N-alkylamino, aminoalkyl, alkylaminoalkyl, alkoxy, halo, acyloxy, oxy, formyl, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N- dialkylaminoacyl, thioalkyl, aminoacyloxy, thiocyanato, isothiocyanato, alkyldioxy, hydroxyalkyl, N-alkylamino, alkoxycarbonyl, alkoxyalkyl, alkenylamino, alkynylamino, alkenyl, alkynyl, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl ; [00188] wherein Sand R are independently selected-from the group consisting of hydrido, alkyl, heteroaryl, heterocycloalkenyl, haloalkyl, aralkylamino, heteroaralkyl, aryl, and aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, haloalkyl, cyano, haloalkoxy, acyl, carboxyl, hydroxy, hydroxyalkoxy, phenoxy, benzyloxy, N, N-dialkylaminoalkoxy, heterocycloalkyl, heterocycloalkenyl, and heteroaryl, wherein R'4a and R'4b may be taken together to form a 3-to 7- membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a; [00189] wherein a, d, and e are independently selected from the group consisting of 0, 1,2, 3,4, 5,6, 7, or 8 ; [00190] wherein b, c, f, and h are independently selected from the group consising of 0,1, or 2; [00191] wherein g is 0 or 1; [00192] wherein x, y, and z are independently 0,1, 2, or 3, and wherein x + y + z < 4 ; [00193] or a pharmaceutically-acceptable salt thereof.

[00194] In one particularly preferred embodiment, the compound of Formula VIII is a compound wherein A is selected from the group consisting of C3-12 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, C512 aryl, and 5-to 12-membered heteroaryl, wherein A may be optionally substituted by one or more substituents selected from the group consisting of halo, C16 alkylsulfinyl, C, 6 alkylsulfonyl, cyano, C2-1 alkoxycarbonyl, C418 alkylaryl, (C16 alkyl) (3-to 12-membered heterocycloalkyl), (C,-6 alkyl) (3-to 12-membered heterocycloalkenyl), (C16 alkyl) (5-to 12- membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C16 haloalkoxy, nitro, C2-10 acylamino, R10, -OR11, -C (=N) NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11,-(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C (=O) N R'23R12b ; [00195] wherein L1 is selected from the group consisting of a bond, -O-, - S c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a, -C(=O)R7a-, - R'aC (=O)-,-OR'aC (=o)-, and C26 alkynylene, wherein said R 7and alkynylene moieties may be substituted by one or more substituents independently selected from R15; [00196] wherein L2 is selected from the group consisting of a bond,-0-, -S(=O)c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7-, -C(=O)R7-, -R7C(=O)-, -OR7C(=O)-, C1-6 alkylene, C2-6 alkenylene, and C26 alkynylene, wherein said R7, alkylene, alkenylene, and alkynylene moieties may be substituted by one or more substituents independently selected from R" ; [00197] wherein R'is selected from the group consisting of hydrido, cyano, C1-6 alkyl, C2-6 alkenyl, halo, C1-6 haloalkyl, C1-6 hydroxyalkyl, cyano (C1-6 alkyl), C5, 2 aryl, 5-to 12-membered heteroaryl, -OR8a, -(CH2)aC(=O)R8a, -(CH2)eC(=O)OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and- (CH,) eS (=O), R", or R'together with R4a and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring moiety having the structure:

[00199] wherein R2 is selected from the group consisting of hydrido, hydroxyl, amino, C1-6 hydroxyalkyl, C2-12 alkoxyalkyl, C1-6 aminoalkyl, C3-13 alkoxycarbonylalkyl, C3_13 alkylcarbonylalkyl, C2., aminocarbonylalkyl, 3-to 12- membered heterocycloalkyl, C,-, alkoxy, C, 1. aryl, and 5- to 12-membered heteroaryl ; [00200] wherein R4a is selected from the group consisting of hydrido, hydroxyl, C1-6 alkoxy, C1-8 alkyl, C1-6 haloalkyl, C5-12 aryl, and 5-to 12-membered heteroaryl, or R4a together with R'and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring having the structure: [00202] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, C1-6 hydroxyalkyl, C2-12 alkoxyalkyl, C1-6 aminoalkyl, C3-13 alkoxycarbonylalkyl, C313 alkylcarbonylalkyl, C27 aminocarbonylalkyl, 3-to 12- membered heterocycloalkyl, C1-6 alkoxy, C1-6 alkyl, C1-6 haloalkyl, C5-13 aryl, and 5- to 12-membered heteroaryl, and wherein R4, when R'together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X ; [00203] wherein R5 is selected from the group consisting of C, 6 alkyl, C3-12 cycloalkyl, C3-12 cycloalkenyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, 5-to 12-membered heteroaryl, and C5-12 aryl,

wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of halo, C,._6 alkylsulfinyl, C, _s alkylsulfonyl, cyano, C27 alkoxycarbonyl, C4-18 alkylaryl, (C1-6 alkyl)(3- to 12-membered heterocycloalkyl), (C1-6 alkyl)(3- to 12-membered heterocycloalkenyl), (C1-6 alkyl)(5- to 12- membered heteroaryl), C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, C16 haloalkoxy, nitro, C2-10 acylamino, R10, -OR11, -C (=N) Nu au -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, -(CH2)aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13b, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b ; [00204]. wherein Ruz is selected from the group consisting of hydride, C5-12 aryl, 5-to 12-membered heteroaryl, C4-18 aralkyl, 3-to 12-membered heterocycloalkenyl, C3-12 cycloalkyl, 3-to 12-membered heterocycloalkyl, C16 haloalkyl, C4-18 aralkylamino, amino, C1-6 aminoalkyl, C2-10 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C1-6 alkylsulfonamido, sulfamyl, C1-6 alkyl, C1-6 alkylthio, C1-6 alkylsulfinyl, C1-6 alkylsulfonyl, N-(C1-6 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C1-6 alkoxy, halo, C2-10 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, c1-6 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C16 alkyl) amino (CQ acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, C16 alkyldioxy, C1-6 hydroxyalkyl, N-(C1-6 alkyl) amino, C27 alkoxycarbonyl, C212 alkoxyalkyl, C26 alkenylamino, C2-6 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N, N- di (C16 alkyl) amino (C1-6 alkoxy), 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [0002] wherein R, Rua R3b R9a R9b R9C, and R15 are independently selected from the group consisting of hydrido, C,-, alkyl, C5-, 2 aryl, 5-to 12- membered heteroaryl, C4-18 aralkyl, 3- to 12-membered heterocycloalkenyl, C3-12

cycloalkyl, 3-to 12-mernbered heterocycloalkyl, C1-6 haloalkyl, C4-18 aralkylamino, amino, C1-6 aminoalkyl, C2-10 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of Cl-,, alkylsulfonamido, sulfamyl, C1-6 alkyl, C1-6 alkylthio, C1- 6alkylsulfinyl, C1-6 alkylsulfonyl, N-(C1-6 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C1. 6 alkoxy, halo, C210 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C16 hydroxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C16 alkyl) amino (C2-10 acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, CI-6 alkyldioxy, Cl-6 hydroxyalkyl, N- (C1-6 alkyl) amino, C27 alkoxycarbonyl, C2-12 alkoxyalkyl, C2-6 alkenylamino, C2-6 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N, N-di (C16 alkyl) amino (C16 alkoxy), 3-to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [00205] wherein R10 is selected from the group consisting of C3-12 cycloalkyl, C3-12 cycloalkenyl, C5-12 aryl, 3-to 12-membered heterocycloalkenyl, 5- to 12-membered heteroaryl, and C26 alkenyl, wherein R'° is optionally substituted with one or more substituents selected from the group consisting of R'3a ; [00206] wherein R", R 12a, and R12b are independently selected from the group consisting of hydrido, C5-12 aryl, 5-to 12-membered heteroaryl, 4-to 18- membered heteroaralkyl, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 hydroxyalkyl, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, N-N-di(C1-6 alkyl) amino (C16 alkyl), C1-6 alkoxy, C2-12 alkoxyalkyl, 3-to 12-membered heterocycloalkyl, 3-to 12- membered heterocycloalkenyl, C3-12 cycloalkyl, C4-18 cycloalkylalkyl, C4-18 aralkyl, and C418 aralkylamino, wherein said aryl is optionally substituted with one or more radicals selected from the group consisting of C 1-6 alkyl, Cl. 6aminoalkyl, Cl-6 alkoxy and halo, wherein R'2a and R'2bmay be taken together to form a 3-to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR13a ;

[00207] wherein R"'and R""are independently selected from the group consisting of hydrido, C1-6 alkyl, C5-12 aryl, 5-to 12-membered heteroaryl, C418 aralkyl, 3-to 12-membered heterocycloalkenyl, C3-12 cycloalkyl, 3-to 12- membered heterocycloalkyl, C16 haloalkyl, C418 aralkylamino, amino, C16 aminoalkyl, C210 aminoacyl, nitro, azido, and 4-to 18-membered heteroaralkyl, wherein said alkyl, aryl, heteroaryl, aminoalkyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C16 alkylsulfonamido, sulfamyl, C16 alkyl, C16 alkylthio, C16 alkylsulfinyl, C16 alkylsulfonyl, N-(C16 alkyl) amino, C1-6 aminoalkyl, C2-12 alkylaminoalkyl, C16 alkoxy, halo, C210 acyloxy, oxy, formyl, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C1-6 hydoxyalkoxy, phenoxy, nitro, azido, benzyloxy, N, N-di (C16 alkyl) amino (C2-10 acyl), C1-6 thioalkyl, C2-10 aminoacyloxy, thiocyanato, isothiocyanato, C1-6 alkyldioxy, C1-6 hydroxyalkyl, N- (C1-6 alkyl) amino, C27 alkoxycarbonyl, C212 alkoxyalkyl, C26 alkenylamino, C26 alkynylamino, C2-6 alkenyl, C2-6 alkynyl, N,N-di(C1-6 alkyl)amino(C1-6 alkoxy), 3- to 12-membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl ; [00208] wherein R14a and R14b are independently selected from the group consisting of hydrido, C1-6 alkyl, 5- to 12-membered heteroaryl, 3-to 12- membered heterocycloalkenyl, C16 haloalkyl, C418 aralkyla~mino, 4-to 18- membered heteroaralkyl, C5-12 aryl, and C4-18 aralkyl, wherein said aryl, heteroaryl, heterocycloalkenyl, and aralkyl moieties are optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl, C1-6 alkoxy, halo, C1-6 haloalkyl, cyano, C1-6 haloalkoxy, C2-10 acyl, carboxyl, hydroxy, C16 hydroxyalkoxy, phenoxy, benzyloxy, N, N-di (C16 alkyl) amino (C16 alkoxy), 3-to 12- membered heterocycloalkyl, 3-to 12-membered heterocycloalkenyl, and 5-to 12-membered heteroaryl, wherein R14a and R14b may be taken together to form a 3- to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR 13a ;

[00209] or a pharmaceutically-acceptable salt thereof.

[00210] In an even more particularly preferred embodiment, the compound of Formula VIII is a compound wherein A is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, wherein A may be optionally-substitute_d..hyone_cor more substituents seeected from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycar-bonyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, methylnaphthyl, ethyinaphthyl, <BR> <BR> <BR> <BR> propylnaphthyl, butylnaphthyl, pentylnaphthyl, hexylnaphthyl, methylpiperidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methylpyrrolidinyl, methylpyrazolidinyl, methylimidazolidinylmethyl,-<BR> <BR> <BR> <BR> <BR> <BR> <BR> methylisoxazolidinyl, methyloxazolidinyl, ethylpiperidinyl, ethylpyrrolidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> ethylpyrazolidinyl, ethyl i m idazolidinyl, ethylisoxazolidinyl, ethyloxazolidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylisoxazolidinyl, propyloxazolidinyl, methylisoindolyl, methyldihydroindolyl, methylisoindoline, methyidihydrothiophenyl, methyidihydropyrrolyl, methyldihydrofuryl, methyldihydropyrazolyl, methyldihydroimidazolyl, methyidihydroisoxazolyl, methyldihydrooxazolyl, ethylisoindolyl, <BR> <BR> <BR> <BR> ethyldihydroindolyl, ethylisoindoline, ethyldihydrothiophenyl, ethyldihydropyrrolyl, ethyldihydrofuryl, ethyldihydropyrazolyl, ethyldihydroimidazolyl, ethyldihydroisoxazolyl, ethyldihydrooxazolyl, propylisoindolyl, propyldihydroindolyl, propylisoindoline, propyldihydrothiophenyl,

propyldihydropyrrolyl, propyldihydrofuryl, propyldihydropyrazolyl, propyldihydroimidazolyl, propyldihydroisoxazolyl, propyldihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl, imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl, ethylpyridinyl, ethylbenzothiophenyl, ethylindolyl, ethylisoquinolinyl, ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl, ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl, propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl, propylpyrazolyl, propylimidazolyl, propylisoxazolyl, propyloxazolyl, propylisoindoledionyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R : OR'1, -C(=N)NR12aR12b, -NR12a-N(=CR13aR13b), -(CH2)aOR11, -(CH2)aNR12aR12b, - (CH2) aS(=O)bR11, -(CH2)aCO2R11, -SO2NR12aR12b, -NR13aR13a, -NR12aC(=O)R13a, -NR12aC(=O)OR13a, -NR13aSO2R14a, -NR13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b, -C(=O)R13a, and -C(=O)NR12aR12b; [00211] wherein L'is selected from the group consisting of a bond,-0-, - S c-, -O(CH2)d-, -C(=O)-, -OC(=O)-, -C(=O)O-, -OC(=O)R7a-, -C(=O)R7a-, - R7aC (=O)-,-OR'aC (=O)-, ethynylene, propynylene, butynylene, and pentynylene, wherein said R7, ethynylene, propynylene, butynylene, and pentynylene moieties may be substituted by one or more substituents independently selected from R'5 ;

[00212] wherein L2 is selected from the group consisting of a bond, -O-, -S(=O)c-, -O(CH2)d-, -C(=O)- -OC(=O)-, -C(=O)O-, -OC(=O)R7-, -C(=O)R7-, -R7C(=O)-, -OR7C(=O)-, methylene, ethylene, propylene, butylene, pentylene, hexylene, ethenylene, propenylene, butenylene, pentenylene, ethynylene, propynylene, butynylene, and pentynylene, wherein said R', methylene, ethylene, propylene, butylene, pentylene, hexylene, ethenylene, propenylene, butenylene, pentenylene, ethynylene, propynylene, butynylene, and pentynylene moieties may be substituted by one or more substituents independently selected from R" ; [00213] wherein R'is selected from the group consisting of hydrido, cyano, mettz. yl, ethyl, +propyl, butyl, pentyl, hexyi, sthenyl. propenyl, butenyi,. pentenyl, chloro, fluoro, bromo, iodo, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl,-OR8a,-(CH2) eC (=O) R8a,-(CH2) eC (=O) OR8a, -(CH2)eC(=O)NR8aR8b, -NR8aR8b, -(CH2)eOR8a, -(CH2)eNR8aR8b, and -(CH2)eS(=O)fR11, or R'together with R4a and the atoms to which they are attached form a 5-to 8- membered heterocyclic ring moiety having the structure: [00215] wherein R2 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl,

aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> butoxycarbonylmethyl, rnethoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl, methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl, butoxycarbonylbutyl, methylcarbonylmethyl, ethylcarbonylmethyl, propylcarbonylmethyl, butylcarbonylmethyl, pentylcarbonylmethyl, hexylcarbonylmethyl, methylcarbonylethyl, ethylcarbonylethyl, <BR> <BR> <BR> <BR> propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl, hexylcarbonylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> methylcarbonylpropyl, ethylcarbnvlpropyl, propylcarbo ylpropyl, butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butylcarbonylbutyl, pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl, aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl,-, quinolinyl, thienyl, pyrrolyi, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00216] wherein R4a is selected from the group consisting of hydrido, hydroxyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, or Together with R'and the atoms to which they are attached form a 5-to 8-membered heterocyclic ring having the structure:

[00218] wherein R4 is selected from the group consisting of hydrido, hydroxyl, amino, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxycarbonylmethyl, ethoxycarbonylmethyl, propoxycarbonylmethyl, butoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylethyl, propoxycarbonylethyl, butoxycarbonylethyl, methoxycarbonylpropyl, <BR> <BR> <BR> <BR> ethoxycarbonylpropyl, propoxycarbonylpropyl, butoxycarbonylpropyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methoxycarbonylbutyl, ethoxycarbonylbutyl, propoxycarbonylbutyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> butoxycarbonylbutyl, methylcarbonylmethyl, ethylcarbonylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylcarbonylmethyl, butylcarbonylmethyl, pentylcarbonylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> hexylcarbonylmethyl, methylcarbonylethyl, ethylcarbonylethyl,. _<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylcarbonylethyl, butylcarbonylethyl, pentylcarbonylethyl, hexylcarbonylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methylcarbonylpropyl, ethylcarbonylpropyl, propylcarbonylpropyl, butylcarbonylpropyl, pentylcarbonylpropyl, hexylcarbonylpropyl, methylcarbonylbutyl, ethylcarbonylbutyl, propylcarbonylbutyl, butylcarbonylbutyl, pentylcarbonylbutyl, hexylcarbonylbutyl, aminocarbonylmethyl, aminocarbonylethyl, aminocarbonylpropyl, aminocarbonylbutyl, aminocarbonylpentyl, aminocarbonylhexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, methoxy, ethoxy, propoxy, butoxy, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, <BR> <BR> <BR> trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, phenyl, biphenyl,

naphthyl, indenyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, and wherein R4, when R'together with R4a and the atoms to which they are attached form a heterocyclic ring having 6 or more members, may form a double bond between the nitrogen to which R4 is attached and X; [00219] wherein R5 is selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroinnidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, and phenyl, biphenyl, naphthyl, indenyl, wherein R5 may be optionally substituted by one or more substituents selected from the group consisting of chloro, fluoro, bromo, iodo, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, cyano, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methylphenyl, ethylphenyl, propylphenyl, butylphenyl, pentylphenyl, hexylphenyl, methyinaphthyl, ethylnaphthyl, propyinaphthyl, butylnaphthyl, pentylnaphthyl, hexylnaphthyl, methylpiperidinyl, methylpyrrolidinyl, methylpyrazolidinyl, methylimidazolidinylmethyl, methylisoxazolidinyl, methyloxazolidinyl, <BR> <BR> <BR> <BR> ethylpiperidinyl, ethylpyrrolidinyl, ethylpyrazolidinyl, ethylimidazolidinyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> ethylisoxazolidinyl, ethyloxazolidinyl, propylpiperidinyl, propylpyrrolidinyl, propylpyrazolidinyl, propylimidazolidinyl, propylisoxazolidinyl, propyloxazolidinyl, <BR> <BR> <BR> <BR> methylisoindolyl, methyldihydroindolyl, methylisoindoline,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyidihydrothiophenyl, methyldihydropyrrolyl, methyldihydrofuryl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> methyldihydropyrazolyl, rnethyldihydroimidazolyl, methyldihydroisoxazolyl, methyldihydrooxazolyl, ethylisoindolyl, ethyldihydroindolyl, ethylisoindoline,

ethyidihydrothiophenyl, ethyldihydropyrrolyl, ethyldihydrofuryl, ethyidihydropyrazolyl, ethyldihydroimidazolyl, ethyldihydroisoxazolyl, ethyidihydrooxazolyl, propylisoindolyl, propyldihydroindolyl, propylisoindoline, propyldihydrothiophenyl, propyldihydropyrrolyl, propyldihydrofuryl, propyldihydropyrazolyl, propyidihydroimidazolyl, propyldihydroisoxazolyl, propyldihydrooxazolyl, methylpyridinyl, methylbenzothiophenyl, methylindolyl, methylisoquinolinyl, methylquinolinyl, methylthienyl, methylpyrrolyl, methylfuryl, methylpyrazolyl, imidazolylmethyl, methylisoxazolyl, methyloxazolyl, methylisoindoledionyl, ethylpyridinyl, ethylbenzothiophenyl, ethylindolyl, ethylisoquinolinyl, ethylquinolinyl, ethylthienyl, ethylpyrrolyl, ethylfuryl, ethylpyrazolyl, ethylimidazolyl, ethylisoxazolyl, ethyloxazolyl <BR> <BR> <BR> <BR> ethylisoindoledionyl, propylpyridinyl, propylbenzothiophenyl, propylindolyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylisoquinolinyl, propylquinolinyl, propylthienyl, propylpyrrolyl, propylfuryl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> propylpyrazolyl, propylimidazolyl, propylisoxazolyl, propyloxazolyl, propylisoindoledionyl, methyl, ethyl, propyl, butyl, pentyl, hexyl,-ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, nitro, methylcarbonylamino, ethylcarbonylamino, propylcarbonylamino, butylcarbonylamino, pentylcarbonylamino, hexylcarbonylamino, phenylcarbonylamino, benzylcarbonylamino, R'°,-OR",-C (=N) NR'2aR'2b,-NR'2a-N (=CR'3aR13b' - N OR'\- (CH2)aNR12aR12b,-(CH2)aS(=O)bR11,-(CH2)aCO2R11,-SO2NR12aR12b , - NR13aR13b,-NR12aC(=O)R13a,-NR12aC(=O)OR13a,-NR13aSO2R14a,-NR 13aSO2NR14aR14b, -NR13aC(=O)NR14aR14b,-C(=O)R13a,and-C(=O)NR12aR12b ; [00220] wherein Ruz is selected from the group consisting of hydrido, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl,

oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, <BR> <BR> <BR> <BR> aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyi, benzothiophenylethyl, indolymethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, benzyf, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl,

propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylarninohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethow. y, hydroxyethoxy, hydroxypropoxy, hydroxybu. toxyy phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl,-N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N-~ propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N-- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy, aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy, aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyidioxy, propyldioxy, butyldioxy, pentyldioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl,

ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl ; [00221] wherein R", R", R", R", R", R and R15 are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl,-isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, aminophenylcarbonyl, aminobenzylcarbonyl, nitro, azido, pyridinylmethyl,

pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, benzyl, and phenylethyl o. ieties are optLonally"_substituted with one or more subst, tuents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, <BR> <BR> <BR> <BR> aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl,

hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-dimethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- <BR> <BR> <BR> <BR> dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiQpropyl ; thiobutyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy,<BR> <BR> <BR> <BR> <BR> <BR> <BR> aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy, aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyldioxy, propyidioxy, butyldioxy, pentyldioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl,

isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl ; [00222] wherein Rlo is selected from the group consisting of cyanomethyl, cyanoethyl, cyanopropyl, cyanobutyl, cyanopentyl, cyanohexyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, phenyl, biphenyl, naphthyl, indenyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, prxridinyl. benzothiophenyi, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, ethenyl, propenyl, butenyl, and pentenyl, wherein R'° is optionally substituted with one or more substituents selected from the group consisting of R13a ; [00223] wherein R", R 12a, and R12b are independently selected from the group consisting of hydrido, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, <BR> <BR> <BR> <BR> furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl,<BR> <BR> <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, isoindoledionylethyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, aminomethyl, aminoethyl, aminopropyl,

aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl, ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylarninopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, N, N- dimethylaminomethyl, N, N-dimethylaminoethyl, N-methyl-N-ethylaminomethyl, N-methyl-N-ethylaminoethyl, N-methyl-N-propylaminomethyl, N-methyl-N- propylaminoethyl, N, N-diethylaminomethyl, N, N-diethylaminoethyl, N-ethyl-N- propylaminomethyl, N-ethyl-N-propylaminoethyl, N, N-dipropylaminomethyl, N, N- dipropylaminoethyl, methoxy, ethoxy, propoxy, butoxy, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl ; propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, benzyl, phenylethyl, benzylamino, and phenylethylamino, wherein said phenyl, biphenyl, naphthyl, indenyl is optionally substituted with one or more radicals selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methoxy, ethoxy, propoxy, butoxy and chloro, fluoro, bromo, iodo, wherein R"'and R'lb may be taken together to form a 3-to 7- membered carbocyclic ring having from 1 to 3 heteroatoms selected from S, SO, SO2, O, N, and NR'3a ; [00224] wherein R"a and R'3b are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl,

thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, benzyl, phenylethyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, amino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, aminomethylcarbonyl, aminoethylcarbonyl, aminopropylcarbonyl, aminobutylcarbonyl, aminopentylcarbonyl, aminohexylcarbonyl, <BR> <BR> <BR> <BR> aminophenylcarbonyJ, arninobeWnzylcarbony". nitroa azidon pyridinylmethyls<BR> <BR> <BR> <BR> <BR> <BR> <BR> pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, <BR> <BR> <BR> <BR> imidazolylethyl, isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl, isoindoledionylmethyl, and isoindoledionylethyl, wherein said methyl, ethyl, propyl, butyl, pentyl, hexyl, phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl,-isoxazolyl, oxazolyl, isoindolédionyl, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, and benzyl, phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methylsulfonamido, ethylsulfonamido, propylsulfonamido, butylsulfonamido, sulfamyl, methyl, ethyl, propyl, butyl, pentyl, hexyl, methylthio, ethylthio, propylthio, butylthio, methylsulfinyl, ethylsulfinyl, propylsulfinyl, butylsulfinyl, methylsulfonyl, ethylsulfonyl, propylsulfonyl, butylsulfonyl, N-methylamino, N-ethylamino, N-propylamino, aminomethyl, aminoethyl, aminopropyl, aminobutyl, aminopentyl, aminohexyl, methylaminomethyl, ethylaminomethyl, propylaminomethyl, methylaminoethyl,

ethylaminoethyl, propylaminoethyl, methylaminopropyl, ethylaminopropyl, propylaminopropyl, methylaminobutyl, ethylaminobutyl, propylaminobutyl, methylaminopentyl, ethylaminopentyl, propylaminopentyl, methylaminohexyl, ethylaminohexyl, propylaminohexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, methylcarbonyloxy, ethylcarbonyloxy, propylcarbonyloxy, butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, phenylcarbonyloxy, benzylcarbonyloxy, oxy, formyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, nitro, azido, benzyloxy, N, N-dimethylaminomethylcarbonyl, N, N- dimethylaminoethylcarbonyl, N, N-d imethylaminophenylcarbonyl, N-methyl-N- ethylaminomethylcarbonyl, N-methyl-N-ethylaminoethylcarbonyl, N-methyl-N- ethylaminophenylcarbonyl, N-methyl-N-propylaminomethylcarbonyl, N-methyl-N- propylaminoethylcarbonyl, N-methyl-N-propylaminophenylcarbonyl, N, N- diethylaminomethylcarbonyl, N, N-diethylaminoethylcarbonyl, N, N- diethylaminophenylcarbonyl, N-ethyl-N-propylaminomethylcarbonyl, N-ethyl-N- propylaminoethylcarbonyl, N-ethyl-N-propylaminophenylcarbonyl, N, N-- dipropylaminomethylcarbonyl, N, N-dipropylaminoethylcarbonyl, N, N- dipropylaminophenylcarbonyl, thiomethyl, thioethyl, thiopropyl, thiobutyl, thiopentyl, thiohexyl, aminomethylcarbonyloxy, aminoethylcarbonyloxy, aminopropylcarbonyloxy, aminobutylcarbonyloxy, aminopentylcarbonyloxy, aminohexylcarbonyloxy, aminophenylcarbonyloxy, aminobenzylcarbonyloxy, thiocyanato, isothiocyanato, methyldioxy, ethyldioxy, propyldioxy, butyldioxy, pentyldioxy, hexyldioxy, hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl, hydroxypentyl, hydroxyhexyl, N-methylamino, N-ethylamino, N- propylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl,

butoxycarbonyl, methoxymethyl, methoxyethyl, methoxypropyl, ethoxymethyl, ethoxyethyl, ethoxypropyl, propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl, butoxyethyl, butoxypropyl, ethenylamino, propenylamino, butenylamino, pentenylamino, ethynylamino, propynylamino, butynylamino, pentynylamino, ethenyl, propenyl, butenyl, pentenyl, ethynyl, propynyl, butynyl, pentynyl, N, N-dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylamEnoethoxy, piperidinyl, pyrrolic5inyl, p\J/r zolidinyl, imidazolidinyl isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, and pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl. pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl ; [00225] wherein R14a and R'4b are independently selected from the group consisting of hydrido, methyl, ethyl, propyl, butyl, pentyl, hexyl, pyridinyl, benzothiophenyl,; indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, benzylamino, phenylethylamino, pyridinylmethyl, pyridinylethyl, benzothiophenylmethyl, benzothiophenylethyl, indolylmethyl, indolylethyl, isoquinolinylmethyl, isoquinolinylethyl, quinolinylmethyl, quinolinylethyl, thienylmethyl, thienylethyl, pyrrolylmethyl, pyrrolylethyl, furylmethyl, furylethyl, <BR> <BR> <BR> pyrazolylmethyl, pyrazolylethyl, imidazolylmethyl, imidazolylethyl,<BR> <BR> <BR> <BR> <BR> <BR> <BR> isoxazolylmethyl, isoxazolylethyl, oxazolylmethyl, oxazolylethyl,

isoindoledionylmethyl, isoindoledionylethyl, phenyl, biphenyl, naphthyl, indenyl, benzyl, and phenylethyl, wherein said phenyl, biphenyl, naphthyl, indenyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, isoindoledionyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, benzyl, and phenylethyl moieties are optionally substituted with one or more substituents selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, hexyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, iodo, chloromethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyano, chlororn. Qtbpxy, dichloromethoxy, trichloromethoxy,- fluoromethoxy, difluoromethoxy, trifluoromethoxy, methylcarbonyl, ethylcarbonyl, propylcarbonyl, butylcarbonyl, pentylcarbonyl, hexylcarbonyl, phenylcarbonyl, benzylcarbonyl, carboxyl, hydroxy, hydroxymethoxy, hydroxyethoxy, hydroxypropoxy, hydroxybutoxy, phenoxy, benzyloxy, N, N- dimethylaminomethoxy, N, N-dimethylaminoethoxy, N-methyl-N- ethylaminomethoxy, N-methyl-N-ethylaminoethoxy, N-methyl-N- propylaminomethoxy, N-methyl-N-propylaminoethoxy, N, N- diethylaminomethoxy, N, N-diethylaminoethoxy, N-ethyl-N-propylaminomethoxy, N-ethyl-N-propylaminoethoxy, N, N-dipropylaminomethoxy, N, N- dipropylaminoethoxy, piperidinyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, isoxazolidinyl, oxazolidinyl, isoindolyl, dihydroindolyl, isoindoline, dihydrothiophenyl, dihydropyrrolyl, dihydrofuryl, dihydropyrazolyl, dihydroimidazolyl, dihydroisoxazolyl, dihydrooxazolyl, pyridinyl, benzothiophenyl, indolyl, isoquinolinyl, quinolinyl, thienyl, pyrrolyl, furyl, pyrazolyl, imidazolyl, isoxazolyl, oxazolyl, and isoindoledionyl, wherein R""and R'lb may be taken together to form a 3-to 7-membered carbocyclic ring having 1 to 3 heteroatoms selected from S, SO, SO,, 0, N, and NR'3a ; [00226] or a pharmaceutical-acceptable salt thereof.

[00227] In a preferred embodiment, the compound of Formula I is a compound of Formula IX :

[00229] wherein L', A, R, R', R2, R4, and R4a are as defined above for Formula VIII.

[00230] In a preferred embodiment, the compound of Formula I is a compound of Formula X:

[00232] wherein L1, A, R, R1, R2, and R4 are as defined-above for Formula 111.

[00233] In a preferred embodiment, the compound of Formula I is selected from the group of compounds consisting of the compounds shown in Table I below : Table I Example Name and Structure I 4- [ (aminocarbonyl) amino]-l- [4-bromo-3- (trifluoromethyl) phenyl]-l H-pyrazole-3- carboxamide NHa CF3 Oi N- Han-- HAN 2 4- ( { [ (aminocarbonyl) amino] carbonyl} amino)-1- [4-bromo-3- (trifluoromethyl) phenyl]-1 H- pyrazole-3-carboxamide NHz zip 9 NXBr HN O% N, H.. _ /NH2 3 4-[(aminocarbonyl) amino]-1-(4-bromo-3-ethoxyphenyl)-1 H-pyrazole-3-carboxamide CHUS Nu2 O pi N- 0 N-d-Br HN 'i'NH2 4 4-[(aminocarbonyl) amino]-1-(4-iodo-2-methylphenyi)-1 H-pyrazole-3-carboxamide NH2 0 N\ XN 4 0-"NH2 '. r'NH2 5 4- [ (aminocarbonyl) amino]-l- (3'-hydroxy-3-methyl-1, l'-biphenyl-4-yl)-l H-pyrazole-3- carboxamide _ OH HN HAN- han Example Name and Structure 6 4-[(aminocarbonyl) amino]-1-(3-chloro-4-iodophenyl)-1 H-pyrazole-3-carboxamide NHa CI pi N- HN O--NH, 7 4-[(aminocarbonyl) ami no]-1-(2-chloro-3'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NH2 C. OH zizi HN 0"NHz 8 4- [ (aminocarbonyl) amino]-l- (4-iodo-3-methylphenyl)-l H-pyrazole-3-carboxa mid e Nu2-.. pi N- han o- - NH2 o>NH2 9 4- [ (aminocarbonyl) amino]-1- [4- (morpholin-4-yl-carbonyl) phenyl]-1H-pyrazole-3- carboxamide NHz/"\ nu2 c 0 N- Han oW NH2 10 4-[(aminocarbonyl) amino]-1-(4-methoxyphenyl)-1 H-pyrazole-3-carboxamide trifluoroacetate NHs /cl3 /"° HN CF3 ' NH2 0 OH Example Name and Structure 4- [ (aminocarbonyl) aminol-l- [3- (3, 4-dimethoxybenzyl) phenyl]-lH-pyrazole-3- carboxamide O-CH3 NHZ 0 N\ CH3 HN HO % \NHZ 12 4-[(aminocarbonothioyl) amino]-1-(3-bromophenyl)-1 H-pyrazole-3-carboxamide NH Br pi\ iN N- HN S% \NHz 1"4- [ (amirtocarbonyt) amino]-1- [3- (2-chtoropyridin-4-y !) phenyij-1H-pyrazo) e-3- carboxamide cl N NHa NH2 HN 0)--NH2 14 4- [ (aminocarbonyl) amino]-1- (4-methoxyphenyl)-1 H-pyrazole-3-carboxamide trifluoroacetate CHg o \ N H2 Nu2 N \ HN ONHs 15 1-(3-bromophenyl)-4-{[(methylamino) carbonyl] amino}-1 H-pyrazole-3-carboxamide NH2 Br CH3 HN ol :--NH CH3 Example Name and Structure 16 : 1- (4-bromophenyl)-4- { [ (methylamino) carbonyl] amino}-1 H-pyrazole-3-carboxamide NHz N, HN HAN o-NH CH3 17 : 1-(4-iodophenyl)-4-{[(methylamino) carbonyl] amino}-1 H-pyrazole-3-carboxamide NHa 0 ZON HAN N HsCN \O I/ HAN 18 4- [ (aminocarbonyl) amino]-l- (4-methylphenyl)-l H-pyrazole-3-carboxamide N OH ? o-NH2 HN O-NHz 19 4-[(aminocarbonyl) amino]-1-(4-bromophenyl)-1 H-pyrazole-3-carboxamide NH2 N\ L No B r HN O-NHz 20 4-[(aminocarbonyl) amino]-1-(3-bromophenyl)-1 H-pyrazole-3-carboxamide NH2 Br HN o-NH2 NH2 21 4-[(aminocarbonyl) amino]-1-(4-pyridin-3-ylphenyl)-1 H-pyrazole-3-carboxamide NH2 psi.-- un H N N Example Name and Structure 22 4- [ (aminocarbonyl) amino]-1- (3'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NH2 OH pi'N- HO NHz 23 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NU2 HO N un o'i'NH2 24. 4- [ (aminocarbonyl) amin, o]-1- (3.'- (trifluoromethcxy)-1 , 1'-bip !-ny !-4-yl]-1H-pyrazole-3- carboxamide NHz oX HAN zozo p'i'NH2 F3C 25 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NH2 Han H N nif HN 'i'NH 26 4- [ (aminocarbonyl) amino]-1- [G.- (1H-pyrrol-2-yl) phenyl]-1H-pyrazole-3-carboxamide oX NHs 0 N N NHZ 27 4- [ (aminocarbonyl) amino]-1- 3'- (cyanomethyl)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3- carboxamide NH2 -- HN 0-'NH, NC Example Name and Structure 28 4- [ (aminocarbonyl) amino]-I- [3'- (aminomethyl)-1, 1'-biphenyl-4-yl]-l H-pyrazole-3- carboxamide NH2 N HN o'NHz H2N 29 methyl 2-amino-4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'- biphenyl-4-carboxylate NU2 HAN 0 0 HN O-CH3 o-NH2 o'i'N H2 30 4-- [ (arn ! nocarbony !) amino]-1- (-2' ? f ! uoro-'t, .'-bipheny !-4-y !)-1 H-pyrar'e-3-carboxam'ds NHz HN/' F NH2 31 4-[(aminocarbo nyl) amino]-1-{3'-[(tert-butylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide NH2 Han (. N HAN °9/t NH H3C CFi3 32 4-[(aminocarbonyi) amino]-1-{3'-[(E)-2-cyanovinyl]-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3- carboxamide CN NH2 ON-- HN ONHz Example Name and Structure 33 4-[(aminocarbonyl) anlino]-1-{4'-[(pyridin-2-ylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide NH2 Q N HN 0 0-NH, 34 4- [ (aminocarbonyl) amino]-1- [4'- (morpholin-4-ylmethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxan ide NHz XN +\ HZN HN .--Di NS, 2-- 35 4-[(aminocarbonyl) arnino]-1-{4'-[(benzylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide NH2 Q X XHNS d'NHz 36 4- [ (aminocarbonyl) am i no]-1- (4'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NH2 Og N/ ONHz oJ NH2 % \NN2 37 4- [ (aminocarbonyl) amino]-1- [4'- (cyanomethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- carboxamide NHz ON-- CON HN 0"NH2 Example Name and Structure 38 4- [ (aminocarbonyl) amino]-1- [4'- (hydroxymethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- carboxamide NHz 0 ONH, o-NH2 39 4- [ (aminocarbonyl) amino]-l- [3'- (hydroxymethyl)-1, 1'-biphenyl-4-yl]-l H-pyrazole-3- carboxamide NH2 ole N O-'NHzH0 40 4-[(aminocarbonyl) amino]-1-(. 4-tddjn-4-ylpheny !)-1 H-pyrazoie-3-carkoxamide-->.--, NHz HN O-NHz 41 4- [ (aminocarbonyl) amino]-l- (3'-fluoro-1, I'-biphenyl-3-yi)-l H-pyrazole-3-carboxamide NHZ HN HAN 'NHz 42 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3-carboxamide NH2 0 F ZON zon o==\ f) ; NU2 - \NHa 43 4-[(aminocarbonyl) amino]-1-(3-thien-3-ylphenyl)-1 H-pyrazole-3-carboxamide NHz 0 N su han : N P H2 Example Name and Structure 44 4- [ (aminocarbonyl) amino]-1- [4'- (cyanomethyl)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3- carboxamide NHs 0 N i'I CN HAN N - \NH I/ 45 4- [ (aminocarbonyl) amino]-1- (3-pyridin-4-ylphenyl)-1 H-pyrazole-3-carboxamide NH 0 N C N \ \I N NHZ I/ 46 4- [ (aminocarbonyl) amino]-1- (3-pyridin-4-ylphenyl)-1 H-pyrazole-3-carboxamide NHz N -N han NU2 NH2 I/ 47 4- [ (aminocarbonyt) amino]-1- (4'-hydroxy-1, 1'-biphenyt-3-yt)-1H-pyrazote-3- carboxamide NHs zu OH ZON HO O I NHz i/ 48 4- [ (aminocarbonyl) amino]-1- [4'- (hydroxymethyl)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3- carboxamide NHz 0 - N OH H N N O NU2 49 4- [ (aminocarbonyl) amino]-1- [3'- (hydroxymethyi)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3- carboxamide NH2 OH 0 _nazi HN ou - \NH2 Example Name and Structure 50 1-(3'-amino-1, 1'-biph enyl-3-yl)-4-[(aminocarbonyl) amino]-1 H-pyrazole-3-carboxamide NHz 0 NHz HAN nu2 zu '\NH2 51 4- [ (aminocarbonyl) arnino]-1- [4'- (morpholin-4-ylmethyl)-1, 1'-biphenyl-3-yl]-1 H- pyrazole-3-carboxamide NH2 0 N/I N i Nu2 \ u O NHZ I/ 52 4- [ (aminocarbonyl) a mino]-1- [4'- (aminomethyl)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3- carboxamide NHz nu2. O N NH2 HN \ NU2 NHz I/ 53 1-(4'-acetyl-1, 1'-biph enyl-3-yl)-4-[(aminocarbonyl) amino]-1 H-pyrazole-3-carboxamide NH O nu2 0 N CH, Ho O NH2 NHz 54 1-(4'-amino-1, 1'-biphenyl-3-yl)-4-[(aminocarbonyl) amino3-1 H-pyrazole-3-carboxamide NHz 0 NU2 HN k I zon Nu2 O 55 1- [4'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- [ (aminocarbonyl) amino]-1 H-pyrazole-3- carboxamide NN2 O\/CH3 0 NH ZON han 0 N NH2 Example Name and Structure 56 4- [ (aminocarbonyl) amino]-1- (3', 4'-dimethoxy-1, 1'-biphenyl-3-yi)-1H-pyrazole-3- carboxamide NHs 0 N OIICH3 HN O NH2 57 4- [ (aminocarbonyi) amino]-l- [3- (l H-pyrazol-4-yl) phenyl]-l H-pyrazole-3-carboxamide NHz 0 T HN I NH N NU2 NH2 58 3'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-4- carboxylic acid_ Nu2 O N I OH HN N NU2 NH 59 4-[(aminocarbonyl) amino]-1-{4'-[(methylsulfonyl) amino]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide NHz 0 H 0 \ N _N/N\SO Han 0/i \ Nu2 NH2 60 4-[(aminocarbonyl) amino]-1-(3-quinolin-5-ylphenyl)-1 H-pyrazole-3-carboxamide NU2 N han NH2 Nhl I _ 61 4- [ (aminocarbonyl) amino]-I- [4'- (dimethylamino)-1, 1'-biphenyl-3-yll-lH-pyrazole-3- carboxamide NU2 zu l : N CH3 han Ou \NHa Example Name and Structure 62 4- [ (aminocarbonyl) amino]-1- [3- (1, 3-benzodioxol-5-yl) phenyl]-1 H-pyrazole-3- carboxamide NHz O Ho nu2 O. NHz ' 63 4- [ (aminocarbonyl) amino]-l- [3- (2-methylpyridin-4-yl) phenyl]-l H-pyrazole-3- carboxamide NH2 O CH3 - N N N NH2 NH 64. 4- [ (aminocarbonyl) amino]-1- 3- (4-methy !-3, 4-dihy. dro-2H-1, 4-benzoxazin-7 ylJphenyl]- 1 H-pyrazoie-3-carboxarnide NH2 0 O HAN N \ O NH2 65 4- [ (aminocarbonyl) amino]-l- [3- (l H-indol-5-yl) phenyl]-l H-pyrazole-3-carboxamide NH2 NU NU han \ 0 NH2 66 4-[(aminocarbonyl) amino]-1- (3-pyrimid in-5-ylphenyl)-1 H-pyrazole-3-carboxamide NHZ 0 _N N HN ON nu2 1 NHz \ 67 4-[(aminocarbonyi) amino]-1-{3-[(E)-2-phenylvinyl] phenyl}-1 H-pyrazole-3-carboxamide NHz 0 N HN Zou O NHZ Example Name and Structure 68 4- [ (aminocarbonyl) amino]-l- [3- (l H-pyrrol-2-yl) phenyl]-l H-pyrazole-3-carboxamide NH 0 N HN - \NHz I/ 69 4- [ (aminocarbonyl) aminol-I- [3- (3-methylpyridin-4-yl) phenyl]-l H-pyrazole-3- carboxamide NH2 0 N ZON N H3C N NEZ HO nu2 70 4- [ (aminocarbonyl) amino]-I- [3- (3, 5-dimethylisoxazol-4-yl) phenyl]-lH-pyrazole-3- carboxamide NHz' 0 HIC ZON HAN N NH2 CH3 71 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3- carboxamide NH2 0 : N Han N ZOU NH2 OH 72 4- [ (aminocarbonyl) amino]-1- (3'-hydroxy-1, 1'-biphenyl-3-yl)-1H-pyrazole-3- carboxamide NHz 0 N 1 HN \ N I OH Uw O - \NHz (/ 73 3'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-3- carboxylic acid NU2 0 OH 0 _nazi 0 !" ! NU2 NH Example Name and Structure 74 4-[(aminocarbonyl) amino]-1-{4'-[(methylamino) carbonyl]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide NHA O N N ICH3 UCN- _N/I, N nu2 O' NHz 75 4- [ (aminocarbonyl) amino]-1- {4'- [ (propylamino) carbonyl]-1, 1'-biphenyi-3-yl}-1H- pyrazole-3-carboxamide NHZ O CH3 N N H HN N NH2 I/ 76 1- [3'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- [ (aminocarbonyl) amino]-1 H-pyrazole-3- carboxam, de-~--~ ~ O NHa NU2 H /N CH3 1 NHz-N HN-- b-0 77 4-[(aminocarbonyl) amino]-1-(3'-amino-4'-methyl-1, 1'-biphenyl-3-yl)-1 H-pyrazo, e-3- carboxamide NH2 NHz N CH3 HAN _nazi \ NH2 I/_ Q 78 4- [ (aminocarbonyl) amino]-1- [3'- (aminomethyl)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide NHz N H2 0 nazi han N NHZ'/ 79 4- [ (aminocarbonyl) amino]-1- [3'- (aminocarbonyl)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide NHa O NH2 0 ZON H2 H2 o-inca NH2 Example Name and Structure 80 4-[(aminocarbonyl) amino]-1-{4'-[(cyciopropylamino) carbonyl]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide NH OUZO han '_ \ N \ \ O NHz I/ 81 4-[(aminocarbonyl) amino]-1-{3'-[(cyclopropylamino) carbonyl]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide H NHz : N HN x N nu2 o NH 82 4-[(aminócarbonyl) amino]-~-(3'-{[(2-cyahoethyl) amino] carbony !}-1, 1'--bipi^, er, yl-3-yl) > 1 H-pyrazole-3-carboxamide H NH2 O N NU2 - N I CN ZON nu2 0 83 4-[(aminocarbonyl) amino]-1-{3'-[(methylamino) carbonyl]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide H NH2 O N O C 3 han nu2 O NH2 84 4-[(aminocarbonyl) amino]-1-(4'-{[(2-cyanoethyl) amino] carbonyl}-1, 1'-biphenyl-3-yl)- 1 H-pyrazole-3-carboxamide NH N NU 0=< N N N NH2 CN \ N NHz' CN Example Name and Structure 85 N-[(3'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-4- yl) carbonyl] glycine NHz o==/o N NH ho oh lof NH2 O 86 4- [ (aminocarbonyl) amino]-1- [2'- (benzyloxy)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide nu2 NHz N\ 0 HAN han 87 4-[(aminocarbonyl) amino]-1-[2'-(hydroxymethyl)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide NH2 0 N H N O H2 HO 88 4-[(aminocarbonyl) amino]-1-(2'-methoxy-1, 1'-biphenyl-3-yl)-1 H-pyrazoie-3- carboxamide NHz 0 Zon H N \ NH2 CH3 89 4-[(aminocarbonyl) amino]-1-(4'-hydroxy-2'-methyl-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3- carboxamide NH 0 ou - N H N 0 N oNHZ I/CH3 Example Name and Structure 90 4-[(aminocarbonyl) amino]-1-{4'-[(4-oxopiperidin-1-yl) carbonyl]-1, 1'-biphenyl-3-yl}-1 H- pyrazole-3-carboxamide NH HAN N No'. : N O NHa 91 1- (2'-acetyl-1, 1'-biphenyl-3-yl)-4- [ (aminocarbonyl) amino]-1 H-pyrazole-3-carboxamide NHz 0 nazi han 0 NH2 0 CH3 2''okcHs 92 4-[(aminocarbonyl) amino]-1-(4'-fl uoro-2'-hydroxy-1, 1'-biphenyl-3-y,)-1 H-pyrazole-3- carboxamide NHz 0 F _nazi han N OH 93 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-hydroxy-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3- carboxamide NHz O H N N \ O NHZ OH NHz O 94 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-5'-fluoro-1, 1'-biphenyl-3-yl]-1 H- pyrazole-3-carboxamide NHZ. O _N NHz f 2 F CON ce Example Name and Structure 95 1- [4'- (aminocarbonyl)-1, 1'-biphenyl-4-yl]-4- { [ (methylamino) carbonyl] amino}-1 H- pyrazole-3-carboxamide HsC nu HN NH2 ni2 ''NH2 96 4'- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino]-1H-pyrazol-1-yl}-1, 1'-biphenyl-3- carboxylic acid 0 NH2 OH oJ~ NH2 HN NHz 97 4'-{3-(aminocarbonyl)-4-[(ami nocarbonyl) amino]-1 H-pyrazol-1-yl}-3-fluoro-1, 1'- biphenyl-4-carboxylic acid NH2 N Ho \ oh F i NH 98 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-2'-hydroxy-1, 1'-biphenyl-4-yl)-1H-pyrazole-3- carboxamide NH2 HA N F HN w O-NHz 99 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NU2 HO F HO F o-NH2 100 4- [ (aminocarbonyl) amino]-1- (4'-cyano-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NH2 p N\-- 'N\ NN i'NH Example Name and Structure 101 4-[(aminocarbonyl) amino]-1-(1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NHz pi'N N.-- HN '/'NH2 102 4- [ (aminocarbonyl) amino]-l- (3'-methyl-1, 1'-biphenyl-4-yl)-l H-pyrazole-3-carboxamide H2NX/= H3 HN -- ol-NH2 p NH 104 4-[(aminocarbonyl) amino]-1-(3'-cyano-1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide CN H XC \/\/ un pNH2 105 4-[(aminocarbonyl) amino]-1-[2'-(hydroxymethyl)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3- carboxamide OH 0 HN HNSN X 0S NH2 106 4-[(aminocarbonyl) amino]-1-(2'-methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide . c O O HZN \-- 0S NH2 107 4-[(aminocarbonyl) amino]-1-(3'-methoxy-1, 1'-biphenyi-4-yl)-1 H-pyrazole-3- carboxamide O X S= O-CH, HAN o-NH2 pNH Example Name and Structure 108 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-2'-methyl-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide H3C han I_'N \ j \/F HN O'NHz 109 4-[(aminocarbonyl) amino]-1-(4'-fluoro-3'-methyl-1,-i'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide O CH3 H2N oS~ NH2 HER O-NHz 1 10 4-[(aminocarbonyl) amino] 9'-chloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-cark. ox3mide b ci Han = N"N H2NX X o'i'NH2 111 4- [ (aminocarbonyl) amino]-1- (3'-chloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ce H2N H N rN' oSNH2 112 4-[(aminocarbonyl) amino]-1-(2', 3'-difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide XN/N F o) ~NH2 N 113 4- [ (aminocarbonyl) amino]-l- (2', 4'-difluoro-1, 1'-biphenyl-4-yl)-l H-pyrazole-3- carboxamide 0 F o F o) ~NH2 p'i'NH2 pNH : Example Name and Structure 114 4- [ (aminocarbonyl) amino]-l- (3', 4'-difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide 0 F H2N H F HNX F o~NH2 115 4-[(aminocarbonyl) amino]-1-(3', 5'-difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide O F Ho nu F o~NH2 116-4-[(aminocarbonyi) amino]-1-(3'-iso propyl-1, 1'-bipheny !-)-1 H-pyrazole-3- carboxam ! de H3C 0 H3 CH3 han HN o-NH2 118 4- [ (aminocarbonyl) amino]-l- [3'- (methylthio)-1, 1'-biphenyl-4-yi]-lH-pyrazole-3- carboxamide 0 S-CH3 H Nr 0-NH, 119 4- [ (aminocarbonyl) amino]-1- [4'- (methylthio)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3- carboxamide o S CH HO p'i NH 120 4-[(aminocarbonyl) amino]-1-(2'-fluoro-3'-methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ? O-CH3 H2N -- han Example Name and Structure 121 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-methOxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide 0 ICH3 0 ! t un F p'i'NH2 122 4- [ (aminocarbonyl) amino]-I- (3'-fluoro-4'-methoxy-1, 1'-biphenyl-4-yi)-IH-pyrazole-3- carboxamide O F H2N CH, HAN p'i'NHa 12 4-[(aminocerbonyl) amino]-1-t zn-ã+nthyl) pinenyi]-1 H-pyrazole-3-carboxamide o H2N N oll,-NH2 125 4-[(aminocarbonyl) amino]-1-(3'-chloro-4'-fluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ce H2N HAN O--NHz 129 4- [ (aminocarbonyl) amino]-l- (5'-chloro-2'-methoxy-1, I'-biphenyl-4-yl)-l H-pyrazole-3- carboxamide 0/CH3 O O N nix Han Nu-" CI N2N'O Example Name and Structure 130 4- [ (aminocarbonyl) amino]-1- [3'- (1H-pyrazol-1-yl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- carboxamide 0 N-N j N tA HO p'i'NH 131 4- [ (aminocarbonyl) amino]-I- [3'- (trifluoromethyl)-1, 1'-biphenyl-4-yl]-IH-pyrazole-3- carboxamide 0 CF3 H2N \^-- N/ f %''NH_ 132 4- [ (aminocarbonyl) amino]-1- [4'- (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- carboxamide o H2N HNJ+N X CF3 H ONH, 133 4-[(aminocarbonyl) amino]-1-(2', 3'-dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide 0 ci ci HZN \^-- HN) 4 pNH2 __ 134 4-[(aminocarbonyl) amino]-1-(2', 4'-dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide j ? a ci - H un pNH2 Example Name and Structure 135 4- [ (aminocarbonyl) amino]-1- (2', 5'-dichloro-1, 1'-biphenyl-4-yl)-1H-pyrazole-3- carboxamide ci HZN \ ^-- N HN CI o>NH2 139 4-[(aminocarbonyl) amino]-1-(1, 1': 3', 1"-terphenyl-4-yl)-1H-pyrazole-3-carboxamide 0 - HNRN"N HN \N 0"NH2 . [. (aminocarbonyl) amino]-l- [4- (lH=itTdol-2-yl) pheny"-IH-oyrZOIP-3-ca,-boxa., ri'ide H2N"r0 i-N, \ NH 142 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) a mino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-4- carboxylic acid NH HN OH HAN han 143 4-[(aminocarbonyl) amino]-1-{4'-[(diethyl a mino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide CH3 N CH3 0, N N Han HN oWNH2 Example Name and Structure 144 ethyl4'- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino]-1H-pyrazol-1-yl}-1, 1'-biphenyl- 3-carboxylate Fui NH2 0 9zNX HN 'i'NH2 145 4-[(aminocarbonyl) amino]-1-{4'-[(methylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide NH2 H3C\ han 0 han 0 HN \ f NHZ . 146 4-[(aminocarbonyl) amino]-1-{4'-[(propylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide HsC NH2 Oa'N <NH HAN p'i'NH 147 ethyl 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl- 4-carboxylate HIC NHZ 2 0 piN--O O HN CH3 Neo 148 4-[(aminocarbonyl) amino]-1-{3'-[(isopropylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- pyrazole-3-carboxamide H2NHtO HN 0 5ho 0 H3c O H3C Example Name and Structure 149 4- [ (aminocarbonyl) amino]-I- [4'- (aminocarbonyl)-I, I'-biphenyl-4-yl]-l H-pyrazole-3- carboxamide Ho HN w IN H2N NHZ 0 150 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(4-methoxybenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamid e H3C H2NsgO b HN N HN N \/\/HN 151 4-[(aminocarbonyl) amino]-1-{4'-[(benzyla rnino) carizonyl]-3'-fluoro-1, 1'-biphenyl-4-yl}- 1 H-pyrazole-3-carboxamide NH2 0 ZON N NU2 NH I/NH F nu 152 4-[(aminocarbonyi) amino]-1-{3'-fluoro-4'-[(methylamino) carbonyl]-1, 1'-biphenyl-4-yl}- 1 H-pyrazole-3-carboxamide NH Hz of -U- Han H, nô HZN'\O 153 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(3-methoxybenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NH2 0 ZON HAN ou - \NHa I/ F ra"CH3 NH 0 Example Name and Structure 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(2-methoxybenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NH2 F O-CH3 F3 X O 0-NH, 155 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(4-fluorobenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yi)-l H-pyrazole-3-carboxamide NHz 0 ZON N \ /F N F NH2 I/NH F 0 156 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(3-fluorobenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamid e NHZ 0 - N F H N N rY NU F 0 157 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{l (2-fluorobenzyl) amino] carbonyl}-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NH2 0 -- N han O 0 : N Fo NH NU Example Name and Structure 158 4- [ (aminocarbonyl) amino]-1- (3'-fluoro-4'- { [ (4-fluorobenzyl) (methyl) amino] carbonyl}- 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NHz 0 un Han OU Cl3 NEZ F 0 F O 159 4- [ (aminocarbonyl) a mino]-1-f3'-fl uoro-4'- [ (1, 2, 3, 4-tetrahydronaphthalen-1- ylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide NHz 0 ZON NON N N NH N H 160 4-[(aminocarbonyl) amino]-1-(4'-{[[2-(d imethylamino) ethyl] (methyl) amino] carbonyl}-3'- fluor-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide NHz 0 ZON N H3C, N, CH3 NH2 F , cl3 I/Nw C O 161 4- [ (aminoca rbonyl) am i no]-1- [5'-fluoro-2'- (2-morp holin-4-yl-2-oxoethoxy)-1, I'-biphenyl- 4-yl]-1 H-pyrazole-3-carboxamide 0 N NC- H2N go 2 0 un W NHZ F NH2 Example Name and Structure 162 2-fluorobenzyl-4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-3- fluoro-1, 1'-biphenyl-4-carboxylate H2Nto r F Han p O NHa F 163 3-fluorobenzyl-4'-{3-(aminocarbonyl)-4-[(aminoca rbonyl) amino]-1 H-pyrazol-1-yl}-3- fluoro-1, 1'-biphenyl-4-carboxylate F H2NyO tF Y HN NHz 164 4-fluorobenzyl-4'-{3-(aminocarbonyl)-4-[(aminoca rbonyl) amino]-1 H-pyrazol-1-yl}-3- fluoro-1, 1'-biphenyl-4-carboxylate F HaN\/O I HN p O NHz F 165 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-3- y) methyl acetate H2NorO HAN N" H2N N O O FCH3 CH, 0 Example Name and Structure 166 4- [ (aminocarbonyl) amino]-l- [3'- (cyanomethoxy)-1, 1'-biphenyl-4-yl]-l H-pyrazole-3- carboxamide NHz OX NH2 CN N HAN zozo \ CN 167 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3- carboxamide NC NUA 2 0 HN o-NH . oS~ N H2 168 4- [ (aminocarbonyl) amino]-l- [3'- (pyridin-2-ylmethoxy)-I, I'-biphenyl-4-yl]-lH-pyrazole- 3-carboxamide NHZ NH HN S X o) ~NH2 ( NO 169 4- [ (aminocarbonyl) amino]-l- [3'- (l-cyanoethoxy)-1, 1'-biphenyl-4-yl]-lH-pyrazole-3- carboxamide NH pN N-- HN zozo CN CN Example Name and Structure 170 4-[(aminocarbonyl) amino]-1h [3'-(pyridin-3-ylmethOxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole- 3-carboxamide NHz p% N, N- N\ NON ho O N- 171 4- [ (aminocarbonyl) amino]-1- [3'- (pyridin-4-ylmethoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole- 3-carboxamide NHz O Nv . oS~ NH2 ( i 0 Q zon - N 172 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-5'-fluoro-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide NC NHz O 2 O HN F NH2 173 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-4'-fluoro-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide NC NU HAN p N\- HN O-NHz Example Name and Structure 174 tert-butyl- [ (4'- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino]-l H-pyrazol-1-yll-1, 1'- biphenyl-3-yl) oxy] acetate NH2 Han-- ( HN zozo 'nu2 H3 po H3C+O CH3 175 4- [ (aminocarbony !) amino]-1- [3'- (2-amino-2-oxoethoxy)-1, 1'-biphenyi-4-y)]-1 H- pyrazole-3-carboxamide NH2 0 N Han NHs N H 2 , tNH2 NH 0 176 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide NH2 CN HN I o==\ Y i O NH7 3 177 4- [ (aminocarbonyl) amino]-1- [4'- (cyanomethoxy)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3- carboxamide NH2 LCN HN o'NH2 178 4- [ (aminocarbonyl) amino]-1- [3'- (cyanomethoxy)-1, 1'-biphenyl-3-yl]-1 H-pyrazole-3- carboxamide NH2 0- : 1N, HN o-N H2 CN Example Name and Structure 179 4- [ (aminocarbonyl) amino]-I- [3'- (cyanomethoxy)-3-fluoro-1, 1'-biphenyl-4-yl]-l H- pyrazole-3-carboxamide 0 H2N-'N zon han- zozo pi _NH CN 180 4-[(aminocarbonyl) amino]-1-[2'-(1-cyanoethoxy)-5'-fluoro-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide 0 HN N HN- O - NHz,",-CH3 NC NC 181 4-[(aminocarbonyl) amino]-1-{3'-[2-(dimethylamino)-2-oxoethoxy]-1, 1'-biphenyl-4-yl}- 1 H-pyrazole-3-carboxamide ACHS H3C-N H2N 0 1=0 /0 Han /NHz 0 O 182 tert-butyl-[(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-5-fluoro- 1, 1'-biphenyl-2-yl) oxy] acetate //0 HN o/-3C "r 0 0 HN CH3 O F 183 4- [ (aminocarbonyl) amino]-1- [4'- (aminocarbonyl)-3'-fluoro-1, 1'-biphenyl-4-yl]-1H- pyrazole-3-carboxamide H2Ny 0 N I N 0 F O Example Name and Structure 184 methyl 4-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl} benzoate H2N sto han 0 Han i N H2N N O-CH3 0 185 methyl 3-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl} benzoate NHz 9 N= N \ HO zozo NH2 H3CO 186 4- [ (aminocarbonyl) amino]-1- [3'- (2-cyanoethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- carboxamide H2NstO HAN N H2N ; 6 < CN 0 187 4- [ (aminocarbonyl) amino]-l- [4'- (l H-tetrazol-5-yi)-1, 1'-biphenyl-4-yl]-l H-pyrazole-3- carboxamide H2N'r0 \I) \N 6 < (/Nl aN H, N o NAIN 11 O 188 4- [ (aminocarbonyl) amino]-1- (3, 4-dichlorophenyl)-1 H-pyrazole-3-carboxamide Nu2 cl - N CI O9g\NA ''NH2 189 1- (3-carbamoyl-1- (4- (cyclohexylthio) phenyl)-1 H-pyrazo 1-4-yl) urea NH2 zain Han HN HO Example Name and Structure 190 1-(1-(4-(2-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 F HN H. nô 191 1-(3-carbamoyl-1-(4-(cyclohexylsu If inyl) phenyl)-1 H-pyrazol-4-yl) urea NHz H2N ° HN 0 H. NO 192 1- (3-carbamoyl-1- (4- (cyclohexylsulfonyl) phenyl)-1 H-pyrazol-4-yl) urea NHz N N\ 0 ,, NH2 H2N'O 193 1- (1- (4- (2-fluorophenylsulfinyl) phenyl)-3-carbarnoyl-1 H-pyrazol-4-yl) urea NH F N\--P- HO HN H2N'O 194 1-(1-(4-(2-fluorophenylsulfonyl) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 N ° NON HN 0 195 1- (3-carbamoyl-1- (3-iodophenyl)-1 H-pyrazol-4-yl) urea NH HN H, Nô HN NZN'\O Example Name and Structure 196 1- (1- (4- (4-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazoi-4-yl) urea NHz N \ l S HAN H2N'O F 197 1- (l- (4- (3-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHz HN -, , N \/S w H F HZN 198 1- (1- (3- (2-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 0 N Fjq han HN \ N S HZN 199 1- (1- (4- (4-hydroxyphenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHZ OH Ho OH OH OH 200 1- (1- (4- (4-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHa O N/O , N \ S F Ho H2N 0 F 201 1-(1-(4-(3-fluorophenylsulfinyr l) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHs f o o o N \ l s' un F H2N' Example Name and Structure 202 1- (1- (3- (2-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 O HN-. F 0 Ho 0 203 1- (1- (4- (3-fiuorophenylsulfonyl) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 F 0 11 Un O H, nô 204 1- (1- (4- (4-fluorophenylsulfonyl) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NH2 0 HN O HN 0 H2N ° 205 : 1- (3-carbamoyl-1- (4- (pyridin-2-ylthio) phenyl)-1 H-pyrazol-4-yl) urea NH2 N w HN H2N ° 206 1- (3-carbamoyl-1- (4- (pyridin-4-ylthio) phenyl)-l H-pyrazol-4-yl) urea Han /v - HN i NHa 207 1- (3-carbamoyl-1- (4- (cyclopentylthio) phenyl)-1 H-pyrazol-4-yl) urea H2NYO p Han N \/S O N NHz Example Name and Structure 208 1- (I- (4- (2-hydroxyphenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea H2NNro i f N- (\/)-S OH O N NHa 209 4-[(Aminocarbonyl) amino]-1-(3-chloro-4-methoxyphenyl)-1 H-pyrazole-3-carboxamide NH2 cI N 0 HN ONHz 'i'NH2 210 1- (1- (4- (2-fluorophenylthio)-2-fluorophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHz p H2N ° ou N \/I HN HNO 211 1- (1- (4- (2-fluorophenylthio)-2-fluorophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea NHz NHz H2N b H2Nr \p 212 4-[(aminocarbonyi) amino]-1-(4-fluorophenyl)-1 H-pyrazoie-3-carboxamide NHz un HN H. NO 213 4-[(aminocarbonyl) amino]-1-(1, 3-benzodioxol-5-yl)-1 H-pyrazole-3-carboxamide NHz O- N Han \ zozo HN'\o Example Name and Structure 214 4-[(aminocarbonyl) amino]-1-(4-chlorophenyl)-1 H-pyrazole-3-ca rboxamide NH2 HAN HN H N/bO 215 4- [ (aminocarbonyl) amino]-1- (4-iodophenyl)-1 H-pyrazole-3-carboxamide H2N o I NHz i N N I NH2 216 4- (aminocarbonyl) amino]-1-(4-isopropylphenyl)-1 H-pyrazole-3-carboxamide H2N'f0 ho N 0 ;) : \N CH3 NHz 217 4-[(aminocarbonyl) amino]-1-(1 H-indol-5-yl)-1 H-pyrazole-3-carboxamide H, N o HN N' N NHz H 218 4- [ (aminocarbonyl) amino]-I- (3, 4-difluorophenyl)-l H-pyrazole-3-carboxamide o HN N NHZ F 219 4- [ (aminocarbonyl) amino]-1- (2-naphthyl)-1 H-pyrazole-3-carboxamide H2NNfo Han oWN , NH NHz Example Name and Structure 220 4-[(aminocarbonyl) amino]-1-[2-chloro-3'-(cyanomethOxy)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide CN H2N /O fizz Han NHz NH2 221 4-[(aminocarbonyl) amino]-1-{3-chloro-4-[(4-fluorophenyl) thio] phenyl}-1 H-pyrazole-3- carboxamide F '/'\-/ CI HN /N S N NHz 223 4-[(aminocarbonyl) amino]-1-(2-chloro-2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide H, N o CI HN H2N""r0 ci j Cl NH2 224 4-[(aminocarbonyl) amino]-1-[2-chloro-2'-(cyanomethoxy)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide Cl un NN NC 225 4- [ (aminocarbonyl) amino]-1- (4-bromo-3-fluorophenyl)-1 H-pyrazole-3-carboxamide H2N gO F '/ Han \N \ Br N NHz Example Name and Structure 226 4-[(aminocarbonyl) amino]-1-(2-fluoro-3'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide H2N"r0 F OH HN t OH NH 227 4- [ (aminocarbonyl) amino]-l- [3'- (cyanomethoxy)-2-fluoro-1, 1'-biphenyl-4-yl]-l H- pyrazole-3-carboxamide CN H2N *"r0 r F o HO NHz..- NH2- 229 4- [ (aminocarbonyl) amino]-1- {4- [ (4-fluorophenyl) sulfonyl]-2-methylphe nyl}-1 H- pyrazole-3-carboxamide NHa 0 N\ , N \ SOa HO HAN F 230 4-[(aminocarbonyl) amino]-1-(2-ethoxy-3'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NH2 0 /c3 HN \ N/O HZN O I OH zur 0'OH 231 4- [ (aminocarbonyl) amino]-l- [3'- (cyanomethoxy)-2-ethoxy-1, 1'-biphenyl-4-yl]-l H- pyrazole-3-carboxamide NH2 0 /cl3 HN X 9 \ C 0 0 Example Name and Structure 232 4-[(aminocarbonyl) amino]-1-(2-ethoxy-2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide CHg 2 0 Nul% N HN PO p'i'NH 233 4- [ (aminocarbonyl) amino]-1- [3'-hydroxy-2- (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide NHZ H HN w HN r H2iv 234 4-[(aminocarbonyl) amino]-1-[2'-hydroxy-2-(trifluoromethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide NH2 CF3 L Ho HO HO HAN 235 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-3-methyl-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide NHZ H3C L HO HN HO HZN'\O 236 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-2-ethoxy-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide NH2 2 0 0 0 o-NH2 \-CN Example Name and Structure 237 4- [ (aminocarbonyl) amino]-1- [3'- (cyanomethoxy)-2- (trifluoromethyl)-1, 1'-biphenyl-4-yl]- 1 H-pyrazole-3-carboxamide NH2 0 - N H2N HN N CF3 CN 40 0 1 238 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-2-(trifluoromethyl)-1, 1'-b iphenyl-4-yl]- 1 H-pyrazole-3-carboxamide NHZ CF3 ON - un H-O') NC 239 1- (3'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3-carboxylic acid amide H2N orSo /CHg OH NHz nu2 NH 240 1- (2'-Hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3-carboxylic acid amide H2N My0 N HA i\ NH2 241 1- (4'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3-carboxylic acid amide HaN /O Y CH3 Han NHZ HO Example Name and Structure 242 1- (5'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3-ca rboxyiic acid amide H, N o c3 F Han i\ Nu2 ho 243 1- (3'-Cyanomethoxy-2-methyl-biphenyi-4-yi)-4-ureido-I H-pyrazole-3-carboxylic acid amide \/NHZ GN NHz HAN N N NH CH3 244 1-(2'-CyanornethOxy-4'-fluoro-2-methyl-biphenyl-4-yl)-4-ucei do.-1H pyrazoif-3- carboxylic acid amide J' CH, HO . N \ \/F NHZ NC Nec 245 1- (4-lodo-3-methyl-phenyl)-4- (3-methyl-ureido)-1H-pyrazole-3-carboxylicacid amide NH2 °9\NX HN HN/ . H2N ° 246 1- (5-chloro-2-fluoro-phenyl)-4-ureido-1 H-pyrazole-3-carboxylic acid amide rR Cl 0 N\ HN HAN HZN 247 4-[(aminocarbonyl) amino]-1-(3-fluoro-3'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide V NoNv F oh F OU HAN p NHZ Example Name and Structure 248 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-3, 3'-d if luoro-1, 1'- biphenyl-4-carboxylic acid °9t NH2 F F HN N °$ OH NHz 249 4- [ (aminocarbonyl) amino]-1- (3-fluoro-2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide HN o F HO Han \/ NN NHz 250 4-[Caminocarbonyl) aminol-1-[2'-(cyarJomaetha. xy)-3-fluoro-1, 1'-biphenyl-4-yl3-1H- pyrazole-3-carboxamide NC H, N o) HzN\/O NHz HAN NN NHZ 251 4-[(aminocarbonyl) amino]-1-(2-chloro-4-iodophenyl)-1 H-pyrazole-3-carboxamide °q, NH2 'CL Han iN O N NHz 252 4-[(aminocarbonyl) amino]-1-[2'-(2-amino-2-oxoethoxy)-5'-fluoro-1, 1'-bi phenyl-4-yl]- 1 H-pyrazole-3-carboxamide NH2 0 H2N 0 0 Han Zu NH Example Name and Structure 253 4- [ (aminocarbonyl) amino]-1- [3'- (2-oxopropoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3- carboxamide Hic zozo O H2N O H3Ct off un nu2 Q NH 254 4- [ (aminocarbonyl) amino]-I- [3'- (1, 3-oxazol-2-ylmethoxy)-1, 1'-biphenyl-4-yl]-l H- pyrazole-3-carboxamide 0 O N r O O HN NHz 255 4- [ (aminocarbonyl) amino]-l- [5'-fluoro-2'- (1, 3-oxazol-2-ylmethoxy)-I, I'-biphenyl-4-yl]- 1 H-pyrazole-3-carboxamide N Non /0 HAN 0 NHz 256 4- [ (aminocarbonyl) amino]-l- {5'-fluoro-2'- [2- (methylamino)-2-oxoethoxy]-1, 1'-biphenyl- 4-yl}-1 H-pyrazole-3-carboxamide HIC NH H 0 un Nu2 NHz NH2 F

Example Name and Structure 257 4- [ (aminocarbonyl) amino]-1- {5'-fluoro-2'- [2- (ethylamino)-2-oxoethoxy]-1, 1'-biphenyl-4- yl}-1 H-pyrazole-3-carboxamide (CH3 NH H2NstO % 'r 0 Han NH 258 [(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-3- yl) oxy] acetic acid HO 0 H2No ( 0 Han NHz 259 [(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-5-fl uoro-1, 1'- biphenyl-2-yl) oxy] acetic acid OH H2N \g0 % 'r 0 Han Nu2 F NH 260 4- [ (aminocarbonyl) amino]-l- [4- (4, 4, 5, 5-tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl]- 1 H-pyrazole-3-carboxamide H2N 0 CH3 HN CH3 N o CH3 Cl3 t CHg NHz [00234] In a particularly preferred embodiment, the compound of Formula I is selected from the group of compounds consisting of: [00235] 4- [ (aminocarbonyl) amino]-1- [4-bromo-3- (trifluoromethyl) phenyl]-1 H-pyrazole-3-carboxamide ;

[00236] 4-[(aminocarbonyl) amino]-1-(4-bromo-3-ethoxyphenyl)-1 H- pyrazole-3-carboxamide ; [00237] 4-[(aminocarbonyl)amino]-1-(4-iodo-2-methylphenyl)-1H- pyrazole-3-carboxamide ; [00238] 4-[(aminocarbonyl) amino]-1-(3'-hydroxy-3-methyl-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00239] 4-[(aminocarbonyl) amino]-1-(3-chloro-4-iodophenyl)-1 H- pyrazole-3-carboxamide ; [00240] 4-[(aminocarbonyl) amino]-1-(2-chloro-3'-hydroxy-1, 1'-biphen yl- 4-yl)-1 H-pyrazole-3-carboxamide ; [Q0241] 4-[(aminocarbonyl)amino]-1-(4-iodo-3-methylphenyl)-1H- pyrazole-3-carboxamide ; [00242] 4- [ (aminocarbonyl) amino]-l- [4- (morpholin-4-yl- carbonyl) phenyl]-1 H-pyrazole-3-carboxamide ; [00243] 4-[(aminocarbonyl)amino]-1-(4-methoxyphenyl)-1H-pyrazole-3- carboxamide trifluoroacetate ; [00244] 4-[(aminocarbonyl)amino]-1-[3-(3,4-dimethoxybenzyl)phenyl]- 1 H-pyrazole-3-carboxamide ; [00245] 4-[(aminocarbonothioyl) amino]-1-(3-bromophenyl)-1 H-pyrazo le- 3-carboxamide; [00246] 4- [ (aminocarbonyl) amino]-1- [3- (2-chloropyridin-4-yl) phenyl]-1 H- pyrazole-3-carboxamide ; [00247] 4-[(aminocarbonyl) amino]-1-(4-methoxyphenyl)-1 H-pyrazole-3- carboxamide trifluoroacetate ; [00248] 1-(3-bromophenyl)-4-{[(methylamino)carbonyl]amino}-1 H- pyrazole-3-carboxamide ; [00249] 1-(4-bromophenyl)-4-{[(methylamino)carbonyl]amino}-1 H- pyrazole-3-carboxamide ;

[00250] 1-(4-iodophenyl)-4-{[(methylamino) carbonyl] amino}-1 H- pyrazole-3-carboxamide ; [00251] 4-[(aminocarbonyl)amino]-1-(4-methylphenyl)-1H-pyrazole-3- carboxamide; [00252] 4-[(aminocarbonyl)amino]-1-(4-bromophenyl)-1H-pyrazole-3- carboxamide; [00253] 4-[(aminocarbonyl) amino]-1-(3-bromophenyl)-1 H-pyrazole-3- carboxamide; [00254] 4- [ (aminocarbonyl) amino]-1- (4-pyridin-3-ylphenyl)-1 H-pyrazole- 3-carboxamide; [00255] 4-[(aminocarbonyl)amino]-1-(3'-hydroxy-1,1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00256] 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00257] 4- [ (aminocarbonyl) amino]-I- [3'- (trifluoromethoxy)-1, 1'-biphenyl- 4-yl]-1 H-pyrazole-3-carboxamide ; [00258] 4-[(aminocarbonyl) amino]-1-(4'-fluoro-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00259] 4-[(aminocarbonyl)amino]-1-[4-(1H-pyrrol-2-yl)phenyl]-1H- pyrazole-3-carboxamide ; [00260] 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethyl)-1,1'-biphenyl-4 - yl]-1 H-pyrazole-3-carboxamide ; [00261] 4- [ (aminocarbonyl) amino]-I- [3'- (aminomethyl)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide ; [00262] methyl 2-amino-4'- {3- (aminocarbonyl)-4- [(aminocarbonyl)amino]-1H-pyrazol-1-yl}-1,1'-biphenyl-4-carb oxylate ; [00263] 4-[(aminocarbonyl)amino]-1-[2'-fluoro-1,1'-biphenyl-4-yl)-1H - pyrazole-3-carboxamide ;

[00264] 4- [ (aminocarbonyl) amino]-1- 3'- [ (tert-butylamino) carbonyl]-1, 1'- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00265] 4- [ (aminocarbonyl) amino]-l- {3'- [ (E)-2-cyanovinyl]-1, 1'-biphenyl- 4-yl}-1 H-pyrazole-3-carboxamide ; [00266] 4-[(aminocarbonyl) amino]-1-{4'-[(pyridin-2-ylamino) carbonyl]- 1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00267] 4-[(aminocarbonyl)amino]-1-[4'-(morpholin-4-ylmethyl)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00268] 4-[(aminocarbonyl)amino]-1-{4'-[benzylamino)carbonyl]-1, 1'- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00269] 4-[(aminocarbonyl)amino]-1-(4'-hydroxy-1,1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00270] 4-[(aminocarbonyl)amino]-1-[4'-(cyanomethyl)-1,1'-biphenyl-4 - yl]-1H-pyrazole-3-carboxamide ; [00271] 4-[(aminocarbonyl)amino]-1-[4'-(hydroxymethyl)-1,1'-biphenyl -4- yl]-1H-pyrazole-3-carboxamide ; [00272] 4- [ (aminocarbonyl) amino]-l- [3'- (hydroxymethyl)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide ; [00273] 4- [ (aminocarbonyl) amino]-l- (4-pyridin-4-ylphenyl)-lH-pyrazole- 3-carboxamide; [00274] 4- [ (aminocarbonyl) amino]-1- (3'-fluoro-1, 1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ; [00275] 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-1, 1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ; [00276] 4-[(aminocarbonyl)amino]-1-(3-thien-3-ylphenyl)-1H-pyrazole- 3- carboxamide; [00277] 4-[(aminocarbonyl)amino]-1-[4'-(cyanomethyl)-1,1'-biphenyl-3 - yl]-1H-pyrazole-3-carboxamide ;

[00278] 4-[(aminocarbonyl) amino]-1-(3-pyridin-4-ylphenyl)-1 H-pyrazole- 3-carboxamide; [00279] 4-[(aminocarbonyl) amino]-1-(3-pyridin-4-ylphenyl)-1 H-pyrazole- 3-carboxamide; [00280] 4-[(aminocarbonyl) amino]-1-(4'-hydroxy-1, 1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ; [00281] 4- [ (aminocarbonyl) amino]-1- [4'- (hydroxymethyl)-1, 1'-biphenyl-3- yl]-1 H-pyrazole-3-carboxamide ; [00282] 4- [ (aminocarbonyl) amino]-l- [3'- (hydroxymethyl)-1, 1'-biphenyl-3- yl]-1 H-pyrazole-3-carboxamide ; [00283] 1-(3'-amino-1,1'-biphenyl-3-yl)-4-[(aminocarbonyl)amino]-1H- pyrazole-3-carboxamide ; [00284] 4-[(aminocarbonyl)amino]-1-[4'-(morpholin-4-ylmethyl)-1, 1'- biphenyl-3-yl]-1 H-pyrazole-3-carboxamide ; [00285] 4- [ (aminocarbonyl) amino]-1- [4'- (aminomethyl)-1, 1'-biphenyl-3- yl]-1 H-pyrazole-3-carboxamide ; [00286] 1-(4'-acetyl-1,1'-biphenyl-3-yl)-4-[(aminocarbonyl)amino]-1H - pyrazole-3-carboxamide ; [00287] 1-(4'-amino-1,1'-biphenyl-3-yl)-4-[(aminocarbonyl)amino]-1H- pyrazole-3-carboxamide ; [00288] 1- [4'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- [(aminocarbonyl) amino]-1 H-pyrazole-3-carboxamide ; [00289] 4-[(aminocarbonyl)amino]-1-(3', 4'-dimethoxy-1, 1'-biphenyl-3-yl)- 1 H-pyrazole-3-carboxamide ; [00290] 4-[(aminocarbonyl)amino]-1-[3-(1H-pyrazol-4-yl)phenyl]-1H- pyrazole-3-carboxamide ; [00291] 3'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1- yl}-1, 1'-biphenyl-4-carboxylic acid;

[00292] 4-[(aminocarbonyl)amino]-1-{4'-[(methylsulfonyl) amino] -1,1'- biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00293] 4- [ (aminocarbonyl) amino]-1- (3-quinolin-5-ylphenyl)-1 H- pyrazole-3-carboxamide ; [00294] 4-[(aminocarbonyl)amino]-1-[4'-(dimethylamino)-1,1'-biphenyl -3- yl]-1 H-pyrazole-3-carboxamide ; [00295] 4- [ (aminocarbonyl) amino]-I- [3- (1, 3-benzodioxol-5-yi) phenyl]- 1 H-pyrazole-3-carboxamide ; [00296] 4-[(aminocarbonyl)amino]-1-[3-(2-methylpyridin-4-yl)phenyl]- 1H- pyrazole-3-carboxamide ; [00297] 4-[(aminocarbonyl)amino]-1-[3-(4-methyl-3,4-dihydro 2H-1,4- benzoxazin-7-yl) phenyl]-1 H-pyrazole-3-carboxamide ; [00298] 4- [ (aminocarbonyl) amino]-1- [3- (1 H-indol-5-yl) phenyl]-1 H- pyrazole-3-carboxamide ; [00299] 4-[(aminocarbonyl)amino]-1-(3-pyrimidin-5-ylphenyl)-1H- pyrazole-3-carboxamide ; [00300] 4-[(aminocarbonyl) amino]-1-{3-[(E)-2-phenylvinyl] phenyl}-1 H- pyrazole-3-carboxamide ; [00301] 4- [ (aminocarbonyl) amino]-1- [3- ( H-pyrrol-2-yl) phenyl]-1 H- pyrazole-3-carboxamide ; [00302] 4- [ (aminocarbonyl) aminc]-1- [3- (3-methylpyridin-4-yl) phenyl]-1 H- pyrazole-3-carboxamide ; [00303] 4- [ (aminocarbonyl) amino]-1- [3- (3, 5-dimethylisoxazol-4- yl) phenyl]-1 H-pyrazole-3-carboxamide ; [00304] 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ; [00305] 4-[(aminocarbonyl)amino]-1-(3'-hydroxy-1,1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ;

[00306] 3'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1- yl}-1, 1'-biphenyl-3-carboxylic acid; [00307] 4-[(aminocarbonyl)amino]-1-{4'-[(methylamino)carbonyl]-1, 1'- biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00308] 4-[(aminocarbonyl)amino]-1-{4'-[(propylamino)carbonyl]-1, 1'- biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00309] 1- [3'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- [(aminocarbonyl) amino]-1 H-pyrazole-3-carboxamide ; [00310] 4-[(aminocarbonyl) amino]-1-(3'-amino-4'-methyl-1, 1'-biphenyl-3- yl)-1 H-pyrazole-3-carboxamide ; [00311] 4-[(aminocarbonyl)amino]-1-[3'-(aminomethyl)-1,1'-biphenyl-3 - yl]-1 H-pyrazole-3-carboxamide ; [00312] 4- [ (aminocarbonyl) amino]-1- [3'- (aminocarbonyl)-1, 1'-biphenyl- 3-yl]-1 H-pyrazole-3-carboxamide ; [00313] 4-[(aminocarbonyl)amino]-1-{4'-[(cyclopropylamino)carbonyl]- 1, 1'-biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00314] 4-[(aminocarbonyl) amino]-1-{3'-[(cyclopropylamino) carbonyl]- 1, 1'-biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00315] 4-[(aminocarbonyl)amino]-1-(3'-{[(2- cyanoethyl) amino] carbonyl}-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3-carboxamide ; [00316] 4-[(aminocarbonyl)amino]-1-{3'-[(methylamino)carbonyl]-1, 1'- biphenyl-3-yl}-1 H-pyrazole-3-carboxamide ; [00317] 4- [ (aminocarbonyl) amino]-1- (4'- { [ (2- cyanoethyl) amino] carbonyl}-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3-carboxamide ; [00318] N-[(3'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1 H- pyrazol-1-yl}-1, 1'-biphenyl-4-yl) carbonyl] glycine ; [00319] 4-[(aminocarbonyl) amino]-1-[2'-(benzyloxy)-1, 1'-biphenyl-3-yl]- 1 H-pyrazole-3-carboxamide ;

[00320] 4-[(aminocarbonyl)amino]-1-[2'-(hydroxymethyl)-1,1'-biphenyl -3- yl]-1 H-pyrazole-3-carboxamide ; [00321] 4-[(aminocarbonyl)amino]-1-[2'-methoxy-1,1'-biphenyl-3-yl)-1 H- pyrazole-3-carboxamide ; [00322] 4- [ (aminocarbonyl) amino]-l- (4'-hydroxy-2'-methyl-1, 1'-biphenyl- 3-yl)-1 H-pyrazole-3-carboxamide ; [00323] 4-[(aminocarbonyl)amino]-1-{4'-[(4-oxopiperidin-1-yl)carbony l]- 1, 1'-biphenyl-3-yl}-1H-pyrazole-3-carboxamide ; [00324] 1-(2'-acetyl-1, 1'-biphenyl-3-yl)-4-[(aminocarbonyl) amino]-1 H- pyrazole-3-carboxamide ; [00325] 4-[(aminocarbonyl)amino]-1-(4'fluoro-2'-hydroxy-1,1-biphenyl - 3-yl)-1 H-pyrazole-3-carboxamide ; [00326] 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-hydroxy-1, 1'-biphenyl- 3-yl)-1 H-pyrazole-3-carboxamide ; [00327] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-5'-fluoro-1, 1'- biphenyl-3-yl]-1 H-pyrazole-3-carboxamide ; [00328] 1- [4'- (aminocarbonyl)-1, 1'-biphenyl-4-yl]-4- {[(methylamino)carbonyl]amino}-1H-pyrazole-3-carboxamide ; [00329] 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1- yl}-1, 1'-biphenyl-3-carboxylic acid; [00330] 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1- yl}-3-fluoro-1, 1'-biphenyl-4-carboxylic acid; [00331] 4- [ (aminocarbonyl) amino]-l- (4'-fluoro-2'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00332] 4- [ (aminocarbonyl) amino]-1- (5'-fluoro-2'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00333] 4- [ (aminocarbonyl) amino]-1- (4'-cyano-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ;

[00334] 4- [ (aminocarbonyl) amino]-1- (1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide; [00335] 4-[(aminocarbonyl) amino]-1-(3'-methyl-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00336] 4- [ (aminocarbonyl) amino]-1- (3'-cyano-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00337] 4- [ (aminocarbonyl) amino]-I- [2'- (hydroxymethyl)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide ; [00338] 4-[(aminocarbonyl)amino]-1-(2'-methoxy-1,1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00339] 4-[(aminocarbonyl)amino]-1-(3'-methoxy-1,1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00340] 4-[(aminocarbonyl) amino]-1-(4'-fluoro-2'-methyl-1, 1'-biphenyl-4- yl)-1 H-pyrazole-3-carboxamide ; [00341] 4-[(aminocarbonyl) amino]-1-(4'-fluoro-3'-methyl-1, 1'-biphenyl-4- yl)-1 H-pyrazole-3-carboxamide ; [00342] 4-[(aminocarbonyl)amino]-1-(2'-chloro-1,1'-biphenyl-4-yl)-1H - pyrazole-3-carboxamide ; [00343] 4- [ (aminocarbonyl) amino]-1- (3'-chloro-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00344] 4-[(aminocarbonyl)amino]-1-(2',3'-difluoro-1,1'-biphenyl-4-y l)- 1 H-pyrazole-3-carboxamide ; [00345] 4-[(aminocarbonyl) amino]-1-(2', 4'-difluoro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamide ; [00346] 4- [ (aminocarbonyl) amino]-l- (3', 4'-difluoro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamide ; [00347] 4- [ (aminocarbonyl) amino]-l- (3', 5'-difluoro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamide ;

[00348] 4- [ (aminocarbonyl) amino]-1- [3'- (methylthio)-1, 1'-biphenyl-4-yl]- 1 H-pyrazole-3-carboxamide ; [00349] 4-[(aminocarbonyl)amino]-1-[4'-(methylthio)-1,1'-biphenyl-4- yl]- 1 H-pyrazole-3-carboxamide ; [00350] 4-[(aminocarbonyl) amino]-1-(2'-fluoro-3'-methoxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00351] 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-methoxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00352] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-methoxy-1,1'-biphen yl- 4-yl)-1H-pyrazole-3-carboxamide ; [00353] 4-[(aminocarbonyl)amino]-1-[4-(1-naphthyl)phenyl]-1H- pyrazole-3-carboxamidel [00354] 4-[(aminocarbonyl)amino]-1-(3'-chloro-4'-fluoro-1,1'-bipheny l-4- yl)-1 H-pyrazole-3-carboxamidel [00355] 4-[(aminocarbonyl)amino]-1-(5'-chloro-2'-methoxy-1,1'-biphen yl- 4-yl)-1 H-pyrazole-3-carboxamidel [00356] 4-[(aminocarbonyl)amino]-1-[3'-(1H-pyrazol-1-yl)-1,1'-biphen yl- 4-yl]-1 H-pyrazole-3-carboxamidel [00357] 4-[(aminocarbonyl)amino]-1-[3'-(trifluoromethyl)-1,1'-biphen yl-4- yl]-1 H-pyrazole-3-carboxamide; [00358] 4-[(aminocarbonyl) amino]-1-(2', 3'-dichloro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamidel [00359] 4-[(aminocarbonyl) amino]-1-(2', 4'-dichloro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamidel [00360] 4-[(aminocarbonyl) amino]-1-(2', 5'-dichloro-1, 1'-biphenyl-4-yl)- 1 H-pyrazole-3-carboxamide; [00361] 4-[(aminocarbonyl)amino]-1-(1,1': 3', 1"-terphenyl-4-yl)-1H- pyrazole-3-carboxamidei

[00362] 4-[(aminocarbonyl)amino]-1-[4-(1H-indol-2-yl)phenyl]-1 H- pyrazole-3-carboxamide ; [00363] 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1- yl}-1, 1'-biphenyl-4-carboxylic acid; [00364] 4-[(aminocarbonyl)amino]-1-{4'-[(diethylamino)carbonyl]-1, 1'- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00365] ethyl 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H- pyrazol-1-yl}-1, 1'-biphenyl-3-carboxylate ; [00366] 4-[(aminocarbonyl)amino]-1-{4'-[(methylamino)carbonyl]-1, 1'- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00367] 4-[(aminocarbonyl)amino]-1-{4'-[(propylamino)carbonyl]-1,1 biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00368] ethyl 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H- pyrazol-1-yl}-1, 1'-biphenyl-4-carboxylate ; [00369] 4-[(aminocarbonyl)amino]-1-{3'-[(isopropylamino)carbonyl]-1, 1'- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00370] 4- [ (aminocarbonyl) amino]-l- [4'- (aminocarbonyl)-1, 1'-biphenyl- 4-yl]-1 H-pyrazole-3-carboxamide ; [00371] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(4- methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ; [00372] 4-[(aminocarbonyl)amino]-1-{4'-[(benzylamino)carbonyl]-3'- fluor-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00373] 4- [ (aminocarbonyt) amino]-1- {3'-ftuoro-4'- [(methylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00374] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(3- methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ; [00375] 4- [ (aminocarbonyl) amino]-1- (3'-fluoro-4'- { [ (2- methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ;

[00376] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(4- fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ; [00377] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(3- fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide ; [00378] 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(2- fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide ; [00379] 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(4- fluorobenzyl) (methyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide; [00380] 4-[(aminocarbonyl)amino]-1-{3'-fluoro-4'-[(1, 2,3, 4- tetrahydronaphthalen-1-ylamino)carbonyl]-1,1'-biphenyl-4-yl} -1H-pyrazole-3- carboxamide; [00381] 4-[(aminocarbonyl)amino]-1-(4'-{[[2- (dimethylamino) ethyl] (methyl) amino] carbonyl}-3'-fluoro-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide ; [00382] 4-[(aminocarbonyl)amino]-1-[5'-fluoro-2'-(2-morpholin-4-yl-2 - oxoethoxy) -1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide ; [00383] 4-fluorobenzyl 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino] - 1 H-pyrazol-1-yl}-3-fluoro-1, 1'-biphenyl-4-carboxylate ; [00384] 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol-1- yl}-1, 1'-biphenyl-3-yl) methyl acetate; [00385] 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethoxy)-1,1'-biphenyl- 4- yl]-1 H-pyrazole-3-carboxamide ; [00386] 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide ; [00387] 4-[(aminocarbonyl)amino]-1-[3'-(pyridin-2-ylmethoxy)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00388] 4- [ (aminocarbonyl) amino]-l- [3'- (l-cyanoethoxy)-1, 1'-biphenyl- 4-yl]-1 H-pyrazole-3-carboxamide ;

[00389] 4- [ (aminocarbonyl) amino]-I- [3'- (pyridin-3-ylmethoxy)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00390] 4- [ (aminocarbonyl) amino]-l- [3'- (pyridin-4-ylmethoxy)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00391] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-5'-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00392] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-4'-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00393] tert-butyl [(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H- pyrazol-1-yl}-1, 1'-biphenyl-3-yl) oxy] acetate; [00394] 4-[(aminocarbonyl)amino]-1-[3'-(2-amino-2-oxoethoxy)-1,1'- biphenyl-4-yl]-1H-pyrazole-3-carboxamide ; [00395] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-1,1'-biphenyl- 3- yl]-1 H-pyrazole-3-carboxamide ; [00396] 4- [ (aminocarbonyl) amino]-1- [4'- (cyanomethoxy)-1, 1'-biphenyl-3- yl]-1 H-pyrazole-3-carboxamide ; [00397] 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethoxy)-1,1'-biphenyl- 3- yl]-1H-pyrazole-3-carboxamide ; [00398] 4- [ (aminocarbonyl) amino]-1- [3'- (cyanomethoxy)-3-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00399] 4-[(aminocarbonyl)amino]-1-[2'-(1-cyanoethoxy)-5'-fluoro-1,1 '- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00400] 4- [ (aminocarbonyl) amino]-l- {3'- [2- (dimethylamino)-2- oxoethoxy] -1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00401] 4-[(aminocarbonyl)amino]-1-[4'-(aminocarbonyl)-3'-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00402] methyl 4- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino]-lH- pyrazol-1-yl} benzoate;

[00403] methyl 3-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H- pyrazol-1-yl} benzoate; [00404] 4- [ (aminocarbonyl) amino]-l- [3'- (2-cyanoethyl)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide ; [00405] 4- [ (aminocarbonyl) amino]-1- [4'- ( H-tetrazol-5-yl)-1, 1'-biphenyl- 4-yl]-1 H-pyrazole-3-carboxamide ; [00406] 4-[(aminocarbonyl) amino]-1-(3, 4-dich lorophenyl)-1 H-pyrazole- 3-carboxamide; [00407] 1- (3-carbamoyl-1- (4- (cyclohexylthio) phenyl)-1 H-pyrazol-4- yl) urea; [00408] 1-(1-(4-(2-fluorophenylthio)phenyl)-3-carbamoyl-1H-pyrazol-4 - yl) urea; [00409] 1- (3-carbamoyl-1- (4- (cyclohexylsulfinyl) phenyl)-1 H-pyrazol-4- yl) urea; [00410] 1- (3-carbamoyl-1- (4- (cyclohexylsulfonyl) phenyl)-1 H-pyrazol-4- yl) urea; [00411] 1- (1- (4- (2-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1H-pyrazol- 4-yl) urea; [00412] 1- (1- (4- (2-fluorophenylsulfonyl) phenyl)-3-carbamoyl-1 H- pyrazol-4-yl) urea; [00413] 1- (3-carbamoyl-1- (3-iodophenyl)-1 H-pyrazol-4-yl) urea; [00414] 1- (1- (4- (4-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4- yl) urea; [00415] 1- (1- (4- (3-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4- yl) urea; [00416] 1- (1- (3- (2-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4- yl) urea; [00417] 1- (1- (4- (4-hydroxyphenylthio) phenyl)-3-carbamoyl-1 H-pyrazol- 4-yl) urea;

[00418] 1- (1- (4- (4-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1 H-pyrazol- 4-yl) urea; [00419] 1- (1- (4- (3-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1 H-pyrazol- 4-yl) urea; [00420] 1- (1- (3- (2-fluorophenylsulfinyl) phenyl)-3-carbamoyl-1 H-pyrazol- 4-yl) urea; [00421] 1-(1-(4-(3-fluorophenylsulfonyl) phenyl)-3-carbamoyl-1 H- pyrazol-4-yl) urea; [00422] 1- (1- (4- (4-fluorophenylsulfonyl) phenyl)-3-carbamoyl-1 H- pyrazol-4-yl) urea; [00423] 1-(3-carbamoyl-1-(4-(pyridin-2-ylthio)phenyl)-1H-pyrazol-4- yl) urea; [00424] 1- (3-carbamoyl-1- (4- (pyridin-4-ylthio) phenyl)-1 H-pyrazol-4- yl) urea; [00425] 1- (3-carbamoyl-1- (4- (cyclopentylthio) phenyl)-1 H-pyrazol-4- yl) urea; [00426] 1- (1- (4- (2-hydroxyphenylthio) phenyl)-3-carbamoyl-1H-pyrazol- 4-yl) urea; [00427] 4- [ (Aminocarbony ) amino]-1- (3-chloro-4-methoxyphenyl)-1H- pyrazole-3-carboxamide ; [00428] 1- (l- (4- (2-fluorophenylthio)-2-fluorophenyl)-3-carbamoyl-1 H- pyrazol-4-yl) urea; [00429] 4-[(aminocarbonyl) amino]-1-(4-fluorophenyl)-1 H-pyrazole-3- carboxamide; [00430] 4-[(aminocarbonyl) amino]-1-(1, 3-benzodioxol-5-yl)-1 H- pyrazole-3-carboxamide ; [00431] 4- [ (aminocarbonyf) amino]-1- (4-chforophenyt)-1H-pyrazote-3- carboxamide;

[00432] 4-[(aminocarbonyl)amino]-1-(4-iodophenyl)-1H-pyrazole-3- carboxamide; [00433] 4-[(aminocarbonyl)amino]-1-(4-isopropylphenyl)-1H-pyrazole-3 - carboxamide; [00434] 4-[(aminocarbonyl) amino]-1-(1 H-indol-5-yl)-1 H-pyrazole-3- carboxamide; [00435] 4-[(aminocarbonyl) amino]-1-(3, 4-difluorophenyl)-1 H-pyrazole-3- carboxamide; [00436] 4-[(aminocarbonyl) amino]-1-(2-naphthyl)-1 H-pyrazole-3- carboxamide; ; [00437] 4-[(aminocarbonyl)amino]-1-[2-chloro-3'-(cyanomethoxy)-1,1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00438] 4- [ (aminocarbonyl) amino]-1- 3-chloro-4- [ (4- fluorophenyl) thio] phenyl}-1 H-pyrazole-3-carboxamide ; [00439] 4-[(aminocarbonyl) amino]-1-(2-chloro-2'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00440] 4-[(aminocarbonyl)amino]-1-[2-chloro-2'-(cyanomethoxy)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00441] 4-[(aminocarbonyl)amino]-1-(4-bromo-3-fluorophenyl)-1H- pyrazole-3-carboxamide ; [00442] 4-[(aminocarbonyl) amino]-1-(2-fluoro-3'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00443] 4- [ (aminocarbonyl) amino]-l- [3'- (cyanomethoxy)-2-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00444] 4-[(aminocarbonyl)amino]-1-{4-[(4-fluorophenyl)sulfonyl]-2- methylphenyl}-1H-pyrazole-3-carboxamide ; [00445] 4-[(aminocarbonyl) amino]-1-(2-ethoxy-3'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ;

[00446] 4- [ (aminocarbonyl) amino]-l- [3'- (cyanomethoxy)-2-ethoxy-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00447] 4-[(aminocarbonyl)amino]-1-[3'-hydroxy-2-(trifluoromethyl)-1 ,1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00448] 4-[(aminocarbonyl) amino]-1-[2'-hydroxy-2-(trifluoromethyl)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00449] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-2-ethoxy-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00450] 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethoxy)-2 (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide ; -. [00451] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-2- (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00452] 1- (3'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3- carboxylic acid amide; [00453] 1-(2'-Hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H-pyrazole-3- carboxylic acid amide ; [00454] 1- (4'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide; [00455] 1- (5'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide; [00456] 1- (3'-Cyanomethoxy-2-methyl-biphenyl-4-yl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide; [00457] 1- (2'-Cyanomethoxy-4'-fluoro-2-methyl-biphenyl-4-yl)-4-ureido- 1 H-pyrazole-3-carboxylic acid amide; [00458] 1- (4-lodo-3-methyl-phenyl)-4- (3-methyl-ureido)-1 H-pyrazole-3- carboxylic acid amide; [00459] 1- loro-2-fluoro-phenyl)-4-ureido-1 H-pyrazole-3-carboxylic acid amide;

[00460] 4- [ (aminocarbonyl) amino]-l- (3-fluoro-3'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00461] 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1- yl}-3, 3'-difluoro-1, 1'-biphenyl-4-carboxylic acid; [00462] 4-[(aminocarbonyl) amino]-1-(3-fluoro-2'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide ; [00463] 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)-3-fluoro-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00464] 4-[(aminocarbonyl) amino]-1-(2-chloro-4-iodophenyl)-1 H- pyrazole-3-carboxamide ; [00465] 4-[(aminocarbonyl)amino]-1-[2'-(2-amino-2-oxoethoxy)-5'-fluo ro- 1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide ; [00466] 4-[(aminocarbonyl)amino]-1-[3'-(2-oxopropoxy)-1,1'-biphenyl- 4- yl]-1 H-pyrazole-3-carboxamide ; [00467] 4-[(aminocarbonyl)amino]-1-[3'-(1,3-oxazol-2-ylmethoxy)-1, 1'- biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00468] 4- [ (aminocarbonyl) amino]-l- [5'-fluoro-2'- (1, 3-oxazol-2- ylmethoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide ; [00469] 4- [ (aminocarbonyl) amino]-l- {5'-fluoro-2'- [2- (methylamino)-2- oxoethoxy]-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamide ; [00470] 4-[(aminocarbonyl) amino]-1-{5'-fl uoro-2'-[2-(ethylamino)-2- oxoethoxy]-1, 1'-biphenyl-4-yl}-1H-pyrazole-3-carboxamide ; [00471] [(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol- 1- yl}-1, 1'-biphenyl-3-yl) oxy] acetic acid; [00472] [(4'-{3-(aminocarbonyl)-4-[(aminocarbonyl)amino]-1H-pyrazol- 1- yl}-5-fluoro-1, 1'-biphenyl-2-yl) oxy] acetic acid; and [00473] 4-[(aminocarbonyl)amino]-1-[4-(4, 4,5, 5-tetramethyl-1, 3,2- dioxaborolan-2-yl) phenyl]-1 H-pyrazole-3-carboxamide.

DEFINITIONS [00474] The term"hydrido"denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CHz-) radical.

[00475] The term"halo"denotes halogen atoms such as fluorine, chlorine, bromine, or iodine.

[00476] The term"carbonyl", whether used alone or with other terms such as"alkylcarbonyl", denotes- (C=O)-.

[00477] The terms"carboxy"or"carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes -CO2H.

[00478] The term"sulfonyl,"whether used alone or linked to other terms such as alkylsulfonyl, denotes the divalent radical-SO2-.

[00479] The term"amido"when used by itself or with other terms such <BR> <BR> as"amidoalkyl","N-monoalkylamido","N-monoarylamido","N, N-dialkylamido", "N-alkyl-N-arylamido","N-alkyl-N-hydroxyamido"and"N-alkyl-N- hydroxyamidoalkyl", embraces a carbonyl radical substituted with an amino radical.

[00480] The terms"N-alkylamido"and"N, N-dialkylamido" denote amido groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively.

[00481] The terms"N-monoarylamido"and"N-alkyl-N-arylamido" denote amido radicals substituted, respectively, with one aryl radical, and one alkyl and one aryl radical.

[00482] The term"N-alkyl-N-hydroxyamido"embraces amido radicals substituted with a hydroxyl radical and with an alkyl radical.

[00483] The terms"sulfamyl"or"sulfonamidyl"denotes a sulfonyl radical substituted with an amino radical, forming a sulfonamide (-SO2NH2). The amino radical may be substituted with alkyl and/or aryl moieties to form, e. g.,"N-

alkylsulfamyl","N-arylsulfamyl","N, N-dialkylsulfamyl,"and"N-alkyl-N-<BR> <BR> <BR> <BR> <BR> arylsulfamyl"radicals.

[00484] The term"amidino"denotes a-C (=NH) NH radical.

[00485] The term"cyanoamidino"denotes a-C (=N-CN) NH radical.

[00486] The term"alkyl,"used alone or within other terms such as "haloalkyl"and"alkylsulfonyl,"embraces linear or branched radicals having one to about twenty carbon atoms. More preferred are"lower alkyl"radicals having one to about eight carbon atoms. Examples of alkyl radicals include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl, and t-butyl), pentyl (including n-pentyl and isoamyl), hexyl, octyl and the like.

[00487] The term"cycloalkyl"embraces radicals having three to ten carbon atoms, and includes monocyclic, bicyclic, and tricyclic radicals. Examples of cycloalkyl radicals include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, .. cycloheptyl, decahydronaphthyl, octahydroindyl, octahydropentalene, bicyclo [1.1. 0] butyl, bicyclo [2.1. 0] pentyl, bicyclo [1.1. 1] pentyl, bicyclo [2.1. 1] hexyl, bicyclo [2.2. 1] heptyl, bicyclo [3.1. 1] heptyl, bicyclo [3.2. 1] octyl, bicyclo [2.2. 2] octyl, and bicyclo [4.2. 2] decyl [00488] The term"alkylcarbonyl"embraces radicals having a carbonyl radical substituted with an alkyl radical. An example of an alkylcarbonyl radical is acetyl.

[00489] The term"alkylthio"embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. An example of an alkylthio radical is methylthio (CH3S-).

[00490] The term"alkylsulfinyl"embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent - S (=O)- radical. An example of an alkylsulfinyl radical is methylsulfinyl (CH3S (=O)-).

[00491] The term"alkylsulfonyl"embraces alkyl radicals as defined above attached to a divalent sulfonyl radical,-SO2.

[00492] The term"amidoalkyl"embraces alkyl radicals substituted with amido radicals.

[00493] The term"N-alkyl-N-hydroxyamidoalkyl"embraces alkyl radicals substituted with an N-alkyl-N-hydroxyamido radical.

[00494] The term"aminoalkyl"embraces alkyl radicals substituted with amino radicals.

[00495] The term"carboxyalkyl"embraces radicals having a carboxyl moiety attached to an alkyl radical.

[00496] The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above.

Specifically embraced are monohaloalkyl, dihaloalkyl, and polyhaloalkyl radicals.

A monohaloalkyl radical, for one example, may have a bromo, chloro, or a fluoro atom within the radical. Dihaloalkyl radicals may have two of the same halo atoms or a combination of different halo radicals; polyhaloalkyl radicals may have more than two of the same halo atoms or a combination of different halo radicals.

[00497] The term"hydroxyalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms, any of which may be substituted with one or more hydroxyl radicals.

[00498] The terms"N-alkylamino"and"N, N-dialkylamino"denote amino groups which have been substituted with one alkyl radical and with two alkyl radicals, respectively.

[00499] The term"alkoxy"embraces linear or branched oxy-containing alkyl radicals having one to about ten carbon atoms. Examples of"alkoxy" radicals include methoxy and butoxy.

[00500] The term"alkoxyalkyl"embraces linear or branched alkyl radicals having one to about ten carbon atoms substituted by one or more alkoxy radicals each having one to about ten carbon atoms.

[00501]"Alkoxy"or"alkoxyalkyl"radicals may be further substituted with one or more halo atoms, such as fluoro, chloro, or bromo, to provide "haloalkoxy"or"haloalkoxyalkyl"radicals.

[00502] The term"alkoxycarbonyl"means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical. Examples of such alkoxycarbonyl radicals include methoxycarbonyl and t-butoxycarbonyl.

[00503] The term "alkoxycarbonylalkyl" embraces radicals having alkoxycarbonyl moiety, as defined above substituted to an alkyl radical.

Examples of such alkoxycarbonylalkyl radicals include methoxycarbonylethyl (-(CH2) 2 (O=) COCH3) and t-butoxycarbonylethyl (-(CH2) 2 (O=) COC (CH3) 3).

[00504] The term"alkylaminoalkyl"embraces aminoalkyl radicals wherein the nitrogen atom is substituted with an alkyl radical.

[00505] The term"alkylcarbonylalkyl"denotes an alkyl radical substituted with an"alkylcarbonyl"radical.

[00506] The term"alkenyl,"used alone or within other terms such as "haloalkenyl,"embraces unsaturated linear or branched radicals having two to about twenty carbon atoms and containing at least one carbon-carbon double bond. Examples of alkenyl radicals include ethenyl, propenyl butenyl, pentenyl, and the like.

[00507] The term"cycloalkenyl"embraces unsaturated radicals having three to ten carbon atoms and containing at least one carbon-carbon double bond, and includes monocyclic, bicyclic, and tricyclic radicals. Examples of cycloalkenyl radicals include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, decahydronaphthenyl, hexahydroindenyl, hexahydropentalenyl, bicyclo [2.1. 0] pentenyl, bicyclo [1.1. 1] pentenyl,

bicyclo [2.1. 1] hexenyl, bicyclo [2.2. 1] heptenyl, bicyclo [3.1. 1] heptenyl, bicyclo [3.2. 1] octenyl, bicyclo [2. 2.2] octenyl, and bicyclo [4.2. 2] decenyl.

[00508] The term"alkynyl,"used alone or within other terms such as "haloalkynyl,"embraces unsaturated linear or branched radicals having two to about twenty carbon atoms and containing at least one carbon-carbon triple bond. Examples of alkynyl radicals include ethynyl, propynyl butynyl, pentynyl, and the like.

[00509] The term"aryl", alone or in combination, means a carbocyclic aromatic system containing one, two, or three rings wherein at least one of the rings is aromatic, and wherein such rings may be attached together in a pendant manner or may be fused. Examptes o. f, aryi radicaisjndude phenyt, naphthyt, tetrahydronapthyl, indyl, and biphenyl. Aryl moieties, alone or in combination, may be optionally substituted by one or more substituents selected from the group consisting of amino, halo, cyano, hydroxyl, alkyl, alkoxy, and carboxyl.

[00510] The term"aralkyl"embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenethyl, and diphenethyl.

[00511] The term"arylsulfonyl"embraces aryl radicals as defined above attached to a sulfonyl radical.

[00512] The term"acyl,"whether used alone or within a term such as "acylamino,"denotes a radical provided by the residue after removal of hydroxyl from an organic acid.

[00513] The term"acylamino"embraces an amino radical substituted with an acyl group. An examples of an"acylamino"radical is acetylamino (CH3C (=O) NH-).

[00514] The term"heterocyclic"or"heterocycle"means a saturated or unsaturated mono-or multi-ring carbocyclic system wherein one or more carbon atoms in the system are replaced by nitrogen, sulfur, phosphorous, and/or oxygen. The term"heterocyclic"embraces"heteroaryl"groups, which means a carbocyclic aromatic system containing one, two, or three rings wherein at least

one of the rings is aromatic, wherein such rings may be attached together in a pendant manner or may be fused, and wherein one or more carbon atoms in the system are replaced by nitrogen, sulfur, phosphorous, and/or oxygen.

"Heterocyclic"includes, for example, the following structures: [00516] wherein Z, Z', z2 and Z3 are independently carbon, sulfur, phosphorous, oxygen, or nitrogen, with the proviso that one of Z, Z1, Z2, or Z3 is other than carbon, but is not oxygen or sulfur when attached to another Z atom by a double bond or when attached to another oxygen or sulfur atom.

Furthermore, the optional substituents are understood to be attached to Z, 7', or Z3 only when each is carbon. For example, the term"heterocyclyl"embraces each of the following groups, although this listing is not meant to limit the definition to these groups only : furanyl ; thienyl ; pyrrolyl ; 2-isopyrrolyl ; 3- isopyrrolyl ; pyrazolyl ; 2-isoimidazolyl ; 1,2, 3-triazolyl ; 1,2, 4-triazolyl ; 1, 2-dithiolyl ; 1, 3-dithiolyl ; 1,2, 3-oxathiolyl ; isoxazolyl ; oxazolyl ; thiazolyl ; isothiazolyl ; 1,2, 3- oxadiazolyl ; 1,2, 4-oxadiazolyl ; 1,2, 5-oxadiazolyl ; 1,3, 4-oxadiazolyl ; 1,2, 3,4- oxatriazolyl ; 1,2, 3, 5-oxatriazolyl ; 1,2, 3-dioxazolyl ; 1,2, 4-dioxazolyl ; 1,3, 2- dioxazolyl ; 1,3, 4-dioxazolyl ; 1,2, 5-oxathiazolyl ; 1, 3-oxathiolyl ; 1, 2-pyranyl ; 1,4- pyranyl ; 1, 2-pyranonyl ; 1, 4-pyranonyl ; 1, 2-dioxinyl ; 1, 3-dioxinyl ; pyridyl ; pyridazyl ; pyrimidyl ; pyrazinyl ; piperazyl ; 1,3, 5-triazinyl ; 1,2, 4-triazinyl ; 1,2, 3- triazinyl ; 1, 2, 4-oxazinyl ; 1,3, 2-oxazinyl ; 1,3, 6-oxazinyl ; 1,2, 6-oxazinyl ; 1,4- oxazinyl ; o-isoxazinyl ; p-isoxazinyl ; 1,2, 5-oxathiazinyl ; 1, 4-oxazinyl ; o-isoxazinyl ; p-isoxazinyl ; 1,2, 5-oxathiainzyl ; 1,2, 6-oxathiainzyl ; 1,4, 2-oxadiainzyl ; 1,3, 5,2- oxadiainzyl ; morpholin ; azepinyl ; oxepinyl ; thiepinyl ; 1,2, 4-diazepinyl ; benzofuranyl ; isobenzofuranyl ; benzothiofuranyl ; isobenzothiofuranyl ; indolyl ; indoleninyl ; 2-isobenzazolyl ; 1, 5-pyrindinyl ; pyrano [3,4-b] pyrrolyl ; isoindazolyl ; indoxazinyl ; benzoxazolyl ; anthranilyl ; 1, 2-benzopyranyl ; quinolyl ; isoquinolyl ; cinnolyl ; quinazolyl ; naphthyridyl ; pyrido [3,4-b] pyridyl ; pyrido [3, 2-b] pyridyl ;

pyrido [4,3-b] pyridyl ; 1, 3., 2-benzoxazyl ; 1,4, 2-benzoxazyl ; 2,1, 3-benzoxazyl ; 3,1, 4-benzoxazyl ; 1, 2-benzoisoxazyl ; 1, 4-benzoisoxazyl ; carbazolyl ; xanthenyl ; acridinyl ; purinyl ; thiazolidyl ; piperidyl ; pyrrolidyl ; 1, 2-dihydroazinyl ; 1,4- dihydroazinyl ; 1,2, 3,6-tetrahydro-1, 3-diazinyl ; perhydro-1, 4-diazinyl ; 1,2- thiapyranyl ; and 1, 4-thiapyranyl. Heterocyclic moieties, alone or in combination, may be optionally substituted by one or more substituents selected from the group consisting of amino, halo, cyano, hydroxyl, alkyl, alkoxy, and carboxyl.

[00517] The term"heteroaryl"also embraces radicals where heterocyclic radicals are fused with aryl radicals as defined herein. Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.

[00518] The term "heterocycloalkyl" embraces heterocyclic-substituted alkyl radicals such as pyridylmethyl and thienylmethyl.

[00519] The terms benzyl and phenylmethyl are interchangeable.

[00520] The phrases"combination therapy","co-administration", "administration with", or"co-therapy", in defining the use of a selective IKK-2 ~ inhibitory agent in combination with another therapeutic agent such as another analgesic agent, is intended to embrace administration of each agent in a sequential manner in a regimen that may provide beneficial effects of the drug combination, and is intended as well to embrace co-administration of these agents in a substantially simultaneous manner, such as in a single capsule or dosage device having a fixed ratio of these active agents or in multiple, separate capsules or dosage devices for each agent, where the separate capsules or dosage devices can be taken together contemporaneously, or taken within a period of time sufficient to receive a beneficial effect from both of the constituent agents of the combination.

[00521] The term"subject"for purposes of treatment includes any human or animal subject who is in need of the prevention of, or who has pain, inflammation and/or any one of the known inflammation-associated disorders.

The subject is typically a human subject.

[00522] The phrase"therapeutic combination"as used herein refers to the combination of two or more therapeutic compounds and, optionally, one or more pharmaceutically acceptable carrier used to provide dosage forms that produce a beneficial effect of each therapeutic compound in the subject at the desired time, whether the therapeutic compounds are administered substantially simultaneously, or sequentially.

[00523] The phrase"therapeutically effective"as used herein refers to an amount of a therapeutic compound, or amounts of combined therapeutic compounds in combination therapy. The amount or combined amounts achieve one or more of the goals of preventing, inhibiting, reducing or eliminating the inflammation or i, lnflmmation-related disease or cond, tis"therapeutically-- effective"amount of each agent in a combination therapy is expected to be less than an amount used in treatment using agent by itself, thus while avoiding adverse side effects typically associated with alternative therapies, namely higher dose monotherapy of each agent by itself.

[00524] The terms"treating"or"to treat"means to alleviate symptoms, eliminate the causation either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms in a subject. The term"treatment"includes alleviation, elimination of causation of or prevention of pain and/or inflammation associated with, but not limited to, any of the diseases or disorders described above.

[00525] Pharmaceutically acceptable salts of the compounds of Formula I include the acid addition and base salts thereof.

[00526] Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include the acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleat, malonate, mesylate,

methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitat, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylat and trifluoroacetate salts.

[00527] Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.

[00528] Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.

[00529] Pharmaceutical acceptable salts of compounds of Formula I may be prepared by one or more of three, methods : (i) by reacting the compound-- of Formula I with the desired acid or base; (ii) by removing an acid-or base- labile protecting group from a suitable precursor of the compound of Formula I or by ring-opening a suitable cyclic precursor, for example, a lactone or lactam, using the desired acid or base; or (iii) by converting one salt of the compound of Formula I to another by reaction with an appropriate acid or base or by means of a suitable ion exchange column. All three reactions are typically carried out in solution. The resulting salt may precipitate-out and be collected by filtration or may be recovered by evaporation of the solvent. The degree of ionization in the resulting salt may vary from completely ionized to almost non-ionized.

[00530] The compounds of the invention may exist in both unsolvated and solvate forms. The term"solvate"is used herein to describe a molecular complex comprising the compound of the invention and a stoichiometric amount of one or more pharmaceutically acceptable solvent molecules, for example, ethanol. The term"hydrate"is employed when said solvent is water.

[00531] Included within the scope of the invention are complexes such as clathrates, drug-host inclusion complexes wherein, in contrast to the aforementioned solvates, the drug and host are present in stoichiometric or non- stoichiometric amounts. Also included are complexes of the drug containing two

or more organic and/or inorganic components which may be in stoichiometric or non-stoichiometric amounts. The resulting complexes may be ionized, partially ionized, or non-ionized. For a review of such complexes, see Haleblian, J.

Pharm. Sci., 64 (8), 1269-1288 (1975).

[00532] Hereinafter all references to compounds of Formula I include references to salts, solvates and complexes thereof and to solvates and complexes of salts thereof.

[00533] The compounds of the invention include compounds of Formula I as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as heceinafteLdefined. and isotopicaHy-fabefed compounds of Formuta 1.

[00534] As indicated, so-called prodrugs of the compounds of Formula I are also within the scope of the invention. The term"prodrug"refers to a compound that is a drug precursor which, following administration to a subject and subsequent absorption, is converted to an active species in vivo via some process, such as a metabolic process. Other products from the conversion process are easily disposed of by the body. The more preferred prodrugs are those involving a conversion process that produces products that are generally accepted as safe. as safe.

[00535] Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the compounds of Formula I with certain moieties known to those skilled in the art as"pro- moieties." [00536] Some examples of prodrugs in accordance with the invention include : (i) where the compound of Formula I contains a carboxylic acid functionality (-COH), an ester thereof, for example, a compound wherein the hydrogen of the carboxylic acid functionality of the compound of Formula I is replaced by C,-C8 alkyl ; (ii) where the compound of Formula I contains an

alcohol functionality (-OH), an ether thereof, for example, a compound wherein the hydrogen of the alcohol functionality of the compound of Formula I is replaced by C,-C6 alkanoyloxymethyl ; and (iii) where the compound of Formula I contains a primary or secondary amino functionality (-NH2 or-NHR where R # H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the compound of Formula I is/are replaced by C,-C, 0 alkanoyl.

[00537] Further examples of replacement groups in accordance with the foregoing examples and examples of other prodrug types may be found in the aforementioned references.

>100538] Moreover, certain compounds of Formula I may themselves act as prodrugs of other compounds of Formula I.

[00539] Also included within the scope of the invention are metabolites of compounds of Formula I, that is, compounds formed in vivo upon administration of the drug. Some examples of metabolites in accordance with the invention include: (i) where the compound of Formula I contains a methyl group, an hydroxymethyl derivative thereof (-CH3 @-CH2OH) ; (ii) where the compound of Formula I contains an alkoxy group, an hydroxy derivative thereof (-OR o-OH) ; (iii) where the compound of Formula I contains a tertiary amino group, a secondary amino derivative-thereof (-NRaRb o-NHRa or-NHRb) ; (iv) where the compound of Formula I contains a secondary amino group, a primary derivative thereof (-NHR o-NH2) ; (v) where the compound of Formula I contains a phenyl moiety, a phenol derivative thereof (-Ph @-PhOH) ; and (vi) where the compound of Formula I contains an amide group, a carboxylic acid derivative thereof (-CONH2 @-COOH).

[00540] Compounds of Formula I containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where a compound of Formula I contains an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low

energy barrier, tautomeric isomerism ("tautomerism") can occur. This can take the form of proton tautomerism in compounds of Formula I containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.

[00541] Included within the scope of the present invention are all stereoisomers, geometric isomers and tautomeric forms of the compounds of Formula I, including compounds exhibiting more than one type of isomerism, and mixtures of one or more thereof. Also included are acid addition or base salts wherein the counterion is optically active, for example, d-lactate or l-lysine, or racemic, for exampJe., dJ-ta. rtrate OLdt-arginine.

[00542] Cis/trans isomers may be separated by conventional . techniques well known to those skilled in the art, for example, chromatography and fractional crystallization.

[00543] Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (chiral HPLC).

[00544] Alternatively, the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the compound of Formula I contains an acidic or basic moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer (s) by means well known to a skilled person.

[00545] Chiral compounds of the invention (and chiral precursors thereof) may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to

50% by volume of isopropanol, typically from 2 to 20%, and from 0 to 5% by volume of an alkylamine, typically 0. 1 % diethylamine. Concentration of the eluate affords the enriched mixture.

[00546] Stereoisomeric conglomerates may be separated by conventional techniques known to those skilled in the art.

[00547] The present invention includes all pharmaceutical acceptable isotopically-labeled compounds of Formula I wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.

.-1005481 Examples of isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2H and 3H, carbon, such as 11C, 13C and 14C, chlorine, such as 36CI, fluorine, such as"F, iodine, such as 123I and'251, nitrogen, such as'3N and 15N, oxygen, such as"0,"0 and"0, phosphorus, such as 32P, and sulphur, such as 35S.

[00549] Certain isotopically-labeled compounds of Formula I, for example, those incorporating a radioactive isotope, are useful in drug and/or substrate tissue distribution studies. The radioactive isotopes tritium (3H) and 14C are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.

[00550] Substitution with heavier isotopes such as deuterium (2H) may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.

[00551] Substitution with positron-emitting isotopes, such as"C,'BF, 15o and'3N, can be useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy.

[00552] Isotopically-labeled compounds of Formula I can generally be prepared by conventional techniques known to those skilled in the art or by

processes analogous to those described in the accompanying Examples using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.

[00553] Pharmaceutical acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e. g. D2O, d-acetone, or d6-DMSO.

[00554] Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying.

Microwave or radio frequency drying may be used for this purpose.

[00555] Generally, the compounds of the invention may be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term"excipient"is used herein to describe any ingredient other-than the compound (s) of the invention. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.

[00556] The compounds of the invention may be administered alone or in combination with one or more other compounds of the invention or in combination with one or more other drugs (or as any combination thereof). For example, compounds of Formula I may be used in co-therapies, partially or completely, in place of other conventional antiinflammatory therapies, such as together with other IKK-2 inhibitors, steroids, NSAIDs, COX-2 selective inhibitors, matrix metalloproteinase inhibitors, 5-lipoxygenase inhibitors, LTB4 antagonists and LTA4 hydrolase inhibitors.

[00557] Pharmaceutical compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art.

[00558] The compounds of the invention may be administered orally.

Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, or buccal or sublingual administration may be employed by which the compound enters the blood stream directly from the mouth.

[00559] Formulations suitable for oral administration include solid formulations such as tablets, capsules containing particulates, liquids, or powders, lozenges (including liquid-filled), chews, multi-and nano-particulates, gels, solid solution, liposome, films, ovules, sprays and liquid formulations.

[00560] Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.

[00561]--The compounds of the invention may also be used in fast- dissolving, fast-disintegrating dosage forms such as those described in Liang and Chen, Expert Opinion in Therapeutic Patents, 11 (6), 981-986 (2001).

[00562] For tablet dosage forms, depending on dose, the drug may make up from 1 to 80 wt. % of the dosage form, more typically from 5 to 60 wt. % of the dosage form. In addition to the drug, tablets generally contain a disintegrant. Examples of disintegrants include sodium starch glycolat, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate. Generally, the disintegrant will comprise from 1 to 25 wt. %, preferably from 5 to 20 wt. % of the dosage form.

[00563] Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone,

pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose. Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.

[00564] Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc. When present, surface active agents may comprise from 0.2 to 5 wt. % of the tablet, and glidants may comprise from 0.2 to 1 wt. % of the tablet.

[00565] Tablets also generally contain lubricants such as magnesium <BR> <BR> <BR> <BR> stearate, ca ! cium. stearate,. zinc stearate,. sodium. steary ! fumarate ; and mixtures- of magnesium stearate with sodium lauryl sulphate. Lubricants generally comprise from 0.25 to 10 wt. %, preferably from 0.5 to 3 wt. % of the tablet.

[00566] Other possible ingredients include anti-oxidants, colorants, flavoring agents, preservatives and taste-masking agents.

[00567] Exemplary tablets contain up to about 80% drug, from about 10 to about 90 wt. % binder, from about 0 to about 85 wt. % diluent, from about 2 to about 10 wt. % disintegrant, and from about 0.25 to about 10 wt. % lubricant.- [00568] Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting. The final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.

[00569] Consumable oral films for human or veterinary use are typically pliable water-soluble or water-swellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise a compound of Formula I, a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabilizer or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.

[00570] The compound of Formula I may be water-soluble or insoluble.

A water-soluble compound typically comprises from 1 to 80 wt. %, more typically from 20 to 50 wt. %, of the soutes. Less soluble compounds may comprise a greater proportion of the composition, typically up to 88 wt. % of the soutes.

Alternatively, the compound of Formula I may be in the form of multiparticulate beads.

[00571] The film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 wt. %, more typically in the range 30 to 80 wt. %.

[00572] Other possible ingredients include anti-oxidants, colorants, flavorings and flavgr enUancers, preservativesi salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti- foaming agents, surfactants and taste-masking agents.

[00573] Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a pelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.

[00574] Solid formulations for oral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-and programmed-release.

[00575] Suitable modified release formulations for the purposes of the invention are described in U. S. Patent No. 6,106, 864. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Verma et al., Pharmaceutical Technology On-line, 25 (2), 1-14 (2001). The use of chewing gum to achieve controlled release is described in PCT Publication No. WO 00/35298.

[00576] The compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ. Suitable means for parenteral administration include intravenous, intraarterial,

intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular and subcutaneous. Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.

[00577] Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.

[00578] The preparation of parenteral formulations under sterile conditions, for example, by ! yophi ! ization, mav.-readi) y be accomplished using standard pharmaceutical techniques well known to those skilled in the art.

[00579] The solubility of compounds of Formula I used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.

[00580] Formulations for parenteral administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-and programmed-release.

Thus compounds of the invention may be formulated as a solid, semi-solid, or thixotropic-liquid for administration as an implanted depot providing modified release of the active compound. Examples of such formulations include drug- coated stents and poly (dl-lactic-coglycolic) acid (PGLA) microspheres.

[00581] The compounds of the invention may also be administered topically to the skin or mucosa, that is, dermally or transdermally. Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibers, bandages and microemulsions. Liposomes may also be used. Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration

enhancers may be incorporated; see, e. g. , Finnin and Morgan, J Pharm Sci, 88 (10), 955-958 (1999).

[00582] Other means of topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e. g. Powderject, Bioject, etc. ) injection.

[00583] Formulations for topical administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-and programmed-release.

[00584] The compounds of the invention-can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with taetose, or as a mixed-component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler or as an aerosol spray from a pressurized container, pump, spray, atomizer (preferably an atomizer using electrohydrodynamics to produce a fine mist), or nebulizer, with or without the use of a suitable propellant, such as 1,1, 1, 2-tetrafluoroethane or 1,1, 1,2, 3,3, 3- heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.

[00585] The pressurized container, pump, spray, atomizer, or nebulizer contains a solution or suspension of the compound (s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilizing, or extending release of the active, a propellant (s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.

[00586] Prior to use in a dry powder or suspension formulation, the drug product is micronized to a size suitable for delivery by inhalation (typically less than 5 um). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenization, or spray drying.

[00587] Capsules (made, for example, from gelatin or hydroxypropylmethylcellulose), blisters and cartridges for use in an inhaler or insulator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate. The lactose may be anhydrous or in the form of the monohydrate, preferably the latter. Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.

[00588] A suitable solution formulation for use in an atomizer using electrohydrodynamics to produce a fine mist may contain from 1 ug to 20 mg of the the compound of the invention per actuation and the actuation volume may vary from 1 to 100 uL. A typical formulation may comprise a compound of Formula I, propylene glycol, sterile water, ethanol and sodium chloride. Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

[00589] Suitable flavors, such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.

[00590] Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using,-for example, PGLA.

Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-and programmed-release.

[00591] In the case of dry powder inhalers and aerosols, the dosage unit is determined by means of a valve which delivers a metered amount. Units in accordance with the invention are typically arranged to administer a metered dose or"puff"containing from 20 to 1000 ug of the compound of Formula I. The overall daily dose will typically be in the range 100 ug to 10 mg which may be administered in a single dose or, more usually, as divided doses throughout the

day, for example 2,3, 4 or 8 times, giving for example, 1,2 or 3 doses each time.

[00592] The compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema.

Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.

[00593] Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-and programmed-release.

[005S , The. compounds oLthe invention may al. so be admíniste, ed » directly to the eye or ear, typically in the form of drops of a micronized suspension or solution in isotonic, pH-adjusted, sterile saline. Other formulations suitable for ocular and aural administration include ointments, biodegradable (e. g., absorbable gel sponges, collagen) and non-biodegradable (e. g., silicone) implants, wafers, lenses and particulate or vesicular systems, such as niosomes or liposoms. A polymer such as crossed-linked polyacrylic acid, polyvinylalcohol, hyaluronic acid, a cellulosic polymer, for example, hydroxypropylmethylcellulose, hydroxyethylcellulose, or methyl cellulose, or a heteropolysaccharide polymer, for example, gelan gum, may be incorporated together with a preservative, such as benzalkonium chloride. Such formulations may also be delivered by iontophoresis.

[00595] Formulations for ocular/aural administration may be formulated to be immediate and/or modified release. Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted-or programmed-release.

[00596] The compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility,

dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.

[00597] Drug-cyclodextrin complexes, for example, are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used. As an alternative to direct complexation with the drug, the cyclodextrin may be used as an auxiliary additive, i. e. , as a carrier, diluent, or solubilizer. Most commonly used for these purposes are alpha-, beta-and gamma-cyclodextrins, such as those described in PCT Publication No. WO 98/55148.

[00598] Inasmuch as it may desirable to administer a combination of açtive cqrnpoun. ds, for example, for the purpose of treating a particular disease or condition, it is within the scope of the present invention that two or more pharmaceutical compositions, at least one of which contains a compound in accordance with the invention, may conveniently be combined in the form of a kit suitable for coadministration of the compositions.

[00599] Such kits comprises two or more separate pharmaceutical compositions, at least one of which contains a compound of Formula I in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet. An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.

[00600] Such kits are particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another. To assist compliance, the kit typically comprises directions for administration and may be provided with a so-called memory aid.

[00601] The amount of therapeutically active compounds that are administered and the dosage regimen for treating a disease condition with the

compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the inflammation or inflammation related disorder, the route and frequency of administration, and the particular compound employed, and thus may vary widely. The pharmaceutical compositions may contain active ingredients in the range of about 0.1 to 1000 mg, preferably in the range of about 7.0 to 350 mg. A daily dose of about 0.01 to 100 mg/kg body weight, preferably between about 0.1 and about 50 mg/kg body weight and most preferably between about 0.5 to 30 mg/kg body weight, may be appropriate. The daily dose can be administered in one to four doses per day. In the case of skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.

[00602] It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

[00603] These dosages are based on an average human subject having a weight of about 60 to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.

[00604] For the avoidance of doubt, references herein to"treatment" include references to curative, palliative and prophylactic treatment.

[00605] "DMF"is N, N-dimethylformamide.

[00606] "DMSO"is dimethylsulfoxide.

[00607]"ESI"is electrospray ionization Mass spectrometry. <BR> <BR> <BR> <BR> <P> [00608] "HATU"is 0-(7-azabenzotriazol-1-yl)-N, N, N', N'-<BR> <BR> <BR> <BR> <BR> <BR> <BR> tetramethyluronium hexafluorophosphate.

[00609]"HBTU"is O-benzotriazolo-1-yl)-N, N, N', N'-tetramethyluronium.

[00610] "HRMS"is high resolution mass spectrometry.

[00611] "NMR"is nuclear magnetic resonance.

[00612]"Ph"is phenyl.

[00613]"i. d." is inner diameter.

[00614]"R. O. water"is reverse osmosis water.

[00615] "EtOAc"is ethyl acetate.

EXAMPLES [00616] Example 1: 4- [ (aminocarbonyl) amino]-l- [4-bromo-3- (trifluoromethyl)phenyl]-1H-pyrazole-3-carboxamide [00618] Step 1: Preparation of (2E)-2-{[4-bromo-3- (trifluoromethyl) phenyl] hydrazono} -3-cyanopropanamide [00620] 4-Bromo-3 (trifluoromethyl) aniline (18. 00 g, 75 mmol) was stirred with conc. HCI (18.75 mL, 187.5 mmol). After about 2-3 min. water (60 mL) was added and the reaction cooled to about-5°C in an ice/acetone bath. A solution of sodium nitrite (5.174 g, 75 mmol) in water (18 mL) was added over about 15-20 min. , maintaining the temperature between about-5 and 0°C.

Meanwhile, a solution of cyano acetamide (18.9 g, 225 mmol) was prepared in

ethanol (75 mL) and water (100 mL). A solution of sodium acetate trihydrate (10.5 g, 75 mmol) in 25 mL water was added and the mixture stirred in an ice/acetone bath. After the diazotization was complete a cold solution of sodium acetate trihydrate (30.6 g, 225 mmol) in water (75 mL) was added slowly, keeping the internal temperature of the reaction mixture about 0°C. The reaction mixture was then pipetted into the flask containing the cyano acetamide solution, 1 mL at a time over about 20 min. The temperature was maintained at 0 to-3°C during the addition. After 1 h a milky brick red material was filtered and washed with water (2 x 150 mL), sucked dry for about 1 h then washed with ether (150 mL), removing much of the red color. After drying, an orangey solid was obtained and used directly in the next step.

[00621] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyf)-1- [4- bromo-3-(trifluoromethyl) phenyl]-1 H-pyrazole-5-carboxylate [00623] Crude hydrazone (13.94 g, 41.6 mmol) from the previous step and powdered anhydrous potassium carbonate (11.5 g, 83.2 mmol) were stirred in DMF (70 mL). Ethyl bromoacetate (11.1 g, 7.37 mL, 66.6 mmol) was added and the reaction heated to 130°C for 1 h then allowed to cool to about 50°C ; triethylamine (8.42 g, 11.6 mL, 83.2 mmol) was then added. Upon cooling the reaction was poured into 650 mL ice/water mixture, filtered and washed with a little water. After drying, a dark blood-red solid was obtained which was used directly in the next step.'H NMR (300 MHz, DMSO-d6) : 5 1.31 (t, J = 7.1 Hz, 3 H), 4.17 (q, J = 7.1 Hz, 2 H), 5.80 (s, 2 H), 7.41 (s, 1 H), 7.74 (m, 2 H), 8.03 (m, 2 H).

[00624] Step 3: Preparation of 4-amino-3- (aminocarbonyl)-1- [4-bromo- 3-(trifluoromethyl) phenyl]-1 H-pyrazole-5-carboxylic acid, potassium salt

[00626] The crude ester (13.67 g, 32.5 mmol) from the previous step was stirred in 95% ethanol (100 mL) and a solution of 15% potassium hydroxide in ethanol (50 mL) was added. After 4 h the mixture was cooled to 0°C and filtered. The precipitate was with ice cold ethanol (200 mL) and ether (200 mL) then dried to afford the potassium salt as a pinkish brown solid. This was used directly in the next step.

[00627] Step 4: Preparation of 4-amino-1- [4-bromo-3- (trifluoromethyl) phenyl]-1 H-pyrazole-3-carboxamide [00629] The potassium salt from the previous experiment (8.158 g, 18. 9 mmol) was stirred with 85% phosphoric acid and heated to 75°C for 2 h, and then cooled. Ice/water (150 mL) was added. Filtration gave a brown solid.'H NMR (300 MHz, DMSO-d6) : # 7.32 (s, 1 H), 7.73 (s, 1 H), 7.96 (s, 2 H), 8. 00 (s, 1 H), 8.04 (s, 1 H), 8.31 (s, 1 H); LCMS: m+ = 352,350.

[00630] Step 5: Preparation of 4- [ (aminocarbonyl) amino]-1- [4-bromo-3- (trifluoromethyl) phenyl]-1 H-pyrazole-3-carboxamide

[00632] Crude amine (4.93 g, 14.12 mmol) from the previous step and potassium cyanate (3.436 g, 42.37 mmol) were stirred in THF (50 mL) and water (40 mL). Acetic acid (12 mL) was added and the mixture stirred for 1 hr. Ice/water was added and the resultant precipitate filtered and washed with water followed by ice cold ethanol (100 mL) and heptane (100 mL). The ethanol and heptane washings were evaporated to give an orange solid, which was chromatographed over silica gel (100 g). Elution with 0-10% methanol-chloroform gave the urea as a yellow solid.'H NMR (300 MHz, DMSO-d6) : 5 6.57 (s, 2 H), 7.60 (s, 1 H), 7.99 (d, J = 9.0 Hz, 1 H), 8.03 (s, 1 H), 8.14 (dd, J = 9.0, 2.4 Hz, 1 H), 8.38 (d, J = 2.4 Hz, 1 H), 8.71 (s, 1 H), 8.74 (s, 1 H); LCMS: m-= 392,390.

[00633] Example 2: 4-({[(aminocarbonyl) amino] carbonyl} amino)-1- [4- bromo-3-(trifluoromethyl) phenyl]-1 H-pyrazole-3-carboxamide [00635] The filtered solid from Step 5 of Example 1 was identified as the desired product and isolated as a-pinkish-gray solid.'H NMR (300 MHz, DMSO-d6) : 8 7.58 (s, 1 H), 8.02 (m, 2 H), 8.19 (m, 1 H), 8.41 (m, 1 H), 8.87 (m, 1 H), 9.41 (s, 1 H), 10.91 (s, 1 H); LCMS: m+ = 437,435 ; m-= 435,433.

[00636] Example 3: 4-[(aminocarbonyl) amino]-1-(4-bromo-3- ethoxyphenyl)-1 H-pyrazole-3-carboxamide [00638] Step 1: Preparation of (2E)-2- [ (4-bromo-3- ethoxyphenyl) hydrazono]-2-cyanoacetamide

[00640] Concentrated HCl (11.9 mL, 119 mol) vas added over about 1-2 min. to 4-bromo-3-ethoxyaniline hydrochloride (20.00 g, 79.2 mmol) followed by water (65 mL) then cooled in an ice/acetone bath. A solution of sodium nitrite (5.46 g, 79.2 mmol) in water (20 mL) was added over about 15-20 min., maintaining the temperature between about-5 and 0°C. Meanwhile, a solution of cyano acetamide (20.0 g, 238 mmol) was prepared in ethanol (80 mL) and water (110 mL). A solution of sodium acetate trihydrate (11.0 g, 80.9 mmol) in water (25 mL) was added and the mixture stirred in an ice/acetone bath. After the diazotization was complete a cold solution of sodium acetate trihydrate (33. 0 g, 242.6 mmol) in water (75 mL) was added slowly, keeping the internal temperature of the reaction mixture at about 0°C. This diazotization mixture was then pipetted into the cyano acetamide flask, 1 mL at a time over about 20 min.

The reaction was filtered and the precipitate washed well with water, then dried.

The hydrazone was obtained as a yellow solid. LCMS: m+ = 313,311 : m-= 311, 309. This material was used directly in the next step.

[00641] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (4- bromo-3-ethoxyphenyl)-1 H-pyrazole-5-carboxylate

[00643] The hydrazone from the previous step (25.7 g, 82.6 mmol), anhydrous potassium carbonate (22.8 g, 165 mmol) and ethyl bromoacetate (22.1 g, 14.60 mL, 132 mmol) were heated to 130°C in DMF (150 mL) for 4 h.

The reaction mixture was cooled to 90°C, then triethylamine (16.7 g, 23.0 mL, 165 mmol) was added. The reaction mixture was cooled in ice and poured into ice/water (1400 mL). The precipitate was filtered and dried to afford the crude pyrazol as a brown solid. A small sample was chromatographed over silica gel (0-2% methanol/chloroform) to give the title compound as a beige solid.'H NMR (300 MHz, DMSO-d6) : 5 1.11 (m, 3 H), 1.31 (m, 3 H), 4.12 (m, 4 H), 5.70 (m, 2 H), 6.96 (m, 1 H), 7. 22 (s, 1 H), 7.33 (s, 1 H), 7.62 (m, 2 H); LCMS: m+ = 400, 398.

[00644] Step 3: Preparation of 4-amino-3- (aminocarbonyl)-1- (4-bromo- 3-ethoxyphenyl)-1 H-pyrazole-5-carboxylic acid, potassium salt [00646] The crude ester from the previous step (19.156 g, 48.2 mmol) was stirred in 95% ethanol (180 mL) and a solution (90 mL) of 15% potassium hydroxide in ethanol was added; the reaction mixture was then heated at 45°C for 4 h. The reaction mixutre was cooled in ice, filtered and the precipitate washed with ethanol (250 mL) and hexane (250 mL). The potassium salt was isolated as a khaki colored solid. LCMS: m+ = 372,370 ; m-= 369,367. This was used directly in the next step.

[00647] Step 4: Preparation of 4-amino-1- (4-bromo-3-ethoxyphenyl)- 1 H-pyrazole-3-carboxamide

[00649] The potassium salt from the previous step (15.19 g, 37.3 mmol) was stirred with 85% phosphoric acid (50 mL) and heated at 75°C for 2 h. After cooling, ice/water (600 mL) was added and the precipitate filtered. The product was obtained as a tan solid. A small sample was chromatographed over silica gel (0-3% methanol-chloroform) to obtain the title compound as a beige solid.

LCMS: m+ = 328,326 and m-= 325, 323 ;'H NMR (300 MHz, DMSO-d6) : 5 1.37 (t, J = 6. 9 Hz, 3 H), 4.20 (q, J = 6. 9 Hz, 2 H), 4.84 (s, 2 H), 7.22 (s, 1 H), 7.32 (m, 1 H), 7.59 (m, 3 H), 7.83 (s, 1 H); [00650] Step 5: Preparation of 4- [ (aminocarbonyl) amino]-1- (4-bromo-3- ethoxyphenyl)-1 H-pyrazole-3-carboxamide [00652] Potassium cyanate (3.38 g, 41.7 mmol) was added to a stirred suspension of amine (12.32 g, 37.9 mmol) from the previous step in a mixture of 2-propanol (180 mL), water (180 mL) and 75% acetic acid (180 mL). After 16 h water (450 mL) was added and the precipitate filtered. After washing with water (50 mL), methanol (50 mL) and ether (100 mL), the urea was obtained as a tan solid. A small sample was chromatographed over silica gel (0-5%

methanol/chloroform) to afford the urea as a yellow solid. LCMS: m+ = 370,368 ; m-= 368, 366.'H NMR (300 MHz, DMSO-D, J = 6. 9 Hz, 2 H), 6.51 (s, 2 H), 7.40 (m, 1 H), 7.61 (m, 3 H), 7.88 (s, 1 H), 8.60 (d, J = 2. 4 Hz, 1 H), 8.65 (s, 1 H).

[00653] Example 4: 4-[(aminocarbonyl) amino]-1-(4-iodo-2- methylphenyl)-1 H-pyrazole-3-carboxamide

[00655] Step 1: Preparation of (2E)-2-cyano-2- [ (4-iodo-2- methylphenyl) hydrazono] acetamide

[00657] Preparation of Solution A: 2-Methyl-4-iodoaniline (23.3 g, 100 mmol) was treated with conc. HCI (25 mL) and diluted with water (100 mL). This mixture was stirred and cooled to-5 to 0°C in an ice/acetone bath. To this was added a solution of sodium nitrite (6.90 g, 100 mmol) in water (20 mL) at-5 to 0°C. The resultant mixture was stirred 20 min. To this was added a-5°C solution of sodium acetate trihydrate (40.8 g, 300 mmol) in water (100 mL).

[00658] Preparation of Solution B: Separately, cyanoacetamide (10.1 g, 120 mmol) was dissolved in water (180 mL) and ethanol (120 mL). The solution was cooled to-5°C. To this was added a cooled (-5°C) solution of sodium acetate trihydrate (13.6 g, 100 mmol) in water (30 mL).

[00659] Solution A was added by pipette dropwise over about 30 min to Solution B at 5°C to make a pasty mixture. After 3 h the mixture was filtered.

The solids were then washed with ether (500 mL) and dried further to give a yellow brown solid. NMR indicated a mixture of stereomers.

[00660] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (4- iodo-2-methylphenyl)-1 H-pyrazole-5-carboxylate

[00662] A mixture of the crude hydrazone from the previous step (20.0 g, 61.0 mmol), anhydrous potassium carbonate (16.8 g, 91.4 mmol) and ethyl bromoacetate (10.2 mL, 15.3 g, 122 mmol) in dry DMF was heated to 110°C for 2 h. An additional 3.4 mL of ethyl bromoacetate (3.4 mL, 5.13 g, 30. 7 mmol) was added. The reaction was allowed to cool and stand overnight then decanted from the solids and diluted with water (500 mL). The resultant solid precipitate was collected by filtration and dried under vacuum leaving a brown solid. A second precipitate was also collected and dried leaving another brown solid which was crystallized from ethyl acetate (75 mL) to give light tan crystals.

LCMS: m+ = 416 ;'H NMR (300 MHz, DMSO-D.

(s, 3 H), 4.09 (q, J = 7.2 Hz, 2 H), 5.69 (s, 2 H), 7.08 (d, J = 8.4 Hz, 1 H), 7.32 (s, 1 H), 7.65 (m, 2 H), 7.78 (s, 1 H).

[00663] Step 3 : Preparation of 4-amino-3- (aminocarbonyl)-1- (4-iodo-2- methylphenyl)-1 H-pyrazole-5-carboxylic acid [00665] The ester from the previous step (20.7 g, 50 mmol) was treated with a 10% ethanolic solution of potassium hydroxide, stirred and warmed to 40°C for 2 h. The reaction was cooled, treated with dry ice to about pH 9, diluted with water and extracted with ethyl acetate. The aqueous layer was neutralized to about pH 5 and the precipitate collected and dried giving the acid as a tan

solid. LCMS: m+ = 388, m-= 385 ;'H NMR (300 MHz, DMSO-D, 7.07 (d, J = 8.0 Hz, 1 H), 7. 28 (s, 1 H), 7.56 (m, 1 H), 7.64 (d, J = 8.0 Hz, 1 H), 7.75 (s, 1 H).

[00666] Step 4: Preparation of 4-amino-1- (4-iodo-2-methylphenyl)-1 H- pyrazole-3-carboxamide [00668] The carboxylic acid from the previous step (4.0 g, 10.4 mmol) was treated with 10.5 mL of 85% phosphoric acid (10.5 mL) and the mixture heated to 85°C for 3 h. The reaction was then neutralized. with a solution of sodium hydroxide (9.75 g) dissolved in water (50 mL). A sticky precipitate was formed which was dissolved in a mixture of THF and ethyl acetate then dried over magnesium sulfate. Filtration and evaporation provided a dark brown foamy gum which was dissolved in methanol and treated with decolorizing carbon.

Filtration and evaporation gave a brown gum. A small sample was chromatographed over silica gel (0-3% methanol/chloroform) to provide the product as a yellow foam. LCMS: m+ = 344;'H NMR (300 MHz, DMSO-d6) : 5 2.20 (s, 3 H), 4.77 (s, 2 H), 7.14 (m, 2 H), 7.34 (m, 2 H), 7.65 (d, J = 8. 1 Hz, 1 H), 7.76 (s, 1-H) ;- [00669] Step 5: Preparation of 4-[(aminocarbonyl) amino]-1-(4-iodo-2- methylphenyl)-1 H-pyrazole-3-carboxamide [00671] Crude amine from the previous step (264 mg, 0.77 mmol) was stirred in 2-propanol (4 mL), 75% acetic acid (4 mL) and water (4 mL).

Potassium isocyanate (71 mg, 0.88 mmol) was added and the reaction stirred

for 1 h. then the solvents evaporated to afford a damp sticky solid.

Chromatography over silica gel (0-4% methanol/chloroform) gave the urea as a pale yellow solid. LCMS: m+ = 386 and m-= 384 ;'H NMR (300 MHz, DMSO-d,) : 6 2.19 (s, 3 H), 6.46 (s, 2 H), 7.19 (m, 1 H), 7.42 (s, 1 H), 7.65 (m, 2 H), 7.79 (s, 1 H), 8.12 (d, J = 3.6 Hz, 1 H), 8.67 (s, 1 H).

[00672] Example 5: 4- [ (aminocarbonyl) amino]-1- (3'-hydroxy-3-methyl- 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide [00674] 4-[(aminocarbonyl) amino]-1-(4-iodo-2-methylphenyl)-1 H- pyrazole-3-carboxamide (Example 4,117 mg, 0.30 mmol) was placed in a vial under nitrogen. 3-hydroxyphenylboronic acid (84 mg, 0.61 mmol) and tetrakis (triphenylphosphine) palladium (0) (53 mg, 0.046 mmol) were added followed by dry DMF (2 mL). Nitrogen was bubbled through the amber solution for 10 min. when a solution of cesium carbonate (297 mg, 0.91 mmol) in water (0.5 mL) water was added. The reaction was heated to 80°C for 16 h, cooled and added to ice/water (50 mL). Filtration gave a yellow solid which was chromatographed over silica gel (0-7% methanol/chloroform) to provide the product as a cream solid. LCMS: m+ = 352 and m-= 350.'H NMR (300 MHz, DMSO-d6) : 5 2.28 (s, 3 H), 6.46 (s, 2 H), 6.77 (m, 1 H), 7.08 (m, 2 H), 7.25 (m, 1 H), 7.44 (m, 2 H), 7.52 (m, 1 H), 7.62 (m, 2 H), 8.16 (s, 1 H), 8.68 (s, 1 H), 9.55 (s, 1 H).

[00675] Example 6: 4-[(aminocarbonyl) amino]-1-(3-chloro-4- iodophenyl)-1 H-pyrazole-3-carboxamide [00677] Step 1: Preparation of (2E)-2- [ (3-chloro-4- iodophenyl) hydrazono] -2-cyanoacetamide

[00679] A 250 mL 2-neck flask, flushed with N2, was charged with a stir bar and 3-chloro-4-lodoaniline (19.01 g, 75 mmol) and was then cooled in acetone/ice bath to 0°C. To this was added conc. HCI (19 mL) dropwise at a rate that maintained the temperature below 5°C. Water (60 mL) was added followed by a solution of sodium nitrite (5.175 g, 75 mmol) in water (15 mL) over a 5 min period. After 75 mins, a solution of sodium acetate trihydrate (30.62 g, 225 mmol) in water (75 mL) was added over a 5 min. period with the temperature maintained at 5°C. The resultant yellowish slurry was then used as described in the following paragraph.

[00680] To a well-stirred solution of cyanoacetamide (12.61 g, 150 mmol) in water (115 mL) and ethanol (75 mL) in a 500-mL round bottom flask was added a solution of acetate trihydrate (10.5 g, 75 mmol) in water (25 mL) and this mixture was cooled to-7°C in an acetone/water bath. To this solution was added the slurry from the previous paragraph dropwise over a 70-minute period with the temperature maintained at 0°C ( 2°C) during the addition. After 2.5 h, the cold mixture was filtered and the solids washed with water (3 X 100 mL) and air-dried. These solids were washed with methanol (4 X 100 mL) and dried in vacuo to give a yellow solid. The methanol washes were concentrated, cooled, and filtered to provide additional product.'H NMR (DMSO-d6) : 5 11.750 (m, 1 H), 7.940 (m, 1 H), 7.860 (m, 1 H), 7.822 (m, 1 H), 7.550 (m, 1 H), 7.330 (m, 1 H). MS (ESI-) for CgH6CIIN40 m/z 347.0 (M-H) -.

[00681] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (3- chloro-4-iodophenyl)-1 H-pyrazole-5-carboxylate

[00683] To a well stirred slurry of the hydrazone from the previous step (19 g, 55 mmol) and anhydrous potassium carbonate (15 g, 109 mmol) in DMF (150 mL) was added ethyl bromoacetate (6.1 mL, 55 mmol) and the reaction heated to 130°C. Additional aliquots of ethyl bromoacetate (3 mL, 17 mmol) were added at 3.5 h, 5.5 h and 6.25 h. After 6.5 h the reaction mixture was cooled, poured into ice/water (600 mL) and stored at 5°C overnight. The slurry was then filtered, washed with water and dried in vacuo to give a reddish-brown solid.'H NMR (300 MHz, DMSO-d6) : 5 8. 010 (m, 1 H), 7.772 (m, 1 H), 7.650 (m, 1 H), 7.390 (m, 1 H), 7.23 (m, 1 H), 5.739 (m, 2 H), 4.157 (m, 2 H), 1.124 (m, 3 H). MS (ESI+) for C13H12CIIN403 m/z 435.9 (M+H) +.

[00684] Step 3: Preparation of 4-amino-3- (aminocarbonyl)-1- (3-chloro- 4-iodophenyl)-1 H-pyrazole-5-carboxylic acid, potassium salt [00686] The ester from Step 2 (20.5 g, 47 mmol) was stirred with 15% KOH/ethanol (210 mL) at room temperature. After 2 h, the heterogeneous mix was transferred to freezer and stored overnight. The mixture was filtered, washed with cold ethanol (3 X 10 mL) and air-dried to give a reddish-brown solid.

[00687] Step 4 : Preparation of 4-amino-1- (4-iodo-2-methylphenyl)-1 H- pyrazole-3-carboxamide

[00689] A slurry of phosphoric acid (50 mL, 85%) and the potassium salt from the preceeding step (9.5 g, 21.3 mmol) in a 500-mL round bottom flask was heated at 80°C for 65 min. The reaction mixture was removed from heat, allowed to cool for 15 minutes, and then poured onto ice (500 mL). This mixture was stirred an additional 75 min, filtered and the solids washed with water (5 X 80 mL), aqueous sodium bicarbonate (1 X 30 mL) and air-dried to give a brown solid. 1H NMR (300 MHz, DMSO-d6): # 8. 158 (d, J = 1. 8 Hz, 1 H), 8.011 (d, J = 8.4 Hz, 1 H), 7.872 (s, 1 H), 7.670 (s, 1 H), 7.594 (dd, J = 2. 7, 8.4 Hz, 1 H), 7.298 (s, 1 H), 4.90 (s, 1 H). MS (ESI+) for C, OH, CIIN40m/z 363. 9 (M+H) +.

[00690] Step 5: Preparation of4- [ (aminocarbonyi) amino]-1- (3-chtoro-4- iodophenyl)-1 H-pyrazole-3-carboxamide [00692] To a well stirred slurry of the amine from the previous step (2.62 g, 7 mmol)-and potassium cyanate (1.32 g, 16 mmol) in methanol (150 mL) /water (150 mL) at room temperature was added 70% acetic acid (80 mL).

Additional aliquots of potassium cyanate were added at 60 min. (1.31 g, 16 mmol) and 18 h (0.330 g, 4 mmol). After 20 h, additional acetic acid solution was added (5 mL, 70%). At 24 h, the mixture was filtered, the solids washed with water (4 X 50 mL) and air-dried. This material was then washed with methanol (3 X 50 mL) and methanol/acetone (1/1,6 X 100 mL). The latter methanol/acetone extracts were combined, filtered and the filtrate concentrated to give a brown solid.'H NMR (300 MHz, DMSO-D,

H), 8.220 (s, 1 H), 8.00 (m, 2 H), 7.62 (m, 2 H), 6.548 (s, 2 H). MS (ESI-) for C11H9CIN5O2 m/z 404.0.

[00693] Example 7: 4-[(aminocarbonyl)amino]-1-(2-chloro-3'-hydroxy- 1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide [00695] A 2-neck roundbottom flask was charged with 4- <BR> <BR> <BR> <BR> [ (aminocarbonyl) amino]-1- (3-chloro-4-iodophenyl.)-1 H-pyrazole-3-carboxamide (Example 6,0. 214 g, 0.5 mmol), tetrakis (triphenylphosphine) Pd (0) (0.044 g, 0.038 mmol), 3-hydroxyphenylboronic acid (0.144 g, 1 mmol) and the mixture was flushed with N2. An aqueous solution of Cs2CO3 (2M, 0.6 mL, 1.2 mmol, under N2) was added via syringe followed by anhydrous DMF (5 mL, via syringe). The reaction was flushed again with N2 and heated to 80°C. After 18 h, the reaction was removed from heat, poured onto ice (40 mL), and the mixture stirred for 10 min. The slurry was filtered and the collected solids washed with water (3 X 20 mL) and air dried to give a pale brown solid.'H NMR (300 MHz, DMSO-d6) : # 9.561 (s, 1 H), 8.649 (m, 2 H), 8. 139 (m, 1 H), 7.885 (m, 2 H), 7.470 (m, 2 H), 7.245 (m, 1 H), 6.815 (m, 3 H), 6.508 (s, 2 H). MS (ESI-) for C17H, 4CINsO3 m/z 370.2 (M-H)-. <BR> <BR> <P> [00696] Example 8: 4-[(aminocarbonyl) amino]-1-(4-iodo-3-<BR> <BR> <BR> <BR> <BR> <BR> methylphenyl)-1 H-pyrazole-3-carboxamide [00698] Step 1: Preparation of (2E)-2-cyano-2- [ (4-iodo-3- methylphenyl) hydrazono] acetamide

[00700] A mechanically stirred slurry of 3-methyl-4-iodoaniline (23.3 g, 0.1 mole) and concentrated HCI (25 mL) in water (80 mL) was cooled to 5°C and a cold solution of sodium nitrite (6.9 g, 0.1 mole, dissolved in 20 mL water) was added slowly over a period of 30 min. , maintaining the reaction temperature at 0-5°C. A solution of sodium acetate trihydrate (40.8 g, 0.3 mole) in water (100 mL) was then added dropwise over 15-30 min.

[00701] This mixture was then slowly added to a cold (5°C) mechanically stirred solution of sodium cyanoacetamide [previously prepared by the dissolution of cyanoacetamide (12.6 g, 0.15 mol) in cold (5°C) water (150 mL)/ethanol (100 mL) followed by the addition of a cold solution of sodium acetate trihydrate (13.6 g, 0.1 mol) in water (30 mL) ] over a period of 30 min. A thick brown slurry was obtained which was stirred for three additional hours in a wet ice bath. The slurry was filtered and the solids washed with water (200 mL).

The material was dried in vacuo to give a reddish brown solid.'H NMR (300 MHz, DMSO-d6) : 5 8.13 (s,-1 H), 8.07-7. 98 (m, 3 H), 7.81 (s, 1 H), 7. 5-0 (d, J = 8.3 Hz, 1 H), 2.65 (s, 3 H). MS (ESI-) for CroHgIN4O m/z 327 (M-H)-.

[00702] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (4- iodo-3-methylphenyl)-1 H-pyrazole-5-carboxylate

[00704] A slurry of freshly ground potassium carbonate (9.75 g, 70.6 mmol), ethyl bromoacetate (7.86g, 47mmol), and the hydrazone from the previous step (10.29 g, 31.4 mmol) was heated to 90°C under nitrogen for 2.5 h.

The solution was cooled and poured into ice (500 g). The aqueous mixture was then stirred at room temperature for 3 h and the precipitate was collected, washed with water and dried in vacuo to give a reddish-brown solid.'H NMR (300 MHz, DMSO-d6) : 5 7.87 (d, J = 8.2 Hz, 1 H), 7.58 (s, 1 H), 7.44 (s, 1 H), 7.33 (s, 1 H), 7.02 (d, J = 8. 2 Hz, 1 H), 5.7 (s, 2 H), 4.13 (q, J = 7.03 Hz, 2 H), 2.38 (s, 3 H), 1.10 (t, J = 7. 03 Hz, 3 H). MS (ESI-) for C, 4H, 5lN403 m/z 413 (M-H)-.

[00705] Step 3: Preparation of 4-amino-3- (aminocarbonyl)-1- (4-iodo-3- methySphenyl)-1 H-pyrazole-5"carboxylic acid, potassium salt [00707] A slurry of potassium hydroxide (8.20 g, 148 mmol) and the ester from the previous step (8.23 g, 19.9 mmol) in ethanol (80 mL) was stirred at room temperature for 48 h. The solution was cooled to 5°C, filtered and the resulting solid dried in vacuo to a brown solid.'H NMR (300 MHz ; DMSO-d6) : 5 7.72 (dd, J = 8.6, 4.2 Hz, 1 H), 7.36 (m, 1 H), 7. 18 (s, 1 H), 7.00-6. 96 (m, 2 H), 5.27 (s, 2 H), 2.33 (s, 3 H). MS (ESI-) for C, O, m/ 385 (M-).

[00708] Step 4: Preparation of 4-amino-1- (4-iodo-3-methylphenyl)-1 H- pyrazole-3-carboxamide [00710] A well stirred slurry of the potassiuim salt from the previous step (2.40 g, 5.7 mmol) and phosphoric acid (10 mL) was heated to 45°C for 2 h.

The temperature was gradually increased at 60 min. intervals until gas evolution

ceased. The final temperature was 65°C. The reaction mixture was cooled in an ice bath, neutralized with 50% sodium hydroxide and the mixture was repeatedly extracted with chloroform. The organics were combined, dried over anhydrous sodium sulfate and concentrated to give a red solid.'H NMR (300 MHz, DMSO- d6) : 6 7. 86-7.83 (m, 2 H), 7.76 (s, 1 H), 7.49 (s, 1 H), 7.41 (dd, J = 8. 3,2. 3 Hz, 1 H), 7.22 (s, 1 H), 4.85 (s, 2 H), 2.39 (s, 3 H). MS (ESI+) for C11H11IN4O m/z 343 (M+H)+.

[00711] Step 5: Preparation of 4-[(aminocarbonyl) amino]-1-(4-iodo-3- methylphenyl)-1 H-pyrazole-3-carboxamide [00713] To a slurry of the amine prepared in the previous step (650 mg, 1.90 mmol) and potassium cyanate (185 mg, 2.28 mmol) in a solvent mixture of isopropanol/water (1: 1,20 mL) was added 75% acetic acid (10 mL) and the reaction mixture stirred at room temperature for 5 h. The mixture was diluted with water (30 mL) and the precipitate filtered, ~ washed with water and air dried to give an off-white solid. This solid was dissolved in 1 mL of anhydrous DMSO and then crystallized through the careful addition of dichloromethane. This solid was filtered to provide the title compound. NMR (300 MHz, DMSO-d6) : # 8.65 (s, 1 H), 8. 56 (m, 1 H), 7.89-7. 89 (m, 2 H), 7.78 (s, 1 H), 7.50-7. 47 (m, 2 H), 6.49 (s, 2 H), 2.42 (s, 3 H). MS (ESI-) for C12H12 IN102, H mlz 384 (M-H)-.

[00714] Example 9: 4- [ (aminocarbonyl) amino]-l- [4- (morpholin-4-yl- carbonyl) phenyl]-1 H-pyrazole-3-carboxamide

[00716] A suspension of 4-[(aminocarbonyl) amino]-1 H-pyrazole-3- carboxamide (150 mg, 0.89 mmol) (prepared according to Example 19, from 4- amino-1 H-pyrazole-3-carboxamide, see J. Am. Chem. Soc. 78, 2418-2422 (1956) ) in pyridine (2.0 mL) and CH2CI2 (1. 0 mL) was treated with 4- (morpholine- 4-carbonyl) phenylboronic acid (208 mg, 0.89 mmol) and Cu (OAc) 2 (161 mg, 0.89 mmol). The reaction was stirred under nitrogen overnight. The crude mixture was concentrated, and redissolved in DMF (2 mL). The reaction mixture was then filtered through a syringe filter (0. 45 um), purified by prep. rpHPLC, and lyophilized to give the title compound as a white solid. ESI mass spectrum for C16H19N6O4+: 359.18 (M+1).

[00717] Example 10: 4-[(aminocarbonyl) amino]-1-(4-methoxyphenyl)- 1 H-pyrazole-3-carboxamide trifluoroacetateE [00719] Prepared according to the same procedure as Example 9.'H NMR (300 MHz, DMSO-d6) : # 3.80 (s, 3 H) 6.52 (s, 2 H) 7.02 (d, 2 H) 7.49 (m, 1 H) 7.70 (s, 1 H) 7.77 (d, 2 H) 8.49 (s, 1 H) 8.67 (s, 1 H). Mass of molecular ion (M + H) : 276.1.

[00720] Example 11: 4-[(aminocarbonyl)amino]-1-[3-(3, 4- dimethoxybenzyl) phenyl]-1 H-pyrazole-3-carboxamide

[00722] To a solution of 3, 4-dimethoxybenzylzinc chloride (0.5 M in THF, 3.1 mL, 3.1 mmol) was added 4- [ (aminocarbonyl) amino]-l- (3- bromophenyl)-1 H-pyrazole-3-carboxamide (Example 20,100 mg, 0.31 mmol), Pd (OAc) 2 (6.90 mg, 0.031 mmol) and triphenylphosphine (16.14 mg, 0.062 mmol). The reaction mixture was flushed with Ar three times. The reaction was heated to 40°C for 16 in a sealed. tube. The reaction was cooled to room temperature, filtered through a syringe filter (0. 45 um), purified by prep. rpHPLC, and lyophilized to give the title compound as a white solid.'H NMR (400 MHz, DMSO-d6) : b 3.68 (s, 3 H) 3.70 (s, 3 H) 3.92 (s, 2 H) 6.49 (m, 2 H) 6.75 (dd, J = 8.19, 2.01 Hz, 1 H) 6.84 (d, J = 8.32 Hz, 1 H) 6.89 (d, J = 1.88 Hz, 1 H) 7.17 (m, 1 H) 7.38 (t, J = 7.92 Hz, 1 H) 7.48 (m, 1 H) 7.67 (m, 1 H) 7.73 (m, 1 H) 7.77 (t, J = 1.75 Hz, 1 H) 8.53 (s, 1 H) 8.65 (s, 1 H). Mass of molecular ion (M + H): 396.1658.

[00723] Example 12: 4-[(aminocarbonothioyl) amino]-1-(3-bromophenyl)- 1 H-pyrazole-3-carboxamide [00725] 4-Amino-1- (3-bromophenyl)-1 H-pyrazole-3-carboxamide (281 mg, 1 mmol, prepared according to the process of Example 214, Steps 1-3) and ammonium thiocyanate (228 mg, 3 mmol) was dissolved in a mixture of conc. HCI (0.15 mL) and distilled water (1 mL). The reaction was stirred at 80°C

overnight. After cooling to room temperature, a white solid precipitated out of the crude mixture. The solid was collected by filtration and washed several times with water and cold methanol to give the title compound as a white solid.'H NMR (300 MHz, DMSO-d6) : 5 7.45-7. 60 (m, 3 H) 7.68 (s, 1 H) 7.86 (m, 1 H) 8.04 (s, 2 H) 8.18 (t, J = 1. 91 Hz, 1 H) 9.31 (m, 1 H) 9.83 (s, 1 H). Mass of molecular ion (M + H): 340.0.

[00726] Example 13: 4- [ (aminocarbonyl) amino]-1- [3- (2-chloropyridin-4- yl) phenyl]-1 H-pyrazole-3-carboxamide [00728] 2-chloropyridine-4-boronic acid (37.4 mg, 0.2 mmol), 4- [ (aminocarbonyl) amino]-1- (3-bromophenyl)-1 H-pyrazole-3-carboxamide (Example 20,78 mg, 0.24 mmol), and bis (triphenylphosphino) palladium dichloride (14 mg, 0.01 mmol) were sequentially added to degassed DMF (1 mL). The mixture was stirred at room temperature for 30 min. Degassed 2M aqueous cesium carbonate (0.3 mL) was added to the mixture, and the reaction mixture was heated to 95°C overnight. The reaction was cooled to room temperature, filtered through a syringe filter (0.45 um), purified by prep. rpHPLC, and lyophilized to give the title compound as a white solid.'H NMR (300 MHz, DMSO-d6) : 5 6.51 (m, 2 H) 7.55 (m, 1 H) 7.65 (t, J = 7. 95 Hz, 1 H) 7.81 (d, J = 7. 85 Hz, 1 H) 7.90 (m, 2 H) 8.03 (m, 2 H) 8.35 (t, J = 1. 81 Hz, 1 H) 8.51 (d, J = 5.24 Hz, 1 H) 8.68 (s, 1 H) 8.76 (s, 1 H). Mass of molecular ion (M + H): 357.1.

[00729] Example 14: 4-[(aminocarbonyl) amino]-1-(4-methoxyphenyl)- 1 H-pyrazole-3-carboxamide trifluoroacetate

[00731] Prepared according to the same procedure as Example 13.'H NMR (300 MHz, DMSO-d6) : õ 3.31 (s, 3 H) 6.50 (m, 2 H) 7.32 (m, 1 H) 7.50 (m, 4 H) 7.76 (m, 1 H) 7.87 (m, J = 7.65 Hz, 2 H) 8.55 (s, 1 H) 8.67 (s, 1 H). Mass of molecular ion (M + H): 387.6.

[00732] Example 15: 1- (3-bromophenyl)-4-<BR> {[(methylamino) carbonyl] amino}-1 H-pyrazole-3-carboxamide [00734] A solution of 4-amino-1- (3-bromophenyl)-1 H-pyrazole-3- carboxamide (100 mg, 0.37 mmol, prepared according to the process of Example 214, Steps 1-3) was treated with methyl isocyanate (23 mg, 0.40 mmol) in THF (1 mL). The reaction was stirred under nitrogen overnight. LC-MS indicated that the reaction was not complete, methyl isocyanate (23 mg, 0.40 mmol) was added to the mixture, and the reaction was stirred for another 4 h.

Water (10 mL) was added to the mixture, and a white solid precipitated out of the solution. The solid was filtered, and washed several times with water and cold methanol to give the title compound as a white solid.'H NMR (300 MHz, DMSO-d6) : 5 2.63 (d, J = 4.63 Hz, 2 H) 7.24 (m, 2 H) 7.43 (m, 3 H) 7.87 (m, 2 H) 8.19 (m, 1 H) 8. 63 (s, 1 H) 8.67 (s, 1 H). Mass of molecular ion (M + H): 338.1.

[00735] Examples 16 and 17 were prepared according to the same procedure as Example 19. Ex. Name and Structure'H NMR MS (ES+) (M+1) 16 1-(4-bromophenyl)-4- (300 MHz, DMSO-d6) : 338. 1 {[(methylamino) carbonyl] amino}-1 H-pyrazole-õ 2. 63 (d, J = 4. 63 Hz, 3-carboxamide 2 H) 7. 20 (m, 2 H) NH2 7. 43 (s, 1 H) 7. 68 (d, N 2 H) 7. 80 (m, 3H) N \N-aE, r 8. 58 (s, 1 H) 8. 67 (s, 1 HN o) ~ NH CH3 17 1- (4-iodophenyl)-4- (400 MHz, DMSO-D, {[(methylamino) carbonyl] amino}-1 H-pyrazole-o 2. 61 (d, J = 3. 76 Hz, 3-carboxamide 3 H) 7. 23 (s, 1 H) 7. 51 NH2 (s, 1 H) 7. 76 (m, 5 H) = ; N 8 57 (s, 1 H) 8. 67 (s, N I H) Han HN4 : N fisc O Hic

[00736] Example 18: 4- [ (aminocarbonyl) amino]-1- (4-methylphenyl)-1 H-<BR> <BR> pyrazole-3-carboxamide [00738] A suspension of 4-[(aminocarbonyl) amino]-1 H-pyrazole-3- carboxamide (30 mg, 0.18 mmol) in DMF (1.0 mL) was treated with p-tolyboronic acid (29 mg, 0.22 mmol) and Cu (I) CI (3.4 mg, 0.03 mmol). Pyridine (0.022 mL) was added to the mixture. The vial was sealed with a crimped cap and the reaction mixture was heated in the CEM Microwave instrument at 75°C for 2 h at full power (300 W). The reaction was cooled to room temperature, filtered

through a syringe filter (0. 45 um), purified by prep. rpHPLC, and lyophilized to give the title compound as a white solid.'H NMR (300 MHz, DMSO-d6) : 5 2.33 (s, 3 H) 6.48 (s, 2 H) 7.29 (d, J = 8.66 Hz, 2 H) 7.49 (s, 1 H) 7.73 (m, 3 H) 8.49 (s, 1 H) 8.65 (s, 1 H). Mass of molecular ion (M + H): 260.1.

[00739] Example 19: 4-[(aminocarbonyl) amino]-1-(4-bromophenyl)-1H- pyrazole-3-carboxamide [00741] 4-Amino-1- (4-bromophenyl)-1 H-pyrazole-3-carboxamide (5 g, 17.8 mmol, prepared according to the process of Example 214, Steps 1-3) and sodium cyanate (4.045 g) were partially dissolved in a mixture of acetic acid (70 mL) and water (20 mL). The suspension was stirred overnight at room temperature. Most of solvents were removed under reduced pressure and water (100 mL) was added to the residue. After trituration for 3 h, the solid was filtered, washed with 2N sodium bicarbonate solution, and dried. The dry solid was dissolved in a minimal amount of DMSO. The obtained solution was added with stirring to 1 L of methylene chloride and after 1 h it was filtered and the solid dried to give the title compound.'H NMR (DMSO-d6) : 5 6.51 (br s, 2H), 7.54 (br s, 1 H), 7.68 (dd, 2H, J = 4.9, 2.0 Hz), 7.82 (br s, 1 H), 7.86 (dd, 2H, J = 5.0, 1.9 Hz), 8.58 (s, 1 H), 8. 67 (s, 1 H). Mass of molecular ion (M + 1): 324.

[00742] Example 20: 4-[(aminocarbonyl) amino]-1-(3-bromophenyl)-1 H- pyrazole-3-carboxamide

[00744] Prepared according to the same procedure as Example 19.'H NMR (300 MHz, DMSO-d6) : # 6.52 (s, 2 H) 7.43 (t, J = 8.06 Hz, 1 H) 7.49 (m, 1 H) 7.52 (m, 1 H) 7.86-7. 92 (m, 2 H) 8.19 (t, J = 1.91 Hz, 1 H) 8.61 (s, 1 H) 8.67 (s, 1 H). ESI mass spectrum for C11H11BrN5O2+: 324. 0059 (M+1).

[00745] Examples 21-95: 4-[(aminocarbonyl) amino]-1-(4-arylphenyl)- 1 H-pyrazole-3-carboxamides [00746] 4-[(aminocarbonyl) amino]-1-(4-bromophenyl)-1 H-pyrazole-3- carboxamide (Example 19 ; 0.19 g, 0.6 mmol), Pd [PPh3] 4 (50 mg), and 0.9 mmol of an arylboronic acid were added to a flask and placed under vacuum then refilled with nitrogen. The vacuum/N2 cycle was repeated twice. DMF (3 mL)-and 0.9 mL of 2M Cs2CO3 solution were injected under N2. (The DMF and Cs2CO3 solutions were bubbled with N2 for 15 minutes before addition). The suspension was heated and stirred at 80°C overnight. Most of liquids were removed under reduced pressure. The solid was triturated with water (80 mL), filtered, triturated with methanol (5-10 mL) for 1-3 h, filtered and dried to give the compounds shown in the following table. Ex. Name and Structure'H NMR MS (ES') (M+1) 21 4-[(aminocarbonyi) amino]-1-(4-pyridin-3- (CD3OD/DMSO-d6 323 ylphenyl)-1 H-pyrazole-3-carboxamide (4 : 1)) : 5 7. 42-7. 50 (m, NHa 1 H), 7. 82 (d, 2H, J = 8. 7 dz), 7. 96 (d, 2H, J N = 8. 7 Hz), 8. 04-8. 14 (m, 1 H), 8. 49-8. 56 (m, HN 1 H), 8. 59 (s, 1 H), 8. 89 oNH, (s. 1H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 22 4-[(aminocarbonyl) amino]-1-(3'-hydroxy-1, 1'- (CD3OD/DMSO-d6 338 biphenyl-4-yl)-1H-pyrazole-3-carboxamide (4 : 1)) : 5 6. 56 (dm, 1H, NH2 OH J = 6. 4 Hz), 7. 08 (t, 1 H, J = 1. 7 Hz), 7. 12 (d, 1 H, J = 7. 8 Hz), HN 7. 25 (t, 1 H, J = 7. 9 Hz), 7. 73 (d, 2H, J = NH2 8. 8 Hz), 7. 88 (d, 2H, J =8. 7Hz), 8. 55 (s, 1H) 23 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'- (CD3OD/DMSO-d6 338 biphenyl-4-yl)-1H-pyrazole-3-carboxamide (4 : 1)) : 5 6. 79-6. 86 (m, NH2 HO 2H), 7. 04-7. 12 (m, 1 H), 7. 22 (dd, 1H, J= 6. 2, 1. 4 Hz), 7. 62 (d, 2H, J = 8. 7 Hz), 7. 78 N p7 - (d, 2H, J=8. 7Hz), O+NH2 8. 47 (s, 1 H) 24 4- [ (aminocarbonyl) amino]-l- [3'- (CD30D) : õ 7. 18 (d, 406 (trifluoromethoxy)-1, 1'-biphenyl-4-yl]-1 H-1 H, J = 8. 2 Hz), 7. 42- pyrazole-3-carboxamide 7. 62 (m, 2H), 7. 68 (d, NH2 1 H, J = 8. 1 Hz), 7. 79 OS N (d, 2H, J = 8. 7 Hz),- N 7. 95 (d, 2H, J = 8. 7 HN Hz), 8. 57 (s, 1H) han zozo 0'NH2 F3C 25 4-[(aminocarbonyl) amino]-1-(4'-fluoro-1, 1'- (DMSO-d6) : õ 6. 50 (br 340 biphenyl-4-yl)-1H-pyrazole-3-carboxamide s, 2H), 7. 29 (t, 2H, J = NH2 8. 8 Hz), 7. 53 (br s, 1 H), 7. 70-7. 87 (m, N 0 N F 5H), 7. 89 (d, 2H, J= 8. 5 dz), 8. 62 (s, 1 H), 8. 69 (s, 1 H) o'NH2 26 4- [ (aminocarbonyl) amino]-l- [4- (l H-pyrrol-2- (CD30D) : 5 5. 52-5. 61 311 yl) phenyl]-1H-pyrazole-3-carboxamide (m, 1H), 6. 52-6. 62 (s, NHz 1H), 6. 71-7. 77 (m, 1 H), 7. 68 (d, 2H, J= 8. 7 Hz), 7. 77 (d, 2H, J HN HNJ = 8. 7 Hz), 8. 49 (s, 1 H) HAN o) ~NH2 Ex. Name and Structure'H NMR MS (ES') (M+1) 27 4- [ (aminocarbonyl) aminol-l- [3'- (DMSO-d, (cyanomethyl)-1, 1'-biphenyl-4-yl]-1 H-2H), 6. 55 (br s, 2H), pyrazole-3-carboxamide 7. 37 (d, 1 H, J = 7. 8 NHz Hz), 7. 48-7. 56 (m, 2H), 7. 66-7. 73 (m, (3H J= \N 2H), 7. 79 (d, 3H, J > tt < 8. 7 Hz), 7. 99 (d, 2H, J = 8. 7 Hz), 8. 60 (s, oll- 1 H), 8. 72 (s, 1H) NH2 NC 28 4- [ (aminocarbonyl) amino]-l- [3'- (CD30D/DMSO-d, 351 (aminomethyi)-1, 1'-biphenyl-4-yl]-1H- (4 : 1)) : 5 3. 79 (s, 2H), pyrazole-3-carboxamide 7. 26 (d, 1 H, J = 7. 5 NHa Hz), 7. 35 (t, 1 H, J = N 7. 6 Hz), 7. 79 (d, 2H, J _ r Na-8. 7. Hz),. 7. 72 (d, 1H, H J = 8. 8 Hz), 7. 62 (s, HN \ 1 H), 7. 84 (d, 2H, J = NH2 H 8. 8 Hz), 8. 50 (s, 1 H) O NH2 H2N/ 29 methyl 2-amino-4'- {3- (aminocarbonyl)-4- (DMSO-d, [(aminocarbonyl) amino]-1H-pyrazol-1-yl}-3H), 5. 18 (s, 2H), 6. 55 1, 1'-biphenyl-4-carboxylate (brs, 2H), 7. 15 (d, 1H, NH2 H2N J = 7. 9 Hz), 7. 19 (dd, 0 N\ 0 1 H, J, = 6. 3, 1. 5 Hz), f NA \ 7. 42 (d, 1 H, J = 1. 5 HN O-CH3 Hz), 7. 55 (br s, 1H), 7. 59 (d, 2H, J= 8. 7 O+NH2 Hz), 7. 90 (br s, 1 H), 7. 99 (d, 2H, J = 8. 7 Hz), 8. 60 (s, 1H), 8. 70 (s, 1H) 30 4-[(aminocarbonyl) amino]-1-(2'-fluoro-1, 1'- (CD3ODtDMSO-d6 340 biphenyl-4-yl)-1H-pyrazole-3-carboxamide (4 : 1)) : 5 7. 15-7. 28 (m, NH2 2H), 7. 30-2. 40 (m, 1 H), 7. 46-7. 56 (m, 1H), 7. 63, (d, 2H, J= 8. 7 Hz), 7. 88 (d, 2H, J HN = 8. 7 Hz), 8. 55 (s, 1 H) O-NHz Ex. Name and Structure'H NMR MS (ES+) (M+1) 31 4-[(aminocarbonyl) amino]-1-{3'-[(tert- (CD3OD/DMSO-d6 421 butylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1H- (4 : 1)) : 6 1. 40 (s, 9H), pyrazole-3-carboxamide 7. 46 (t, 1 H, J = 7. 8 NHz Hz), 7. 67 (d, 1 H, J = 8. 0 Hz), 7. 73 (s, 1 H), 0 N 7. 77 (d, 2H, J = 8. 9 Hz), 7. 89 (d, 2H, J= HN NH 8. 9 Hz), 7. 94-8. 00 (m, -NH I H), 8. 52 (s, 1 H) H3C CH3 32 4-[(aminocarbonyl) amino]-1-{3'-[(E)-2- (DMSO-d6) : 56. 52 (br 373 cyanovinyl]-1, 1'-biphenyl-4-yl}-1H-pyrazole-3-s, 2H), 6. 64 (d, 1H, J carboxamide = 16. 7 Hz), 7. 45-7. 60 CN (m, 2H), 7. 66 (d, 1 H, J = 7. 8 Hz), 7. 79-7. 92 0 q. (m, 4H), 7. 96-8. 08 (m, N 4H), 8. 63 (s, 1H), 8. 71 HN (s, 1 H) ''NH2 33 4-[(aminocarbonyl) amino]-1-{4'-[(pyridin-2- (DMSO-d6) : 6 6. 52 (br 442 ylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H-s, 2H), 7. 18 (t, 1H, J= pyrazole-3-carboxamide 6. 1 Hz), 7. 55 (br s, 1 H), 7. 80-7. 90 (m, NH2 \ 6H), 8. 02 (d, 2H, J = 8. 6 dz), 8. 15 (d, 2H, J Oz JNX NH = 8. 5 Hz), 8. 20 (d, 1 H, J = 8. 5 Hz), 8. 38 (d, HN ° 1 H, J = 3. 4 Hz), 8. 65 k (s, 1 H), 8. 70 (s, 1 H) o//NH2 34 4- [ (aminocarbonyl) amino]-1- [4'- (morpholin-4- (CD3OD/DMSO-ds 421 ylmethyl)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3- (4 : 1)) : õ 2. 20-2. 40 (m, carboxamide 4H), 3. 50-3. 70 (m, NH2 4H), 7. 33 (d, 2H, J = od\ N 7. 7Hz), 7. 56 (d, 2H, J 0 N-7. 7 Hz), 7. 67 (d, 2H, HN N J = 8. 3 Hz), 7. 81 (d, HNI g n 2H, J = 8. 2 Hz), 8. 47 'NHZ Ex. Name and Structure'H NMR MS (ES+) (M+1) 35 4- [ (aminocarbonyl) amino]-l- {4'- (DMSO-d,) : õ 4. 50 (d, 455 [(benzylamino) carbonyl]-1, 1'-biphenyl-4-yl}-2H, J = 5. 7Hz), 6. 51 1H-pyrazole-3-carboxamide (br s, 2H), 7. 20-7. 40 NHz (m, 5H), 7. 53 (br s, 0 uo I H), 7. 78-7. 89 (m, 5H), 7. 98 (d, 4H, J = 8. 1 Hz), 8. 62 (s, 1H), HN 8. 68 (s, 1 H), 9. 20 (t, NH, 1 H, J = 5. 7 Hz) 36 4-[(aminocarbonyl) amino]-1-(4'-hydroxy-1, 1'- (CD3OD/DMSO-d6 338 biphenyl-4-yl)-1H-pyrazole-3-carboxamide (4 : 1)) : 5 6. 81 (d, 2H, J NH2 = 8. 6 Hz), 7. 46 (d, 2H, O\ N J = 8. 6 Hz), 7. 63 (d, 2H, J = 8. 7 Hz), 7. 79 HN (d, 2H. J=8. 7Hz). 8. 50 (s, 1 H) ONH, 37 4- [ (aminocarbonyl) amino]-l- [4'- (CD, OD/DMSO-d. 361 (cyanomethyl)-1, 1'-biphenyl-4-yl]-1H- (4 : 1)) : 5 3. 97 (s, 2H), pyrazole-3-carboxamide 7. 40 (d, 2H, J = 8. 2 NH2 Hz), 7. 67 (d, 2H, J = 8. 2 Hz), 7. 75 (d, 2H, J \N = 8. 7 Hz), 7. 88 (d, 2H, J = 8. 7 Hz), 8. 55 (s, 1 H) o-NHz 38 4- [ (aminocarbonyl) amino]-1- [4'- (CD3 OD/DMSO-ds 352 (hydroxymethyl)-1, 1'-biphenyl-4-yl]-1H- (4 : 1)) : 6 4. 57 (s, 2H), pyrazole-3-carboxamide 7. 37 (d, 2H, J = 8. 1 NHz Hz), 7. 60 (d, 2H, J = 8. 1 Hz), 7. 73 (d, 2H, J = 8. 6 Hz), 7. 83 (d, 2H, N Ho OH J 8. 6 Hz), 8. 52 (s, 1 H) 'NHZ Ex. Name and Structure'H NMR MS (ES+) (M+1) 39 4- [ (aminocarbonyl) amino]-1- [3'- (CD3 OD/DMSO-ds 352 (hydroxymethyl)-1, 1'-biphenyl-4-yl]-1H- (4 : 1)) : 6 4. 57 (s, 2H), pyrazole-3-carboxamide 7. 22-7. 28 (m, 1 H), NH2 7. 30-2. 38 (m, 1 H), 7. 43-7. 50 (m, 1H), Oz \ NX 7. 54-7. 58 (m, 1H), 7. 67 (d, 2H, J = 8. 7 N Hz), 7. 80 (d, 2H, J = 8. 7 Hz), 8. 46 (s, 1H) NHa HO 40 4-[(aminocarbonyl) amino]-1-(4-pyridin-4- (CD3OD/DMSO d6 323 ylphenyl)-1H-pyrazole-3-carboxamide (4 : 1)) : 6 7. 72 (d, 2H, J NH2 = 5. 3 Hz), 7. 91 (d, 2H, J = 8. 5 Hz), 8. 00 (d, pi N-- 2H, J = 8. 6 Hz), 8. 56- 8. 64 (s, 3H) HN O-NHz O 2 41 4- [ (aminocarbonyl) amino]-l- (3'-fluoro-1, 1'- (300 MHz, DMSO-d6) : 340. 17 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide õ 6. 51 (br s, 2H), 7. 24 NHz F (m, 1H), 7. 47-7. 70 (m, 6H) 7. 88 (s, 1 H) 7. 90 (d, J, =1. 2Hz1 H) 8. 22 (m, 1 H) 8. 68 (s, HNX 1 H) 8. 71 (s, 1 H) % \NH2 42 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-1, 1'- (300 MHz, DMSO-d,) : 340. 17 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide õ 6. 51 (br s, 2H) 7. 28 NHz (t, J = 8. 9 Hz, 2 H) o= (7. 48-7. 65 (m, 3H) N 7. 77-7. 91 (m, 4H) HN 8. 16 (m, 1H) 8. 68 (s, N NH2 v 43 4-[(aminocarbonyl) amino]-1-(3-thien-3- (300 MHz, DMSO-d,) : 328. 0867 ylphenyl)-1 H-pyrazole-3-carboxamide õ 6. 52 (br s, 2H), NH2 7. 50-7. 60 (m, 2H), o= (7. 66-7. 72 (m, 3H), N s 7. 82 (d, J = 7. 5 Hz, 1 HN H), 7. 87 (s, 1H), 8. 06 o I (m, 1 H), 8. 23 (s, 1 H), NH2 8. 67 (m, 2H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 44 4- [ (aminocarbonyl) amino]-1- [4'- (300 MHz, DMSO-d,) : 361. 1406 (cyanomethyl)-1, 1'-biphenyl-3-yl]-1H-o 4. 10 (s, 2H), 6. 52 pyrazole-3-carboxamide (br s, 2H), 7. 48 (d, J = NH2 7. 90 Hz, 2 H), 7. 53 (s, 1 H), 7. 62 (m, 2H), N CN 7. 860-7. 90 (m, 4H), HN \ N 8. 19 (s, 1 H), 8. 67 (m, N NH2 45 4- [ (aminocarbonyl) amino]-I- (3-pyridin-4- (300 MHz, DMSO-d,) : 323. 1270 ylphenyl)-1 H-pyrazole-3-carboxamide 5 6. 52 (br s, 2H), 7. 55 NH2 (br s, 1 H), 7. 64 (t, J = o= (8. 02 Hz, 1 H), 7. 76 (d, J = 8. 33 Hz, 1 H), 7. 84 (m, 2H), 7. 90 (s, 4 V 1 Hj, 7. 99 (d, J = 8. 02 NHz 9 Hz, 1 H), 8. 32 (s, 1H), 8. 67 (m, 3H), 8. 73 (s, 1 H) 46 4-[(aminocarbonyl) amino]-1-(3-pyridin-4- (300 MHz, DMSO-d6) : 323. 1 ylphenyl)-l H-pyrazole-3-carboxa mid e 5 6. 51 (m, 2 H) 7. 50- NHz 7. 58 (m, 2 H) 7. 61 (t, 0 N J = 7. 95 Hz, 1 H) 7. 70 N (m, I H) 7. 88-7. 95 (m, HN 2 H) 8. 20 (m, I H) N NH2 9 H) 8. 62 (m, 1 H) 8. 68 (s, 1 H) 8. 72 (s, 1 H) 9. 02 (d, J = 2. 22 Hz, 1 H) 47 4- [ (aminocarbonyl) amino]-l- (4'-hydroxy-1, 1'- 338. 1 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide NH2 0 OH \ NHz I/ Ex. Name and Structure'H NMR MS (ES+) (M+1) 48 4- [ (aminocarbonyl) amino]-1- [4'- (300 MHz, DMSO-d,) : 352. 1 (hydroxymethyl)-1, 1'-biphenyl-3-yl]-1 H-õ 4. 55 (d, J = 4. 03 Hz, pyrazole-3-carboxamide 2 H) 5. 24 (t, J = 4. 03 NHz Hz, 1 H) 6. 51 (s, 2 H) o= (7. 43 (d, J = 8. 05 Hz, 2 oH H) 7. 60-7. 65 (m, 3 H) H N 7. 75 (d, J = 8. 05 Hz, 2 H) 7. 83 (m, 1 H) 7. 88 NH2 9 (s, 1 H) 8. 18 (t, J = 1. 81 Hz, 1 H) 8. 67 (s, 1 H) 8. 69 (s, 1 H) 49 4- [ (aminocarbonyl) amino]-1- [3'- (300 MHz, DMSO-d,) : 352. 1380 (hydroxymethyl)-1, 1'-biphenyi-3-yl]-1 H-õ 4. 59 (d, J = 5. 64 Hz, pyrazole-3-carboxamide 2 H) 5. 26 (t, J = 5. 64 NH2 OH Hz, 1 H) 6. 52 (s, 2 H) 7. 30-7. 75 (rni-7 H) ) 7. 85 (m, 2 H) 8. 14 (m, H N I H) 8. 66 (s, 1 H) 8. 69 NH2 0 NHz I/ 50 1-(3'-amino-1, 1'-biphenyl-3-yl)-4- (300 MHz, DMSO-d6) : 337. 1400 [ (aminocarbonyl) amino]-1H-pyrazole-3-b 5. 19 (s, 2 H) 6. 52 (s, carboxamide 2 H) 6. 60 (d, J = 7. 85 NH2 NH Hz, 1 H) 6. 90-6. 97 (m, 2H) 7. 12 (t, J = 7. 75 ) N Hz, 1 H) 7. 48-7. 60 (m, HN 3 H) 7. 80 (d, J = 7. 05 Hz, I H) 7. 85 (s, 1 H) NHz 8. 03 (s, 1 H) 8. 62 (s, 1 H) 8. 69 (s, 1 H) 51 4- [ (aminocarbonyl) amino]-l- [4'- (morpholin-4- (300 MHz, DMSO-d,,) : 421. 1987 ylmethyl)-1, 1'-biphenyl-3-yl]-1H-pyrazole-3-õ 2. 37 (m, 4 H) 3. 50 carboxamide (s, 2 H) 3. 57 (m, 4 H) NH2 6. 52 (s, 2 H) 7. 41 (d ; J o= (= 8. 06 Hz, 2 H) 7. 50- - N N 7. 90 (m, 7 H) 8. 17 (s, HN 1 H) 8. 67 (s, I H) 8. 69 (s, 1 H) NH2 Ex. Name and Structure'H NMR MS (ES+) (M+1) 52 4- [ (aminocarbony !) amino]-1- [4'- (300MHz, DMSO-d,) : 351. 1595 (aminomethyl)-1, 1'-biphenyl-3-yl]-1H-b 3. 80 (s, 2H) 6. 50 (br pyrazole-3-carboxamide s, 2H) 7. 50 (d, J = 8. 1 NH2 Hz 2 H) 7. 51-7. 64 (m, 3H) 7. 73 (d, J = 8. 3 SN I~NH2 Hz 2 H) 7. 82 (d, 1 H) HN 7. 88 (1, 1H) 8. 17 (m, 0 1 H) 8. 60 (s, I H) 8. 69 (s, I H) 53 1- (4'-acetyl-1, 1'-biphenyl-3-yl)-4- (300 MHz, DMSO-ds) : 364. 1435 [ (aminocarbonyl) amino]-l H-pyrazole-3-5 2. 62 (s, 3H) 6. 52 (br carboxamide s, 2H) 7. 51-7. 79 (m, NHz o 3H) 7. 89 (d, J = 6. 3 Hz, 2H) 7. 94 (d, J= N q3 8. 1 Hz 2 H) 8. 05 (d, J HN4\ N l ffi = 8. 1 Hz 2 H) 8. 26 (1, 1H) 8. 69 (s, 1 H) 8. 71 o NNZ I/ (s, 1 H) 54 1- (4'-amino-1, 1'-biphenyl-3-yl)-4- (300 MHz, DMSO-d,) : 337. 1 [ (aminocarbonyl) amino]-1 H-pyrazole-3-b 6. 52 (br s, 2H) 6. 66 carboxamide (d, 2H) 7. 39-7. 60 (m, NH2 6H) 7. 86 (s, 1 H) 7. 98 O /NH (s, 1H) 8. 57 (s, 1H) < No< NH2 8. 69 (s, 1H) HN N Ioula NH2 v 55 1- [4'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- (300 MHz, DMSO-ds) : 379. 1 [ (aminocarbonyl) amino]-l H-pyrazole-3-6 2. 06 (s, 1 H) 6. 52 (br carboxamide s, 2H) 7. 50-7. 95 (m, NH2 O. CHs 9H) 8. 32 (s, 1 H) 8. 66 (s, 1 H) 8. 68 (s, 1 H) N NH 10. 06 (s, 1 H) HN 0 : N NU2 NH2 I/ 56 4- [ (aminocarbonyl) amino]-l- (3', 4'-d imethoxy- (300 M Hz, DMSO-d6) : 382. 1550 _ 1, 1'-biphenyl-3-yl)-1H-pyrazole-3-õ 3. 80 (s, 3H) 3. 87 (s, carboxamide 3H) 6. 52 (br s, 2H) NHz 7. 04 (d, J 9 Hz, 1 H) 7. 31 (m, 2H) 7. 56 (m, -N CH3 3H) 7. 78 (d, J = 9 Hz, HN 1 H) 7. 86 (s, 1 H) 8. 12 0 N O.-ICH3 (s, I H) 8. 66 (s, 1 H) Nu2 8. 69 (m, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 57 4- [ (aminocarbonyl) amino]-l- [3- (l H-pyrazol-4-312. 1 yl) phenyl]-1 H-pyrazole-3-carboxamide NHz 0 N.-N HO NU \ O NH2 NHz 58 3'- {3- (aminocarbony))-4- (300MHz, DMSO-d,) : 366. 1190 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-õ 6. 52 (br s, 2H) 7. 54 1, 1'-biphenyl-4-carboxylic acid (s, 1H) 7. 62 (m, 1H) NH2 0 7. 69 (d, J = 7. 8 Hz 1 H) 7. 87-8. 00 (m, 4H) - N OH 8. 06 (d, J = 8. 7 Hz 2 HN H) 8. 26 (s, 1 H) 8. 68 N H2 NHz 59 4-[(aminocarbonyl) amino]-1-{4'- (300 MHz, DMSO-d,) : 415. 1226 [(methylsulfonyl) amino]-1, 1'-biphenyl-3-yl}-õ 3. 01 (s, 3 H) 6. 51 (s, 1 H-pyrazole-3-carboxamide 2 H) 7. 31 (m, 2 H) NHz 7. 56 (m, 3 H) 7. 77 (m, H o 2 H) 7. 82 (dt, J = 7. 60, /N SCH 1. 74 Hz, 1 H) 7. 86 (s, HN Oli CH3 1 H) 8. 15 (t, J=1. 71 p Hz, 1 H) 8. 66 (s, 1 H) NHz 8. 68 (s, 1 H) 9. 90 (m, 1 H) 60 4-[(aminocarbonyl) amino]-1-(3-quinolin-5- (300 MHz, DMSO-d6) : 373. 1 ylphenyl)-1 H-pyrazole-3-carboxamide õ 6. 48 (m, 2 H) 7. 40- NH2 N 8. 00 (m, 8 H) 8. 07 (m, 2 H) 8. 21 (m, 1 H) N 8. 68 (m, 2 H) 8. 95 HN (dd, J = 4. 23, 1. 61 Hz, o w u 1 H) NH2 NH2 61 4- [ (aminocarbonyl) amino]-l- [4'- (300 MHz, DMSO-d,) : 365. 2 (dimethylamino)-1, 1'-biphenyl-3-yl]-1H-õ 2. 95 (s, 6 H) 6. 47 pyrazole-3-carboxamide (m, 2 H) 6. 81 (d, J = NHz 8. 86 Hz, 2 H) 7. 52 (m, 0 1 3 H) 7. 64 (d, J = 8. 86 kN NscH3 Hz, 2 H) 7. 71 (m, 1 H) N CN3 HN 7. 86 (m, 1 H) 8. 08 (m, 0== I H) 8. 63 (s, I H) 8. 68 NH 9 (s, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 62 4- [ (aminocarbonyl) amino]-I- [3- (1, 3- (300 MHz, DMSO-d6) : 366. 1 benzodioxol-5-yl) phenyl]-1H-pyrazole-3-o 6. 07 (s, 2 H) 6. 51 carboxamide (m, 2 H) 7. 02 (d, J = NHz 8. 06 Hz, 1 H) 7. 28 o= (dd, J= 8. 16, 1. 91 Hz, N 1 H) 7. 40 (d, J = 1. 81 HN N I Hz, 1 H) 7. 52 (m, 3 H) 7. 80 (m, 1 H) 7. 88 (m, NHz 1 H) 8. 11 (t, J= 1. 71 Hz, 1 H) 8. 67 (m, 2 H) 63 4- [ (aminocarbonyl) amino]-l- [3- (2- (300 MHz, DMSO-d,,) : 337. 1 methylpyridin-4-yl) phenyl]-1 H-pyrazole-3-õ 2. 55 (s, 3 H) 6. 51 carboxamide (m, 2 H) 7. 55 (m, 1 H) NH2 7. 62 (m, 2 H) 7. 72 (m, 0 2 H) 7. 89 (m, 1 H) . 7. 97 (d, J = 8. 05- Hz ; i HN N I H) 8. 28 (t, J =-i. 9 i N NHz 5. 24 Hz, 1 H) 8. 68 (m, 1 H) 8. 71 (s, 1 H) 64 4- [ (aminocarbonyl) amino]-l- [3- (4-methyl-3, 4- (300 MHz, DMSO-d,) : 393. 1663 dihydro-2H-1, 4-benzoxazin-7-yl) phenyl]-1 H-õ 2. 86 (m, 3 H) 3. 26 pyrazole-3-carboxamide (m, 2 H) 4. 25 (m, 2 H) Nu2 0 6. 48 (m, 2 H) 6. 77 (d, J = 8. 46 Hz, 1 H) 7. 12 - N N, CH3 (m, 1 H) 7. 23 (d, J= HN N 1 6. 65 Hz, 1 H) 7. 51 (m, 0-- 1 3 H) 7. 70 (d, J=6. 65 NHz 9 Hz, 1 H) 7. 88 (m, 1 H) 8. 04 (m, 1 H) 8. 63 (s, 1 H) 8. 69 (s, 1 H) 65 4- [ (aminocarbonyl) amino]-1- [3- (1H-indol-5- (300 MHz, DMSO-d,) : 361. 1403 yl) phenyl]-1 H-pyrazole-3-carboxamide 6 6. 51 (m, 3 H) 7. 39 NHz (m, 1 H) 7. 50 (m, 4 H) NH 7. 63 (m, 1 H) 7. 76 (m, N Y 1 H) 7. 88 (m, 1 H) \ I t. u !) (m, I H) 8. 17 (t, 0 J = 1. 81 Hz, 1 H) 8. 65 Nu2 9 (s, 1 H) 8. 69 (s, 1 H) 11. 17 (s, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 66 4- [ (aminocarbonyl) amino]-1- (3-pyrimidin-5- (300 MHz, DMSO-d6) : 324. 1 ylphenyl)-1 H-pyrazole-3-carboxamide 5 6. 51 (m, 2 H) 7. 53 NH2 (m, 1 H) 7. 65 (t, J = o 7. 95 Hz, 1 H) 7. 78 (m, 1 H) 7. 91 (m, 2 H) HN 8. 01 (m, 1 H) 8. 40 (m, p"1 H) 8. 66 (m, 1 H) NH2 8. 76 (s, 1 H) 9. 22 (s, 1 H) 9. 28 (s, 1 H) 67 4-[(aminocarbonyl) a mino]-1-{3-[(E)-2- (300 MHz, DMSO-d,) : 348. 1 phenylvinyl] phenyl}-1H-pyrazole-3-b 6. 51 (m, 2 H) 7. 26- carboxamide 7. 69 (m, 10 H) 7. 79 NH2 (m, 2 H) 8. 14 (m, 1 H) dz 64 (s, 1 H) 8. 69 (s, 1 SN 1< H) _N/I H) HN N NH2 v 68 4- [ (aminocarbonyl) amino]-l- [3- (l H-pyrrol-2-311. 1256 yl) phenyl]-1 H-pyrazole-3-carboxamide NH2 0 N Ho - \NHa I.- 69 4- [ (aminocarbonyl) amino]-l- [3- (3- (400 MHz, DMSO-d,) : 337. 1422 methylpyridin-4-yl) phenyl]-1 H-pyrazole-3-b 2. 36 (s, 3 H) 6. 50 carboxamide (m, 2 H) 7. 41 (m, 1 H) NHz 7. 52 (s, 1 H) 7. 64 (t, J o= (, = 8. 19 Hz, 1 H) 7. 72 - N N (d, J = 5. 37 Hz, 1 H) 7. 82 (s, 1 H) 8. 00 (dd, o= (< v J = 2. 28, 0. 94 Hz, 1 NHz 9 H) 8. 02 (d, J = 0. 81 Hz, 1 H) 8. 66 (m, 2 H) 8. 69 (d, J = 5. 37 Hz, 1 H) 8. 76 (s, 1 H) Ex. Name and Structure'H NMR MS (ES') (MHz 70 4- [ (aminocarbonyl) amino]-l- [3- (3, 5- 341. 1290 dimethylisoxazol-4-yl) phenyl]-1 H-pyrazole-3- carboxamide NHz 0 H3C HAN N HN N I s N HN<N x<N 04 11 1 NH2 9 CH3 71 4-[(aminocarbonyl) amino]-1-(2'-hydroxy-1, 1'- (400 MHz, DMSO-d,) : 338. 1247 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide õ 6. 48 (m, 2 H) 6. 90 NHz (m, 2 H) 7. 16 (m, 1 H) o= (7. 32 (m, 1 H) 7. 48 (m, N 3 H) 7. 76 (m, 2 H) HN 7. 99 (m, 1 H) 8. 56 (s, 1 H) 8. 67 krn, 1 H) NH2 9 OH 9. 62 (s, 1 H) 72 4-[(aminocarbonyl) amino]-1-(3'-hydroxy-1, 1'- (400 MHz, DMSO-d6) : 338. 1 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide õ 6. 50 (m, 2 H) 6. 79 NH2 (m, 1 H) 7. 10 (m, 1 H) o=¢ 7. 16 (d, J= 8. 32 Hz, 1 - N H) 7. 27 (t, J= 7. 79 HN Hz, 1 H) 7. 49 (s, 1 H) o OH 7. 54 (m, 3 H) 7. 82 (m, NH2 2 H) 8. 08 (m, J = 1. 34 Hz, 1 H) 8. 63 (s, 1 H) 8. 67 (s, 1 H) 9. 54 (m, 1 H) 73 3'- {3- (aminocarbonyl)-4- (300 MHz, DMSO-d,) : 366. 1 [(aminocarbonyi) amino]-1 H-pyrazol-1-yl}-õ 6. 48 (m, 2 H) 7. 51 1, 1'-biphenyl-3-carboxylic acid (m, 1 H) 7. 63 (m, 3 H) NH2 O » OH 7. 91 (m, 2 H) 7. 98 (d, o= (l J = 7. 65 Hz, 1 H) 8. 04 ) (d, J=7. 85 Hz, 1 H) HN 8. 23 (dt, J= 15. 71, og < v 1. 61 Hz, 2 H) 8. 68 (s, NH2 I H) 8. 70 (s, 1 H) 13. 21 (m, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 74 4- [ (aminocarbonyl) amino]-1- {4'- (300 MHz, DMSO-D, [(methylamino) carbonyl]-1, 1'-biphenyl-3-yl}-õ 2. 80 (m, 3 H) 6. 51 1 H-pyrazole-3-carboxamide (s, 2 H) 7. 52 (m, 1 H) NHz 7. 59 (t, J = 7. 85 Hz, 1 0"CH3 H) 7. 69 (d, J = 8. 05 ) : N N Hz, I H) 7. 84-8. 03 (m, HN H 6 H) 8. 24 (t, J = 1. 81 Hz, 1 H) 8. 52 (d, J = NHz 4. 63 Hz, 1 H) 8. 69 (s, z 1 H) 8. 70 (s, 1 H) 75 4-[(aminocarbonyl) amino]-1-{4'- (300 MHz, DMSO-d6) : 407. 1821 [(propylamino) carbonyl]-1, 1'-biphenyl-3-yl}-õ 0. 90 (m, 3 H) 1. 54 1 H-pyrazole-3-carboxamide (m, 2 H) 3. 23 (m, 2 H) NH2 o 6. 50 (m, 2 H) 7. 52 (m, o= (11 1 H) 7. 59 (t, J = 7. 95 _ N-, _, CH, Hz-J. H) 7. 69 (m, 1 H) HN H 7. 84-8. 01 (m, 5 H) o= (Tl T 8. 12 (s1 H) 8. 24 (t, J H2 = 1. 81 Hz, 1 H) 8. 53 (t, J = 5. 54 Hz, 1 H) 8. 69 (s, 1 H) 8. 70 (s, 1 H) 76 1- [3'- (acetylamino)-1, 1'-biphenyl-3-yl]-4- (300 MHz, DMSO-d,) : 379. 1559 [(aminocarbonyl) amino]-1 H-pyrazole-3-õ 2. 05 (m, J = 2. 42 carboxamide Hz, 3 H) 6. 51 (m, 2 H) O NH 7. 30-7. 70 (m, 6 H) 7. 85 (m, 3 H) 8. 09 (m, N 1 H) 8. 64 (s, 1 H) 8. 68 /N CH3 (s, 1 H) 10. 02 (s, 1 H) NH2 N iN - o 77 4-[(aminocarbonyl) amino]-1-(3'-amino-4'- (300 MHz, DMSO-d6) : 351. 1540 methyl-1, 1'-biphenyl-3-yl)-1H-pyrazole-3-õ 2. 22 (s, 3 H) 6. 50 carboxamide (m, 2 H) 7. 16-7. 36 (m, NH2 NH2 3 H) 7. 56 (m, 3 H) 0 CH3 7. 84 (m, 2 H) 8. 06 (m, J = 1. 41 Hz, 1 H) 8. 63 H N (s, I H) 8. 69 (s, 1 H) NH2 W Nu2 ' \NH2 I/ Ex. Name and Structure'H NMR MS (ES') (M+1) 78 4- [ (aminocarbonyl) amino]-1- [3'- (300 MHz, DMSO-d,) : 351. 1 (aminomethyl)-1, 1'-biphenyl-3-yl]-1 H-õ 4. 05 (s, 2 H) 6. 50 pyrazole-3-carboxamide (m, 2 H) 7. 37-7. 69 (m, NH NH2 5 H) 7. 75 (d, 1 H) o= 7. 81-7. 96 (m, 3 H) N 8. 17 (s, 1 H) 8. 65 (s, 1 HN H) 8. 69 (s, 1 H) oX 0 - \NH2 I/ 79 4- [ (aminocarbonyl) amino]-l- [3'- (300 MHz, DMSO-d,) : 365. 1 (aminocarbonyl)-1, 1'-biphenyl-3-yl]-1H-õ 6. 48 (m, 2 H) 7. 41- pyrazole-3-carboxamide 7. 74 (m, 5 H) 7. 85- NH2 o NH2 7. 97 (m, 4 H) 8. 13 (m, 0 1 H) 8. 23 (m, 2 H) -N 8. 69 (m, 2 H) HN N NH2 v 80 4- [ (aminocarbonyl) amino]-l- {4'- (300 MHz, DMSO-d,) : 405. 1 [(cyclopropylamino) carbonyl]-1, 1'-biphenyl-3-õ 0. 50-0. 80 (m, 4 H) yl}-1 H-pyrazole-3-carboxamide 2. 87 (m, 1 H) 6. 51 (m, NHz 2 H) 7. 49-7. 71 (m, 4 o= (ll H) 7. 83-8. 00 (m, J = N NH 9. 46 Hz, 5 H) 8. 22 (m, I H) 8. 52 (m, 1 H) o= N 8. 68 (s, 1 H) 8. 69 (s, 1 NHs 9 H) 81 4-[(aminocarbonyl) amino]-1-{3'- (300 MHz, DMSO-d,) : 405. 1 [(cyclopropylamino) carbonyl]-1, 1'-biphenyl-3-õ 0. 52-0. 80 (m, 4 H) yl}-1 H-pyrazole-3-carboxamide 2. 87 (m, 1 H) 6. 44 (m, H 2 H) 7. 47-7. 74 (m, 4 H) 7. 83-7. 96 (m, 4 H) 8. 19 (m, 2 H) 8. 57 (d, J = 4. 03 Hz, 1 H) 8. 69 HN \ N \ I (m, 2 H) oX O NH2 v NHz Ex. Name and Structure'H NMR MS (ES+) (Ms1) 82 4-[(aminocarbonyl) amino]-1-(3'-{[(2- (300 MHz, DMSO-d6) : 418. 1 cyanoethyl) amino] carbonyl}-1, 1'-biphenyl-3- 2. 80 (t, J = 6. 44 Hz, yl)-1 H-pyrazole-3-carboxamide 2 H) 3. 53 (t, J = 6. 44 H Hz, 2 H) 6. 48 (m, 2H) 7. 49-7. 63 (m, 4 H) oG I. \ 1 s 7. 80-8. 03 (m, 4 H) iJ CN ho I HN \ N \ 2 H) 8. 99 (s, 1 H) u NH2 W \NHz I/ 83 4-[(aminocarbonyl) amino]-1-{3'- (400 MHz, DMSO-d6) : 379. 1498 [ (methylamino) carbonyl]-I, I'-biphenyl-3-yl)-5 2. 80 (d, J = 4. 56 Hz, 1 H-pyrazole-3-carboxamide 3 H) 6. 53 (m, 2 H) H 7. 50-7. 70 (m, 4 H) O NH2 o% NscH 7. 81-8. 00 (m, 4 H) 8. 17 (d, f-1. 61 Hz,-1-- N H) 8. 20 (t, J = 1. 88 Hz, 1 H) 8. 56 (d, J = o=3 (l | 4. 56 Hz, 1 H) 8. 68 (s, NH2 2 H) 84 4-[(aminocarbonyl) amino]-1-(4'-{[(2- (300 MHz, DMSO-d6) : 418. 1623 cyanoethyl) amino] carbonyl}-1, 1'-biphenyl-3-õ 2. 78 (t, J = 6. 76 Hz, yl)-1 H-pyrazole-3-carboxamide 2 H) 3. 51 (t, J = 6. 76 NH2 o Hz, 2 H) 6. 48 (s, 2 H) o= (11 7. 52 (s 1 H) 7. 61 (t, J -N NH = 7. 64 Hz, 1 H) 7. 70 (d, J = 8. 17 Hz, 1 H) 7. 82-8. 02 (m, 6 H) NH2 CN 8. 23 (m, 1 H) 8. 67 (s, 1 H) 8. 68 (s 1 H) 8. 91 (m, 1 H). 85 N- [ (3'- {3- (aminocarbonyl)-4- (400 MHz, DMSO-d6) : 423. 1412 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-õ 3. 93 (d, J = 5. 91 Hz, 1, 1'-biphenyl-4-yl) carbonyl] glycine 2 H) 6. 51 (m, 2 H) NH2 0 7. 52 (m, 1 H) 7. 59 (t, o= (11 J = 7. 92 Hz, 1 H) 7. 70 SN eNH (d, J = 8. 59 Hz, 1 H) HN 7. 84-8. 01 (m, J = 0-17. 99 Hz, 7 H) 8. 25 NH o (m, 1 H) 8. 67 (m, 1 H) 8. 69 (s, 1 H) 8. 91 (t, J = 5. 91 Hz, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 86 4-[(aminocarbonyl) amino]-1-[2'-(benzyloxy)- (400 MHz, DMSO-d,) : 428. 1694 1, 1'-biphenyl-3-yl]-1H-pyrazole-3-o 5. 12 (s, 2 H) 6. 50 carboxamide (m, 2 H) 7. 06 (td, J = 7. 45, 0. 94 Hz, 1 H) NH2 7. 19-7. 29 (m, 4 H) NH 7. 32-7. 52 (m, 7 H) o N 0 7. 75 (s, 1 H) 7. 78 (m, N 1 H) 8. 09 (t, J = 1. 75 HN Hz, 1 H) 8. 59 (s, 1 H) 8. 68 (s, 1 H) H2N ° 87 4-[(aminocarbonyl) amino]-1-[2'- (400 MHz, DMSO-d,) : 352. 1430 (hydroxymethyl)-1, 1'-biphenyl-3-yl]-l H-6 4. 40 (s, 2 H) 6. 50 pyrazole-3-carboxamide (m, 2 H) 7. 30-7. 60 (m, NH2 7 H) 7. 78 (s, 1 H) 7. 85 o. (m, 1 H) 7. 91. (m, 1 H) N 8. 61 (s, I H) 8. 68 (s, 1 AN<, N g t, J H) HN H) NH2 HO HO 88 4-[(aminocarbonyl) amino]-1-(2'-methoxy-1, 1'- (300 MHz, DMSO-d6) : 352. 1425 biphenyl-3-yl)-1 H-pyrazole-3-carboxamide 5 3. 78 (s, 3 H) 6. 50 NH2 (m, 2 H) 7. 05 (t, J = 0 7. 55 Hz, 1 H) 7. 14 (d, -N J = 8. 66 Hz, I H) HN 7. 33-7. 58 (m, 5 H) 0 7. 79 (m, 2 H) 7. 94 (m, NH2 0*11 1 H) 8. 59 (m, 1 H) CH3 8. 68 (m, 1 H) 89 4-[(aminocarbonyl) amino]-1-(4'-hydroxy-2'- (400 MHz, DMSO-d6) : 352. 1403 methyl-1, 1'-biphenyl-3-yl)-1H-pyrazole-3-b 2. 17 (s, 3 H) 6. 47 carboxamide (m, 2 H) 6. 65 (dd, J = NH2 8. 59, 2. 69 Hz, 1 H) o= (6. 69 (d, J = 2. 42 Hz, 1 N H) 7. 06 (d, J = 8. 32 HN Hz, 1 H) 7. 22 (d, J = o 8. 32 Hz, 1 H) 7. 45 (m, NHz CHs 1 H) 7. 48 (t, J = 7. 92 Hz, 1 H) 7. 78 (m, 3 H) 8. 58 (s, 1 H) 8. 66 (s, 1 H) 9. 38 (m, 1 H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 90 4-[(aminocarbonyl) amino]-1-{4'-[(4- (300 MHz, DMSO-d6) : 447. 1 oxopiperidin-1-yl) carbonyl]-1, 1'-biphenyl-3-õ 3. 84 (m, 8 H) 6. 52 yl}-1 H-pyrazole-3-carboxamide (m, 2 H) 7. 55-7. 70 (m, NH2 o 5 H) 7. 90 (m, 4 H) 8. 24 (t, J = 1. 81 Hz, 1 - N/N H) 8. 69 (s, 1 H) 8. 70 HN N 1 H) /,/ O H2 '\NHa I/ 91 1- (2'-acetyl-1, 1'-biphenyl-3-yl)-4- (300 MHz, DMSO-ds) : 364. 1 [(aminocarbonyl) amino]-1 H-pyrazole-3-õ 2. 24 (s, 3 H) 6. 44 carboxamide (m, 2 H) 7. 19 (d, J = NHz 7. 45 Hz, 1 H) 7. 47- 0 7. 70 (m, 6 H) 7. 82- N 7. 90 (m, 3 H) 8. 63 (s, How 1 H) 8. 68 (s, 1-N)- : :-, N '\NH2 I/ 0 CHg 92 4-[(aminocarbonyl) amino]-1-(4'-fluoro-2'- (300 MHz, DMSO-d6) : 356. 1190 hydroxy-1, 1'-biphenyl-3-yl)-1 H-pyrazole-3-õ 6. 49 (s, 2 H) 6. 66 carboxamide (m, 2 H) 7. 35 (m, 1 H) NH2 7. 49 (m, 3 H) 7. 77 (m, 2 H) 7. 97 (m, 1 H) - N 8. 56 (s, 1 H) 8. 68 (s, 1 H N <, N H) NH2 OH NHz 0 93 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'- (400 MHz, DMSO-d6) : 356. 1196 hydroxy-1, 1'-biphenyl-3-yl)-1H-pyrazole-3-õ 6. 49 (s, 2 H) 6. 93 carboxamide (dd, J = 8. 86, 5. 10 Hz, NHz 1 H) 7. 02 (td, J = 8. 53, oW I 3. 09 Hz, 1 H) 7. 21 N (dd, J = 9. 67, 3. 22 Hz, HN I H) 7. 50 (m, 4 H) o 7. 80 (m, 2 H) 8. 01 (m, NHz 9 OH 1 H) 8. 59 (s, 1 H) 8. 67 (s, 1 H)

Ex. Name and Structure'H NMR MS (ES+) (M+1) 94 4-[(aminocarbonyl) amino]-1-[2'- (300 MHz, DMSO-d,) : 395. 1 (cyanomethoxy)-5'-fluoro-1, 1'-biphenyl-3-yl]-õ 5. 15 (s, 2 H) 6. 50 (s, 1 H-pyrazole-3-carboxamide 2 H) 7. 30-7. 60 (m, 6 NHz F H) 7. 77 (s, 1 H) 7. 87 omf I (d, J = 8. 46 Hz, 1 H) ) =N < 7. 99 (m, 1 H) 8. 63 (s, 1N H H) 8. 67 (s, 1 H) o NHZ CN 95 1- [4'- (aminocarbonyl)-1, 1'-biphenyl-4-yl]-4- (400 MHz, DMSO-d,) : 379. 10 {[(methylamino) carbonyl] amino}-1 H-pyrazole-õ 2. 63 (d, J = 4. 30 Hz, 3-carboxamide 3 H) 7. 24 (m, 1 H) His 7. 37 (s, 1 H) 7. 55 (s, 1 NH. H) 7. 75-8. 15 (m, 10 -N 0 H) 8. 64 (s, 1 H) 8. 7G N (s, I H) HN NH2 0-"NHz [00747] Examples 96-141: 4-[(aminocarbonyl)amino]-1-(4-arylphenyl)- 1 H-pyrazole-3-carboxamides [00748] 4-[(aminocarbonyl) amino]-1-(4-iodophenyl)-1 H-pyrazole-3- carboxamide (0.22 g, 0.6 mmol, prepared according to the process of Example 214), Pd [PPh3] 4 (50 mg), and 0.9 mmol of an arylboronic acid were added to a flask and placed under vacuum then refilled with nitrogen. The vacuum/N2 cycle was repeated twice. DMF (3 mL) and 0.9 mL of 2M Cs2CO3 solution were injected under N2. (The DMF and Cs2CO3 solutions were bubbled with N2 for 15 minutes before addition). The suspension was heated and stirred at 80°C overnight. Most of liquids were removed under reduced pressure. The solid was triturated with water (80 mL), filtered, triturated with methanol (5-10 mL) for 1-3 h, filtered and dried to give the compounds shown in the following table. Ex. Name and Structure ¹H NMR MS(ES+) (M+1) Ex. Name and Structure'H NMR MS (ES+) (M+1) 96 4'-{3-(aminocarbonyl)-4- (CD3OD)/DMSO-d6 (4 : 1) : 5 366 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-7. 48 (t, 1 H, J = 8. 7 Hz), 1, 1'-biphenyl-3-carboxylic acid 7. 72-7. 86 (m, 3H), 7. 87- 0 8. 00 (m, 3H), 8. 20 (s, 1H), og N\/="/E, oN\-- 0- :-"ion ONH, HN 97 4'-{3-(aminocarbonyl)-4- (CD3OD)/DMSO-d6 (4 : 1) : 5 384 [(aminocarbonyl) amino]-1H-pyrazol-1-yl}-7. 63-7. 71 (m, 2H), 7. 83- 3-fluoro-1, 1'-biphenyl-4-carboxylic acid 8. 02 (m, 5H), 8. 62 (s, 1H) NH2 _ NN f--. O HN ON F o-NH2 98 4- [ (aminocarbonyl) amino]-l- (4'-fluoro-2'- DMSO-d,, : 6 6. 51 (br s, 2H), 356 hydroxy-1, 1'-biphenyl-4-yl)-1H-pyrazole-6. 63-6. 79 (m, 2H), 7. 32 (t, 3-carboxamide 1 H, J = 7. 8 Hz), 7. 50 (br s, NH2 HO 1 H), 7. 65 (d, 2H, J = 8. 7 dz), 7. 78 (br s, 1 H), 7. 88 (d, 2H, J = 8. 7 Hz), 8. 58 (s, HN/+/Lb Lb 1H), 8. 68 (s, 1H), 10. 20 (br HN s, 1 H) o" 99 4-[(aminocarbonyl) amino]-1-(5'-fluoro-2'-DMSO-d6 : 6 6. 51 (br s, 2H), 356 hydroxy-1, 1'-biphenyl-4-yl)-1H-pyrazole-6. 91-7. 15 (m, 2H), 7. 35 (dd, 3-carboxamide 1 H, J, = 2. 8 Hz, J2 = 6. 8 NHz Ho Hz), 7. 51 (brs, 1H), 7. 71 0 N (d, 2H, J = 8. 6 Hz), 7. 78 (br N-"s, I H), 7. 88 (d, 2H, J = 8. 6 r Nw % S, 1 H), 7. 88 (d, 2H, J = 8. 6 dz), 8. 58 (s, 1 H), 8. 68 (s, HN 1 H), 10. 20 (br s, 1H) o-NH, % NHz Ex. Name and Structure'H NMR MS (ES+) (M+1) 100 4-[(aminocarbonyl) amino]-1-(4'-cyano-DMSO-d6 : 6 6. 53 (br s, 2H), 347 1, 1'-biphenyl-4-yl)-1H-pyrazole-3-7. 55 (brs, 1H), 7. 83 (brs, carboxamide 1 H), 7. 88-8. 00 (m, 6H), NHz 8. 02 (d, 2H, J = 8. 7 Hz), N\ 8. 64 (s, 1 H), 8. 70 (s, 1 H) HN/4/m CN HN 0-NH, 101 4- [ (aminocarbonyl) amino]-l- (I, I'-DMSO-d, : 6 6. 53 (br s, 2H), 322 biphenyl-4-yl)-1 H-pyrazole-3-7. 32-7. 56 (m, 4H), 7. 72 (d, carboxamide 2H, J = 7. 4 Hz), 7. 80 (d, NH2 3H, J = 8. 6 Hz), 7. 96 (d, 2H, J = 8. 7 Hz), 8. 62 (s, N-1 H), 8. 69 (s, 1 H) HN O-NHz 102 4- [ (aminocarbonyl) amino]-I- (3'-methyl- 336 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide O CH3 HZN \ ^-- AN\oN X O-NHz 103 4- [ (aminocarbonyl) amino]-l- (4'-methyl- 336 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide o H2N--- HO o-NH2 104 4- [ (aminocarbonyl) amino]-l- (3'-cyano- 347 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide o CN CON han w iN HN O--NHs Ex. Name and Structure'H NMR MS (ES+) (M+1) 105 4- [ (aminocarbonyl) amino]-1- [2'- 352 (hydroxymethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide OH 0 H2N N p'i'NH 106 4- [ (aminocarbonyl) amino]-l- (2'-methoxy- 352 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide /cl3 - cl. HN) 4 < HO 0-NH, 107 4- [ (aminocarbonyl) amino]-l- (3'-methoxy- 352 1, 1-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide R O-CH3 HZN \ ^-- 0-NH, oSNH2 108 4- [ (aminocarbonyl) amino]-1- (4'-fluoro-2'- 354 methyl-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ! H3C -- HN NHz Ex. Name and Structure'H NMR MS (ES+) (M+1) 109 4-[(aminocarbonyl) amino]-1-(4'-fluoro-3'-354 methyl-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide O CH3 H2N HAN oS~ NH2 110 4-[(aminocarbonyl) amino]-1-(2'-chloro-356 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ce i ; N 0"NH2 111 4- [ (aminocarbonyl) amino]-l- (3'-chloro- 356 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ci 0 ci HAN NHZ 112 4-[(aminocarbonyl) amino]-1-(21, 3'-358 difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide F F H2N \^-- HNX ONH, 113 4- [ (aminocarbonyl) amino]-l- (2', 4'- 358 difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0 ! N- -- -F H2N-" r-N"F han Ex. Name and Structure'H NMR MS (ES+) (M+1) 114 4- [ (aminocarbonyl) amino]-l- (3', 4'- 358 difluoro-1, 1'-biphenyl-4-yi)-1 H-pyrazole- 3-carboxamide O F - Han 0-NHz 115 4-[(aminocarbonyi) amino]-1-(3', 5'-358 difluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0 F _. HN F o-NH2 116 4-[(aminocarbonyl) amino]-1-(3'-isopropyl-364 1, 1'-biphenyl-4-yl)-1H-pyrazole-3- carboxamide c 0 H3 CH3 -' z oW NH2 0'NHz 117 4- [ (aminocarbonyl) amino]-l- (4'-isopropyl- 364 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide 0 H2N'CH3 N HAN O--NHs Ex. Name and Structure'H NMR MS (ES+) (M+1) 118 4- [ (aminocarbonyl) amino)-l- [3'- 368 (methylthio)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide O S_CH3 HN -- HAN p'i'NHZ 119 4- [ (aminocarbonyl) amino]-I- [4'- 368 (methylthio)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide o HaN -- WN N_..' SCH HN p'i-NH2 120 4- [ (aminocarbonyl) amino]-l- (2'-fluoro-3'- 370 methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide F O-CH3 HN) 4 Han HN N o~NH2 121 4- [ (aminocarbonyl) amino]-1- (5'-fluoro-2'- 370 methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0'PH3 O HX < HAN HNRN'N-" NHz Ex. Name and Structure'H NMR MS (ES+) (M+1) 122 4- [ (aminocarbonyl) amino]-l- (3'-fluoro-4'- 370 methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0 F H2N-'/CH3 CH3 N o) ~NH2 123 4- [ (aminocarbonyl) amino]-l- [4- (2- 372 naphthyl) phenyl]-1 H-pyrazole-3- carboxamide 0 oJs NH2 HAN o-NH2 124 4- [ (aminocarbonyl) amino]-l- [4- (l-372 naphthyl) phenyl]-1 H-pyrazole-3- carboxamide o H2N HN HZN \ ^-- p'i'NHZ 125 4- [ (aminocarbonyl) amino]-l- (3'-chloro-4'- 374 fluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ci H2N HAN O--NHz Ex. Name and Structure'H NMR MS (ES) (M+1) 126 4- [ (aminocarbonyl) amino]-l- (4'-tert-butyl- 378 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide 0 H2N CH HN \N N CH Ha 'i'NHa 127 4- [ (aminocarbonyl) amino]-1- (4'-isobutyl- 378 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide ß CH3 H2N CH3 N HO HZN'O 128 4- [ (aminocarbonyl) amino]-l- (4'-butyl- 378 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide CH3 H2N ° HAN l vN HN 129 4- [ (aminocarbonyl) amino]-l- (5'-chloro-2'- 386 methoxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0/CH3 O O H2N Zon CI H, NEO Ex. Name and Structure'H NMR MS (ES-) (M+1) 130 4- [ (aminocarbonyl) amino]-l- [3'- (l H-388 pyrazol-1-yl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide o H nu HN- o-NH2 131 4- [ (aminocarbonyl) amino]-l- [3'- 390 (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide 0 CF3 H2N'N HZN o-NH2 132 4- [ (aminocarbonyl) amino]-l- [4'- 390 (trifluoromethyl)-1, 1'-biphenyl-4-yl]-1 H- pyrazole-3-carboxamide o Ha CF3 HN p-NH2 133 4- [ (aminocarbonyl) amino]-1- (2', 3'- 390 dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide H\ H2N \ -- NHz NHz Ex. Name and Structure'H NMR MS (ES") (M+1) 134 4-[(aminocarbonyl) amino]-1-(2', 4'-390 dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide ce han N CI HN HN y oWNH2 135 4-[(aminocarbonyl) amino]-1-(2l, 5l-390 dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide ci J cl han CI HAN 136 4-[(aminocarbonyl) amino]-1-(3', 4'-390 dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide 0 H2N CI HAN cl pNH2 137 4-[(aminocarbonyl) amino]-1-(3', 5'-390 dichloro-1, 1'-biphenyl-4-yl)-1 H-pyrazole- 3-carboxamide cl H2N N CRI o-NH2 ci Ex. Name and Structure'H NMR MS (ES") (M+1) 138 4- [ (aminocarbonyl) amino]-l- (4'-pentyl- 392 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3- carboxamide H3C 0 ,) tN 4 Ou O-NHz 139 4-[(aminocarbonyl) amino]-1-(1, 1': 3', 1"- 398 terphenyl-4-yl)-1 H-pyrazole-3- carboxamide o.. = Han H N N 0"NHz 140 4-[(aminocarbonyl) amino]-1-(4'-404 cyclohexyl-1, 1'-biphenyl-4-yl)-1 H- pyrazole-3-carboxamide 0 R HAN pi'NH 141 4- [ (aminocarbonyl) amino]-l- [4- (l H-indol- 2-yl) phenyl]-1 H-pyrazole-3-carboxamide H2N, ro HAN N p NN / NH2 [00749] Example 142: 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino] - 1 H-pyrazol-1-yl}-1,1'-biphenyl-4-carboxylic acid

[00751] 4-[(aminocarbonyl) amino]-1-(4-bromophenyl)-1 H-pyrazole-3- carboxamide (Example 19,0. 19 g, 0.6 mmol), Pd [PPh3] 4 (50 mg), and 0.9 mmol of an arylboronic acid were added to a flask and placed under vacuum then refilled with nitrogen. The vacuum/N2 cycle was repeated twice. DMF (3 mL) and 0.9 mL of 2M Cs2CO3 solution were injected under N2. (The DMF and Cs2CO3 solutions were bubbled with N for 15 minutes before addition). The suspension was heated and stirred at 80°C overnight. Most of liquids were removed under reduced pressure. The solid was triturated with 1 N HCI (80 mL), filtered, triturated with a saturated bicarbonate solution (5-10 mL) for 1-3 h, filtered and dried. 'H NMR (CD3OD)/DMSO-d6 (4: 1): 5 7.18-7. 25 (m, 4H), 7.26-7. 42 (m, 4H), 8.00 (s, 1 H). ESI mass spectrum for C18H'6N504 : 366 (M+1).

[00752] Examples 143-164: 4- [ (aminocarbonyl) amino]-1- {4'- [ (R, R'- amino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H-pyrazole-3-carboxamides and alkyl 4'- {3- (aminocarbonyl)-4-[(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-4- carboxylates [00753] An arylcarboxylic acid (0.03 mmol), prepared according to Example 142, was combined with 0.06 mmol of an amine, or an alcohol, HBTU (BF4) (0.06 mmol), N, N-dimethylethylamine (0.06 mL), and DMSO (1.0 mL). The mixture was stirred overnight, then most of liquids were stripped off. The residue was triturated in 50 mL of water for 6 h and filtered. The solid was triturated with ethanol (5 mL) for 3 h and filtered, then dried under reduced pressure. Ex. Name and Structure 1H NMR MS(ES+) (M+1) Ex. Name and Structure'H NMR MS (ES+) (M+1) 143 4-[(aminocarbonyl) amino]-1-{4'- (CD3OD)/DMSO-d6 421 [(diethylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1H- (4 : 1) : 5 1. 00-1. 22 pyrazole-3-carboxamide (m, 6H), 3. 21 (br s, NH CH3 2H), 3. 44 (br s, 2H), NH2 2 (CH3 7. 39 (d, 2H, J = 8. 2 0 N\ fN Hz), 7. 62-7. 80 (m, 4H), 7. 89 (d, 2H, J = HN o 8. 6 Hz), 8. 5 (s, 1H) oSNH2 144 ethyl 4'-f3- (aminocarbonyl)-4- (CD 3OD) : õ 1. 42 (t, 394 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-3H, J = 7. 1 Hz), 4. 42 biphenyl-3-carboxylate (q, 2H, J = 7. 1 Hz), H3C 7. 58 (t, 1 H, J = 7. 8 o, O\) Hz), 7. 82 (d, 2H, J= NHz _ o'8 : 7 Hz), 7. 91 (s, 1 H), 0 N\-7. 95 (d, 2H, J = 8. 7 N Hz), 8. 25 (d, 1 H, J = HN 8. 7 Hz), 8. 30 (s, 1H), 8. 57 (s, 1 H) O--NH, 145 4-[(aminocarbonyl) amino]-1-{4'- (CD3OD)/DMSO-d6 379 [(methylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1H- (4 : 1) : 6 2. 80 (s, 3H), pyrazole-3-carboxamide 7. 70 (d, 2H, J = 8. 3 Hz), 7. 75 (d, 2H, J = O\ N NH 8. 7 Hz), 7. 82 (d, 2H, N J = 8. 3 Hz), 7. 87 (d,. -i 2H, J = 8. 7 Hz), 8. 48 (s, 1 H) 'NHZ 146 4-[(aminocarbonyl) amino]-1-{4'- (CD3OD)/DMSO-d6 407 [(propylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H- (4 : 1) : 5 0. 95 (t, 3H, J pyrazole-3-carboxamide = 7. 3 Hz), 1. 55 HsQ (sextet, 2H, J = 7. 2 Hz), 3. 22 (t, 2H, J = NH2 7. 2 Hz), 7. 73 (d, 2H, N\ NH J = 8. 3 Hz), 7. 90 (d, N 2H, J = 8. 7 Hz), HN 0 7. 83-7. 93 (m, 4H), 8. 48 (s, 1H) O-NHz Ex. Name and Structure'H NMR MS (ES+) (M+1) 147 ethyl 4'-{3-(aminocarbonyl)-4-DMSO-d6 : õ 1. 38 (t, 394 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-3H, J = 7. 1 Hz), 4. 38 biphenyl-4-carboxylate (q, 2H, J = 7. 1 Hz), H3C 6. 50 (br s, 2H), 7. 52 o) (brs, 1H), 7. 78-7. 93 2 So (m, 5H), 7. 99-8. 09 p N\ o (m, 4H), 8. 62 (s, 1 H), 8. 73 (s, 1 H) Han H, NO 148 4- [ (aminocarbonyl) amino]-l-f3'- CD30D : 51. 29 (d, 407 [(isopropylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1H-6H, J= 6. 6 Hz), 4. 38 pyrazole-3-carboxamide (septet, 1 H, J = 6. 6 HzN\/p Hz), 7. 48 (t, 1 H, J = jT 7. 8 Hz), 7. 78-7. 88 HN o (m, 4H), 7. 85 (d, 2H, J = 8. 8 Hz), 8. 12 (t, H2N N-CH3 I H, J = 1. 6 Hz), 8. 58 (s, 1 H) 149 4- [ (aminocarbonyl) amino]-1- [4'- (aminocarbonyl)- (CD30D)/DMSO-d, 365 1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide (4 : 1) : 5 7. 72 (d, 2H, H2N 0 J = 8. 3 Hz), 7. 76 (d, 2H, J = 8. 6 Hz), HN O 7. 83-7. 93 (m, 4H), \./8. 51 (s, 1 H) HZN N NHZ 0 150 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(4- (CD3OD)/DMSO-d6 503 methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4- (4 : 1) : 5 3. 65 (s, 3H), yl)-1H-pyrazole-3-carboxamide 4. 40 (s, 2H), 6. 81 (d, H3C\ 2H, J = 8. 7 Hz), 7. 21 (d, 2H, J = 8. 7 Hz), HaNO O 7. 46-7. 57 (m, 2H), HNß O g 7. 70 (d, 1H, J=8. 0 Hz), 7. 76 (d, 2H, J = H2N N HN-/8. 9 Hz), 7. 88 (d, 2H, O F J=8. 9Hz), 8. 52 (s, 1H) Ex. Name and Structure'H NMR MS (ES') (M+1) 151 4-[(aminocarbonyl) amino]-1-{4'-DMSO-d6 : õ 4. 48 (d, 473 [(benzylamino) carbonyl]-3'-fluoro-1, 1'-biphenyl-4-2H, J = 5. 9 Hz), 6. 52 yl}-1 H-pyrazole-3-carboxamide (br s, 2H), 7. 20-7. 30 NHz (m, 1 H), 7. 35 (d, 4H, o= (J = 4. 4 Hz), 7. 55 (br ) N s, 1 H), 7. 65-7. 78 (m, 3H), 7. 84 (br s, 1 H), 7. 91 (d, 2H, J = 8. 8 NH2 % </< Hz), 8. 05 (d, 2H, J = h"] 8. 8Hz), 8. 64 (s, 1H), NH 8. 69 (s, 1H) F u 152 4-[(aminocarbonyl) amino]-1-{3'-fluoro-4'-DMSO-d6 : õ 2. 79 (d, 397 [(methylamino) carbonyl]-1, 1'-biphenyl-4-yl}-1 H-3H, J = 4. 5 Hz), 6. 52 pyrazole-3-carboxamide (br s, 2H), 7. 45 (br s, NH2 H3 1 H), 7. 62-7. 78 (m, O<N NH 3H), 7. 84 (br s, 1 H), 7. 90 (d, 2H, J = 8. 8 A/LY Hz), 8. 00 (d, 2H, J = HN- F 8. 8 Hz), 8. 20-8. 29 F H2N (m, 1H), 8. 63 (s, 1 H), 8. 68 (s, 1H) 153 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(3-DMSO-d6 : 53. 75 (s, 503 methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4-3H), 4. 47 (d, 2H, J = yl)-1 H-pyrazole-3-carboxamide 5. 7 Hz), 6. 52 (br s, NH2 2H), 6. 71 (d, 1 H, J = o=< 8. 1 Hz), 6. 81 (d, 2H, N J= 2. 4 Hz), 7. 25 (t, N I H, J = 8. 0 Hz), 7. 55 0 (I I (br s, 1 H), 7. 60-7. 80 / F \ oN3 (m, 3H), 7. 85 (br s, 1 H), 7. 90 (d, 2H, J = 8. 7 Hz), 8. 05 (d, 2H, o J = 8. 7 Hz), 8. 64 (s, 1 H), 8. 69 (s, 1 H), 8. 88 (t, 1 H, J = 5. 7 Hz) Ex. Name and Structure'H NMR MS (ES) (M+1) 154 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(2-DMSO-d6 : 6 3. 92 (s, 503 methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4- 3H), 4. 48 (d, 2H, J= yl)-1 H-pyrazole-3-carboxamide 5. 7 Hz), 6. 55 (br s, 2H), 6. 95 (t, 1 H, J = 7. 5 Hz), 7. 00 (d, 1 H, J = 8. 5 Hz), 7. 20-7. F O-CH3 33 (m, 2H), 7. 55 (br N NH 1H), 7. 65-7. 82 (m, o s, N 3H), 7. 85 (br s, 1 H), HN \ 7. 92 (d, 2H, J = 8. 7 ; Hz), 8. 05 (d, 2H, J = o"NHz g 7 Hz), 8. 60-8. 75 (m, 3H) 155 4- [ (aminocarbonyl) amino]-l- (3'-fluoro-4'- { [ (4- DMSO-d, : õ 4. 45 (d, 491 fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-2H, J = 5. 7 Hz), 6. 51 1H-pyrazo ! e-3-carboxam ! de (brs, 2H), 7. 24 (t, NHz 2H, J = 8. 9 Hz), o= (7. 32-7. 45 (m, 2H), ) == ; N 7. 53 (brs, 1H), 7. 61- HN 7. 80 (m, 3H), 7. 85 o I I (br s, 1 H), 7. 93 (d, NH2/ 2H, J = 8. 8 Hz), 8. 03 | (d, 2H, J=8. 8Hz),- NH 8. 62 (s, 1 H), 8. 68 (s, 1 H), 9. 90 (t, 1H, J= 5. 7 Hz) 156 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(3-DMSO-d6 : 54. 49 (d, 491 fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)- 2H, J = 5. 7 Hz), 6. 52 1 H-pyrazole-3-carboxamide (br s, 2H), 7. 02-7. 22 NH2 (m, 3H), 7. 32-7. 45 0 (m, 1 H), 7. 53 (br s, ) >N F 1 H), 7. 65-7. 80 (m, 3H), 7. 85 (br s, 1 H), o= (7. 93 (d, 2H, J = 8. 8 NH2 Hz), 8. 03 (d, 2H, J = 8. 8 Hz), 8. 64 (s, 1H), 8. 70 (s, 1 H), 9. 95 (t, F Õ 1 H, J = 5. 7 Hz) F o Ex. Name and Structure'H NMR MS (ES+) (M+1) 157 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(2-DMSO-d6 : 6 4. 53 (d, 491 fluorobenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-2H, J = 5. 6 Hz), 6. 52 1H-pyrazole-3-carboxamide (brs, 2H), 7. 12-7. 45 NH2 (m, 4H), 7. 55 (br s, 1 H), 7. 65-7. 80 (m, -N 3H), 7. 85 (br s, 1 H), HN<N F 7. 94 (d, 2H, J = 8. 8 /H), 8 05 (d, 2H, J= NH2 8. 8 Hz), 8. 64 (s, 1 H), 8. 69 (s, 1H), 9. 89 (t, NH 1 H, J = 5. 6 Hz) F O 158 4-[(aminocarbonyl) amino]-1-(3'-fluoro-4'-{[(4-DMSO-d6 : 5 2. 80 (s, 505 fluorobenzyl) (methyl) amino] carbonyl}-1, 1'- 3H), 4. 73 (s, 2H), biphenyl-4-yl)-l H-pvrazole-3-carboxamide 6. 52 (brs, 2H), 7-1 ?- NH2-7. 28 (m, 3H), 7. 34- of 7. 44 (m, 1 H), 7. 54 (t, ) >N 2H, J = 7. 2 Hz), HN 7. 62-7. 78 (m, 2H), o I w I 7. 79-7. 95 (m, NH2 7. 95-8. 08 (m, 2H), 8. 64 (s, 1 H), 8. 69 (s, NcH3 1H) F O 159 4- [ (aminocarbonyl) aminol-I-13'-fluoro-4'- [ (1, 2, 3, 4- DMSO-d6 : 61. 73- 513 tetrahydronaphthalen-1-ylamino) carbonyl]-1, 1'-2. 05 (m, 4H), 2. 67- biphenyl-4-yl}-1 H-pyrazole-3-carboxamide 2. 81 (m, 2H), 5. 17- NH2 5. 28 (m, 1 H), 6. 52 (br s, 2H), 7. 06-7 20 zon (m, 3H), 7. 26-7. 33 (m, 1 H), 7. 56 (br s, 1 H), 7. 63-7. 73 (m, 3H), 7. 83 (br s, 1 H), Tl 1 T 7. 86-7. 93 (m, 2H), NH 8. 01 (d, 2H, J = 8. 8 I II Hz), 8. 62 (s, 1H), 8. 64-8. 69 (m, 2H) Ex. Name and Structure'H NMR MS (ES+) (M+1) 160 4-[(aminocarbonyl) amino]-1-(4'-{[[2- (CD30D) : 62. 98 (s, 468 (dimethylamino) ethyl] (methyl) amino] carbonyl}-3'-6H), 3. 07 (s, 3H), fluoro-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-3. 45 (t, 2H, J = 6. 2 carboxamide Hz), 3. 94 (t, 2H, J = NH2 6. 2 Hz), 7. 52-7. 70 (m, 3H), 7. 84 (d, 2H, ) aN J = 8. 6 Hz), 7. 96 (d, HN 2H, J = 8. 6 Hz), 8. 59 NH2 <F 0 N CH /NEZ 0 O 161 4- [ (aminocarbonyl) amino]-l- [5'-fluoro-2'- (2- CD30D : 5 3. 38-3. 66 482 morpholin-4-yl-2-oxoethoxy)-1, 1'-biphenyl-4-yl]- (m, 8HJ, 4. 79 (s,. 1 -pyrazole-3-carboxamide 2H), 7. 04-7. 10 (m, 2H), 7. 12-7. 20 (m, 9 9 1H), 7. 72 (d, 2H, J= N 8. 7 Hz), 7. 89 (d, 2H, J = 8. 7 Hz), 8. 58 (s, sO o 1 H) "r 0 Han I\ p NH 162 2-fluorobenzyl 4'-{3-(aminocarbonyl)-4-DMSO-d6 : 6 5. 38 (s, 492 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-3-fluoro-2H), 6. 53 (br s, 2H), 1, 1'-biphenyl-4-carboxylate 7. 20-7. 63 (m, 5H), 7. 72-7. 90 (m, 3H), 7. 90-8. 08 (m, 5H), H2N'p 8. 63 (s, 1 H), 8. 69 (s, PFF 1 H) 0 z O NH Ex. Name and Structure'H NMR MS (ES+) (M+1) 163 3-fluorobenzyl 4'-{3-(aminocarbonyl)-4-DMSO-d6 : õ 5. 38 (s, 492 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-3-fluoro-2H), 6. 52 (br s, 2H), 1, 1'-biphenyl-4-carboxylate 7. 18 (t, 1H, J= 8. 9 Hz), 7. 33 (d, 2H, J = \_/F 8. 9 Hz), 7. 40-7. 60 HN H2NgO r (m, 2H), 7. 70 7 90 (m, 3H), 7. 90-8. 10 (m, 5H), 8. 62 (s, 1 H), 8. 67 (s, 1 H) NH2 F NHz 164 4-fluorobenzyl 4'- {3- (aminocarbonyl)-4- DMSO-d, : 6 5. 38 (s, 492 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-3-fluoro-2H), 6. 53 (br s, 2H), 1, 1'-biphenyl-4-carboxylate 7. 25 (t, 2H, J= 8. 9 F Hz), 7. 48-7. 60 (m, ,-\ 3H). 7. 71-7. 89 (n, 3H), 7. 90-8. 08 (m, H2N p 5H), 8. 63 (s, 1H), 8. 68 (s, 1H) un i\ NHz NH2 [00754] Example 165: 4'- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino] - 1H-pyrazol-1-yl}-1,1'-biphenyl-3-yl)methyl acetate

[00756] 4- [ (aminocarbonyl) amino]-1- [4'- (hydroxymethyl)-1, 1'-biphenyl-4- yl]-1 H-pyrazole-3-carboxamide (Example 38,0. 105 g, 0.03 mmol) was combined with 0.06 mmol of an acetic acid, HBTU (BF4) (0.06 mmol), N, N- dimethylethylamine (0.06 mL), and DMSO (1.0 mL). The mixture was stirred overnight, then most of the liquids were stripped off. The residue was triturated

in 25 mL of water for 6 h and filtered. The solid was triturated with ethanol (5 mL) for 3 h and filtered. The product was dried under reduced pressure.'H NMR ((CD3OD)/DMSO-d6 (4: 1) ): 5 2.10 (s, 3H), 5.20 (s, 2H), 7.38 (d, 1 H, J = 7.4 Hz), 7.47 (t, 1 H, J = 7.6 Hz), 7.64 (d, 1 H, J = 7.5 Hz), 7.68 (s, 1 H), 7.78 (d, 2H, J = 8.7 Hz), 7.93 (d, 2H, J = 8.7 Hz), 8.57 (s, 1 H). ESI mass spectrum for C20 H20 N504+ : 394 (M+I).<BR> <BR> <P> [00757] Examples 166-182: Alkylation of Phenois [00758] A mixture of phenol prepared according to Examples 21-141 (0.03 mmol), K2CO3 (0.062 g, 0.045 mmol), and 0.045 mmol of a bromomethyl- derivative (bromoacetonitri) e, bromomethyipyridines, bromoacetic acid and its esters or amide) in a DMF/acetone (1: 1) mixture (3 mL) was stirred at room temperature for 48 h. Solvents were removed, and water (30 mL) was added.

The suspension was sonicated for 30 min and triturated for 3 h to give the desired product after drying. Ex. Name and Structure'H NMR (DMSO-d6, MS (ES+) unless indicated (M+1) otherwise) 166 4- [ (aminocarbonyl) amino]-l- [3'- 6 5. 28 (s, 2H), 6. 50 (br 377 (cyanomethoxy)-1, 1'-biphenyl-4-yl]-1H-s, 2H), 7. 08 (d, 1H, J= pyrazole-3-carboxamide 7. 2 Hz), 7. 39-7. 50 (m, NHz 3H), 7. 54 (br s, 1 H), OA N 7. 67 (d, 2H, J = 8. 7 Hz), \N__, D_q 7. 78-7. 90 (m, 3H), 8. 62 HN A (S, 1 H), 8. 92 (s, 1 H) o-NH2 < CN CN Ex. Name and Structure'H NMR (DMSO-d,, MS (ES') unless indicated (M+1) otherwise) 167 4-[(aminocarbonyl) amino3-1-[2'-õ 5. 18 (s, 2H), 6. 50 (br 377 (cyanomethoxy)-1, 1'-biphenyl-4-yl]-1 H-s, 2H), 7. 88 (t, 1 H, J = pyrazole-3-carboxamide 7. 5 Hz), 7. 26 (d, 1 H, J = NC 8. 1 Hz), 7. 42 (d, 2H, J= NH) 7. 4 Hz), 7. 52 (br s, 1 H), nu2 0 7. 59 (d, 2H, J=8. 3Hz), o \ 7. 79 (br s, 1 H), 7. 93 (d, 2H, J = 8. 3 Hz), 8. 62 (s, HN 1 H), 8. 72 (s, 1 H) o) ~NH2 168 4- [ (aminocarbonyl) amino]-l- [3'- (pyridin-2- (CD30D)/DMSO-d,, (4 : 1) : 429 ylmethoxy)-1, 1'-biphenyl-4-yl]-1H-õ 5. 28 (s, 2H), 6. 93 (dd, pyrazole-3-carboxamide 1 H, J, = 6. 3, 1. 7 Hz), ---NH2 7. 15-7 ; 33'm, 4H), 7. 5o- O\ N (d, 1H, J=7. 9Hz), 7. 65 (d, 2H, J = 8. 8 Hz), 7. 75 (dd, 1 H, J, = 6. 2, 1. 7 HN H \ b Hz), 7. 80 (d, 2H, J = 8. 8 Dz), 8. 40-8. 50 (m, 2H) N 169 4- [ (aminocarbonyl) amino]-I- [3'- (I- 6 1. 71 (d, 3H, J = 6. 7 391 cyanoethoxy)-1, 1'-biphenyl-4-yl]-1 H-Hz), 5. 60 (q, 1 H, J = 6. 7 pyrazole-3-carboxamide Hz), 6. 51 (br s, 2H), NH2 7. 15-7. 23 (m, 1H), 7. 40- O\ N 7. 48 (m, 3H), 7. 53 (br s, 1 N X 1 H), 7. 75-7. 87 (m, 3H), 7. 98 (d, 2H, J = 8. 7 Hz), HN 8. 61 (s, 1 H), 8. 68 (s, - NH2 H 1 H) CN 170 4- [ (aminocarbonyl) amino]-l- [3'- (pyridin-3- 6 5. 23 (s, 2H), 6. 55 (br 429 ylmethoxy)-1, 1'-biphenyl-4-yl]-1H-s, 2H), 7. 10 (dd, 1H, J= pyrazole-3-carboxamide 5. 8, 2. 2 Hz), 7. 30-7. 48 NHz (m, 4H), 7. 53 (br s, 1 H), 7. 78-7. 86 (m, 3H), 7. 82 1< XN v (d, 1 H, J = 7. 9 Hz), 7. 95 (d, 2H, J = 8. 8 Hz), 8. 55 HN \ (d, 1 H, J = 3. 5 Hz), 8. 61 0 NH,/ (s, 1 H), 8. 65-8. 75 (m, 2H) N Ex. Name and Structure'H NMR (DMSO-d6, MS (ES+) unless indicated (M+1) otherwise) 171 4- [ (aminocarbonyl) amino]-l- [3'- (pyridin-4- 6 5. 58 (s, 2H), 6. 54 (br 429 ylmethoxy)-1, 1'-biphenyl-4-yl]-1H-s, 2H), 7. 10 (dd, 1H, J= pyrazole-3-carboxamide 6. 4, 1. 7 Hz), 7. 30-7. 45 NHz (m, 3H), 7. 48 (d, 2H, J = 7. 9 Hz), 7. 53 (br s, 1 H), | \N4\/ 7. 78-7. 86 (m, 3H), 7. 93 (d, 2H, J = 8. 8 Hz), 8. 55- HN 8. 65 (m, 3H), 8. 68 (s, 0 o-NH2 IH) -N 172 4-[(aminocarbonyl) amino]-1-[2'-o 5. 27 (s, 2H), 6. 53 (br 395 (cyanomethoxy)-5'-fluoro-1, 1'-biphenyl-4- s, 2H), 6. 25-7. 38 (m,. y !]-1H-pyrazo) e-3-carboxam ! de"""3H), 7. 52 (br s, 1 H), NC 7. 65 (d, 2H, J = 8. 7 Hz), NH 7. 82 (br s, 1 H), 7. 95 (d, 1 2 O 2H, J = 8. 7 Hz), 8. 62 (s, 0HN N-"1 H), 8. 69 (s, 1 H) F un F HAN o) ~ NH2 F 173 4- [ (aminocarbonyl) amino]-1- [2'- b 5. 24 (s, 2H), 6. 53 (br 395 (cyanomethoxy)-4'-fluoro-1, 1'-biphenyl-4-s, 2H), 7. 04 (dt, 1H, J= yl]-1H-pyrazole-3-carboxamide 6. 1, 2. 1 Hz), 7. 25 (dd, NC 1H, J=8. 9, 2. 1 Hz), NH 7. 40-7. 62 (m, 4H), 7. 78 2 o (brs, 1H), 7. 93 (d, 2H, J -'iN\ = 8. 7 Hz), 8. 60 (s, 1 H), 8. 69 (s, 1 H) HN o'NH2 Ex. Name and Structure'H NMR (DMSO-d,, MS (ES+) unless indicated (M+1) otherwise) 174 tert-butyl [ (4'- {3- (aminocarbonyl)-4- (CD30D) : 5 1. 51 (s, 9H), 452 [(aminocarbonyl) amino]-1 H-pyrazoi-1-yl}-4. 42 (s, 2H), 6. 94 (d, 1, 1'-biphenyl-3-yl) oxy] acetate 1H, J= 9. 0 Hz), 7. 18- NHz 7. 22 (m, 1 H), 7. 23-7. 34 OA N (m, 1 H), 7. 37-7. 42 (m, 1 H), 7. 78 (d, 2H, J = 8. 6 Hz), 7. 95 (d, 2H, J = 8. 6 HN Hz), 8. 58 (s, 1 H) i'NHz H3c 0 H3C---0 CH3 175 4- [ (aminocarbonyl) amino]-l- [3'- (2-amino- 6 4. 48 (s, 2H), 6. 55 (br 395 2-oXoet. shoxy) 1'-biph. e. nyl-4-yl]-1 H--r ~ 5 2H), 6. 99 (d, 1 H, J = pyrazole-3-carboxamide 7. 7 Hz), 7. 28-7. 46 (m, NH2 4H), 7. 56 (d, 2H, J = 7. 4 Hz), 7. 77-7. 86 (m, 3H), 7. 99 (d, 2H, J = 8. 7 Hz), HN 8. 62 (s, 1H), 8. 72 (s, HN \ 1 H) zozo o'NH2 NH2 0 176 4-[(aminocarbonyl) amino]-1-[2'-õ 2. 90 (s, 2 H) 6. 50 (s, 2 377. 1 (cyanomethoxy)-1, 1'-biphenyl-3-yl]-1H-H) 7. 20 (t, 1 H) 7. 30 (d, pyrazole-3-carboxamide 1 H) 7. 40-7. 60 (m, 5 H) NHz CN 7. 75 (s, 1 H) 7. 83 (d, 1 o= H) 8. 00 (m, 1 H) 8. 65 (s, N 1 H) 8. 69 (s, 1 H) HN zu Nu2 NH2 177 4- [ (aminocarbonyi) amino]-l- [4'- 6 5. 21 (m, 2 H) 6. 50 (m, 377. 1 (cyanomethoxy)-1, 1'-biphenyl-3-yl]-1 H-2 H) 7. 19 (m, J = 9. 06 pyrazole-3-carboxamide Hz, 2 H) 7. 47-7. 66 (m, 3 NH2 H) 7. 77-7. 94 (m, 4 H) ; ; 8 17 (m, 1 H) 8. 65 (m, 2 HN \-CN CN HN 'NHz Ex. Name and Structure'H NMR (DMSO-d,, MS (ES+) unless indicated (M+1) otherwise) 178 4- [ (aminocarbonyl) amino]-l- [3'- 6 5. 28 (s, 2 H) 6. 50 (m, 377. 1326 (cyanomethoxy)-1, 1'-biphenyl-3-yl]-1 H-2 H) 7. 13 (dd, J = 4. 13, pyrazole-3-carboxamide 2. 92 Hz, 1 H) 7. 45-7. 70 NH2 (m, 6 H) 7. 89 (m, 2 H) O ; N 8. 19 (t, J= 1. 81 Hz, 1 H) 8. 69 (s, 2 H) Han_ NH2 CN 179 4- [ (aminocarbonyl) amino]-l- [3'- 6 5. 30 (s, 2H), 6. 55 (br 395 (cyanomethoxy)-3-fluoro-1, 1'-biphenyl-4- s, 2H), 7. 10-7. 18 (m, yl]-1 H-pyrazole-3-carboxamide 1 H), 7. 45-7. 62 (m, 4H), o 7. 72-7. 90 (m, 3H), 8. 05 .. (t 1H J-11 5 7 Hz) /\/\ 8. 51 (s, 1 H), 8. 71 (s, 1 H) un HAN F 0 CN 180 4-[(aminocarbonyl) amino]-1-[2'-(1-õ 1. 58 (d, 3H, J = 6. 7 409 cyanoethoxy)-5'-fluoro-1, 1'-biphenyl-4-yl]- Hz), 5. 34 (q, 1 H, J = 6. 7 1 H-pyrazole-3-carboxamide Hz), 6. 53 (br s, 2H), o F 7. 24-7. 40 (m, 3H), 7. 53 (br s, 1 H), 7. 65 (d, 2H, J H2N = 8. 7 Hz), 7. 82 (br s, N HN 1 H), 7. 96 (d, 2H, J = 8. 7 HNX O/Hz), 8. 63 (s, 1H), 8. 69 CH3 (s, I H) NC nu NC 181 4-[(aminocarbonyl) amino]-1-{3'-[2-õ 2. 85 (s, 3H), 3. 03 (s, 423 (dimethylamino)-2-oxoethoxy]-1, 1'-3H), 4. 90 (s, 2H), 6. 53 biphenyl-4-yl}-1 H-pyrazole-3-carboxamide (br s, 2H), 6. 78-6. 92 (m, cH3 1 H), 7. 20-7. 42 (m, 3H), H3C-N 7. 53 (br s, 1 H), 7. 78 (d, H2N o 0 3H, J = 8. 4 Hz), 7. 93 (d, Y o 2H, J = 8. 4 Hz), 8. 63 (s, oW 1H), 8. 69 (s, 1H) zu o Ex. Name and Structure'H NMR (DMSO-d,, MS (ES+) unless indicated (M+1) otherwise) 182 tert-butyl [(4'-{3-(aminocarbonyl)-4-õ 1. 40 (s, 9H), 5. 39 (s, 470 [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-2H), 6. 52 (br s, 2H), 5-fluoro-1, 1'-biphenyl-2-yl) oxy] acetate 6. 98-7. 17 (m, 1H), 7. 20- o 7. 32 (m, 1 H), 7. 25 (dd, H2N » o H tH3C 1 H, J = 6. 2, 3. 0 Hz), I ° o+CH3 7. 53 (br s, 1 H), 7. 75 (d, - CH3 2H, J = 8. 8 Hz), 7. 80 (s, w 1 H), 7. 94 (d, 2H, J = 8. 8 Dz), 8. 60 (s, 1H), 8. 69 (s, 1 H) [00759] Example 183 : 4- [ (aminocarbonyl) amino]-l- [4'- (aminocarbonyl)-<BR> <BR> 3'-fluoro-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide

[00761] A mixture of 4-[(aminocarbonyl)amino]-1-(3'-fluoro-4'-{[(4- methoxybenzyl) amino] carbonyl}-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide (Example 150,0. 104 g, 0.2 mmol), 2.5 mL of TFA, 0.5 mL of triflic acid, and anisole (1 mL) was placed in a flask with stir-bar, under nitrogen. After stirring overnight the liquids were removed under reduced pressure, and the solid was triturated with a saturated sodium bicarbonate solution (15 mL), filtered, washed with water, partially dried, and triturated with methanol (5 mL) for 1 h. After filtration and drying, the desired product was obtained.'H NMR (DMSO-d6 : 5 6.52 (br s, 2H), 7.45 (br s, 1 H), 7.62-7. 80 (m, 5H), 7.83 (br s, 1 H), 7.90 (d, 2H, J = 8.8 Hz), 8.02 (d, 2H, J = 8.8 Hz), 8.63 (s, 1 H), 8.69 (s, 1 H). ESI mass spectrum for C, 8H, 6FN603 : 383 (M+1).

[00762] Example 184 : methyl 4- {3- (aminocarbonyl)-4- [(aminocarbonyl)amino]-1H-pyrazol-1-yl} benzoate [00764] Step 1: Preparation of methyl 4- [4-amino-3- (aminocarbonyl)- 1 H-pyrazol-1-yl] benzoate

[00766] 4-Amino-1- (4-bromophenyl)-1 H-pyrazole-3-carboxamide (5 g, 17. 8 mmol, prepared according to the process of Example 214, Steps 1-3), DPPF (0.382 g, 0.6 mmol), DMF (24 mL), and methanol (20 mL) were combined in a tube containing a stir-bar. Nitrogen was bubbled through the solution for 30 minutes to remove oxygen, after that Pd (OAc) 2 (0.166 g, 0.74 mmol) was added, and the reaction mixture was purged again with nitrogen. The tube was placed in an oil bath at 80°C, and CO was bubbled in for 6 h under vigorous stirring.

The reaction mixture was filtered through celite and washed with 10 mL of DMF.

Most of the liquids were removed under reduced pressure, and 60 mL of methylene chloride was added to the residue. The mixture was triturated for 2 h, filtered, and dried. The solid was triturated with water (60 mL) for 5 h, filtered, dried, and triturated with 25 mL of ethanol overnight, to give after filtration and drying the desired product.'H NMR (CD30D) : 5 3.95 (s, 3H), 7.84 (s, 1H), 7.91 (d, 2H, J = 8. 8 Hz), 8.12 (d, 2H, J = 8.8 Hz). ESI mass spectrum for C, 2H, 3N403+ : 261 (M + 1).

[00767] Step 2: Preparation of methyl 4-{3-(aminocarbonyl)-4- [(aminocarbonyl) amino]-1 H-pyrazol-1-yl} benzoate

[00769] Methyl 4- [4-amino-3- (aminocarbonyl)-1 H-pyrazol-1-yl] benzoate (Step 1,0. 465 g, 1.78 mmol) and sodium cyanate (0.405 g) were partially dissolved in a mixture of acetic acid (7 mL) and water (2 mL). The suspension was stirred overnight at room temperature. Most of solvents were removed after reduced pressure and water (25 mL) was added to the residue. After trituration for 3 h, the solid was filtered, washed with 2N sodium bicarbonate solution, and dried. The dry solid was dissolved in a. minima ! amount of DMSO. The obtained solution was added with stirring to 100 mL of methylene chloride and after 1 h was filtered and dried to give the desired product.'H NMR (DMSO-d6) : # 3.85 (s, 3H 6.57 (br s, 2H), 7.58 (br s, 1 H), 7.85 (br s, 1 H), 8.07 (s, 4H), 8.65 (s, 1 H), 8.7 (s, 1 H). ESI mass spectrum for C13H14N5O4+: 304 (M + 1).

[00770] Example 185 : methyl 3-{3-(aminocarbonyl)-4- [(aminocarbonyl)amino]-1H-pyrazol-1-yl}benzoate [00772] Prepared according to the same procedure as Example 184.

'H NMR (300 MHz, DMSO-d6) : # 3.90 (s, 3 H) 6.54 (m, 2 H) 7.55 (m, 1 H) 7.65 (t, J = 7.85 Hz, 1 H) 7.89 (m, 2 H) 8.14 (m, 1 H) 8.37 (m, 1 H) 8.62 (s, 1 H) 8.70 (s, 1 H). ESI mass spectrum for C13H14NsO4+ : 304. 1 (M+1).

[00773] Example 186 : 4-[(aminocarbonyl)amino]-1-[3'-(2-cyanoethyl)- 1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide

[00775] 4-[(aminocarbonyl) amino]-1-{3'-[(E)-2-cyanovinyl]-1, 1'-biphenyl- 4-yl}-1H-pyrazole-3-carboxamide (Example 32,0. 126 g, 0.3 mmol) and sodium borohydride (0.015 g, 0.4 mmol) were partially dissolved in the mixture of pyridine (2 mL) and methanol (4 mL). The suspension was stirred 24 h under reflux. Most of solvents were removed after reduced pressure and water (25 mL) was added to the residue. After trituration for 3 h, the solid was filtered, and dried. HPLG/MS showed the presence of the starting material and the desired product. A preparative reverse phase chromatography was used to isolate the desired product.'H NMR (DMSO-d6) : 5 2.85-3. 03 (m, 4H), 6.53 (br s, 2H), 7.32 (d, 1H, J = 7.6 Hz), 7.45 (t, 1H, J = 7.6 Hz), 7.55 (brs, 1H), 7.62 (d, 1H, J = 7. 6 Hz) ; 7.69 (s, 1 H), 7.80-7. 87 (m, 3H), 8.00 (d, 2H, J = 8.8 Hz), 8.62 (s, 1 H), 8.71 (s, 1 H). ESI mass spectrum for C20HrgN602+ 375 (M+1).

[00776] Example 187 : 4- [ (aminocarbonyl) amino]-l- [4'- (l H-tetrazol-5-yl)- 1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide [00778] To a solution of4- [ (aminocarbonyi) amino]-1- (4'-cyano-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamide (Example 100,0. 29 g, 0.84 mmol) in DMF (3 mL), sodium azide (0.06 g, 0.92 mmol), and NH4Cl (0.05 g, 0.92 mmol) were added and the mixture was heated to 100°C for 24 h. The solvent was removed under reduced pressure, and the residue was triturated with 25 mL of water for 3 h, filtered, partially dried and triturated with methanol (10 mL) for 3 h.

After filtration and drying, the desired product was obtained.'H NMR (DMSO-d6 : 6.55 (br s, 2H), 7.56 (brs, 1H), 7.67-8. 20 (m, 10H), 8.62 (s, 1H), 8.72 (s, 1H).

ESI mass spectrum for C18H16N9O2+: 390 (M+1).

[00779] Example 188: 4-[(aminocarbonyl]amino]-1-(3,4-dihlorophenyl)- 1 H-pyrazole-3-carboxamide [007811 Prepared according to Example 214, step 4 1H NMR (300 MHz, DMSO-d6) : 5 6.53 (s, 2 H) 7.55 (s, 1 H) 7.73 (d, J = 8.86 Hz, 1 H) 7.90 (d, J = 2. 62 Hz, 1 H) 7.93 (d, J = 2. 62 Hz, 1 H) 8.28 (d, J = 2. 42 Hz, 1 H) 8.65 (s, 1 H) 8.67 (s, 1 H). ES1 mass spectrum for C11H10C12N5O2+ : 314. 0 (M+1).

[00782] Example 189: 1-(3-carbamoyl-1-(4-(cyclohexylthio)phenyl)1H- pyrazol-4-yl) urea [00784] A mixture (0 106 g) containing 67 mole% 4- [(aminocarbonyl) amino]-1-(4-i odophenyl)-1 H-pyrazole-3-carboxamide (0.200 mmol, prepared according to the process of Example 214) and 33 mole% 4- [ (aminocarbonyl) amino]-l- (4-bromophenyl)-l H-pyrazole-3-carboxamide (Example 19,0. 098 mmol) was combined with copper (t) iodide (0.061 g, 0.32 mmol), cesium acetate (0.168 g, 0.875 mmol), and anhydrous DMF (0.40 mL).

The reaction flask was partially evacuated and backfilled with nitrogen three times, then cyclohexyl mercaptan (0.038 mL, 0.31 mmol) was added and the

flask placed in an oil bath at 90°C. Upon heating the excess pressure was vented off. After 16 h, 1.0 mL anhydrous DMF was added and the flask heated at 100°C for 24.5 h. The DMF was then stripped, the contents sonicated in 25 mL water for 30 min. , filtered, and then the product washed with 25 mL water.

The product was then mostly dissolved in 100 mL of 20: 80 methanol : ethyl acetate and filtered through a silica plug. The solvents were then stripped and the product further purified by reverse phase preparative HPLC. The fractions containing product were then partially stripped of solvents, the resulting precipitate was filtered, and the product was washed with 25 mL water. The purified product was dried under vacuum to give a white solid.'H NMR (CD30D) : ¢w1. 24-1. 44(m, 5H), 1.58-1.66(m,1H), 1. 72-1.83(m, 2H), 1.93-2.04 (m, 2H), 3.15-3. 24 (m, 1 H), 7.49 (dm, 2H, J = 8. 9 Hz), 7.75 (dm, 2H, J = 8.9 Hz), 8.48 (s, 1 H). ESI mass spectrum: 360 (M + 1).

[00785] Example 190: 1- (1- (4- (2-fluorophenylthio) phenyl)-3-carbamoyl- 1 H-pyrazol-4-yl) urea [00787] A mixture (0.499 g) containing 67 mole% 4- [ (aminocarbonyl) amino]-1- (4-iodophenyl)-1 H-pyrazole-3-carboxamide (prepared according to the process of Example 214) and 33 mole% 4- [ (aminocarbonyl) ami no]-l- (4-bromophenyl)-l H-pyrazole-3-carboxamide (Example 19,0. 463 mmol) was combined with copper (l) iodide (0.274 g, 1.44 mmol), cesium acetate (0.536 g, 2.79 mmol), and anhydrous DMF (7 mL). The reaction flask was partially evacuated and backfilled with nitrogen three times, then 2-fluorobenzenethiol (0.16 mL, 1.5 mmol) was added and the flask placed in an oil bath at 100°C. Upon heating the excess pressure was vented off. After

37 h at 100°C the solvent was stripped and the residue was sonicated in 100 mL water for 30 min., filtered, and washed with 50 mL water. The product was then purified by reverse phase preparative HPLC and then dried under vacuum to give a white solid.'H NMR (CD30D) : 5 7.14-7. 21 (m, 2H), 7.33-7. 43 (m, 4H), 7.79 (dm, 2H, J = 8.9 Hz), 8.49 (s, 1 H). ESI mass spectrum: 372 (M + 1).

[00788] Example 191: 1- (3-carbamoyl-1- (4- (cyclohexylsulfinyl) phenyl)- 1 H-pyrazol-4-yl) urea [00790] 1- (3-carbamoyl-1-(4-(cyclohexylthio)phenyl)-1H-pyrazol-4 yl) urea (Example 189,0. 034 g, 0.095 mmol), glacial acetic acid (0.30 mL), and 30% hydrogen peroxide (0.011 mL, 0.11 mmol) were combined in a vial and the mixture stirred overnight at room temperature. Water was added, and the resulting precipitate was filtered and washed several times with 1-2 mL water.

The product was air dried to give the title compound as a white solid.'H NMR (DMSO-d6) : # 1.03-1. 36 (m, 5H), 1.44-1. 52 (m, 1H), 1.52-1. 60 (m, 1H), 1.67-1. 79 (m, 2H), 1.82-1. 90 (m, 1 H), 2.68-2. 77 (m, 1 H), 6.51 (br s, 2H), 7.54 (br s, 1 H), 7.69 (dm, 2H, J = 8.9 Hz), 7.82 (br s, 1 H), 8.08 (dm, 2H, J = 8.9 Hz), 8.63 (s, 1 H), 8.67 (s, 1 H). ESI rnass spectrum: 376 (M+1).

[00791] Example 192: 1- (3-carbamoyl-1- (4- (cyclohexylsulfonyl) phenyl)- 1 H-pyrazol-4-yl) urea

[00793] 1- (3-carbamoyl-1- (4- (cyclohexylthio) phenyl)-1 H-pyrazol-4- yl) urea (Example 189, 0.038 g, 0.11 mmol), glacial acetic acid (0.30 mL), and 30% hydrogen peroxide (0.030 mL, 0.29 mmol), were combined in a vial and the vial was placed in an oil bath at 100°C for 60 min. The acetic acid was stripped, then the residue triturated in 5 mL water for 30 min, followed by trituration in 1.4 mL anhydrous diethyl ether overnight, filtering, and washing with 2 mL anhydrous diethyl ether. The solid was then dried under vacuum to give a tan solid.'H NMR (DMSO-d6) : 5 1.00-1. 32 (m, 6H), 1.52-1. 61 (m, 1H), 1. 68-1. 77 (m, 2H), 1.83-1. 92 (m, 2H), 6.54 (br s, 2H), 7.60 (br s, 1 H), 7.90 (dm + br s, 3H, J = 9.0 Hz), 8.16 (dm, 2H, J = 8.9 Hz), 8.69 (s, 2H). ESI mass spectrum: 392 (M+1).

[00794] Example 193: 1- (1- (4- (2-fluorophenylsulfinyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00796] 1- (1- (4- (2-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4- yl) urea (Example 190,0. 050 g, 0.13 mmol), glacial acetic acid (0.4 mL), and 30% hydrogen peroxide (0.0145 mL, 0.14 mmol) were combined in a vial and the mixture stirred overnight at room temperature. 5 mL water was added and the resulting precipitate was filtered and washed with 5 mL water. Then glacial acetic acid (0.5 mL), and 30% hydrogen peroxide (0.009 mL, 0.009 mmol) were added to the product and the mixture was stirred for 20 h at room temperature.

Again 5 mL water was added, and the resulting precipitate was filtered and washed twice with 5 mL water. Then glacial acetic acid (0.4 mL), and 30% hydrogen peroxide (0.011 mL, 0.011 mmol) were added to the product and the mixture was stirred overnight at room temperature. 5 mL water was added and the resulting precipitate was filtered and washed twice with 5 mL water. The

product was dried under vacuum to give a white solid.'H NMR (DMSO-d6) : 8 6.50 (br s, 2H), 7.29-7. 35 (m, 1 H), 7.47 (td, 1 H, J = 7.6, 0.94 Hz), 7.53-7. 62 (m, 2H), 7.75-7. 86 (m, 4H), 8.06 (dm, 2H, J = 8.9 Hz), 8.54 (s, 1 H), 8.60 (s, 1 H). ESI mass spectrum: 388 (M+1).

[00797] Example 194: 1- (1- (4- (2-fluorophenylsulfonyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00799] 1- (1- (4- (2-fluorophenylthio) phenyl)-3-carbamoyl-1 H-pyrazol-4- yl) urea (Example 190, (0.049 g, 0.13 mmol), glacial acetic acid (0.6 mL), and 30% hydrogen peroxide (0.040 mL, 0.39 mmol) were combined in a vial and the vial was placed in an oil bath at 100°C for 1.2 h. The solvent was then mostly stripped, 5 mL water was added, the resulting precipitate was filtered, and washed with 5mL water. Then glacial acetic acid (0.50 mL) and 30% hydrogen peroxide (0.023 mL, 0.22 mmol) was added to the product and the mixture was placed in an oil bath at 100°C for 1.0 h. Water (5 mL) was then added, the resulting precipitate filtered, and washed twice with 5mL water. The product was then triturated overnight with roughly 2 mL anhydrous diethyl ether, filtered, and washed with 2 mL anhydrous diethyl ether. The product was dried under vacuum to give a tan solid.'H NMR (CD30D) : 5 7.22-7. 29 (m, 1 H), 7.41-7. 46 (m, 1H), 7.67-7. 75 (m, 1H), 8.05-8. 15 (m, 5H), 8.62 (s, 1 H). ESI mass spectrum: 404 (M+1).

[00800] Example 195: 1- (3-carbamoyl-1- (3-iodophenyl)-1 H-pyrazol-4- yl) urea

[00802] 4- [ (arninocarbonyl) amino]-l- (3-bromophenyl)-lH-pyrazole-3- carboxamide (Example 20,1. 736 g, 5.356 mmol), copper (l) iodide (1.008 g, 5.29 mmol), sodium iodide (1.611 g, 10.75 mmol), N, N'-dimethylethylenediamine (1.1 mL, 10. 3mmol), and anhydrous 1,4-dioxane (11 mL) were combined in a Fisher Porter bottle. The bottle was flushed with nitrogen, sealed, and then placed in an oil bath at 110°C. After 42 h the bottle was removed from the oil bath. The contents were stripped of so ! vent, 200 mL water was added, ther- sonicated for 30 min, filtered, and washed twice with 50 mL portions of water.

The product was then purified by reverse phase preparative HPLC. The purified product was dried under vacuum to give a white solid.'H NMR (CD3OD) : # 7.25 (t, 1H, J=8. 1 Hz), 7.69 (dm, 1H J=7.8 Hz), 7.80 (dm, 1H, J=8.2 Hz), 8. 24 (t, 1 H, J = 1.9 Hz), 8.50 (s, 1 H). ESI mass spectrum: 372 (M+1).

[00803] Example 196: 1- (1- (4- (4-fluorophenylthio) phenyl)-3-carbamoyl- 1 H-pyrazol-4-yl) urea [00805] A mixture (0.502 g) containing 67 mole% 4- [ (aminocarbonyl) amino]-l- (4-iodophenyl)-l H-pyrazole-3-carboxamide (0.946 mmol, prepared according to the process of Example 214) and 33 mole% 1- (1- (4-bromophenyl)-3-carbamoyl-1H-pyrazol-4-yl) urea (Example 19,0. 466 mmol) was combined with copper (l) iodide (0.285 g, 1.5 mmol), cesium acetate (0.872

g, 4.54 mmol), and anhydrous DMF (7 mL). The reaction flask was partially evacuated and backfilled with nitrogen three times, then 4-fluorobenzenethiol (0.175 mL, 1.63 mmol) was added and the flask placed in an oil bath at 100°C.

Upon heating the excess pressure was vented off. After 22.5 h at 100°C the solvent was stripped and the residue sonicated in 100 mL water for 30 min., filtered, and washed with 50 mL water. After air drying, sodium cyanate (0.145 g, 2.23 mmol), water (2.4 mL), and glacial acetic acid (8.5 mL) were added and stirred overnight. Then 3.0 mL water was added, the slurry filtered, and washed twice with 5mL water. After air drying, the product was sonicated in 25 mL ethanol, filtered, and the solid washed with 5mL ethanol. The ethanol was then stripped dowrrtp roughiy 10 mL and 100 mL water was added. The resulting-. precipitate was then filtered, washed with 50 mL water, and allowed to air dry 3 days. The title compound was a yellow solid.'H NMR (CD30D) : 6 7.13 (t m, 2H, J = 1.9 Hz), 7.36 (dm, 2H, J = 8.9 Hz), 7. 42-7. 48 (m, 2H),-7. 77 (dm, 2H, J = 8-. 9 Hz), 8. 48 (s, 1 H). ESI mass spectrum : 372 (M+1).

[00806] Example 197: 1- (1- (4- (3-fluorophenylthio) phenyl)-3-carbamoyl- 1 H-pyrazol-4-yl) urea [00808] A mixture (0.407 g) containing 67 mole% 4- [ (aminocarbonyl) amino]-l- (4-iodophenyl)-l H-pyrazole-3-carboxamide (0.767 mmol, prepared according to the process of Example 214) and 33 mole% 1- (l- (4-bromophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea (Example 19,0. 378 mmol) was combined with copper (l) iodide (0.227 g, 1.19 mmol), cesium acetate (0.537 g, 2.80 mmol), and anhydrous DMF (6 mL). The reaction flask was partially evacuated and backfilled with nitrogen three times, then 3-

fluorobenzenethiol (0.110 mL, 1.30 mmol) was added and the flask placed in an oil bath at 100°C. Upon heating the excess pressure was vented off. After 40 h at 100°C, the DMF was stripped and the residue sonicated in 50 mL water for 30 min., filtered, and washed with 25 mL water. The product was partially purified by reverse phase preparative HPLC. The fractions containing product were combined and partially stripped of solvent. Then saturated sodium bicarbonate was added, the mixture filtered, and the product washed with water. The product was the sonicated for 30 min. in 2.0 mL ethanol and filtered. After air drying, sodium cyanate (0.044 g, 0.68 mmol), water (1.3 mL), and glacial acetic acid (4.5 mL) were added and stirred overnight. Then 1.5 mL water was added, the slurry filtered, and the solid washed twice with 5 mL water. The product precipitated in the filtrate when the water washes were added and the resulting mixture was filtered, washed with 5 mL water, and then dried under vacuum. The title compound was a tan solid.'H NMR (CD30D) : d 6.95-7. 03 (m, 2H), 7.11 (dm, 1 H, J = 7.9 Hz), 7.30-7. 37 (m, 1 H), 7.52 (dm, 2H, J = 8.9 Hz), 7.85 (dm, 2H, J = 8.9 Hz), 8. 53 (s, 1 H). ESI mass spectrum: 372 (M+1).

[00809] Example 198: 1- (1- (3- (2-fluorophenylthio) phenyl)-3-carbamoyl- 1 H-pyrazol-4-yl) urea [00811] 1-(3-carbamoyl-1-(3-iodophenyl)-1 H-pyrazol-4-yl) urea (Example 195,0. 100 g, 0.269 mmol), copper (l) iodide (0. 062 g, 0.33 mmol), cesium acetate (0. 162 g, 0.844 mmol), and anhydrous DMF (1.4 mL) were combined. The reaction flask was partially evacuated and backfilled with nitrogen three times, then 2-fluorobenzenethiol (0.040 mL, 0.37 mmol) was added and the flask placed in an oil bath at 100°C. Upon heating the excess

pressure was vented off. After 24 h at 100°C, the DMF was stripped and the residue was sonicated in 25 mL water for 30 min., filtered, and washed with 25 mL water. After air drying, sodium cyanate (0.045 g, 0.69 mmol), water (1.3 mL), and glacial acetic acid (4.5 mL) were added and stirred overnight. Then 1.5 mL water was added, the slurry filtered, and the solid washed twice with 5 mL water.

Product precipitated in the filtrate when the water washes were added and the resulting mixture was filtered, washed with 5 mL water, and then dried under vacuum. The title compound was a light pink solid.'H NMR (CD30D) : õ 7. 15- 7.23 (m, 3H), 7.37-7. 47 (m, 3H), 7.69 (ddd, 1 H, J = 8.2, 2.3, 0.88 Hz), 7.79 (t, 1 H, J = 1.9 Hz), 8. 45 (s, 1 H). ESI mass spectrum: 372 (M+1) [00812] Example 199: 1- (l- (4- (4-hydroxyphenylthio) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00814] A mixture (0.500 g) containing 67 mole% 4- [(aminocarbo nyl) amino]-1-(4-iodophenyl)-1 H-pyrazole-3-carboxamide (0.942 mmol, prepared according to the process of Example 214) and 33 mole% 1- (l- (4-bromophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea (Example 19,0. 464 mmol) was combined with 4-mercaptophenol (0.230 g, 1.82 mmol), copper (l) iodide (0.287 g, 1. 51 mmol), cesium acetate (0.675 g, 3.52 mmol), and anhydrous DMF (7 mL). The reaction flask was partially evacuated and backfilled with nitrogen three times, then placed in an oil bath at 100°C. Upon heating the excess pressure was vented off. After 22.5 h at 100°C the solvent was stripped and the residue sonicated in 100 mL water for 30 min. , filtered, and washed with 50 mL water. The product was then triturated in 25 mL chloroform for 1.5 h, sonicated for 30 min., filtered, and washed with 25 mL chloroform. The product was then

sonicated for 30 min. in 25 mL ethanol, filtered, and the solid washed with 5-6 mL ethanol. The ethanol filtrate was stripped to 10 mL, 100 mL water was added, the resulting slurry filtered, and the product washed with 25 mL water.

The product was sonicated for 5 min. in 150 mL 1 N NaOH solution, filtered, and the solid washed with 25 mL water. The filtrate was neutralized with ~150 mL 1 N HCI solution. The resulting precipitate was filtered and washed with 25 mL water. After air drying, sodium cyanate (0.265 g, 4.08 mmol), water (1.3 mL), and glacial acetic acid (4.5 mL) were added and stirred overnight. Then 1.5 mL water was added, the slurry filtered, and the solid washed twice with 5 mL water.

Product precipitated in the filtrate when the water washes were added, and the mixture was then filtered and washed with 5 mL water. The product was further purified by reverse phase preparative HPLC, and dried under vacuum to give a white solid. 1H NMR (CD30D) : 6 6.83 (dm, 2H, J = 8.7 Hz), 7.19 (dm, 2H, J = 8.9 Hz), 7.35 (dm, 2H, J = 8.7 Hz), 7.68 (dm, 2H, J = 8.9 Hz), 8.43 (s, 1 H). ESI mass spectrum: 370 (M+1).

[00815] Example 200: 1- (4-(4-fluorophenylsulfinyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00817] 1- (1- (4- (4-fluorophenylthio) phenyl)-3-carbamoyl-1H-pyrazol-4- yl) urea (Example 196,0. 080 g, 0.19 mmol), glacial acetic acid (0.80 mL), and 30% hydrogen peroxide (0.026 mL, 0.25 mmol), were combined in a vial and the mixture stirred for 89 h at room temperature. The solvent was then stripped off, and the product purified by reverse phase preparative HPLC. The purified product was dried under vacuum to give a yellow solid.'H NMR (CD30D/DMSO-

d6 (1 : 4) ) : d 7.31 (t m, 2H, J = 8. 9), 7.72-7. 79 (m, 4H), 7.99 (dm, 2H, J = 8.9 Hz), 8.57 (s, 1H). ESI mass spectrum: 388 (M+1).

[00818] Example 201: 1- (1- (4- (3-fluorophenylsulfinyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00820] Prepared according to Example 200 (starting with Example 197). The title compound was a white solid.'H NMR (CD30D/DMSO-d6 (1 : 4) ) : d 7.23-7. 29 (m, 1 H), 7.49-7. 57 (m, 3H), 7.81 (dm, 2H, J = 8.9 Hz), 7.99 (dm, 2H, J = 8.9 Hz), 8. 56 (s, 1 H). ESI mass spectrum: 388 (M+1).

[00821] Example 202: 1-(1-(3-(2-fluorophenylsulfinyl)phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00823] Prepared according to Example 200 (starting with Example 198). The title compound was a yellow solid.'H NMR (CD30D/DMSO-d6 (1 : 4) ) : d 7.21-7. 27 (m, 1 H), 7.40 (td, 1 H, J = 7.6, 1.0 Hz), 7.50-7. 57 (m, 2H), 7.62 (t, 1 H, J = 7. 9 Hz), 7. 80-7. 86 (m, 1 H), 7.97 (ddd, 1 H, J = 8.1, 1.1, 0.87 Hz), 8.17- 8.20 (m, 1 H), 8.57 s, 1 H). ESI mass spectrum: 388 (M+1) [00824] Example 203: 1- (1- (4- (3-fluorophenylsulfonyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea

[00826] 1- (1- (4- (3-fluorophenylthio) phenyl)-3-carbamoyl-1H-pyrazol-4- yl) urea (Example 197,0. 22 g, 0.052 mmol, glacial acetic acid (0.40 mL), and 30% hydrogen peroxide (0.014 mL, 0.14 mmol) were combined in a vial and then the vial was placed in an oil bath at 100°C for 68 h. The vial was removed from the oil bath, the solvent stripped, and the product was then purified by reverse phase preparative HPLC. The purified product was dried under vacuum to give a tan solid. 1 H NMR (CD3OD/DMSO-d6 (1 : 4)) : d 7.41-7. 49 (m, 1 H), 7.58-7. 65 (m, 1 H), 7.74-7. 81 (m, 2H), 8.05 (s, 4H), 8.62 (s, 1 H). ESI mass spectrum: 404 (M+1).

[00827] Example 204: 1- (1- (4- (4-fluorophenylsulfonyl) phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00829] 1- (3-carbamoyl-l- (4-iodophenyl)-lH-pyrazol-4-yl) urea (Example 215,1. 004 g, 2.71 mmol), copper (I) iodide (0.051 g, 0.27 mmol), (trans, 6E, 7E)-N1, N2-bis ((pyridin-2-yl) methylene) cyclohexane-1, 2-diamine (0.161 g, 0.551 mmol), cesium carbonate (0.878 g, 2.69 mmol), 4A molecular sieves (0.809 g), and anhydrous DMF (4.0 mL) were combined. The reaction flask was partially evacuated and backfilled with nitrogen several times, then 4- fluorobenzenethiol (0.43 mL, 4.0 mmol) was added and the flask placed in an oil bath at 110°C. Upon heating the excess pressure was vented off. After 4.0 h at 110°C, 40 mL DMF was added, the mixture was filtered at room temp.,

and the solid was washed with 10 mL of DMF. The DMF filtrate was stripped of solvent, the residue was sonicated for 30 min. in 75 mL of water, filtered, and the solid was washed with 25 mL of water. The solid was then dissolved in 250 mL THF, filtered, the filtrate was stripped of solvent, and the residue dried under vacuum. The residue was then combined with 11.5 mL glacial acetic acid, and 30% hydrogen peroxide (0.80 mL, 7.8 mmol). The reaction vessel was then place in a 100°C oil bath. After 1 h, hydrogen peroxide (0.55 mL, 5.4 mmol) was added. After another 1.1 h, the vessel was removed from the oil bath, 90 mL water was added, and the resulting precipitate filtered. The product was then partially purified by reverse phase preparative HPLC. The purer fractions were combined, partially stripped of solvent, and filtered. The less pure fractions were combined, stripped of solvent, and were recrystalized from acetonitrile and water several times. The purified product was dried under vacuum to give a yellow solid. 1H NMR (DMSO-d6) : d 6.53 (br s, 2H), 7.42-7. 49 (m, 2H), 7.59 (br s, 1 H), 7.88 (br s, 1 H), 8.03-8. 15 (m, 6H), 8.65 (s, 1 H), 8.67 (s, 1 H). ESI mass spectrum: 404 (M+1) [00830] Example 205 : 1- (3-carbamoyl-1- (4- (pyridin-2-ylthio) phenyl)-1 H- pyrazol-4-yl) urea [00832] 4-[(aminocarbonyl) amino]-1-(4-iodophenyl)-1 H-pyrazole-3- carboxamide (0.595 g, 1.60 mmol, prepared according to the process of Example 214), 2-mercaptopyridine (0.272 g, 2.45 mmol), copper (I) iodide (0. 033 g, 0.17 mmol), (trans, 6E, 7E)-N1, N2-bis ( (pyridin-2- yl) methylene) cyclohexane-1, 2-diamine (0.095g, 0.32 mmol), cesium carbonate (0. 689 g, 2.11 mmol), 4A molecular sieves (0.495 g), and anhydrous DMF (2.0

mL) were combined. The reaction flask was partially evacuated and backfilled with nitrogen three times, and the flask placed in an oil bath at 110°C. Upon heating the excess pressure was vented off. After 23 h at 110°C, 70 mL DMF was added after cooling to room temperature, the mixture filtered, and the filtrate stripped of solvent. The residue was then sonicated in 75 mL water for 30 min., filtered, and washed with 25 mL water. The product was then partially purified by reverse phase preparative HPLC. The product was then mostly dissolved in 25 mL 1 N HCI solution and filtered. The filtrate was then neutralized with saturated sodium bicarbonate, the resulting precipitate filtered, and the product washed with 25 mL water. Then 20 mL of 0.2N HCI solution was added, followed by more HCI until roughly 25 mL 0.6N HCl was added The slurry was then filtered, 25-30 mL 1 N HCI was added to the HCI salt, and the slurry filtered. Then 100 mL water was added, and the product salt partially dissolved. The resulting mixture was neutralized with saturated sodium bicarbonate, the slurry was then filtered, washed with 25 mL water, and air dried overnight to give a white solid.

H NMR (D MSO-d,) : 66. 51 (br s, 2H), 7.00 (d, 1H, J = 8. 1 Hz), 7.12-7. 17 (m, 1 H), 7.53 (br s, 1 H), 7.61-7. 70 (m, 3H), 7.81 (br s, 1 H), 7.99 (dm, 2H, J = 8. 6 Hz), 8.39 (dm, 1 H, J = 3. 9 Hz), 8.61 (s, 1 H), 8.67 (s, 1 H). ESI mass spectrum: 355 (M+1) [00833] Example 206: 1- (3-carbamoyl-1- (4- (pyridin-4-ylthio) phenyl)-1 H- pyrazol-4-yl) urea [00835] Made similarly to Example 205, except 4-mercaptopyridine was used, and when the 0.2N HCI was added, the product dissolved. The HCI solution was then partially neutralized with saturated sodium bicarbonate and

the resulting precipitate filtered. The filtrate was then neutralized with more saturated sodium bicarbonate and the resulting precipitate was filtered, washed with water, and purified by reverse phase preparative HPLC. The product was dried under vacuum. The title compound was a yellow solid. 1H NMR (DMSO-d6) : d 6.52 (br s, 2H), 7.04 (dd, 2H, J = 4.7, 1.5 Hz), 7.55 (br s, 1 H), 7.69 (dm, 2H, J = 8.7 Hz), 7.83 (br s, 1 H), 8.04 (dm, 2H, J = 8.9 Hz), 8.36 (br d, 2H, J = 5.2 Hz), 8.63 (s, 1 H), 8.68 (s, 1 H). ESI mass spectrum: 355 (M+1).

[00836] Example 207: 1- (3-carbamoyl-1- (4- (cyclopentylthio) phenyl)-1 H- pyrazol-4-yl) urea [00838] Made similarly to Example 205, except that the cyclopentyl mercaptan was added after the flask was partially evacuated and backfilled with nitrogen several times and after 6 h at 110°C, the flask was removed from the oil bath and additional copper (I) iodide (0.030 g, 0.16 mmol), (trans, 6E, 7E)- N1, N2-bis ((pyridin-2-yl) methylene) cyclohexane-1, 2-diamine (0.093 g, 0.32 mmol), and anhydrous DMF (2.0 mL) were added. The reaction flask was then partially evacuated and backfilled with nitrogen as before, and the flask placed back in the 110°C oil bath. The excess pressure was again vented upon heating. Then after another 5 h at 110°C, 40 mL DMF was added, the mixture was filtered, and the solid was washed with 10 mL of DMF. The DMF filtrate was stripped of solvent, the residue sonicated for 30 min. in 75 mL of water, filtered, and the solid was washed with 25 mL of water. The solid was then mostly dissolved in 500 mL boiling THF and filtered hot. The THF was then stripped and the residue purified by reverse phase preparative HPLC. The purified product was dried under vacuum. The title compound was a light tan solid.'H NMR

(DMSO-d6) : 6 1.44-1. 63 (m, 4H), 1.63-1. 75 (m, 2H), 1.98-2. 08 (m, 2H), 3.68-3. 76 (m, 1 H), 6.49 (br s, 2H), 7.43 (dm, 2H, J = 8.7 Hz), 7.49 (br s, 1 H), 7.74 (br s, 1 H), 7.80 (dm, 2H, J = 8.7 Hz), 8.52 (s, 1 H), 8.65 (s, 1 H). ESI mass spectrum: 346 (M+1).

[00839] Example 208: 1-(1-(4-(2-hydroxyphenylthio)phenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00841] Made similarly to Example 205, except the 2-mercaptophenol was added after the flask was partially evacuated and backfilled with nitrogen several times and after 4 h at 110°C, 40 mL DMF was added, the mixture filtered, and the solid washed with 10 mL of DMF. The DMF filtrate was stripped of solvent, the residue was sonicated for 30 min. in 75 mL of water, filtered, and the solid was washed with 25 mL of water. The solid was then mostly dissolved in 500 mL boiling THF and filtered hot. The THF filtrate was then stripped of solvent and the residue purified by reverse phase preparative HPLC. The purified product was dried under vacuum. The title compound was a light tan solid.'H NMR (DMSO-dfi) : 5 6.48 (br s, 2H), 6.79 (tm, 1 H, J = 7.5 Hz), 6.92 (dd, 1 H, J = 8. 1,0. 9 Hz), 7.14 (dd, 1H, J=7. 7,1. 4 Hz), 7.19 (tm, 1 H, J = 7. 7 Hz), 7.27 (dm, 2H, J = 8.7 Hz), 7.49 (br s, 1 H), 7.72 (br s, 1 H), 7.81 (dm, 2H, J = 8.9 Hz), 8.51 (s, 1 H), 8.65 (s, 1 H), 10.01 (br s, 1 H). ESI mass spectrum: 370 <BR> <BR> <BR> <BR> (M+1).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> [00842] Example 209: 4- [ (Aminocarbonyl) amino]-l- (3-chloro-4- methoxyphenyl)-1 H-pyrazole-3-carboxamide [00844] Step 1: Preparation of ethyl 4-nitro-1 H-pyrazole-3-carboxylate

[00846] 4-Nitro-1 H-pyrazole-3-carboxylic acid (2 g, 12.73 mmol ; Aldrich) was refluxed in absolute ethanol (25 mL) containing trace sulfuric acid (0. 2. mol) for 5 h. The reaction was evaporated and partitioned between EtOAc and 5% NaHCO3. The EtOAc layer was separated, dried over MgSO4 and filtered. The EtOAc was removed to give a white solid.'H. NMR (300 MHz, DMSO-d6) : 5 1.28 (t, J=7 Hz, 3 H), 4. 34 (q, J=7 Hz, 2 H), 8.91 (s, 1 H), 14.39 (br s, 1 H); MS (ESI+) for CH N 186. 1 (M+H) +.

[00847] Step 2: Preparation of N-(2, 4-Dimethoxybenzyl)-4-nitro-1H- pyrazole-3-carboxamide [00849] The carboxylate from Step 1 (3.32 g, 17.93 mmol) was stirred in excess 2, 4-dimethoxybenzylamine at 120 °C for 1.5 h. The resulting product was triturated with hot EtOH and filtered to give 8.45 g of product as the 2,4- dimethoxybenzylamine salt (1: 1). The salt was dissolve in MeOH (300 mL, 60 °C for 0.5 h), acidified using conc. HCI and diluted to a total volume of 1 L with

water. The resulting precipitate was filtered, rinsed with water and air-dried to give an off-white solid.'H NMR (300 MHz, DMSO-d6) : # 3.74 (s, 3 H), 3.79 (s, 3 H), 4.33 (d, 2 H), 6.50 (m, 2 H), 7.19 (d, 1 H), 8. 8 (br s, 1 H), 8.87 (br s, 1 H), 14.05 (br s, 1 H); MS (ESI+) for C, 3H, 4N4O5 m/z 307.0 (M+H) +.

[00850] Step 3: Preparation of 4-amino-N-(2, 4-dimethoxybenzyl)-1 H- pyrazole-3-carboxamide [00852] The carboxamide from Step 2 (4.60 g, 15 mmol) was hydrogenated using 10% Pd/C (0.4 g) in MeOH/THF (30 mL/200 mL) at atmospheric pressure (Ha-balloon) for 4 h. The reaction was filtered through Celite and evaporated to give the desired product as a foam.'H NMR (300 MHz, DMSO-d,) : 5 3.72 (s, 3 H), 3.79 (s, 3 H), 4.29 (d, 2 H), 4.55 (s, 2 H), 6.42 (m, 1 H), 6.54 (m, 1 H), 7.07 (m, 2 H), 7.9 (br s, 1 H), 12.53 (s, 1 H); MS (ESI+) for C13H16N403 m/z 277.0 (M+H) +.

[00853] Step 4: Preparation of 4-[(aminocarbonyl) amino]-N-(2, 4- dimethoxybe nzyl)-1 H-pyrazole-3-carboxamide

[00855] The product of Step 3 (4.07 g, 14.73 mmol) and sodium cyanate (1.91 g, 29.4 mmol) were suspended in water (40 mL). Tetrahydrofuran (40 mL) was added, followed by HOAc (15 mL) and the reaction was stirred at room temperature for 10 min. The reaction was evaporated and partitioned between EtOAc and 1 N NaOH. The EtOAc layer was separated, dried over MgS04, filtered and evaporated to give 5.25 g of product. A portion of this was triturated from EtOAc to give the title compound.'H NMR (300 MHz, DMSO-d6) : # 3.72 (s, 3 H), 3.79 (s, 3 H), 4.33 (d, 2 H), 6.32 (br s, 2 H), 6.47 (m, 1 H), 6.54 (s, 1 H), 7.07 (m, 1 H), 7.95 (s, 1 H), 8.24 (m, 1 H), 8.57 (s, 1 H), 12.95 (brs, 1 H); MS (ESI+) for C1 7NsO4 m/z 320.0 (M+H) +.

[00856] Step 5 : Preparation of 4-[(Aminocarbonyl)amino]-1-(3-chloro-4- methoxyphenyl)-N-(2, 4-dimethoxybenzyl)-1 H-pyrazole-3-carboxamide [00858] The product of Step 4 (0.250 g, 0.783 mmol), 3-chloro-4- methoxyphenylboronic acid (0.146 g, 0.783 mmol), copper (li) acetate (0.014 g, 0.078 mmol) and pyridine (0.093 g, 1.17 mmol) were combined in MeOH (3 mL) and heated overnight at 70 °C. The reaction was evaporated, partitioned between EtOAc and 1 N HCI and the EtOAc layer was removed to give a brown oil. The product was purified on silica gel, eluting with 5% MeOH/CH2CI2 to give the product as a foam.'H NMR (300 MHz, CDCI3) : # 3.79 (s, 3 H), 3.86 (s, 3 H), 3.92 (s, 3 H), 4.53 (d, 2 H), 5.06 (m, 2 H), 6.46 (m, 2 H), 6.94 (m, 1 H), 7.21 (m, 1 H), 7.34 (m, 1 H), 7.48 (m, 1 H), 7.78 (m, 1 H), 8.43 (s, 1 H), 8.93 (s, 1 H); MS (ESI+) for C2, H22CINsO5 m/z 460.0 (M+H) +.

[00859] Step 6: Preparation of4- [ (aminocarbony)) amino]-1- (3-chtoro-4- methoxyphenyl)-1 H-pyrazole-3-carboxamide

[00861] The product of Step 5 (0.022 g, 0.048 mmol) was stirred in neat trifluoroacetic acid for 10 min. and evaporated to give the title compound. 1H NMR (300 MHz, DMSO-d,) : # 3.89 (s, 3 H), 6.5 (br s, 2 H), 7.22 (m, 1 H), 7.43 (s, 1 H), 7.82 (m, 2 H), 8.03 (m, 1 H), 8.52 (s, 1 H), 8.65 (s, 1 H); MS (ESI+) for C12H12CIN503-m/z 310. 0 (M+H) +.

[00862] Example 210 : 1-(1-(4-(2-fluorophenylthio)-2-fluorophenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00864] Step 1: Preparation of (2Z)-2-cyano-2-[(2-fluoro-4- iodophenyl) hydrazono] acetamide

[00866] A suspension of 2-fluoro-4-iodoaniline (24.7 g, 104.2 mM) in concentrated HCI (25 mL) and R. O. water (75 mL) was cooled in an ice salt water bath to-10°C. To this suspension was added a solution of sodium nitrite (7.28 g, 1 05. 5 mM) in 20 mL distilled water over 5 min. The mixture was stirred for 25 min. , keeping the reaction mixture cold (0-5°C). An ice-cold solution of sodium acetate trihydrate (41.13 g, 302 mM) in 100 mL water was added to the diazonium salt suspension. This mixture was stirred at-10°C for 10 minutes, then added through an ice-jacketed dropping funnel to a-4°C mixture of 2- cyanoacetamide (25 g, 313 mM), 95% ethanol (95 mL), R. O. water (140 mL) + ice cold sodium acetate (13.865 g, 102 mM) in 30 mL water. During the addition and reaction, the reaction was vigorously stirred with. amechanica ! stirrer. iThe addition took 15 minutes. The orange suspension was stirred an additional 90 min. , then the solid product was filtered out, washing with R. O. water (almost 2 gal.) until little yellow color was left in the washings. A sample of the solid product was chromatographed via HPLC, confirming the presence of only the desired product. The product was dried open to the air in a dark hood for three days to give an orange solid.'H NMR (300 MHz, DMSO-d6) : 5 7.59 (m, 2H); 7.75 (m, 2H); 7.90 (bs, 1 H) ; 11.11 (s, 1 H). LCMS (ESI+) for CgH6F, I, N4O, m/z 332. 9- (M + H) +.

[00867] Step 2: Preparation of 4-amino-1-(2-fluoro-4-iodophenyl)-5- propionyl-1 H-pyrazole-3-carboxamide [00869] A pressure bottle was charged with the hydrazone from Step 1 (21.2 g, 64 mM), DMF (55 mL), ground potassium carbonate (18.6 g), and ethyl

bromoacetate (7.6 mL, 68.5 mM). The solution was purged with nitrogen, the cap was screwed onto the bottle, and the reaction was heated to 110°C for 1 h.

The reaction was cooled and poured onto ice. The dark mass at the bottom of the flask was poured on ice separately. Both suspensions were filtered and dried in the vacuum oven to give the desired product. A sample of the product was purified by extraction into ethyl acetate followed by crystallization from ethyl acetate-heptane. R, = 0.58 in 5% methanol-chloroform.'H NMR (300 MHz, DMSO-d6) : õ 1.11 (t, 3H); 4.15 (q, 2H); 5.73 (s, 2H); 7.38 (m, 2H); 7.71 (m, 2H); 7.89 (m, 1 H). LCMS (ESI+) for C 13H12 Fll, N403m/z 419. 6 (M + 2H)+.

[00870] Step 3: Preparation of 4-amino-3-carbamoyl-1-(2-fluoro-4- iodophenyl)-1H-pyrazole-5-carboxylic acid [00872] The product from Step 2 (22.5 g, 54 mM) was treated with 95% ethanol (90 mL) followed by 45 mL of 3.5 M KOH in ethanol. The reaction was stirred at room temperature overnight, then warmed to 46°C for 105 minutes.

The reaction was partially evaporated, cooled and treated with 6N HCI to pH 3.

The filtered product was washed with water, and dried in vacuum oven.'H NMR ,) : 5 7.38 (m, 2H); 7.71 (m, 2H); 7.90 (m, 1 H). LCMS (ESI+) for C11H8F1I1N4O3 m/z 391. 9 (M + 2H) +.

[00873] Step 4: Preparation of 4-amino-1-(2-fluoro-4-iodophenyl)-1H- pyrazole-3-carboxamide

[00875] The carboxylic acid from Step 3 (1.84 g, 4.71 mmol) was treated with 10 mL 85% phosphoric acid. The reaction was heated to 68°C for 1- 1.5 h. The reaction was cooled in an ice bath and diluted with 20 mL water. The pH was adjusted to 7 by the addition of most of a solution of 11.7 g sodium hydroxide in 60 mL water, and the product was filtered, washed with water and dried under high vacuum to give a tan solid. By thin-layer chromatography (5% methanol-methylene chloride), the starting material appeared at the origin, while the product had an Rf of 0.55.'H NMR (300 MHz, DMSO-D, 7.30 (s, 1 H); 7.55 (m, 2H); 7.71 (m, 2H); 7.92 (m, 1 H). LCMS (ESI+) for C, 0H8F, lt N40, m/z 348.0 (M + 2H) +.

[00876] Step 5: Preparation of 1- (1- (4- (2-fluorophenylthio)-2- fluorophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea [00878] The amide from Step 4 (1.004 g, 2.90 mM) was added to a 100-mL round bottom flask and rotary evaporated from toluene in order to dry the solid and flask. Nitrogen was let in the flask as it was removed from the rotary evaporator, and the flask was septum-stoppered. The solid was then dissolved in 10 mL dry THF and treated with diisopropylethylamine (0.51 mL).

The solution was cooled in a dry ice-methanol bath under nitrogen. Commercial

20% phosgene in toluene (1.6 mL) was added by syringe, forming a yellow precipitate. Ammonia gas was condensed into a microware flask, allowed to evaporate through a tygon tube and recondense intod 5 mL THF at-78°C. One equivalent (0.5 mL) of diisopropylethylamine was added to the ammonia solution, and the carbamoyl chloride suspension was added to the ammonia solution. The reaction was then removed from the cold bath and stirred at room temperature overnight. The mixture was evaporated and treated with water, filtered, and the solid triturated with CH2CI. The solid was then dissolved in about 300 mL of methanol-methylene chloride and filtered ; evaporation of the methylene chloride resulted in crystallization.'H NMR (300 MHz, DMSO-d6) : # 6. 50 (bs, 2H); 7.54 (s, 1H); 7.70 (m, 2H); 7. 80 (s, 1 H) ; 7.91 (m, 1 H) ; 8. 41 (s, 1 id) ; 8.66 (s, 1 H). LCMS (ESI-) for C11H9F1I1N5O2 m/z 388.0 (M-H).

[00879] Example 211 : 1- (1- (4- (2-fluorophenylthio)-2-fluorophenyl)-3- carbamoyl-1 H-pyrazol-4-yl) urea [00881] A 4 mL screw-capped vial was charged with 1- (1- (4- (2- fluorophenylthio)-2-fluorophenyl)-3-carbamoyl-1 H-pyrazol-4-yl) urea (Example 210,797 mg, 2.0 mM). To this was added potassium carbonate (569 mg, 4.1 mM), isopropanol (3 mL), and ethylene glycol (240, uL). Nitrogen was bubbled through the suspension. Copper (I) iodide (32.7 mg) was added, followed by 2- fluorobenzenethiol (230 pL, 2.1 mM). The vial was capped tightly and heated to 80°C overnight. The starting material never appeared to go into solution. The

reaction mixture was cooled, then worked up with methylene chloride and water.

The organic layer was washed with dilute sodium hydroxide to remove any remaining thiol. Crude product was filtered from the methylene chloride layer, adsorbed onto silica gel from DMF and chromatographed on a 70 g silica column in 10% and 20% DMF-toluene. Fractions containing the desired product were evaporated and the title compound was recrystallized a number of times from minimal DMF, adding methanol or water.'H NMR (300 MHz, DMSO-d6) : 5 6.49 (bs, 2H); 7.17 (m, 1H) ; 7.30 (m, 3 H); 7.50 (m, 3 H); 7.75 (s, 1H) ; 7.87 (m, 1 H) ; 8.39 (m, 1 H) ; 8.64 (m, 1 H). LCMS (ESI+) for C"H, 3FN502S, m/z 390.0 (M+H) +.

[00882] Example 212: 4-[(aminocarbonyl)amino]-1-(4-fluorophenyl)-1H- pyrazole-3-carboxamide

[00884] Step 1: Preparation of N-cyano-2- [ (4- fluorophenyl) hydrazono] acetamide

[00886] Following the procedure of Stanczak et al., Pharamzie 49,884- 89,1994), the title material was prepared by coupling the diazonium salt from 4- fluoroaniline and cyanoacetamide in the presence of sodium acetate. The crude material was recrystallized from ethanol. CgH7FN40. MW= 206.18. CaIc : C, 52.43 ; H, 3.42 ; N, 27.17. Found: C, 52.20 ; H, 3.55 ; N, 27.27. mp= 265-267 °C.

[00887] Step 2: Preparation of 1- (4-fluorophenyl)-3-carboxamido-4- amino-5-carboxyethylpyrazole

[00889] N-cyano-2- [ (4-fluorophenyl) hydrazono] acetamide from Step 1 (2.06 g, 10 mmol) was dissolved in DMF (20 mL). K2CO3 (2.8 g, 20 mmol) and ethylbromoacetate (2.2 g 15 mmol) was added to the mixture and heated to 130°C under N2 for 2 h. The mixture was cooled to 90°C, excess triethylamine (2 mL) was added and the temperature maintained for 1 h. The mixture was cooled to room temperature, poured into ice water (160 mL), and stirred for 1 h. The mixture was cooled in the refrigerator overnight and filtered. The crude product was recrystallized from ethanol to give the title compound. C13H13FN403. MW= 292.27. Calc : C, 53.42 ; H, 4.48 ; N, 19.17. Found: C, 53.22 ; H, 4.61 ; N, 19.00.

[00890] Step 3: Preparation of 1- (4-fluorophenyl)-3-carboxamido-4- amino-5-carboxypyrazole [00892] 1- (4-fluorophenyl)-3-carboxamido-4-amino-5- carboxyethylpyrazole from Step 2 (1.5 g, 5 mmol) was warmed to reflux in a 20% solution of KOH (3 g) in ethanol (15 mL) for 1 h. The mixture was cooled and diluted with water (25 mL). The mixture was cooled in an ice bath and acidified to pH=4-6 with 10% HCI. The precipitate formed was filtered cold and air dried to give the title compound. C"H9FN4O3. MW= 264.22. Calc : C, 50.00 ; H, 3.43 ; N, 21.20. Found: C, 49.60 ; H, 3.66 ; N, 20.82.

[00893] Step 4: Preparation of 1- (4-fluorophenyl)-3-carboxamido-4- aminopyrazole

[00895] 1- (4-fluorophenyl)-3-carboxamido-4-amino-5-carboxypyrazole from Step 3 (750 mg, 3 mmol) and H3PO4 (5 mL) were warmed to 80°C for 45 minutes until evolution of CO2 ceased. Sufficient water was added to bring the volume of the mixture to approximately 30 mL, then neutralized with K2CO3to pH=8-9. The precipitate was filtered and washed with aqueous K2CO3. The crude material was recrystallized from ethanol to give the title compound.

CIOH 9FN4 0. MW= 220.21. Calc : C, 54.54 ; H, 4.12 ; N, 25.44. Found: C, 54. 18 ; H, 4.38 ; N, 25.01.

[00896] Step 5: Preparation of 4- [ (aminocarbonyl) amino]-1- (4- fluorophenyl)-1 H-pyrazole-3-carboxamide [00898] 1- (4-fluorophenyl)-3-carboxamido-4-aminopyrazole from Step 4 (220 mg, 1 mmol) was stirred in a mixture of acetic acid (4 mL) and water (1 mL). NaCNO (275 mg, 4 mmol) was added and the contents stirred 3 days at room temperature. The contents were diluted with water (25 mis) and filtered.

The crude material was recrystallized from ethanol/water to give the title compound. C11H10FN5O2. MW= 263.23. Calc : C, 50.19 ; H, 3.83 ; N, 26.61. Found: C, 50.01 ; H, 3.99 ; N, 26.13.

[00899] Example 213: 4-[(aminocarbonyl) amino]-1-(1, 3-benzodioxol-5-<BR> yl)-1 H-pyrazole-3-carboxamide [00901] Prepared according to the procedure of Example 212.

C12H, H, 0. MW= 307.27. Calc : C, 46.91 ; H, 4.26 ; N, 22.79. Found: C, 46.55 ; H, 4.33 ; N, 22.16.

[00902] Example 214: 4-[(aminocarbonyl)amino]-1-(4-chlorophenyl)-1H- pyrazole-3-carboxamide [00904] Step 1: Preparation of (2E)-3- (aminooxy)-2- [ (4- chlorophenyl) hydrazono]-3-oxopropanenitrile [00906] A stirred mixture of 4-chlorobenzenamine (12. 8 g, 100 mmol), conc. HCI (25 mL) and water (75 mL) at 0-5°C was added portion-wise to a solution of NaN02 (6.9 g, 100 mmol) in water (20 mL) over 30 min. NaOAc (25 g)

in water (100 mL) was added at 0°C, followed by portion-wise addition of a mixture of cyanoacetamide (8. 4 g, 100 mmol), NaOAc (25 g), ethanol (100 mL) and water (100 mL). The mixture was stored at-20°C overnight, filtered, washed with water (5 X 100 mL), and dried over 60°C in a vacuum to give the title compound as a yellow solid. LCMS (M+1) = 254.

[00907] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (4- chlorophenyl)-1 H-pyrazole-5-carboxylate [00909] A mixture of (2E)-3- (aminooxy)-2- [ (4-chlorophenyl) hydrazono] - 3-oxopropanenitrile from Step 1 (11.15 g, 50 mmol), bromo ethylacetate (8.35 g, 50 mmol), K 2CO3 (13.8 g, 100 mmol) in DMF (100 mL) was heated to 130°C over 2 h. The mixture was cooled to 90°C, TEA (20 mL) was added and the mixture stirred for 2 h. The mixture was cooled, water (150 mL) added and filtered, washed with water, and air dry to give the title compound as a brown solid.'H NMR, LCMS (M+1 = 310) confirmed its structure.

[00910] Step 3: Preparation of 4-amino-1- (4-chlorophenyl)-1 H-pyrazole- 3-carboxamide [00912] A mixture of the ester from Step 2 (6.18 g, 20 mmol) and KOH (11 g) in EtOH (100 mL) was heated to reflux for 2 h. The mixture was cooled to

0°C, and ice-water (100 mL) and conc. HCI (17 mL) were added. The mixture was filtered, washed with water, and air dry to give the acid. This acid (1.41 g, 5 mmol) was heated with Lil (0.66 g, 25 mmol) in DMF (10 mL) to 150°C for 6 h.

The mixture was cooled and filtered. The DMF solution was added to 30 mL water, filtered to give a yellow solid with excellent'H NMR, LCMS, CNH profile.

Calculated for CroHgCIN4O C, 50.75 ; H, 3.83 ; N, 23.67. Found C, 50.12 ; H, 3.88 ; N, 23.11.

[00913] Step 4: Preparation of 4- [ (aminocarbonyl) amino]-1- (4- chlorophenyl)-1 H-pyrazole-3-carboxamide [00915] A mixture of the amide from Step 3 (319 mg, 1.35 mmol) in CH3CN (8 mL) at room temperature was added to trichloroacetyl isocyanate (267 mg, 1.41 mmol), stirred for 2 h, and NH3 in methanol (2 M, 10 mL) was added.

After stirring overnight, the mixture was filtered, the solid washed with ethanol and air dried to give the title compound as an off white solid with excellent'H NMR and LCMS profiles. 'H NMR (400 MHz, DMSO-d,) : 6 6.50 (s, 2 H) 7.50 (m, 2 H) 7.54 (d, J = 8.86 Hz, 2 H) 7.91 (d, J = 8. 86 Hz, 2 H) 8.56 (s, 1 H) 8.66 (s, 1 H). LC MS (M+H) : 280. 18. Calculated for C11H10ClN5O2(H2O)0.3: C, 46. 34; H, 3.75 : N, 24.57. Found C, 46.68 ; H, 3.56 ; N, 24.40.

[00916] Example 215: 4-[(aminocarbonyl) amino]-1-(4-iodophenyl)-1H- pyrazole-3-carboxamide

[00918] Prepared according to the same procedure as Example 214.

[00919] Example 216 : 4- [ (aminocarbonyl) amino]-l- (4-isopropylphenyl)- 1 H-pyrazole-3-carboxamide [00921] A suspension of 4-[(aminocarbonyl) amino]-N-(2, 4- dimethoxybenzyl)-1 H-pyrazole-3-carboxamide (Example 209, Step 4,100 mg, 0.31 mmol) in DMF (5.0 mL) was treated with p-isopropylbenzeneboronic acid (61 mg, 0.37 mmol) and Cu (I) CI (6.1 mg, 0.062 mmol). Pyridine (0.047 mL, 0.465 mmol) was added to the mixture. The reaction mixture was stirred in open air overnight at 80°C. DMF was evaporated under pressure. The crude mixture was stirred in neat trifluoroacetic acid (2 mL) for 10 min, evaporated, re- dissolved in DMF, and filtered through a syringe filter (0. 45 um) and purified by prep rpHPLC, and lyophilized to give the title compound as a white solid.'H NMR (400 MHz, DMSO-d6) : 5 1.19 (s, 3 H) 1.21 (s, 3 H) 2.91 (m, 1 H) 6.48 (m, 2 H) 7.34 (m, 2 H) 7.47 (m, 1 H) 7.69 (m, 1 H) 7.75 (m, 2 H) 8.49 (s, 1 H) 8.63 (s, 1 H). ESI Mass Spectrum for C,, H, 8N5O2+ : 288. 1 (M + H).

[00922] Examples 217-219 were prepared according to the same procedure as Example 216. Example Name and Structure 1H NMR (500 MS (M + H) MHz, CD30D) 217 4-[(aminocarbonyl) amino]-1-(1 H-õ 6. 56 (d, 1 H), 285. 10 indol-5-yl)-1H-pyrazole-3-7. 36 (d, 1 H), 7. 51 carboxamide (d, 1 H), 7. 55 (dd, 1 H2N>o H), 7. 93 (d, 1 H), 8. 46 (s, 1 H) HN zon NID NH2 H 218 4- [ (aminocarbonyl) amino]-l- (3, 4- 6 7. 43 (m, 1 H), 282. 1 difluorophenyl)-1 H-pyrazole-3-7. 65 (m, 1 H), 7. 88 carboxamide (m, 1 H), 8. 52 (s, 1 Han /\N \ F R NHz 219 4-[(aminocarbonyl) amino]-1-(2-296. 1 naphthyl)-1 H-pyrazole-3- carboxamide HzN o - NHz O ; r-N NH

[00923] Example 220: 4-[(aminocarbonyl)amino]-1-[2-chloro-3'- (cyanomethoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide [00925] To a flask were added 4-[(aminocarbonyl) amino]-1-(2-chloro-3'- hydroxy-1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide (Example 7,0. 087 g, 0.23 mmol), DMF (5 mL, dry), K2CO3 (0.097 g, 0.7 mmol) ; the mixture was then

flushed with vacuum/N2 and then acetone (1 mL) and bromoacetonitrile (0.04 mL, 57 mmol) were added. The mixture was stirred under N2. After overnight stirring, the mixture was evaporated to a dark, oily solid, stirred with H2O (20 mL), filtered and the filtered brown solid washed with H2O (5 X 5 mL) to give a brown solid. Trituration with CH2Cl2 (4 X 5ml) gave the title compound as a light brown solid.'H NMR (300 MHz, DMSO-d6) : 5 8.66 (brs, 2 H), 8. 18 (brs, 1 H), 7.92 (m, 2 H), 7.50 (m, 3 H), 7.14 (m, 3 H), 6.52 (brs, 2 H), 5.21 (brs, 2 H). MS (ESI-) for C, 9H, SCIN6O : m/z 409.1 (M-H)-.

[00926] Example 221 : 4- [ (aminocarbonyl) amino]-l-f3-chloro-4- [ (4- fluorophenyl) thio] phenyl}-1 H-pyrazole-3-carboxamide [00928] A stirring solution of 4- [ (aminocarbonyl) amino]-l- (3-chloro-4- iodophenyl)-1 H-pyrazole-3-carboxamide (Example 6,0. 610 g, 1.5 mmol), Cul (0.29 g, 1.5 mmol), N, N-diisopropylethylamine (5ml), ethylene glycol (1 mL, 75 mmol), 4-fluorothiophenol (0.20 mL, 4.5 mmol), and DMF (10 mL) was placed under vacuum for 20 min and then placed under N2. The stirring mixture was then immersed in an oil bath (105°C). After 3.5 h, the heat was turned off and the mixture stirred overnight. The mixture was then poured onto ice (100 mL) plus Na2CO3 (0.3 g in 10 mu HO ; after stirring for 1 h, the mixture was filtered to give a brown solid. This solid was triturated with CH2C12 (5 X 20 mL) to give the title compound as a light brown solid.'H NMR (300 MHz, DMSO-d6) : 5 8.65 (s, 1 H), 8. 57 (m, 1 H), 8.18 (m, 1 H), 7.88 (brs, 1 H), 7. 80 (m, 1 H), 7.53 (m, 3 H), 7.30 (m, 2 H), 7.03 (m, 1 H), 6.51 (brs, 2 H). MS (ESI-) for C17H13CIFN5O2S m/z 404.0 (M-H)-.

[00929] Example 222: 4- [ (aminocarbonyl) amino]-l- {3-chloro-4- [ (4- fluorophenyl) sulfonyl] phenyl}-1 H-pyrazole-3-carboxamide

[00931] To a flask containing 4- [ (aminocarbonyl) amino]-l- {3-chloro-4- [ (4-fluorophenyl) thio] phenyl}-1 H-pyrazole-3-carboxamide (Example 221,0. 220 g, 0.54 mmol) and meta-chloroperbenzoic acid (0.617 g, about 77%, 2.7 mmol) was added CH 2ci, (10 mL). After overnight stirring, more meta-chloroperbenzoic acid (0. 29 gj 1.6 mmol)-was-added. After the reaction stirred for five days; Na2CO3 (1 g, 10 mmol, in 30 mL H2O) was added to the heterogeneous reaction mixture; after stirring another hour, the mixture was filtered through a sintered glass funnel (5 X 10 mL H20 washes), the filtered solid air dried 3 h and then placed under high vacuum for 2 days to give the title compound as a cream- colored solid.'H NMR (300 MHz, DMSO-d,) : # 8.70 (m, 2 H), 8.30 (m, 2 H), 8.17 (m, 1 H), 8.01 (m, 3 H), 7.63 (s, 1 H), 7.45 (m, 2 H), 6.57 (brs, 2 H). MS (ESI-) for C"H, 3CIFN5O4S m/z 435.9 (M-H)-.

[00932] Example 223: 4-[(aminocarbonyl)amino]-1-(2-chloro-2'-hydroxy- 1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide [00934] To a 2-neck flask were added a stir bar, 4- <BR> <BR> [(aminocarbonyl) amino]-1-(3-chloro-4-iodophenyl)-1 H-pyrazole-3-carboxamide (Example 6,0. 302 g, 0.745 mmol), tetrakis (triphenylphosphine) rhodium (0) (0.086 g, 0.0745 mmol), 2-hydroxyphenylboronic acid (0.205 g, 1.5 mmol), and

dry DMF (5 mL). This stirring solution was flushed with vacuum for 10 minutes. Cs2CO3 (0.588 g, 1.8 mmol) was mixed with H2O (0.9 mL) and N2 was bubbled through the resultant solution for 10 min. The solution was then added by syringe to the reaction mixture above which was then immersed in an oil bath (80°C). After overnight stirring, the heat bath was removed and, after 10 min, the mix was poured onto ice (100 mL), stirred 20 minutes, and filtered (4 X 30ml H2O washes). A greyish tan solid was isolated; this solid was triturated with CHzCI2 (50 mL) and air-dried to give the title compound as a light brown solid.'H NMR (300 MHz, DMSO-d6) : # 9.62 (brs, 1 H), 8.68 (m, 1 H), 8.63 (m, 1 H), 8.10 (m, 1 H), 7.86 (m, 2 H), 7.54 (brs, 1 H), 7.40 (m, 1 H), 7.19 (m, 1 H), 7.10 (m, 1 H), 6. 89 (m, 2 H), 6.53 (brs, 2 H). MS (ESI-) for C17H14CIN5O3 m/z 370. 1 (M-H).

[00935] Example 224: 4-[(aminocarbonyl) amino]-1-[2-chloro-2'- (cyanomethoxy)-1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide [00937] To a stirring solution of 4-[(aminocarbonyl) amino]-1-(2-chloro- 2'-hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide (Example 223,0. 080 g, 0.22 mmol) in DMF (4 mL) and acetone (1 mL) was added bromoacetonitrile (0.030 mL, 0.43 mmol) and K2CO3 (0.094 g, 0.65 mmol). After stirring for 20 h, the reaction mixture was evaporated to a dark, oily solid which was stirred with HO (15 mL) for 60 min then filtered (4 X 15 mL H2O washes) and air dried to give the title compound as a brown solid.'H NMR (300 MHz, DMSO-d6) : # 8.66 (m, 2 H), 8.14 (brs, 1 H), 7.88 (m, 2 H), 7.50 (m, 3 H), 7.21 (m, 3 H), 6.53 (brs, 2 H), 5.15 (s, 2 H). MS (ESI-) for C9H, CIN6O3 m/z 408.9 (M-H)-.

[00938] Example 225: 4-[(aminocarbonyl) amino]-1-(4-bromo-3- fluorophenyl)-1 H-pyrazole-3-carboxamide

[00940] Step 1: Preparation of 2- [ (4-bromo-3-fluorophenyl) hydrazono] - 2-cyanoacetamide [00942] To a 500 mL flask was added 3-fluoro-4-bromoaniline (23.902 g, 190.0 mmol) and a stir bar; the flask cooled to-4°C in acetone/ice bath. To this was added conc. HCI (31. 5ml) dropwise over a period of 5 min, the temperature staying below 5°C. To this was added HO (100 mL) in 3 portions over 3 min, temperature rising to 22°C before dropping back below 5°C. To this slurry was added a solution of NaNO2 (8. 68 g, 69 mmol) in H2O (25 mL plus a 3 mL rinse) over a 5 min period, the temp staying below 5°C (10 mL ice was added to aid in temp control; a little more liquid also appeared to help with stirrability of the mixture). This mixture was a heterogeneous yellow/light brown.

After 90 minutes, a cooled solution of NaOAc3H2O (51.4 g, 136.1 mmol) in H20 (125 mL) was added over a 5 min period, the temp staying below 5°C. The resultant yellowish slurry was then used as described in the following paragraph.

[00943] A stirring solution of cyanoacetamide (21.15 g, 251 mmol)), and NaOAC3H, 0 (17.1 g, 208 mmol) in H20 (2400 mL) and ethanol (125 mL) in a 1000-mL beaker was cooled in an acetone/water bath. To this stirring solution was added (dropwise over a 75 minute period) the slurry from the previous

paragraph, a mostly bright yellow (heterogeneous) mixture resulting and becoming difficult to stir. 40 min later, the still cold (5°C) mixture was filtered (sintered glass funnel, 5 X 200ml H2O rinses), air-dried 10 min, and dried on rotary evaporator. The solid material was triturated with methanol (6 X 150 mL) until orange color no longer came off. Air drying gave the title compound as a bright yellow solid.'H NMR (300 MHz, DMSO-d,) : 5 11.83 (s, 1 H), 7.98 (s, 1 H), 7.80 (m, 1 H), 7.68 (m, 2 H), 7.36 (m, 1 H). MS (ESI-) for CgH6BrFN4O m/z 285.0 (M-H)-.

[00944] Step 2: Preparation of ethyl 4-amino-3- (aminocarbonyl)-1- (4- bromo-3-fluorophenyl)-1 H-pyrazole-5-carboxylate [00946] A stirring mixture of the cyanoacetamide from Step 1 (33.00 g, 116 mmol), potassium carbonate (16 g, 116 mmol), ethyl bromoacetate (19 mL, 174 mmol), and DMF (250 mL) under N2 was immersed in an oil bath (80°C).

After 3hrs, more ethyl bromoacetate (10 mL, 87 mmol) and K2CO3 (1.0 g, 7 mmol) were added. After 30 minutes, Et3N (15 mL, 108 mmol) was added to the mixture; after 90 more minutes, the heat was turned off, the stirring mixture being allowed to gradually cool to room temperature overnight. The red mixture was poured onto ice (500 mL), stirred and then allowed to sit for 2 h, followed by filtration through a sintered glass funnel (5 X 200 mL H2O washes) to give a reddish-brown solid which was triturated with CH2C12 (3 X 50 mL) to give the title compound as a white solid. 'H NMR (300 MHz, DMSO-d,) : 6 7.79 (m, 1 H), 7.66 (m, 2 H), 7.39 (brs, 1 H), 7.32 (m, 1 H), 5.68 (m, 2 H), 4.15 (m, 2 H), 1.12 (m, 3 H). MS (ESI+) for C, 3H, 2BrFN4O3 m/z 371.9 (M+H) +.

[00947] Step 3: Preparation of 4-amino-3- (aminocarbonyl)-1- (4-bromo- 3-fluorophenyl)-1 H-pyrazole-5-carboxylic acid, potassium salt

[00949] A stirring mixture of the ester from Step 2 (33.81 g, 91.1 mmol), KOH (6.64 g, 118.0 mmol), and ethanol (180 mL, anhydrous), was immersed in a water bath at 80°C. After 3.5 h, the mixture was removed from heat and filtered (still warm), washed with methanol (2 X 200 mL), and air dried to the title compound as a white solid.'H NMR (300 MHz, DMSO-d6) : 5 7.62 (m, 1 H), 7.50 (m, 1 H), 7.29 (m, 2 H), 7.09 (brs, 1 H), 5.33 (brs, 2 H). MS (ESI+) for C1, H7BrFKN403 m/z 344.0 (M+H) +.

[00950] Step 4: Preparation of 4-amino-1-(4-bromo-3-fluorophenyl)-1H- pyrazole-3-carboxamide [00952] The potassium salt from Step 3 (26.53 g, 70 mmol) was placed in a 500-mL flask ; to this was added H3PO4 (200 mL) and the stirring mixture immersed in oil bath (80°C). At 4 h, more H3PO4 (50 mL) added. At 5 h; the reaction mixture was removed from heat, poured onto ice (800 mL) and filtered, washed with Ho (5 X 150 mL), sat'd aqueous sodium bicarbonate (100 mL), and H 20 (3 X 100ml), and then air-dried to give the title compound as an off- white solid.'H NMR (300 MHz, DMSO-d6) : # 7.93 (m, 1 H), 7.79 (m, 2 H), 7.64 (m, 2 H), 7.27 (m, 1 H), 4.90 (brs, 2 H). MS (ESI+) for C10H8BrFN4O m/z 300.1 (M+H) +.

[00953] Step 5: Preparation of4- [ (aminocarbonyt) amino]-1- (4-bromo-3- fluorophenyl)-1 H-pyrazole-3-carboxamide

[00955] A mixture of 4-amino-1- (4-bromo-3-fluorophenyl)-1 H-pyrazole- 3-carboxamide from Step 4 (5.33 g, 18 mmol), 70% acetic acid (220 mL) and 2- propanol (330 mL) was stirred at room temperature. To this was added a solution of potassium cyanate (1.73 g, 21 mmol) in H2O (330 mL). After overnight stirring, more KOCN (1 g, 12 mmol, in 5 mL H2O) was added. After a second night, more KOCN (1 g, 12 mmol, in 5 mL H2O) was added. After a third night, the mixture was diluted with H2O (100 mL) and filtered (4 X 150 mL H20 washes), air-dried to give the title compound as a white solid.'H NMR (300 MHz, DMSO-d,) : 5 8. 64 (m, 2 H), 8.03 (m, 1 H), 7.67 (m, 3 H), 7.56 (m, 1 H), 6.53 (brs, 2 H). MS (ESI-) for C"HgBrFN502 m/z 340.0 (M-H)-.

[00956] Example 226: 4-[(aminocarbonyl) amino]-1-(2-fluoro-3'-hydroxy- 1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide [00958] To a 2-neck flask were added a stir bar, 4- <BR> <BR> [ (aminocarbonyl) amino]-l- (4-bromo-3-fluorophenyl)-l H-pyrazole-3-carboxamide (Example 225,0. 558 g, 1.6 mmol), tetrakis (triphenylphosphine) palladium (0)

(0.188 g, 0.16 mmol), 3-hydroxyphenylboronic acid (0.450 g, 3.3 mmol), and dry DMF (10 mL) via syringe; this stirring solution was flushed with vacuum/N2.

Cs2CO3 (1.29 g, 3.9 mmol) was mixed with H20 (1. 8 mL) and N was bubbled through the resultant solution for 10 min. The solution was then added by syringe to the reaction mixture above which was then immersed in an oil bath (80°C). After overnight stirring, the heat bath was removed and after 10 min, the reaction mixture was poured onto ice (200ml), stirred 30 minutes, and filtered (4 X 30ml HO washes); the filtered solid was air-dried to give an off-white solid.

This off-white solid was stirred with CH2CI2 (3 X 30 mL) and filtered to give the title compound as an ivory solid.'H NMR (300 MHz, DMSO-d6) : 5 9.60 (m, 1 H), 8. 67 (m, 2 H), 7. 84 (m, 3 H), 7.54 (m, 2 H), 7. 24 (m, 1 H), 6.96 (m, 2 H), 6.78 (m, 1 H), 6.54 (brs, 2 H). MS (ESI-) for C17H, 4FN5O3 m/z 354.1 (M-H)-.

[00959] Example 227: 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethoxy)- 2-fluoro-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide [00961] To a stirring solution of 4-[(aminocarbonyl) amino]-1-(2-fluoro-3'- hydroxy-1, 1'-biphenyl-4-yl)-1H-pyrazole-3-carboxamide (Example 226,0. 186 g, 0.52 mmol) in DMF (10 mL) and acetone (2 mL) was added bromoacetonitrile (0.070 mL, 1.0 mmol) and K2CO3 (0.207 g, 1.5 mmol). The reaction was stirred three days and then more K2CO3 (0.020 g, 0.14 mmol) was added, followed 1 h later by more bromoacetonitrile (0.010 mL, 0.14 mmol). After another night of stirring, the mixture was evaporated to a brown solid, mixed with water (30 mL), stirred 30 min and filtered (5 X 5 mL H2O washes) to give a dark brown solid.

This solid was washed sequentially with 2-propanol (3 X 5 mL), ethanol (95%, 3 X 5 mL), methanol (3 X 5 mL), and CH2CI2 (3 X 5 mL); air drying gave the title

compound as a light brown solid.'H NMR (300 MHz, DMSO-d6) : # 8.67 (brs, 2 H), 7.90 (m, 3 H), 7.58 (m, 3 H), (, H), 7.26 (m, 2 H), 7.11 (m, 1 H), 6.53 (brs, 2 H), 5.20 (m, 2 H). MS (ESI-) for C,,, H,, FNO, mlz 393.1 (M-H)-.

[00962] Example 228: 4-[(aminocarbonyl) amino]-1-{4-[(4-<BR> fluorophenyl) thio]-2-methylphenyl}-1 H-pyrazole-3-carboxamide [00964] To a mixture of 1- (4-iodo-2-methyl-phenyl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide (Example 4,501 mg, 1.30 mmol) and cuprous iodide (248 mg, 1.30 mmol) was added dry DMF (8 mL). The mixture was placed under nitrogen and ethylene glycol (364 µL, 404 mg, 6.50 mmol), di- isopropylethylamine (1.13 mL, 841 mg, 6.50 mmol) and 4-fluorothiophenol (279 pL, 333 mg, 2.60 mmol) was added. The reaction was then heated at 105°C for 5 h, cooled and poured into ice cold aqueous 1 % sodium hydroxide solution.

Filtration afforded a dirty yellow solid which was washed with methanol (12 mL), ether (12 mL), acetone (15 mL) and hexane (10 mL). The resulting solid was digested with a boiling mixture (50 mL) of chloroform-methanol-acetone, cooled and filtered to afford the sulfide as a yellow solid.'H NMR (300 MHz, DMSO-d6) : # 2.16 (s, 3 H), 6.45 (s, 2 H), 7.12 (d, J = 7.8 Hz, 1 H), 7.35 (m, 7 H), 7.63 (s, 1 H), 8.10 (s, 1 H), 8. 65 (s, 1 H); LCMS: m+ = 386, m-= 384.

[00965] Example 229: 4-[(aminocarbonyl)amino]-1-{4-[(4- fluorophenyl) sulfonyl]-2-methylphenyl}-1 H-pyrazole-3-carboxamide

[00967] To a stirred suspension of 4-[(aminocarbonyl) amino]-1-{4-[(4- fluorophenyl) thio]-2-methylphenyl}-1 H-pyrazole-3-carboxamide (Example 228, 127 mg, 0.330 mmol) in methylene chloride (7 mL) was added m- chloroperbenzoic acid (227 mg, 1.32 mmol) After 18 h additional m- chloroperbenzoic acid (124 mg, 0.72 mmol) was added. After 1 h the reaction was filtered and the precipitate washed with methylene chloride (10 mL) and a 1% aquebus"so) ution of sodium hydroxide (12 mL). The organic layer was evaporated and the resulting solid washed with 1 % aqueous sodium hydroxide (20 mL) and water (10 mL). The resulting solid was chromatographed over silica gel (5% methanol-chloroform) to afford the sulfone as a yellow solid.'H NMR (300 MHz, DMSO-d,) : 5 2.36 (s, 3 H), 6.47 (s, 2 H), 7.46 (m, 3 H), 7.65 (m, 2 H), 7.88 (d, J = 8.1 Hz, 1 H), 8.06 (m, 3 H), 8.24 (s, 1 H), 8.66 (s, 1 H); LCMS: m+ = 418, m-=416.

[00968] Example 230: 4-[(aminocarbonyl) amino]-1-(2-ethoxy-3'- hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide [00970] To a suspension of 1- (4-bromo-3-ethoxyphenyl)-4-ureido-1H- pyrazole-3-carboxylic acid amide (517 mg, 1.40 mmol, prepared according to the process of Example 3), 3-hydroxyphenylboronic acid (387 mg, 2.81 mmol) and tetrakis (triphenylphosphine) palladium (0) (243 mg, 0.211 mmol) in dry DMF (10

mL) under nitrogen was added a solution of cesium carbonate (1.37 g, 4.21 mmol) in water (2.5 mL). The stirred mixture was heated at 80°C for 16 h, cooled and poured into ice-water (100 mL). The precipitate was filtered, washed with water, dried then dissolved in hot 10% methanol-chloroform and filtered through a plug of silica gel. The product was obtained as a sand-colored solid.'H NMR (300 MHz, DMSO-d6) : 5 1.29 (t, J = 6.9 Hz, 3 H), 4.15 (q, J = 6.9 Hz, 2 H), 6.51 (s, 2 H), 6.69 (m, 1 H), 6.93 (m, 2 H), 7.17 (m, 1 H), 7.35 (m, 1 H), 7.46 (m, 1 H), 7.54 (s, 1 H), 7.59 (s, 1 H), 7. 86 (s, 1 H), 8.60 (s, 1 H), 8.66 (s, 1 H), 9.38 (s, 1 H); LCMS: m+ = 382 and m-= 380.

[0097. j1. Example 231 : 4-[(aminocarbonyl)amino]-1-[3'-(cyanomethoxy)- 2-ethoxy-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide [00973] Bromoacetonitrile (100 pL, 180 mg, 1.50 mmol) was added to a stirred suspension of 4-[(aminocarbonyl) amino]-1-(2-ethoxy-3'-hydroxy-1, 1'- biphenyl-4-yl)-1 H-pyrazole-3-carboxamide (Example 230,192 mg, 0.503 mmol) and cesium carbonate (328 mg, 1.01 mmol) in dry DMF (6.0 mL) and stirred under nitrogen for 40 h. The solvent was evaporated and the residue treated with water (30 mL) then filtered. The residue was chromatographed over silica (5% methanol-chloroform) to afford the product as a white solid.'H NMR (300 MHz, DMSO-d,) : 5 1.31 (t, J = 6.5 Hz, 3 H), 4.18 (q, J = 6.5 Hz, 2 H), 5.19 (s, 2 H), 6.51 (s, 2 H), 7.00 (m, 1 H), 7.24 (s, 2 H), 7.40 (m, 2 H), 7.50 (m, 2 H), 7.62 (s, 1 H), 7.87 (s, 1 H), 8.62 (s, 1 H), 8.67 (s, 1 H); LCMS: m+ = 421 and m-= 419.

[00974] Example 232: 4-[(aminocarbonyl)amino]-1-(2-ethoxy-2'- hydroxy-1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide

[00976] To a stirred mixture of 1- (4-bromo-3-ethoxyphenyl)-ureido-1 H- pyrazole-3-carboxylic acid amide (485 mg, 1.32 mmol), 2-hydroxyphenylboronic acid (363 mg, 2.63 mmol) and tetrakis (triphenylphosphine) palladium (0) (228mg, 0.198 mmoi) in dry DMF (10 mL) under nitrogen a solution, of cesium carbonate (1.29 g, 3.95 mmol) in water (2.5 mL) was added. The mixture was heated at 80°C for 15 h then cooled and poured into water (80 mL). Filtration gave a brown solid which was chromatographed over silica gel (4% methanol- chloroform) to afford the product as a cream solid.'H NMR (300 MHz, DMSO- d6) : 01. 21 (t, J=6. 9Hz, 3H), 4.11 (q, J=6. 9Hz, 2H), 6.48 (s, 2 H), 6.79 (m, 1 H), 6.86 (m, 1 H), 7.11 (m, 2 H), 7.24 (d, J = 7.8 Hz, 1 H), 7.40 (m, 1 H), 7.53 (m, 2 H), 7.81 (s, 1 H), 8.58 (s, 1 H), 8.66 (s, 1 H), 9.17 (s, 1 H); LCMS: m+ = 382, m-= 380.

[00977] Examples 233-235 were prepared according to the same procedure as Example 232. Example Name and Structure'H NMR LCMS I (300 MHz, DMSO-d6) Example Name and Structure'H NMR LCMS (300 MHz, DMSO-d6) 233 4- [ (aminocarbonyl) amino]-l- [3'- 6 6. 55 (s, 2 H), 6. 72 (m, 2 H), m+ = hydroxy-2-(trifluoromethyl)-1, 1'-6. 80 (d, J = 8. 4 Hz, 1 H), 7. 24 406 biphenyl-4-yl]-1 H-pyrazole-3- (m, 1 H), 7. 47 (d, J = 8. 1 Hz, m-= carboxamide 1 H), 7. 57 (s, 1 H), 7. 98 (s, 1 404 NH2 CF3 OH H), 8. 17 (d, J = 7. 8 Hz, 1 H), 8. 32 (s, 1 H), 8. 71 (m, 2 H), N 9. 59 (s, 1 H) HN H. NO 234 4-[(aminocarbonyl) amino]-1-[2'-õ 6. 54 (s, 2 H), 6. 81 (m, 1 H), m+ = hydroxy-2- (trifluoromethyl)-1, 1'- 6. 89 (d, J = 7. 2 Hz, 1 H), 7. 04 406 biphenyl-4-yl]-1H-pyrazole-3- (m, 1 H), 7. 20 (m, 1 H), 7. 40 m-= carboxamide (d, J = 7. 8 Hz, 1 H), 7. 56 (s, 1 404 NH F3 H), 7. 96 (s, 1 H), 8. 13 (d, J = N 7. 8 Hz, 1 H), 8. 29 (s, 1 H), N 8. 7*1 (s, 2 H), 9. 48 (s,-. 1-H) HO L HO H2N"-l-0 235 4-[(aminocarbonylamino]-1-(2'-o 3. 31 (s, 2 H), 6. 46 (s, 2 H), m+ = hydroxy-3-methyl-1, 1'-biphenyl-4- 6. 90 (m, 2 H), 7. 16 (m, 1 H), 352 yl)-1 H-pyrazole-3-carboxamide 7. 28 (d, J = 7. 5 Hz, 1 H), 7. 45 m-= NH2 (m, 5 H), 7. 63 (s, 1 H), 8. 14 350 3C (s, I H), 8. 68 (s, 1 H), 9. 61 (s, Han L HO H2N NO [00978] Example 236: 4-[(aminocarbonyl)amino]-1-[2'-(cyanomethoxy)- 2-ethoxy-1, 1'-biphenyl-4-yl]-1H-pyrazole-3-carboxamide

[00980] Bromoacetonitrile (78 µL, 141 mg, 1.17 mmol) was added to a stirred mixture of 4-[(aminocarbonyl) amino]-1-(2-ethoxy-2'-hydroxy-1, 1'-biphenyl- 4-yl)-1 H-pyrazole-3-carboxamide (Example 232,149 mg, 0.391 mmol) and

anhydrous potassium carbonate (108 mg, 0. 781 mmol) in dry DMF (4 mL).

Stirring was continued for 60 h then the solvent evaporated and water (25 mL) added to the residue. Filtration gave a brown solid which was chromatographed over silica gel (4% methanol-chloroform) to afford the product as a cream solid.

'H NMR (300 MHz, DMSO-d6) : 5 1.21 (t, J = 6.9 Hz, 3 H), 4.12 (q, J = 6.9 Hz, 2 H), 5.09 (s, 2 H), 6.50 (s, 2 H), 7.20 (m, 4 H), 7.40 (m, 2 H), 7.55 (m, 2 H), 7. 85 (s, 1 H), 8.60 (s, 1 H), 8.66 (s, 1 H); LCMS: m+ = 421, m-= 419.

[00981] Examples 237 and 238 were prepared according to the same procedure as Example 236. Example Name and Structure'H NMR LCMS (300 MHz, DMSO-d,) : 237 4- [ (aminocarbonyl) amino]-l- [3'- 6 5. 20 (s, 2 H), 6. 54 (s, 2 m+ = (cyanomethoxy)-2- (trifluoromethyl)-1, 1'- H), 7. 04 (s, 2 H), 7. 13 (d, J 445 biphenyl-4-yl]-1H-pyrazole-3-= 7. 5 Hz, 1 H), 7. 11 (m, 1 m-= carboxamide H), 7. 50 (m, 1 H), 7. 57 (s, 1 443 NHz H), 7. 99 (s, 1 H), 8. 22 (d, J o=< = 7. 5 Hz, 1 H), 8. 37 (s, 1 ) aN H), 8. 70 (s, 1 H), 8. 73 (s, 1 H2N40 N CF3 CN HzN- F jt F 1 0 238 4-[(aminocarbonyl) amino]-1-[2'- (300 MHz, DMSO-d,) : õ m+ = (cyanomethoxy)-2- (trifluoromethyl)-1, 1'- 5. 11 (s, 2 H), 6. 53 (s, 2 H), 445 biphenyl-4-yl]-1H-pyrazole-3-7. 15 (m, 1 H), 7. 22 (m, 2 m-= carboxamide H), 7. 47 (m, 2 H), 7. 56 (s, 1 443 NHz CF H), 7. 97 (s, 1 H), 8. 18 (d, J = 7. 8 Hz, 1 H), 8. 33 (s, 1 N-"H), 8. 69 (s, 1 H), 8. 71 (s, 1 Han/ H, H) NC [00982] Example 239: 1- (3'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido- 1 H-pyrazole-3-carboxylic acid amide

[00984] A slurry of 1- (4-iodo-3-methyl-phenyl)-4-ureido-1 H-pyrazole-3- carboxylic acid amide (Example 8,385 mg, 1.0 mmol), 3-hydroxyphenylboronic acid (276 mg, 2.0 mmol)) and (PPh3) 4Pd (173 mg, 0.15 mmol) in anhydrous DMF (8 mL) was stirred at room temperature and degassed with N2 for 10 min. A solution of cesium carbonate (977 ng, 3.0 mmol) in water (2 mL) was added and degassing continued for an additional 10 min. The reaction mixture was sealed under N2, heated to 80for 7 h, cooled to room temperature and diluted with water. The resulting precipitate was collected, washed with water and air-dried.

The residue was adsorbed onto silica gel (methanol/acetone) and purified by column chromatography on silica gel (Biotage i40S; elution with 10% MeOH/chloroform) to give the title compound.'H NMR (300 MHz, DMSO-d6) : 5 9.48 (d, J = 6.37 Hz, 1 H), 8.66 (d, J = 5.71 Hz, 1 H), 8.56 (d, J = 6.37 Hz, 1 H), 7.80-7. 69 (m, 3 H), 7.49 (brs, 1 H), 7.27-7. 17 (m, 2 H), 6.76-6. 69 (m, 3 H), 6.49 (brs, 2 H), 2.27 (s, 3 H). MS (ESI-) for C, BH, ; N5O3 m/z 350.1 (M-H)-.

[00985] Example 240: 1- (2'-Hydroxy-2-methyl-biphenyl-4-yl)-4-ureido- 1 H-pyrazole-3-carboxylic acid amide [00987] A slurry of 1- (4-iodo-3-methyl-phenyl)-4-ureido-1 H-pyrazole-3- carboxylic acid amide (Example 8,385 mg, 1.0 mmol), 2-hydroxyphenylboronic acid (276 mg, 2.0 mmol)) and (PPh3) 4Pd (173 mg, 0.15 mmol) in anhydrous DMF (8 mL) was stirred at room temperature and degassed with N2 for 10 min. A

solution of cesium carbonate (977 ng, 3.0 mmol) in water (2 mL) was added and degassing continued for an additional 10 min. The reaction mixture was sealed under N2, heated to 80°C for 7 h, cooled to room temperature and diluted with water. The resulting precipitate was collected, washed with water and air-dried.

The residue was adsorbed onto silica gel (methanol/acetone) and purified by column chromatography on silica gel (Biotage i40S; elution gradient from 5% to 20% MeOH/chloroform) to give the desired product.'H NMR (300 MHz, DMSO- d,) : 5 9.43 (s, 1 H), 8.68 (s, 1 H), 8.56 (s, 1 H), 7.76-7. 51 (m, 4 H), 7.20-7. 15 (m, 2 H); 7.05-7. 03 (m, 1 H), 6.92-6. 82 (m, 2 H), 6.52 (brs, 2 H), 2.17 (s, 3 H). MS (ESI-) for C18H17N503 m/z 350.1 (M-H)-.

[00988] Example 241: 1- (4'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4- ureido-1 H-pyrazole-3-carboxylic acid amide [00990] A slurry of 1- (4-iodo-3-methyl-phenyl)-4-ureido-1 H-pyrazole-3- carboxylic acid amide (Example 8, 385 mg, 1.0 mmol), 2-hydroxy-4- fluorophenylboronic acid (155 mg, 1.0 mmol)) and (PPh3) 4Pd (173 mg, 0.15 mmol) in anhydrous DMF (8mL) was stirred at room temperature and degassed with N2 for 10 min. A solution of cesium carbonate (977 ng, 3.0 mmol) in water (2 mL) was added and degassing continued for an additional 10 min. The reaction mixture was sealed under N2, heated to 80°C for 14 h, cooled to room temperature and diluted with water. The resulting precipitate was collected, washed with water and air-dried. The residue was purified by column chromatography on silica gel (Biotage i40S; elution with 5% MeOH/chloroform) to give the desired product.'H NMR (300 MHz, DMSO-d6) : 5 9.95 (s, 1 H), 8.67 (s, 1 H), 8.55 (s, 1 H), 7.76 (s, 2 H), 7.67 (d, J = 7.79 Hz, 1 H), 7.49 (s, 1 H),

7.18 (d, J = 8.39 Hz, 1 H), 7.09-7. 05 (m, 1 H), 6.70-6. 65 (m, 2 H), 6.50 (s, 2 H), 2.15 (s, 3 H). MS (ESI-) for C18H16FNsO3 m/z 368.0 (M-H)-.

[00991] Example 242: 1- (5'-Fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4- ureido-1 H-pyrazole-3-carboxylic acid amide [00993] A slurry of 1- H-pyrazole-3- carboxylic acid amide (Example 8, 385 mg, 1 0 mmol), 2-hydroxy-5- fluorophenylboronic (155 mg, 1.0 mmol) and (PPh3) 4Pd (173 mg, 0.15 mmol) in anhydrous DMF (8 mL) was stirred at room temperature and degassed with N2 for 10 min. A solution of cesium carbonate (977 ng, 3.0 mmol) in water (2 mL) was added and degassing continued for an additional 10 min. The reaction mixture was sealed under N2, heated to 80°C for 14 h, cooled to room temperature and diluted with water. The resulting precipitate was collected, washed with water and air-dried. The residue was purified by column chromatography on silica gel (Biotage i40S; elution with 4% methanol/chloroform) to give the title compound.'H NMR (300 MHz, DMSO-d6) : # 9.45 (s, 1 H), 8.68 (s, 1 H), 8.57 (s, 1 H), 7.78-7. 50 (m, 4 H), 7.20 (d, J = 8.20 Hz, 1 H), 7.04-6. 86 (m, 3 H), 6.52 (s, 2 H), 2.19 (s, 3 H). MS (ESI-) for C18H16FN503 m/z 368.0 (M-H)-.

[00994] Example 243: 1- (3'-Cyanomethoxy-2-methyl-biphenyl-4-yl)-4- ureido-1 H-pyrazole-3-carboxylic acid amide

[00996] A slurry of 1- (3'-hydroxy-2-methyl-biphenyl-4-yl)-4-ureido-1H- pyrazole-3-carboxylic acid amide (Example 239,82 mg, 0.23 mmol), bromoacetonitile (84 mg, 0.70 mmol) and potassium carbonate (65 mg, 0.47 mmol) in dry DMF (5 mL) was stirred under nitrogen for 18 h. The reaction was concentrated in vacuo, the residue was re-suspended in water and the resulting precipitate collected via filtration. The solid was triturated with ether and dichloromethane. Chromatography on silica (Biotage i40S, elution with 3% MeOH/chloroform) was followed by trituration with ether to the title compound as a white solid.'H NMR (300 MHz, DMSO-d,) : 5 8. 68 (s, 1 H), 8.59 (s, 1 H), 7.86- 7.76 (m, 3 H), 7.52 (s, 1 H), 7.43 (t, J = 7.19 Hz, 1 H), 7.33 (d, J = 8.39 Hz, 1 H), 7.08-7. 04 (m, 3 H), 6. 51 (s, 2 H), 5.21 (s, 2 H), 2. 32 (s, 3 H). MS (ESI-) for- C20H, 8N603 m/z 389 1 (M-H)-.

[00997]-. Example 244: 1- (2'-Cyanomethoxy-4'-fluoro-2-methyl-biphenyl-, 4-yl)-4-ureido-1-H-pyrazole-3-carboxylic acid amide [00999] A slurry of 1- (4'-fluoro-2'-hydroxy-2-methyl-biphenyl-4-yl)-4- ureido-1 H-pyrazole-3-carboxylic acid amide (Example 241,61 mg, 0.17 mmol), bromoacetonitile (62 mg, 0.52 mmol) and potassium carbonate (48 mg, 0.35 mmol) in dry DMF (5 mL) was stirred under nitrogen for 18 h. The reaction was concentrated in vacuo, the residue was re-suspended in water and the resulting precipitate collected via filtration. The precipitate was triturated with

dichloromethane to the title compound as an off-white solid.'H NMR (300 MHz, DMSO-d,) : 5 8.67 (s, 1 H), 8.58 (s, 1 H), 7.81-7. 71 (m, 3 H), 7.52 (s, 1 H), 7.31- 7.19 (m, 3 H), 6.99 (t, J=8. 39Hz, 1 H), 6.51 (s, 2H), 5.18 (s, 2H), 2.18 (s, 3 H). MS (ESI-) for C20H17FN6O3 m/z 407.0 (M-H)-.

[001000] Example 245: 1- (4-lodo-3-methyl-phenyl)-4- (3-methyl-ureido)- 1 H-pyrazole-3-carboxylic acid amide [0. 01002] A slurry of 4-amino-1- (4-iodo-3-methyl-phenyl)-l H-pyrazole-3- carboxylic acid amide (Example 8,111 mg, 0.32 mmol) and p- nitrophenylchloroformate (79 mg, 0.39 mmol) in pyridine (2 mL) was stirred under nitrogen at room temperature for 4 h. The thick white slurry was filtered and the solids washed with water and air dried to give [3-carbamoyl-1- (4-iodo-3- methyl-phenyl)-1 H-pyrazol-4-yl]-carbamic acid 4-nitro-phenyl ester. A slurry of this ester (59 mg, 0. 10 mmol) and methylamine (2 2. 0M in THF, 4 mmol) was stirred under nitrogen at room temperature for 5 days. The reaction mixture was diluted with water and filterd. The solids were washed with additional water and air dried to give the title compound. 'H NMR (300 MHz, DMSO-d6) : # 8.66 (s, 1 H), 8.59 (s, 1 H), 7.95-7. 85 (m, 2 H), 7.80 (s, 1 H), 7.51-7. 45 (m, 2 H), 7.22 (s, 1 H), 2.61 (d, J = 3.9 Hz, 3H), 2.41 (s, 3 H). MS (ESI-) for C, 3H141N5O2 m/z 398.0 (M-H)-.

[001003] Example 246: 1- (5-chloro-2-fluoro-phenyl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide [001005] Step 1: Preparation of 2- [ (5-chloro-2-fluoro-phenyl)-hydrazono]- 2-cyano-acetamide

[001007] A well stirred slurry of 5-chloro-2-fluoroaniline (13.4 g, 89 mmol) and concentrated HCI (22 mL) in water (80 mL) was cooled to 5°C and a cold solution of sodium nitrite (6.1 g, 89 mmol) in water (20 mL) was added slowly over a period of 30 min, maintaining the reaction temperature at 5°C. A cold solution of sodium acetate trihydrate (36 g, 266 mmol) in water. (100 mL) was then added dropwise over 15-30 min, again maintaining the reaction temperature at 5°C. This viscous, yellow mixture was then added over a period of 30 minutes to a cold (5°C) solution of sodium cyanoacetamide [previously prepared by the dissolution of cyanoacetamide (22 g, 266 mmol) in cold (5°C) water (150 mL)/ethanol (100 mL) followed by the addition of a cold solution of sodium acetate trihydrate (12.1 g, 89 mmol) in water (30 mL) ]. A thick orange slurry was obtained which was stirred for three additional hours in a wet ice bath.

The slurry was filtered and the solids washed with water (200 mL). This material was air-dried overnight to give an orange solid. This material was washed repeatedly with dichloromethane and the remaining yellow solid collected to provide the title compound. MS (ESI-) for CgH6CIFN40 m/z 239.1 (M-H)-.

[001008] Step 2: Preparation of 4-amino-5-carbamoyl-2- (5-chloro-2- fluoro-phenyl)-2H-pyrazole-3-carboxylic acid ethyl ester

[001010] A slurry of the acetamide from Step 1 (2.04 g, 8.48 mmol) and ethyl bromoacetate (2.12 g, 12.7 mmol) was heated to 90°C under nitrogen for 5 h. The solution was cooled and poured into ice. The aqueous mixture was then stirred at room temperature for 3 h and filtered. The precipitate was washed with water and dried in vacuo to give the title compound as a reddish-brown solid.

MS tESl+) for C13H 2CIFN4O m/z 328.1 (N+H)+ [001011] Step 3: Preparation of 4-amino-5-carbamoyl-2- (5-chloro-2- fluoro-phenyl)-2H-pyrazole-3-carboxylic acid, potassium salt [001013] To a well stirred slurry of the ester from Step 2 (1.0 g, 3.1 mmol) in ethanol (10 mL) was added solid potassium hydroxide (1.0 g, 18 mmol) and the solution stirred at room temperature overnight. The reaction mixture was cooled to 5°C, filtered and the solids washed with cold ethanol and air dried to give the title compound as a light brown solid.

[001014] Step 4: Preparation of

[001016] A well stirred slurry of the potassium salt from Step 3 (650 mg, 2.0 mmol) in phosphoric acid (5 mL) was slowly heated to 45°C. The mixture was held at that temperature for 2 h. The temperature was increased to 65°C until gas evolution ceased (3 h). The solution was diluted with water (10 mL), neutralized (pH 7) with 50% sodium hydroxide solution, and the precipitate collected via filtration. The solids were washed with 5% sodium carbonate solution and air-dried to give the title compound as a light yellow solid. MS (ESI+) for C,, H, CtFN, 0 m/z 256.0 (M+H) +.

[001017] Step 5: Preparation of 1- (5-chloro-2-fluoro-phenyl)-4-ureido-1 H- pyrazole-3-carboxylic acid amide [001019] To a slurry of the amide from Step 4 (260 mg, 1.0 mmol) and potassium cyanate (99 mg, 1.2 mmol) in a solvent mixture of isopropanol/water (14 mL, 1: 1) was added 75% acetic acid (7 mL) and the reaction mixture stirred at room temperature for 18 h. The mixture was diluted with water (30 mL) and filtered. The precipitate was washed with water and dried in vacuo to give the title compound as a light yellow solid.'H NMR (300 MHz, DMSO-d6) : 5 8.65 (s, 1 H), 8.47 (s, 1 H), 8.09 (d, J = 6.81 Hz, 1 H), 7.94 (s, 1 H), 7.56-7. 46 (m, 3 H), 6.51 (s, 2 H). MS (ESI-) for C"HgCIFN502 m/z 296.1 (M-H)-.

[001020] Example 247: 4- [ (aminocarbonyl) amino]-l- (3-fluoro-3'-hydroxy- 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide

[001022] A 113 mg quantity (0.29 mmol) of Example 210 was combined in a screw-capped vial with 3-hydroxyboronic acid (0.083 g, 0.6 mmol). Cesium carbonate (0.295 g, 0.91 mmol) was weighed out and dissolved in 350 pL water and purged with nitrogen. The starting material and boronic acid were dissolved in 2.5 mL DMF, and nitrogen was bubbled slowly through the solution. During the bubbling, the cesium carbonate solution was added, then tetrakistriphenylphosphine palladium (0) (23 mg) was added and the vial was sealed. The reaction was heated to 83°C overnight. The reaction was diluted with water and brought to neutrality with a few drops of 6N HCI. The product was filtered and dried under high vacuum, then triturated with methanol to give the title compound 1H NMR (300 MHz, DMSO-d6): # 6.50 (bs, 2H); 6.79 (m, 1H); 7.08-7. 40 (m, 4H); 7.50-7. 86 (m, 4 H); 7.98 (m, 1 H); 8.45 (s, 1 H) ; 8.67 (s, 1 H).

LCMS (ESI-) for C"H, 4F, N5O3 m/z 354.2 (M-H)-.

[001023] Example 248: 4'-{3-(aminocarbonyl)-4-[(aminocarbonyl) amino]- 1 H-pyrazol-1-yl}-3, 3'-difluoro-1, 1'-biphenyl-4-carboxylic acid [001025] A 150 mg quantity (0.39 mmol) of Example 210 was combined in a screw-capped vial with (4-carboxy-3-fluorophenyl) boronic acid (0.1408 g, 0.771 mmol). Cesium carbonate (0.421 g, 1.29 mmol) was weighed out and dissolved in 0.5 mL of water and purged with nitrogen. The starting material and boronic acid were dissolved in 3.4 mL DMF, and nitrogen was bubbled slowly through the solution. During the bubbling, the cesium carbonate solution was added, then tetrakistriphenylphosphine palladium (0) (30.1 mg) was added and the vial was sealed. The reaction was heated to 83°C overnight. The reaction was diluted with water and brought to neutrality with a few drops of 6N HCI. It

was then filtered and triturated with methanol. The product was purified by recrystallization from methanol-methylene chloride to give the title compound. 1H NMR (300 MHz, DMSO-d6) : õ 6.53 (bs, 2H); 7.55 (s, 1 H) ; 7.72-8. 14 (m, 8H); 8.53 (s, 1 H); 8.67 (s, 1 H). LCMS (ESI-) for C18H14F2N504 m/z 400 1 (M-H) [001026] Example 249: 4-[(aminocarbonyl)amino]-1-(3-fluoro-2'-hydroxy- 1, 1'-biphenyl-4-yl)-1 H-pyrazole-3-carboxamide [001028] A 330 mg quantity (0.85 mmol) of Example 210 was combined in a screw-capped vial with (2-hydroxyphenyl) boronic acid (0.221 g, 0.1. 6 mmol).

Cesium carbonate (0.9104 g, 2.79 mmol) was weighed out and dissolved in 1 mL of water and purged with nitrogen. The starting material and boronic acid were dissolved in 6 mL DMF, and nitrogen was bubbled slowly through the solution. During the bubbling, the cesium carbonate solution was added, then tetrakistriphenylphosphine palladium (0) (60 mg) was added and the vial was sealed. The reaction was heated to 83°C overnight. The reaction mixture was diluted with water and brought to neutrality with a few drops of 6N HCI. The reaction was filtered, dissolved in methanol, and refiltered. The product was then recrystallized from methanol-toluene and DMF-water, and triturated with methanol-methylene chloride. The remainder of material was purified by reverse phase chromatography on a C-8 column in DMF-water mixtures.'H NMR (300 MHz, DMSO-d,) : 5 6.68 (bs, 2H); 7.10 (m, 2H); 7.38 (m, 1H) ; 7.55 (m, 1 H); 7.71 (m, 2H); 7.83 (m, 1H) ; 7.96 (S, 1H) ; 8.10 (m, 1H) ; 8.62 (s, 1H) ; 8.85 (s, 1H).

LCMS (ESI-) for C17H14F1NsO3 m/z 354.1 (M-H)-.

[001029] Example 250: 4-[(aminocarbonyl) amino]-1-[2'-(cyanomethoxy)- 3-fluoro-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide

[001031] The starting material phenol (Example 249,90 mg, 0.3 mmol) was treated with 2 mL dry DMF, ground potassium carbonate (73 mg, 0.53 mmol), and bromoacetonitrile (50 µL, 0.75 mmol). The reaction was stirred at room temperature overnight, then evaporated under high vacuum, taken up in water, and filtered. The product was suspended in methanol and filtered. nH NMR (300 MHz, DMSO-d,) : õ 5.20 (s, 2H); 6.52 (bs, 2H); 7.19 (m, 1H) ; 7.28 (m, 1 H); 7.50 (m, 5H); 7.81 (bs, 1 H); 7.96 (m, 1 H); 8.47 (s, 1 H); 8.69 (s, 1 H). LCMS (ESI+) for C19H15F1N6O3 m/z 395.0 (M+H) +.

[001032] Example 251 : 4-[(aminocarbonyl) amino]-1-(2-chloro-4- iodophenyl)-1 H-pyrazole-3-carboxamide [001034] Step 1: Preparation of 2-[(2-chloro-4-iodophenyl) hydrazono] -2- cyanoacetamide

[001036] A suspension of 2-chloro-4-iodoaniline (16 g, 63 mmol) in conc.

HCI (16 mL) and distilled water (50 mL) was cooled in an ice bath to 0°C. To this suspension was added a solution of sodium nitrite (4.355 g, 63 mmol) in 14 mL water over 5 min. The solution was stirred cold for 20 min. An ice-cold solution of sodium acetate trihydrate (26.048 g, 0.191 mol) in 75 mL water was added to the diazonium salt solution, and the solution was stirred a few min. In another flask, 2-cyanoacetamide (9.83 g, 0.117 mol) in 40 mL 95% ethanol and 60 ml water was cooled in an ice/salt-water bath and treated with an ice-cold solution of sodium acetate trihydrate (8.74 g, 64 mmol) in 20 mL water. The diazonium salt suspension was added to the cold cyanoacetamide with an ice-jacketed dropping funnel, over about 13 min with fast stirring. The reaction mixture was stirred cold for 15 minutes. The reaction was filtered on a large Buchner funnel and vacuum dried to give a brick red solid in chunks. The solid was evaporated 5 days in the vacuum oven, and purified by HPLC to yield the title compound. 1H NMR (300 MHz, DMSO-d6) : 5 7. 40 (m, 2H); 7.53 (m, 1 H) ; 7.64 (m, 1H) ; 7.77 (bs, 1 H). LCMS (ESI+) for CgH6CI, I, N40, m/z 348. 9 (m+H) +.

[001037] Step 2: Preparation of 2-amino-3- (aminocarbonyl)-5- (2-chloro- 4-iodophenyl) cyclopenta-1, 3-diene-1-carboxylic acid [001039] A pressure bottle was charged with pulverized 2- [ (2-chloro-4- iodophenyl) hydrazono] -2-cyanoacetamide from Step 1 (19.858g, 57 mmol), DMF (50 mL), ground potassium carbonate (16 g, 116 mM), and 10.0 mL ethyl bromoacetate (85.5 mM). The bottle was flushed with nitrogen and heated to 90°C for 2 h. The crude product was saponified by adding a solution of KOH (7.63 g) in 95% ethanol (50 ml). The reaction was warmed (43°C) for 40 min

then allowed to stir at room temperature overnight. It was diluted with water and filtered. The filtrate was then cooled in ice and acidified with 6 N HCI. The product was obtained by filtration and analyzed by HPLC.

[001040] The red solid filtered out from the basic solution was analyzed by HPLC, and appeared to contain considerable unhydrolyzed ester. It was re- treated with KOH (9.92 g, 177 mmol) in 95% ethanol (150 mL) at 47°C for 1 h, then stirred at room temperature overnight. The reaction mixture was diluted with water and filtered to give a dark red material. The pH was then adjusted to approx. 8 and the solution was filtered, giving a reddish solid. The filtrate was then acidified further to pH 1-2, giving the product as a yellow solid. The product was recrystallized (twice) by diss. olvin. g in. MeOH, adding a little water, and evaporating until crystallization started.

[001041] Step 3: Preparation of 5-amino-3- (2-chloro-4- iodophenyl) cyclopenta-1, 4-diene-1-carboxamide [001043] 2-amino-3- (aminocarbonyl)-5- (2-chloro-4- iodophenyl) cyclopenta-1, 3-diene-1-carboxylic acid from Step 2 (1.6746 g, 4.1 mmol) was treated with 8.0 mL of 85% phosphoric acid. The reaction was heated to 80°C for 100 min, then cooled and neutralized with 2N NaOH. The reaction was filtered to give a light yellow solid, which was then triturated with methanol. The total sample was treated with acetic acid and filtered. The solid was washed with water, and then washed with methanol to give the title compound.'H NMR (300 MHz, DMSO-d6) : # 7.19 (s, 1H) ; 7.37 (m, 2H); 7.45 (s, 1 H) ; 7.83 (m, 1 H) ; 8.04 (m, 1 H). LCMS (ESI+) for C, 0H8CI, 11N401 m/z 363.9 (M+2H) +.

[001044] Step 4: Preparation of 4-[(aminocarbonyl) amino]-1-(2-chloro-4- iodophenyl)-1 H-pyrazole-3-carboxamide

[001046] A 50-mL round bottom flask was charged with 2 mL water, 3 mL acetic acid and 3 mL isopropanol. To this mixture was added sodium cyanate (38 mg, 0.586 mmol) followed by 5-amino-3- (2-chloro-4- iodophenyl) cyclopenta-1, 4-diene-1-carboxamide from Step 3 (146 mg, 0.403 mM). The reaction was stirred at room temperature overnight. Upon addition of water, the product crystallized. The solid was filtered and washed with water, triturated with methanol-methylene chloride, and then dissolved partially in DMF and water added. The final purification was done by dissolving in DMSO and adding methylene chloride to yield crystals of the title compound. 1H NMR (300 MHz, DMSO-d6) : õ 6.48 (bs, 1 H) ; 7.43 (m, 2H); 7.70 (bs, 1 H) ; 7.85 (m, 1 H) ; 8.07 (s, 1 H); 8.27 (m, 1 H); 8.67 (s, 1 H). LCMS (ESI-) for C11H9Cl1I1N5O2 m/z 403.8 (M- H)-.

[001047] Examples 252-257: Alkylation of Phenols [001048] A mixture of phenol (0.03 mmol) prepared according to Examples 21-141, K2CO3 (0.062 g, 0.045 mol), ksi (0.003 g, 0.02 mmol), and 0.045 mmol of an appropriate chloromethyl-derivative (esters or amides of chloroacetic acid, 2-chloromethyloxazole, or chloroacetone) in DMF (2 mL) was stirred at room temperature for 24-48 h. Solvents were removed, and water (30 mL) was added. The suspension was sonicated for 30 min and triturated for 3 h to give, after drying, the desired product. Example Name and Structure'H NMR MS (M+1) 252 4-[(aminocarbonyl) amino]-1-[2'-(2-amino-2-DMSO-d6 : õ 4. 49 (s, 2H), 413 oxoethoxy)-5'-fluoro-1, 1'-biphenyl-4-yl]-1 H-6. 51 (br s, 2H), 6. 99-7. 18 pyrazole-3-carboxamide (m, 1H), 7. 12-7. 30 (m, NH 3H), 7. 48 (br s, 1 H), 7. 52 0 (br s, 1 H), 7. 75 (d, 2H, J H2N p = 8. 7 Hz), 7. 61 (br s, I 1 H), 7. 94 (d, 2H, J = 8. 7 HN Hz), 8. 61 (s, 1 H), 8. 69 (s, 1 H) NEZ F NHs 253 4- [ (aminocarbonyl) amino]-l- [3'- (2-oxopropoxy)- DMSO-d, :. 6 2. 19 (s, 3H), 394 1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-carboxamide 4. 91 (s, 2H), 6. 53 (br s, H3C 2H), 6. 77-6. 93 (m, 1H), 0 7. 20-7. 44 (m, 3H), 7. 53 H2N, ro (br s, I H), 7. 65-7. 80 (m, 0 3H), 7. 95 (d, 2H, J = 8. 4 HN Hz), 8. 63 (s, 1 H), 8. 69 (s, NHa NHz 254 4- [ (aminocarbonyl) amino]-l- [3'- (1, 3-oxazol-2- DMSO-d,, : 6 5. 35 (s, 2H), 419 ylmethoxy)-1, 1'-biphenyl-4-yl]-1 H-pyrazole-3-6. 53 (br s, 2H), 7. 05 (d, carboxamide 1 H, J = 7. 3 Hz), 7. 29 (s, o/% 1 H), 7. 30-7. 42 (m, 3H), N 7. 53 (br s, 1 H), 7. 75-7. 88 H2NNro (m, 3H), 7. 96 (d, 2H, J = 8. 7 Hz), 7. 99 (s, 1 H), 8. 62 (s, 1 H), 8. 69 (s, 1 H) H N NH2 255 4- [ (aminocarbonyl) amino]-l- [5'-fluoro-2'- (1, 3- CD30D : 6 5. 13 (s, 2H), 437 oxazol-2-ylmethoxy)-1, 1'-biphenyl-4-yl]-1H-7. 02-7. 25 (m, 4H), 7. 66 pyrazole-3-carboxamide (d, 2H, J = 8. 7 Hz), 7. 85 (d, 2H, J = 8. 7 Hz), 7. 90 (d, 1 H, J = 0. 7 Hz), 8. 55 W F HZN HO un NHz NH2 F Example Name and Structure'H NMR MS (M i 1) 256 4-[(aminocarbonyl) amino]-1-{5'-fluoro-2'-[2-DMSO-d6 : 52. 63 (d, 3H, 427 (methylamino)-2-oxoethoxy]-1, 1'-biphenyl-4-yl}-J = 4. 5 Hz), 4. 48 (s, 2H), 1 H-pyrazole-3-carboxamide 6. 52 (br s, 2H), 6. 98-7. 07 (m, 1 H), 7. 12-7. 23 (m, NH 1H), 7. 26 (dd, 1H, J= o= 6. 2, 3. 1 Hz), 7. 53 (br s, H2N 0 1 H), 7. 72-7. 88 (m, 3H), I o 7. 95 (d, 2H, J=8. 8Hz), 8. 60 (s, 1 H), 8. 69 (s, 1 H) °eN N w NH2 F 257 4-[(aminocarbonyl) amino]-1-{5'-fluoro-2'-[2-DMSO-d6 : o 0. 99 (t, 3H, J 441 (ethylamino)-2-oxoethoxy]-1, 1'-biphenyl-4-yl}-= 7. 2 Hz), 3. 10 (quintet, 1 H-pyrazole-3-carboxamide 2H, J = 7. 1 Hz), 4. 46 (s, CH3 2H), 6. 51 (br s, 2H). (6. 98-7. 08 (m, 1H), 7. 12- NH 7. 22 (m, 1 H), 7. 26 (dd, oC 1 H, J = 6. 2, 3. 1 Hz), 7. 53 H2N ro (br s, 1 H), 7. 70-7. 87 (m, 0 3H), 7. 95 (d, 2H, J = 8. 7 Hz), 8. 61 (s, 1 H), 8. 69 (s, Nu2 F NH2 NHs

[001049] Examples 258-259: Hydrolysis of t-Butyl Esters [001050] Concentrated HCI (3 mL) was added dropwise at room temperature over 3 minutes to 0.1 g of tert-butyl [ (4'- {3- (aminocarbonyl)-4- [(aminocarbonyl) amino]-1 H-pyrazol-1-yl}-1, 1'-biphenyl-3-yl) oxy] acetate (Example 174) or tert-butyl [ (4'- {3- (aminocarbonyl)-4- [ (aminocarbonyl) amino] - 1H-pyrazol-1-yl}-5-fluoro-1, 1'-biphenyl-2-yl) oxy] acetate (Example 182). The suspension was stirred for 15 minutes, filtered, and washed with 10 mL of chloroform to give, after drying under reduced pressure, the desired products. Example Name and Structure 1H NMR (DMSO-d6) MS (M + 1) Example Name and Structure 1H NMR (DMSO-d6) MS (M + 1) 258 [(4'-{3-(aminocarbonyl)-4- # 5.88 (s, 2H), 6.00-6.90 396 [(aminocarbonyl) amino]-1 H-pyrazol-1- (br s, 2H), 6.94 (dd, 1 H, J yl}-1, 1'-biphenyl-3-yl) oxy] acetic acid = 8. 0,1. 7 Hz), 7.20-7. 25 HO (m, 1H), 7.28-7. 42 (m, 0 2H), 7.53 (br s, 1 H), 7.79 H2N#O # (d, 3H, J = 8.7 Hz), 7.95 F o (d, 2H, J = 8. 7 Hz), 8.51 (s, 1H), 8.67 (s, 1 H) NHz 259 [(4'-{3-(aminocarbonyl)-4- # 4. 90 (s, 2H), 6.53 (br s, 414 [(aminocarbonyl)amino]-1H-pyrazol-1- 2H), 6. 86-6.93 (m, 1H), yl}-5-fluoro-1, 1'-biphenyl-2-yl) oxy] acetic 7.22 (br s, 1 H), 7.25-7. 40 acid (m, 2H), 7.53 (br s, 1 H), OH 7. 75-7. 85 (m, 3H), 7.95 (d, O# 2H, J=8.4 Hz), 8. 62 (s, H2N, ro 1 H), 8.69 (s, 1 H) 0 HN #N## O#N F NH2 [001051] Example 260: 4-[(aminocarbonyl)amino]-1-[4-(4, 4,5, 5- tetramethyl-1, 3, 2-dioxaborolan-2-yl) phenyl]-1 H-pyrazole-3-carboxamide

[001053] 4-[(Aminocarbonyl) amino]-1-(4-iodophenyl)-1H-pyrazole-3- carboxamide (1.93 g, 5.2 mmol, prepared according to the process of Example 214), palladium acetate (0.04 g, 0.16 mmol), potassium acetate (1.53 g, 15.6 mmol), and 1.43 g (5.62 mmol) of bis (pinacolato) diboron were added to a flask and placed under vacuum, then refilled with nitrogen. The vacuum-N2 cycle was repeated twice. The DMF (20 mL) was injected under N2. (The DMF was bubbled with N2 for 15 min before addition). The mixture was heated and stirred

at 85°C for 5 h. Most of liquids were removed under reduced pressure. The solid was triturated with water (80 mL) for 30 min., filtered, triturated with the petroleum ether (50 mL) for 1 h, filtered and dried. Most of the solid was dissolved in 1 L of the chloroform and filtered. The solvent was removed under reduced pressure to give, after drying, the desired product.'H NMR (CDCI3) : 5 1.37 (s, 12H), 4.70 (br s, 2H), 5.46 (br s, 1 H), 6. 88 (br s, 1 H), 7.38 (d, 2H, J = 8.7 Hz), 7.90 (d, 2H, J = 8.7 Hz), 8.59 (s, 1 H), 8. 69 (br s, 1 H). ESI mass spectrum for C17H23BN504+ : 372 (M+ 1).

[001054] Example 261: human IKK-2 enzyme assay [001055] Materials [001056] SAM2 96 Biotin capture plates were from Promega. Anti- FLAG affinity resin, FLAG-peptide, NP-40 (Nonidet P-40), BSA, ATP, ADP, AMP, LPS (E. coli serotype 0111 : B4), and dithiothreitol were obtained from Sigma Chemicals. Antibodies specific for NEMO (IKK-y) (FL-419), IKK-1 (H-744), IKK-2 (H-470) and IKBa (C-21) were purchased from Santa Cruz Biotechnology.

Ni-NTA resin was purchased from Qiagen. Peptides were purchased from American Peptide Company. Protease inhibitor cocktail tablets were from Boehringer Mannheim. Sephacryl S-300 column was from Pharmacia LKB Biotechnology. Centriprep-10 concentrators with a molecular weight cutoff of 10 kDa and membranes with molecular weight cut-off of 30 kDa were obtained from Amicon. [Y-33P] ATP (2500 Ci/mmol) and [T_32p] ATP (6000 Ci/mmol) were purchased from Amersham. The other reagents used were of the highest grade commercially available.

[001057] Cloning and Expression [001058] cDNAs of human IKK-1 and IKK-2 were amplified by reverse transcriptase-polymerase chain reaction from human placenta RNA (Clonetech). hIKK-1 was subcloned into pFastBac HTa (Life Technologies) and expressed as N-terminal Hiss-tagged fusion protein. The hIKK-2 cDNA was

amplified using a reverse oligonucleotide primer which incorporated the peptide sequence for a FLAG-epitope tag at the C-terminus of the IKK-2 coding region (DYKDDDDKD). The h) KK-2 : FLAG cDNA was subcloned into the baculovirus vector pFastBac. The rhIKK-2 (S177S, E177E) mutant was constructed in the same vector used for wild type rhIKK-2 using a QuikChangeT" mutagenesis kit (Stratagene). Viral stocks of each construct were used to infect insect cells grown in 40 L suspension culture. The cells were lysed at a time that maximal expression and rhIKK activity were demonstrated. Cell lysates were stored at- 80°C until purification of the recombinant proteins was undertaken as described below.

[001059] Enzyme isolation [001060] All purification procedures were carried out at 4°C unless otherwise noted. Buffers used are : buffer A: 20 mM Tris-HCI, pH 7.6, containing 50 mM NaCI, 20 mM NaF, 20 mM ß-Glycerophosphate, 500 uM sodium orthovanadate, 2-; 5 mM metabisulfite,-5 mM benzamidine, 1 mM EDTA, 0.5 mM EGTA, 10% glycerol, 1 mM DTT, 1X CompleteT""protease inhibitors; buffer B: same as buffer A, except 150 mM NaCI, and buffer C: same as buffer A, except <BR> <BR> <BR> <BR> 500 mM NaCl. mM NaCI.

[001061] Isolation of rhIKK-1 homodimer [001062] Cells from an 8-liter fermentation of baculovirus-expressed IKK- 1 tagged with His peptide were centrifuged and the cell pellet (MOI 0. 1, 1=72 h) was re-suspended in 100 mL of buffer C. The cells were microfluidized and centrifuged at 100,000 X g for 45 min. The supernatant was collected, imidazole added to the final concentration of 10 mM and incubated with 25 mL of Ni-NTA resin for 2 h. The suspension was poured into a 25 mL column and washed with 250 mL of buffer C and then with 125 mL of 50 mM imidazole in buffer C. rhiKK- 1 homodimer was eluted using 300 mM imidazole in buffer C. BSA and NP-40 were added to the enzyme fractions to the final concentration of 0.1 %. The enzyme was dialyzed against buffer B, aliquote and stored at-80°C.

[001063] Isolation of rhlKK-2 homodimer [001064] A 10-liter culture of baculovirus-expressing IKK-2 tagged with FLAG peptide was centrifuged and the cell pellet (MOI=0. 1 and l=72 h) was re- suspended in buffer A. These cells were microfluidized, and centrifuged at 100,000 X g for 45 min. Supernatant was passed over a G-25 column equilibrated with Buffer A. Protein peak was collected and incubated with anti- FLAG affinity resin on a rotator overnight in buffer B. The resin was washed in batch with 10-15 bed volumes of buffer C. Washed resin was poured into a column and rhIKK-2 homodimer was eluted using 5 bed volumes of buffer B containing FLAG peptide. 5 mM DTT, 0. 1% NP-40 and BSA (concentrated to 0. 1 % in final amount) was added to-the eluted enzyme before concentrating in using an Amicon membrane with a molecular weight cut-off of 30 kDa. Enzyme was aliquote and stored at-80°C.

[001065] Isolation of rhlKK-1/lKK-2 heterodimer [001066] The heterodimer enzyme was produced by coinfection in a baculovirus system (FLAG IKK-2/IKK-1 His; MOI=0. 1 and l=72 h). Infected cells were centrifuged and the cell pellet (10.0 g) was suspended in 50 mL of buffer A. The protein suspension was microfluidized and centrifuged at 100,000 X g for 45 min. Imidazole was added to the supernatant to a final concentration of 10- mM. The protein was allowed to bind 25 mL of Ni-NTA resin by mixing for 2 h.

The protein-resin slurry was poured into a 25 mL column and washed with 250 mL of buffer A containing 10 mM imidazole followed by 125 mL of buffer A containing 50 mM imidazole. Buffer A, containing 300 mM imidazole, was then used to elute the protein. A 75 mL pool was collected and NP-40 was added to a final concentration of 0. 1%. The protein solution was then dialyzed against buffer B. The dialyzed heterodimer enzyme was then allowed to bind to 25 mL of anti-FLAG M2 agarose affinity gel overnight with constant mixing. The protein- resin slurry was then centrifuged for 5 min at 2,000 rpm. The supernatant was collected and the resin re-suspended in 100 mL of buffer C containing 0. 1 % NP-

40. The resin was washed with 375 mL of buffer C containing 0.1 % NP-40. The protein-resin was poured into a 25 mL column and the enzyme eluted using buffer B containing FLAG peptide. Enzyme fractions (100 mL) were collected and concentrated to 20 mL using an Amicon membrane with molecular weight cut-off of 30 kDa. Bovine serum albumin was added to the concentrated enzyme to final concentration of 0.1 %. The enzyme was then aliquote and stored at- 80°C.

[001067] Cell Culture [001068] The wild type (wt) human pre-B cell line, 70Z/3, and its mutant, 1.3E2, were generously provided by Dr. Carol Sibley. Wt 70Z/3 and 1.3E2 cells . were grown in RPM ! 1. 640 (Gibcp) supplemented with 7 % defined bovine serum (Hyclone) and 50 uM 2-mercaptoethanol. Human monocytic leukemia THP-1 cells, obtained from ATCC, were cultured in RPMI 1640 supplemented with 10% defined bovine serum, 10 mM HEPES, 1.0 mM sodium pyruvate and 50 pM 2- mercaptoethanol. For experiments, cells were plated in 6 well plates at 1 x 106 cells/mL in fresh media. Pre-B cells were stimulated by the addition of 10 pg/mL LPS for varying lengths of time ranging from 0-4 h. THP-1 cells were stimulated by the addition of 1 ug/mL LPS for 45 minutes. Cells were pelleted, washed with cold 50 mM sodium phosphate buffer, pH 7 ; 4 containing 0.15 M NaCI and lysed at 4°C in 20 mM Hepes buffer, pH 7.6 containing 50 mM NaCI, 1 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 10 mM ß-glycerophosphate, 1 mM NaF, 1 mM PMSF, 1 mM DTT and 0.5 % NP40 (lysis buffer). The cytosolic fractions obtained following centrifugation at 10,000 X g were stored at-80°C until used.

[001069] Immunoprecipitation and Western Blotting [001070] SF9 cells paste containing rhIKKs were centrifuged (100,000 X g, 10 min) to remove debris. rhl KKs were immunoprecipitated (100 pg of cell paste) from the cell supernatant using 3 ug of anti-NEMO antibody (FL-419), followed by coupling to protein A sepharose beads. rhIKKs were also

immunoprecipitated from affinity chromatography purified protein preparations (1 , ug) using anti-FLAG, anti-His or anti-NEMO antibodies (1-4 ug) followed by protein A sepharose coupling. The native, human IKK complex was immunoprecipitated from THP-1 cell homogenates (300 ug/condition) using the anti-NEMO antibody. Immune complexes were pelleted and washed 3 times with 1 mL cold lysis buffer. Immunoprecipitated rhIKKs were chromatographed by SDS-PAGE (8% Tris-glycine) and transferred to nitrocellulose membranes (Novex) and detected by chemiluminescense (SuperSignal) using specific anti- IKK antibodies (IKK-2 H-470, IKK-1 H-744). Native IKK-2, iKBa, and NEMO proteins from cytosolic lysates (20-80 pg) were separated by SDS-PAGE and visualized by chemiluminescense using specific antibodies.

[001071] Phosphatase Treatment [001072] Immunoprecipitated rhIKKs were washed 2 times in 50 mM Tris-HCI, pH 8.2 containing 0.1 mM EDTA, 1 mM DTT, 1 mM PMSF and 2 mM MnCI2. and resuspended in 50-p L. Phosphatase (APPase, 1000 U) was pre- diluted in the same buffer and added to the IKK samples. Following incubation at room temperature for 30 minutes with intermittent mixing, cold lysis buffer was added to the tubes to stop the reaction. After several washes, 10 % of the beads were removed for Western analysis, and the remaining material was pelleted- and resuspended in 100 pL of the buffer used for the in vitro kinase assay.

[001073] IKK-1 SAM Enzyme Assay [001074] IKK-1 kinase activity was measured using a biotinylated IKBa peptide (Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-Asp-Ser32-G ly-Leu- Asp-Ser36-Met-Lys-Asp-Glu-Glu), a SAM2 tu 96 Biotin capture plate and a vacuum system. The standard reaction mixture contained 5 uM biotinylated IKBa peptide, 1 uM [y-33P] ATP (about 1 X 105 cpm), 1 mM DTT, 50 mM KCI, 2 mM MgCl2, 2 mM MnCi,, 10 mM NaF, 25 mM Hepes buffer, pH. 7.6 and enzyme solution (1-10 pL) in a final volume of 50 pL. After incubation at 25°C for 30 min, 25 pL of the reaction mixture was withdrawn and added to a SAM2 TM 96 Biotin

capture 96-well plate. Each well was then washed successively with 800 uL 2 M NaCl, 1.2 mL of NaCI containing 1 % H3PO4, 400 µL H2O, and 200 pL 95% ethanol. The plate was allowed to dry in a hood at 25°C for 1 h and then 25 uL of scintillation fluid (Microscint 20) was added to each well. Incorporation of [y- 33P] ATP was measured using a Top-Count NXT (Packard). Under each assay condition, the degree of phosphorylation of IKBa peptide substrate was linear with time and concentration for all purified enzymes. Results from the biotinylated peptide assay were confirmed by SDS-PAGE analysis of kinase reaction utilizing a GST-IKBa, s4and [y_32p] ATP. The resulting radiolabeled substrate was quantitated by Phosphoimager (Molecular Dynamics). An ion exchange resin assay was also employed using [Y-33P] ATP and ka, fusion protein as the substrates. Each assay system yielded consistent results in regard to Km and specific activities for each of the purified kinase isoforms. One unit of enzyme activity was defined as the amount required to catalyze the transfer of 1 nmole of phosphate from ATP to I-KB-A peptide per min. Specific activity was expressed as units per mg of protein. For experiments related to Km determination of purified enzymes, various concentrations of ATP or IKBa peptide were used in the assay at either a fixed IKBa or ATP-concentration. For IKBa peptide Km, assays were carried out with 0.1 pg of enzyme, 5 uM-ATP and IkBα peptide from 0.5 to 20 µM. For ATP Km, assays were carried out with 0.1 µg of enzyme, 10 uM IKBa peptide and ATP from 0.1 to 10 uM. For Km determination of rhiKK-1 homodimer, due to its low activity and higher Km for ISBA peptide, rhIKK-1 homodimer (0. 3 ug) was assayed with 125 uM IKBa peptide and a 5-fold higher specific activity of ATP (from 0.1 to 10 uM) for ATP Km experiments and a 5-fold higher specific activity of 5 uM ATP and IKBa peptide (from 5 to 200 pM) for IKBa peptide Km experiments.

[001075] IKK heterodimer Resin Enzyme Assay [001076] IKK heterodimer kinase activity was measured using a biotinylated kBa peptide (Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-

Asp-Ser32-Gly-Leu-Asp-Ser3s-Met-Lys-Asp-Glu-Glu) (American Peptide Co. ). 20 pL of the standard reaction mixture contained 5 uM biotinylated IKBa peptide, 0. 1 uCi/reaction [y-33P] ATP (Amersham) (about 1 X 105 cpm), 1 µM ATP (Sigma), 1 mM DTT (Sigma), 2 mM MgCI2 (Sigma), 2 mM MnCl2 (Sigma), 10 mM NaF (Sigma), 25 mM Hepes (Sigma) buffer, pH 7.6 and 20 uL enzyme solution and 10 pu inhibitor in a final volume of 50 pL. After incubation at 25°C for 30 min, 150 uL resin (Dowex anion-exchange resin AG1X8 200-400 mesh) in 900 mM formate, pH 3.0 was added to each well to stop the reaction. Resin was allowed to settle for 1 h and 50 pL of supernatant was removed to a Micolite-2 flat bottom plate (Dynex). 150 uL of scintillation fluid (Microscint 40) (Packard) was added to each well. Incorporatlon of [y-33P] ATP. was measuredvusing a Top- Count NXT (Packard).

[001077] IKK-2 Resin Enzyme Assay [001078] IKK-2 kinase activity was measured using a biotinylated IKBa <BR> <BR> <BR> peptide (Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-Asp-Ser32 Gly-Leu- Asp-Ser36-Met-Lys-Asp-Glu-Glu) (American Peptide Co. ). 20 pL of the standard reaction mixture contained 5 uM biotinylated IkBα peptide, 0.1 µCi/reaction [y- 33P] ATP (Amersham) (about 1 X 105 cpm), 1 µM ATP (Sigma), 1 mM DTT (Sigma), 2 mM MgCI2 (Sigma), 2 mM MnCI2 (Sigma), 10 mM NaF (Sigma), 25 mM Hepes (Sigma) buffer, pH 7.6 and 20 uL enzyme solution and 10 µL inhibitor in a final volume of 50 uL. After incubation at 25°C for 30 min, 150 uL resin (Dowex anion-exchange resin AG1X8 200-400 mesh) in 900 mM formate, pH 3.0 was added to each well to stop the reaction. Resin was allowed to settle for 1 h and 50 uL of supernatant was removed to a Micolite-2 flat bottom plate (Dynex). 150 uL of scintillation fluid (Microscint 40) (Packard) was added to each well. Incorporation of [Y-33P] ATP was measured using a Top-Count NXT (Packard).

[001079] IKK-2 IC50 values obtained from the assay described above are shown in Table III below (Example 262).

[001080] Example 262: Rat IKK-2 enzyme assay [001081] Kinase activity was measured using a biotinylated IKBa peptide (Gly-Leu-Lys-Lys-Glu-Arg-Leu-Leu-Asp-Asp-Arg-His-Asp-Ser32 Gly-Leu-Asp- Ser36-Met-Lys-Asp-Glu-Glu) (American Peptide Co. ). 20 pL of the standard reaction mixture contained 5 uM biotinylated IKBa peptide, 0. 1µCi/reaction [Y=33P] ATP (Amersham) (about 1 x 105 cpm), 1, uM ATP (Sigma), 1 mM DTT (Sigma), 2 mM MgCl2 (Sigma), 2 mM MnCI2 (Sigma), 10 mM NaF (Sigma), 25 mM Hepes (Sigma) buffer, pH. 7.6 and 20 uL enzyme solution (50 nM/rxn or 200 ng/rxn) and 10 pL inhibitor in a final volume of 50 uL. After incubation at 25°C for 60 min, 150 uL resin was added to each well to stop the reaction. Resin was mixed and allowed to settle for 1 h and 50 uL of supernatant was removed to a Micolite 2 flat bottom plate (Dynex). 150 uL of scintillation fluid (Microscint 40) (Packard) was added to each well. Incorporation of [Y-33P] ATP was measured using a Top- Count NXT (Packard).

[001082] IKK-2 ICso values obtained from the assay described above are shown in Table III below.

Table Table III Ex. ICso pM) Ex. ICSO (M) Ex. ICSO (M) No. KK-2 rlKK-2 hlKK-2 rlKK-2 hlKK-2 rlKK-2 1 0. 307 0. 108 32 1. 16 63 0. 59 2 10. 7 33 0. 89 64 6. 08 3 1. 35 0. 787 34 4. 21 65 1. 80 4 2. 87 1. 933 35 1. 33 66 5. 20 5 5. 09 3. 710 36 1. 63 67 5. 24 6 0. 546 37 0. 79 68 0. 55 7 0. 355 0. 121-38 0. 83 69 0. 65 8 0. 0676 0. 089 39 1. 34 70 0. 88 9 1. 43 40 0. 351 71 2. 25 10 1 41 7. 59 72 0. 44 11 6. 36 42 9. 22 73 8. 03 12 1. 43 43 8. 54 74 0. 94 13 0. 38 44 2. 08 75 0. 48 14 8. 95 45 0. 31 76 0. 90 15 8. 05 4. 449 46 5. 20 77 0. 80 16 3. 10 2. 828 47 0. 66 78 0. 81 17 1. 72 48 1. 04 79 5. 67 18 0. 30 49 2. 48 80 0. 60 19 0. 31 0. 352 50 2. 08 81 1. 65 20 0. 61 51 5. 99 82 1. 19 21 2. 86 52 4. 86 83 1. 29 22 1. 20 53 4. 07 84 2. 06 23 1. 64 54 1. 16 85 0. 58 24 7. 73 55 1. 04 86 5. 91 25 1. 55 56 2. 16 87 1. 52 26 0. 59 57 0. 29 88 3. 20 27 1. 36 58 2. 81 89 0. 70 28 2. 79 59 1. 64 90 2. 81 29 0. 53 60 3. 75 91 3. 45 30 3. 00 61 6. 21 92 6. 61 2. 656 31 4. 79 62 7. 91 93 3. 10 1. 816 Ex. C,. pM) Ex. ICSO (NM) Ex. ICSO (NM) No. hiKK-2 riKK-2--] rIKK-2 94 0. 22 0. 220 126 >20. 0 158 4. 04 95 2. 68 127 >20. 0 159 5. 97 96 1. 45 128 >20. 0 160 4. 79 7. 190 97 0. 14 0. 180 129 1. 82 161 1. 36 98 1. 04 0. 668 130 1. 79 162 13. 7 13. 605 99 0. 75 0. 555 131 3. 15 163 16. 6 17. 353 100 1. 15 0. 171 132 12. 8 164 11. 3 7. 270 101 5. 23 1. 885 133 1. 63 165 5. 99 102 2. 82 134 3. 84 166 0. 38 103 >20 135 1. 66 167 0. 50 . 104-0. 677 1-136--'468''1. 99 105 0. 351 137 >20. 0 169 1. 83 106 1. 06 138 >20. 0 170 1. 58 107 0. 651 139 7. 82 171 6. 84 108 0. 947 140 >20. 0 172 0. 044 0. 033 109 5. 52 141 11. 4 3. 996 173 0. 15 0. 105 110 0. 743 142 0. 17 174 3. 67 2. 488 111 4. 38 143 3. 31 175 0. 18 0. 181 112. 1. 99 144 5. 05 176 0. 18 113 0. 355 145 0. 24 177 1. 02 114 3. 19 146 6. 28 178 1. 99 115 5. 81 147 6. 01 179 0. 510 116 11 148 7. 14 180 0. 228 117 >20 149 0. 05 181 0. 105 118 3. 07 150 0. 63 182 11. 2 119 0. 664 151 0. 31 183 0. 13 120 0. 972 152 0. 11 184 5. 49 121 0. 385 153 0. 32 185 5. 88 122 6. 99 154 0. 26 186 0. 86 0. 475 123 >20. 0 155 0. 45 187 0. 52 0. 441 124 7. 42 156 0. 61 188 0. 46 125 3. 95 157 8. 08 189 1. 04 Ex. ( (pM) Ex.) C,. (pM) Ex.) C,. (pM) No. hlKK-2 rIKK-2 hIKK-2 rIKK-2 hIKK-2 rIKK-2 190 0. 831 214 0. 382 238 1. 11 191 2. 54 215 0. 322 0. 091 239 0. 161 192 0. 237 0. 297 216 0. 159 240 2. 02 193 3. 75 217 0. 383 241 1. 68 194 0. 150 0. 173 218 1. 31 242 1. 35 195 0. 387 219 0. 175 243 8. 11 196 0. 718 220 1. 57 244 0. 866 197 0. 561 221 2. 60 245 5. 51 198 6. 52 222 >20 246 3. 30 199 6. 56 223 1. 15 247 0. 457 0. 249 200 0. 326--224 0. 327 248''0. 386 201 0. 532 225 0. 378 0. 292 249 0. 892 202 5. 97 0. 128 226 1. 06 250 0. 279 203 0. 153 227 1. 53 251 0. 662 204 0. 013 0. 023 228 >20. 0 252 0. 492 205 1. 13 0. 258 229 2. 19 253 1. 01 206 0. 0514 230 2. 02 254 0. 352 207 1. 32 231 4. 88 255 0. 762 208 0. 328 232 10. 3 256 1. 07 209 1. 04 1. 078 233 0. 375 257 1. 35 210 0. 0947 234 1. 71 258 1. 02 211 10. 5 235 13. 2 259 4. 01 212 0. 844 236 3. 05 260 0. 512 213 3. 91 237 3. 90